{
  "filename": "ehac262.pdf",
  "title": null,
  "type": "heart_failure",
  "year": 2022,
  "chapters": [
    {
      "number": "1",
      "title": "2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death",
      "start_page": 0,
      "end_page": 6,
      "content": "2022 ESC Guidelines for the management of\npatients with ventricular arrhythmias and the\nprevention of sudden cardiac death\nDeveloped by the task force for the management of patients with\nventricular arrhythmias and the prevention of sudden cardiac\ndeath of the European Society of Cardiology (ESC)\nEndorsed by the Association for European Paediatric and\nCongenital Cardiology (AEPC)\nAuthors/Task Force Members: Katja Zeppenfeld*† (Chairperson) (Netherlands),\nJacob Tfelt-Hansen\n*† (Chairperson) (Denmark), Marta de Riva** (Task Force\nCoordinator) (Netherlands), Bo Gregers Winkel** (Task Force Coordinator)\n(Denmark), Elijah R. Behr (United Kingdom), Nico A. Blom1 (Netherlands),\nPhilippe Charron (France), Domenico Corrado (Italy), Nikolaos Dagres\n(Germany), Christian de Chillou (France), Lars Eckardt (Germany), Tim Friede\n(Germany), Kristina H. Haugaa (Norway), Mélèze Hocini (France), Pier\nD. Lambiase (United Kingdom), Eloi Marijon (France), Jose L. Merino (Spain),\nPetr Peichl (Czech Republic), Silvia G. Priori (Italy), Tobias Reichlin (Switzerland),\nJeanette Schulz-Menger (Germany), Christian Sticherling (Switzerland),\nStylianos Tzeis (Greece), Axel Verstrael (Belgium), Maurizio Volterrani (Italy),\nand ESC Scientiﬁc Document Group\n*Corresponding authors: Katja Zeppenfeld, Department of Cardiology, Leiden University Medical Centre, Albinusdreef 2, 2333 ZA Leiden, Netherlands. Tel +31 715262020, E-mail:\nK.Zeppenfeld@LUMC.nl\nJacob Tfelt-Hansen, The Department of Cardiology, The Heart Centre, Copenhagen University Hospital, Rigshospitalet, Blegdamsvej 9, 2100, Copenhagen, Denmark. Tel +45 61360399,\nE-mail: jacob.tfelt@regionh.dk\n†The two chairpersons contributed equally to the document and are joint corresponding authors.\n**The two task force Coordinators contributed equally to the document.\nAuthor/task force Member afﬁliations are listed in Author information.\n1Representing the Association for European Paediatric and Congenital Cardiology (AEPC).\nESC Clinical Practice Guidelines (CPG) Committee: listed in the Appendix.\nESC subspecialty communities having participated in the development of this document:\nAssociations: Association for Acute CardioVascular Care (ACVC), Association of Cardiovascular Nursing & Allied Professions (ACNAP), European Association of Cardiovascular\nImaging (EACVI), European Association of Percutaneous Cardiovascular Interventions (EAPCI), European Heart Rhythm Association (EHRA), Heart Failure Association (HFA).\nWorking Groups: Cardiac Cellular Electrophysiology, Myocardial and Pericardial Diseases.\nPatient Forum\nThe content of these European Society of Cardiology (ESC) Guidelines has been published for personal and educational use only. No commercial use is authorized. No part of the ESC\nGuidelines may be translated or reproduced in any form without written permission from the ESC. Permission can be obtained upon submission of a written request to Oxford University\nPress, the publisher of the European Heart Journal and the party authorized to handle such permissions on behalf of the ESC (Journals.Permissions@oup.com).\nEuropean Heart Journal (2022) 43, 3997–4126\nhttps://doi.org/10.1093/eurheartj/ehac262\nESC GUIDELINES\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026\n\n\nDocument-Reviewers: Maja Cikes (CPG Review Coordinator) (Croatia), Paulus Kirchhof (CPG Review\nCoordinator) (Germany), Magdy Abdelhamid (Egypt), Victor Aboyans (France), Elena Arbelo (Spain),\nFernando Arribas (Spain), Riccardo Asteggiano (Italy), Cristina Basso (Italy), Axel Bauer (Austria),\nEmanuele Bertaglia (Italy), Tor Biering-Sørensen (Denmark), Carina Blomström-Lundqvist (Sweden),\nMichael A. Borger (Germany), Jelena Čelutkienė (Lithuania), Bernard Cosyns (Belgium), Volkmar Falk\n(Germany), Laurent Fauchier (France), Bulent Gorenek (Turkey), Sigrun Halvorsen (Norway), Robert Hatala\n(Slovakia), Hein Heidbuchel (Belgium), Stefan Kaab (Germany), Aleksandra Konradi (Russian Federation),\nKonstantinos C. Koskinas (Switzerland), Dipak Kotecha (United Kingdom), Ulf Landmesser (Germany),\nBasil S. Lewis (Israel), Ales Linhart (Czech Republic), Maja-Lisa Løchen (Norway), Lars H. Lund (Sweden),\nAndreas Metzner (Germany), Richard Mindham (United Kingdom), Jens Cosedis Nielsen (Denmark),\nTone M. Norekvål (Norway), Monica Patten (Germany), Eva Prescott (Denmark), Amina Rakisheva\n(Kazakhstan), Carol Ann Remme (Netherlands), Ivo Roca-Luque (Spain), Andrea Sarkozy (Belgium),\nDaniel Scherr (Austria), Marta Sitges (Spain), Rhian M. Touyz (Canada/United Kingdom), Nicolas Van Mieghem\n(Netherlands), Vedran Velagic (Croatia), Sami Viskin (Israel), and Paul G. A. Volders (Netherlands)\nAll experts involved in the development of these guidelines have submitted declarations of interest. These have\nbeen compiled in a report and published in a supplementary document simultaneously to the guidelines. The\nreport is also available on the ESC website www.escardio.org/Guidelines\nSee the European Heart Journal online for supplementary data that includes background information and\ndetailed discussion of the data that have provided the basis of the guidelines.\nClick here to access the corresponding ESC CardioMed chapters.\nKeywords\nGuidelines • Anti-arrhythmic drugs • Cardiac magnetic resonance • Cardiomyopathies • Catheter ablation •\nChronic coronary artery disease • Genetic testing • Implantable cardioverter deﬁbrillator • Premature ventricular\ncomplex • Primary electrical disease • Recommendations • Risk calculator • Risk stratiﬁcation • Sudden cardiac\ndeath • Sudden death • Ventricular arrhythmia • Ventricular ﬁbrillation • Ventricular tachycardia\nTable of contents\n1. Preamble ........................................................................................................\n4003\n2. Introduction .................................................................................................\n4005\n2.1. What is new ........................................................................................ 4005\n3. Deﬁnitions .....................................................................................................\n4011\n3.1. Ventricular arrhythmia subtypes ................................................ 4011\n3.2. Sudden cardiac death ....................................................................... 4011\n3.3. Syncope ................................................................................................. 4011\n3.4. Specialized centres ............................................................................ 4011\n3.5. Genetics ................................................................................................. 4011\n4. Epidemiology of sudden cardiac death, public awareness, and\nrisk stratiﬁcation ..............................................................................................\n4011\n4.1. Incidence of sudden cardiac death ............................................. 4011\n4.2. Causes of sudden cardiac death in different age groups . 4012\n4.3. Population vs. individual risk prediction .................................. 4012\n4.4. Risk calculators for sudden cardiac death and review of the\nmethodology ................................................................................................ 4012\n4.5. Awareness and intervention: public basic life support, and\naccess to automated external deﬁbrillators ................................... 4012\n5. Evaluation and treatment. General aspects ....................................\n4014\n5.1. Diagnostic tools ................................................................................. 4014\n5.1.1. History and physical examination ......................................\n4014\n5.1.2. Laboratory testing ....................................................................\n4014\n5.1.3. Non-invasive and invasive tests ..........................................\n4014\n5.1.3.1. Electrocardiogram and ambulatory\nelectrocardiographic monitoring ................................................ 4014\n5.1.3.2. Signal-averaged electrocardiogram ............................ 4014\n5.1.3.3. Exercise testing .................................................................. 4014\n5.1.3.4. Imaging ................................................................................... 4014\n5.1.3.5. Provocative diagnostic tests ......................................... 4015\n5.1.3.6. Electrophysiological study ............................................. 4015\nDisclaimer: The ESC Guidelines represent the views of the ESC and were produced after careful consideration of the scientiﬁc and medical knowledge and the evidence available at the\ntime of their publication. The ESC is not responsible in the event of any contradiction, discrepancy, and/or ambiguity between the ESC Guidelines and any other ofﬁcial recommendations\nor guidelines issued by the relevant public health authorities, in particular in relation to good use of healthcare or therapeutic strategies. Health professionals are encouraged to take the\nESC Guidelines fully into account when exercising their clinical judgment, as well as in the determination and the implementation of preventive, diagnostic, or therapeutic medical strat-\negies; however, the ESC Guidelines do not override, in any way whatsoever, the individual responsibility of health professionals to make appropriate and accurate decisions in consid-\neration of each patient’s health condition and in consultation with that patient and, where appropriate and/or necessary, the patient’s caregiver. Nor do the ESC Guidelines exempt health\nprofessionals from taking into full and careful consideration the relevant ofﬁcial updated recommendations or guidelines issued by the competent public health authorities, in order to\nmanage each patient’s case in light of the scientiﬁcally accepted data pursuant to their respective ethical and professional obligations. It is also the health professional’s responsibility to\nverify the applicable rules and regulations relating to drugs and medical devices at the time of prescription.\n© The European Society of Cardiology 2022. All rights reserved. For permissions please e-mail: Journals.Permissions@oup.com\n3998\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026\n\n\n5.1.4. Genetic testing ...........................................................................\n4015\n5.2. Diagnostic evaluation at ﬁrst presentation with\nventricular arrhythmia in patients without known cardiac\ndisease .................................................................................................... 4018\n5.2.1. Scenario 1: Incidental ﬁnding of a non-sustained\nventricular tachycardia ........................................................................\n4018\n5.2.2. Scenario 2: First presentation of sustained\nmonomorphic ventricular tachycardia .........................................\n4018\n5.2.3. Scenario 3: Sudden cardiac arrest survivor ...................\n4020\n5.2.4. Scenario 4: Sudden death victim ........................................\n4023\n5.2.5. Scenario 5: Relatives of sudden arrhythmic death\nsyndrome decedents ...........................................................................\n4024\n6. Therapies for ventricular arrhythmias. General aspects ...........\n4027\n6.1. Acute management .......................................................................... 4027\n6.1.1. Treatment of reversible causes ..........................................\n4027\n6.1.2. Acute management of sustained monomorphic\nventricular tachycardia ........................................................................\n4029\n6.1.3. Management of electrical storm and incessant\nventricular tachycardia ........................................................................\n4030\n6.2. Long-term management ................................................................. 4034\n6.2.1. Pharmacotherapy ......................................................................\n4034\n6.2.2. Device therapy ...........................................................................\n4038\n6.2.2.1. Implantable cardioverter deﬁbrillator ....................... 4038\n6.2.2.2. Adding cardiac resynchronization therapy ............. 4040\n6.2.2.3. Wearable cardioverter deﬁbrillator .......................... 4040\n6.2.3. Special aspects of device therapy ......................................\n4041\n6.2.3.1. Optimization of device programming ...................... 4041\n6.2.3.2. Concomitant treatment to avoid inappropriate\nimplantable cardioverter deﬁbrillator therapy ..................... 4041\n6.2.3.3. Psychosocial impact of implantable cardioverter\ndeﬁbrillator treatment .................................................................... 4042\n6.2.3.4. Patients with left ventricular assist devices ............ 4042\n6.2.3.5. Complications of devices ............................................... 4042\n6.2.3.6. End-of-life issues ................................................................ 4043\n6.2.4. Interventional therapy ............................................................\n4043\n6.2.4.1. Catheter ablation .............................................................. 4043\n6.2.4.1.1. Patients with structural heart disease ............. 4043\n6.2.4.1.2. Patients without apparent structural heart\ndisease ............................................................................................... 4044\n6.2.4.2. Autonomic modulation .................................................. 4044\n7. Diagnostic evaluation, management, and risk\nstratiﬁcation according to clinical presentation and known (likely)\ndisease ..................................................................................................................\n4044\n7.1. Speciﬁc structural heart diseases ................................................ 4044\n7.1.1. Coronary artery disease ........................................................\n4044\n7.1.1.1. Acute coronary syndromes and vasospasm .......... 4044\n7.1.1.1.1. Acute coronary syndromes ................................. 4044\n7.1.1.1.2. Vasospasm ................................................................... 4045\n7.1.1.2. Early after myocardial infarction ................................. 4046\n7.1.1.3. Chronic coronary artery disease ................................ 4046\n7.1.1.3.1. Primary prevention of sudden cardiac death in\npatients with reduced ejection fraction ............................. 4046\n7.1.1.3.2. Primary prevention of sudden cardiac death in\npatients with preserved or mildly reduced ejection\nfraction ............................................................................................. 4047\n7.1.1.3.3. Secondary prevention of sudden cardiac\ndeath .................................................................................................. 4047\n7.1.1.3.4. Management of patients with\nhaemodynamically tolerated ventricular tachycardia and\npreserved and mildly reduced ejection fraction ............. 4048\n7.1.1.3.5. Management of recurrent ventricular\ntachycardia in implantable cardioverter deﬁbrillator\ncarriers .............................................................................................. 4049\n7.1.1.4. Coronary anomalies ......................................................... 4049\n7.1.2. Idiopathic premature ventricular complexes/\nventricular tachycardia and premature ventricular complex-\ninduced cardiomyopathy ...................................................................\n4050\n7.1.2.1. Idiopathic premature ventricular complexes/\nventricular tachycardia .................................................................... 4050\n7.1.2.2. Premature ventricular complex-induced/-\naggravated cardiomyopathy .......................................................... 4052\n7.1.3. Cardiomyopathies ....................................................................\n4054\n7.1.3.1. Dilated cardiomyopathy and hypokinetic non-\ndilated cardiomyopathy .................................................................. 4054\n7.1.3.1.1. Diagnostic evaluation and risk stratiﬁcation .. 4054\n7.1.3.1.2. Primary prevention of sudden cardiac death\n4055\n7.1.3.1.3. Secondary prevention of sudden cardiac death\nand management of ventricular arrhythmias ................... 4057\n7.1.3.2. Arrhythmogenic right ventricular\ncardiomyopathy ................................................................................. 4058\n7.1.3.2.1. Risk stratiﬁcation ....................................................... 4058\n7.1.3.2.2. Treatment .................................................................... 4060\n7.1.3.3. Hypertrophic cardiomyopathy .................................... 4060\n7.1.3.3.1. Risk stratiﬁcation and primary prevention of\nsudden cardiac death .................................................................. 4061\n7.1.3.3.2. Treatment to prevent ventricular arrhythmia\nrecurrence ....................................................................................... 4062\n7.1.3.4. Left ventricular non-compaction ................................ 4063\n7.1.3.5. Restrictive cardiomyopathy .......................................... 4063\n7.1.3.6. Neuromuscular disorders ............................................. 4063\n7.1.4. Inﬂammatory cardiac diseases .............................................\n4066\n7.1.4.1. Myocarditis ........................................................................... 4066\n7.1.4.2. Cardiac sarcoidosis ........................................................... 4067\n7.1.4.3. Chagas’ cardiomyopathy ................................................ 4068\n7.1.5. Valvular heart disease .............................................................\n4070\n7.1.6. Congenital heart disease ........................................................\n4071\n7.2. Primary electrical disease ............................................................... 4073\n7.2.1. Idiopathic ventricular ﬁbrillation .........................................\n4073\n7.2.2. Long QT syndrome (including acquired long QT\nsyndrome) ................................................................................................\n4074\n7.2.3. Andersen–Tawil syndrome Type 1 ..................................\n4079\n7.2.4. Brugada syndrome ...................................................................\n4079\n7.2.5. Early repolarization syndromes ..........................................\n4081\n7.2.6. Catecholaminergic polymorphic ventricular\ntachycardia ...............................................................................................\n4084\n7.2.7. Short QT syndrome ................................................................\n4086\n8. Special aspects in selected populations ............................................\n4088\n8.1. Pregnant patients and peri-partum cardiomyopathy ......... 4088\n8.1.1. Electrocardioversion and implantable cardioverter\ndeﬁbrillator therapy in pregnancy ..................................................\n4088\n8.1.2. Pharmacological treatment ...................................................\n4088\n8.1.3. Catheter ablation ......................................................................\n4088\n8.2. Heart transplantation ...................................................................... 4089\n8.3. Sudden cardiac death in athletes ................................................ 4089\nESC Guidelines\n3999\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026\n\n\n8.4. Wolff–Parkinson–White syndrome .......................................... 4090\n8.5. Prevention of sudden cardiac death in the elderly ............. 4090\n9. Key messages ...............................................................................................\n4090\n9.1. General aspects .................................................................................. 4090\n9.2. Structural heart disease .................................................................. 4090\n9.3. Primary electrical disease ............................................................... 4091\n10. Gaps in evidence ......................................................................................\n4091\n10.1. General aspects ............................................................................... 4091\n10.2. Structural heart disease—general ........................................... 4091\n10.3. Idiopathic premature ventricular complexes/ventricular\ntachycardia .................................................................................................... 4091\n10.4. Coronary artery disease .............................................................. 4091\n10.5. Cardiomyopathies .......................................................................... 4091\n10.6. Valvular heart disease ................................................................... 4091\n10.7. Congenital heart disease .............................................................. 4091\n10.8. Primary electrical disease ............................................................ 4091\n11. ‘What to do’ and ‘what not to do’ messages from the\nGuidelines ...........................................................................................................\n4092\n12. Quality indicators ....................................................................................\n4099\n13. Supplementary data ................................................................................\n4099\n14. Data availability statement ...................................................................\n4099\n15. Author information ................................................................................\n4099\n16. Appendix .....................................................................................................\n4100\n17. References ..................................................................................................\n4101\nTables of Recommendations\nRecommendation Table 1 — Recommendations for public\nbasic life support and access to automated external\ndeﬁbrillators ............................................................................................ 4014\nRecommendation Table 2 — Recommendations for genetic\ntesting ...................................................................................................................\n4018\nRecommendation Table 3 — Recommendations for evaluation\nof patients presenting with newly documented ventricular\narrhythmia ..........................................................................................................\n4018\nRecommendation Table 4 — Recommendations for evaluation of\npatients presenting with a ﬁrst episode of sustained\nmonomorphic ventricular tachycardia ...................................................\n4020\nRecommendation Table 5 — Recommendations for evaluation of\nsudden cardiac arrest survivors ................................................................\n4022\nRecommendation Table 6 — Recommendations for evaluation of\nsudden death victims .....................................................................................\n4023\nRecommendation Table 7 — Recommendations for evaluation of\nrelatives of sudden arrhythmic death syndrome decedents ........\n4027\nRecommendation Table 8 — Recommendations for treatment of\nreversible conditions ......................................................................................\n4029\nRecommendation Table 9 — Recommendations for the acute\nmanagement of sustained ventricular tachycardia and electrical\nstorm ....................................................................................................................\n4033\nRecommendation Table 10 — Recommendations for treatment\nwith heart failure medication .....................................................................\n4034\nRecommendation Table 11 — Recommendations for implantable\ncardioverter deﬁbrillator implantation (general aspects) ..............\n4040\nRecommendation Table 12 — Recommendations for secondary\nprevention of sudden cardiac death .......................................................\n4040\nRecommendation Table 13 — Recommendations for\nsubcutaneous implantable cardioverter deﬁbrillator .......................\n4040\nRecommendation Table 14 — Recommendations for adding\ncardiac resynchronization therapy to implantable cardioverter\ndeﬁbrillator ........................................................................................................\n4040\nRecommendation Table 15 — Recommendations for wearable\ncardioverter deﬁbrillator ..............................................................................\n4040\nRecommendation Table 16 — Recommendations for\noptimization of device programming .....................................................\n4041\nRecommendation Table 17 — Recommendations for\nconcomitant treatment to avoid inappropriate implantable\ncardioverter deﬁbrillator therapy ............................................................\n4042\nRecommendation Table 18 — Recommendations for\npsychosocial management after implantable cardioverter\ndeﬁbrillator implantation .............................................................................\n4042\nRecommendation Table 19 — Recommendations for implantable\ncardioverter deﬁbrillator implantation in left ventricular assist\ndevice recipients ..............................................................................................\n4042\nRecommendation Table 20 — Recommendations for prevention\nof implantable cardioverter deﬁbrillator complications .................\n4043\nRecommendation Table 21 — Recommendations for end-of-life\nissues in implantable cardioverter deﬁbrillator carriers .................\n4043\nRecommendation Table 22 — Recommendations for treatment\nof ventricular arrhythmias in acute coronary syndrome and\nvasospasm ..........................................................................................................\n4046\nRecommendation Table 23 — Recommendations for risk\nstratiﬁcation and treatment of ventricular arrhythmias early after\nmyocardial infarction .....................................................................................\n4046\nRecommendation Table 24 — Recommendations for risk\nstratiﬁcation, sudden cardiac death prevention, and treatment of\nventricular arrhythmias in chronic coronary artery disease .........\n4047\nRecommendation Table 25 — Recommendations for sudden\ncardiac death prevention in patients with coronary anomalies .......\n4050\nRecommendation Table 26 — Recommendations for the\nmanagement of patients with idiopathic premature ventricular\ncomplexes/ventricular tachycardia ..........................................................\n4052\nRecommendation Table 27 — Recommendations for the\nmanagement of patients with premature ventricular\ncomplex-induced or premature ventricular complex-aggravated\ncardiomyopathy ............................................................................................................. 4053\nRecommendation Table 28 — Recommendations for risk\nstratiﬁcation, sudden cardiac death prevention, and treatment\nof ventricular arrhythmias in dilated cardiomyopathy/\nhypokinetic non-dilated cardiomyopathy ......................................\n4057\nRecommendation Table 29 — Recommendations for diagnostic,\nrisk stratiﬁcation, sudden cardiac death prevention, and\ntreatment of ventricular arrhythmias in arrhythmogenic right\nventricular cardiomyopathy ........................................................................\n4060\nRecommendation Table 30 — Recommendations for risk\nstratiﬁcation, sudden cardiac death prevention, and treatment of\nventricular arrhythmias in hypertropic cardiomyopathy ...............\n4062\nRecommendation Table 31 — Recommendations for implantable\ncardioverter deﬁbrillator implantation in left ventricular\nnon-compaction ..............................................................................................\n4063\nRecommendation Table 32 — Recommendations for implantable\ncardioverter deﬁbrillator implantation in patients with cardiac\namyloidosis .........................................................................................................\n4063\nRecommendation Table 33 — Recommendations for risk\nstratiﬁcation, sudden cardiac death prevention, and treatment of\nventricular arrhythmias in neuromuscular diseases .........................\n4065\n4000\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026\n\n\nRecommendation Table 34 — Recommendations for sudden\ncardiac death prevention and treatment of ventricular\narrhythmias in myocarditis ..........................................................................\n4066\nRecommendation Table 35 — Recommendations for risk\nstratiﬁcation, sudden cardiac death prevention, and treatment of\nventricular arrhythmias in cardiac sarcoidosis ....................................\n4067\nRecommendation Table 36 — Recommendations for the\ntreatment of ventricular arrhythmias in Chagas’\ncardiomyopathy ....................................................................................... 4070\nRecommendation Table 37 — Recommendations for sudden\ncardiac death prevention and treatment of ventricular\narrhythmias in valvular heart disease ......................................................\n4070\nRecommendation Table 38 — Recommendations for risk\nstratiﬁcation and primary prevention of sudden cardiac death in\ncongenital heart disease ...............................................................................\n4072\nRecommendation Table 39 — Recommendations for secondary\nprevention of sudden cardiac death and treatment of ventricular\narrhythmia in congenital heart disease ..................................................\n4072\nRecommendation Table 40 — Recommendations for the\nmanagement of patients with idiopathic ventricular ﬁbrillation ..\n4073\nRecommendation Table 41 — Recommendations for the\nmanagement of patients with long QT syndrome ...........................\n4077\nRecommendation Table 42 — Recommendations for\nmanagement of patients with Andersen–Tawil syndrome ...........\n4079\nRecommendation Table 43 — Recommendations for\nmanagement of patients with Brugada syndrome ............................\n4080\nRecommendation Table 44 — Recommendations for the\nmanagement of patients with early repolarization pattern/\nsyndrome ............................................................................................................\n4083\nRecommendation Table 45 — Recommendations for the\nmanagement of patients with catecholaminergic polymorphic\nventricular tachycardia ..................................................................................\n4086\nRecommendation Table 46 — Recommendations for the\nmanagement of patients with short QT syndrome .........................\n4087\nRecommendation Table 47 — Recommendations for the\nprevention of sudden cardiac death and management of\nventricular arrhythmia during pregnancy ..............................................\n4088\nRecommendation Table 48 — Recommendations for the\nprevention of sudden cardiac death before and after heart\ntransplantation .................................................................................................\n4089\nRecommendation Table 49 — Recommendations for risk\nstratiﬁcation and prevention of sudden cardiac death in athletes\n4089\nRecommendation Table 50 — Recommendations for implantable\ncardioverter deﬁbrillator implantation in the elderly ......................\n4090\nList of tables\nTable 1 Classes of recommendations ....................................................\n4003\nTable 2 Levels of evidence ..........................................................................\n4004\nTable 3 New sections and concepts ......................................................\n4005\nTable 4 New recommendations in 2022 .............................................\n4005\nTable 5 Changes in recommendations since 2015 ...........................\n4010\nTable 6 Intravenous provocative diagnostic tests .............................\n4016\nTable 7 Genetic tests and suggested work-up of probands and\nrelatives with primary electrical diseases ..............................................\n4017\nTable 8 Anti-arrhythmic drugs (acute and chronic treatment) ..\n4035\nTable 9 Summary of the recommendations for the treatment of\npatients with frequent idiopathic premature ventricular\ncomplexes/ventricular tachycardia or premature ventricular\ncomplex-induced cardiomyopathy ..........................................................\n4051\nTable 10 Modiﬁed long QT syndrome diagnostic score ...................... 4076\nList of ﬁgures\nFigure 1 Central ﬁgure ..................................................................................\n4013\nFigure 2 Algorithm for the evaluation of patients presenting with\nan incidental ﬁnding of non-sustained ventricular tachycardia ....\n4019\nFigure 4 Algorithm for the evaluation of patients presenting with a\nﬁrst sustained monomorphic ventricular tachycardia episode ....\n4021\nFigure 3 Typical idiopathic ventricular tachycardia morphologies\n4020\nFigure 5 Bundle branch re-entrant ventricular tachycardia ..........\n4022\nFigure 6 Part One. Algorithm for the evaluation of sudden cardiac\narrest survivors ................................................................................................\n4024\nFigure 6 Part Two. Algorithm for the evaluation of sudden cardiac\narrest survivors ................................................................................................\n4025\nFigure 7 Algorithm for the evaluation of sudden death victims .\n4026\nFigure 8 Algorithm for the evaluation of relatives of unexplained\nsudden death decedents ..............................................................................\n4028\nFigure 9 Algorithm for the acute management of regular wide\nQRS complex tachycardia ...........................................................................\n4029\nFigure 10 Repetitive runs of ventricular tachycardia interrupted\nby occasional sinus beats .............................................................................\n4030\nFigure 11 Part One. Management of patients with electrical\nstorm or repeated implantable cardioverter deﬁbrillator\ndischarges ......................................................................................................... 4031\nFigure 11 Part Two.Management of patients with electrical\nstorm or repeated implantable cardioverter deﬁbrillator\ndischarges ................................................................................................... 4032\nFigure 11 Part Three. Management of patients with electrical\nstorm or repeated implantable cardioverter deﬁbrillator\ndischarges ...........................................................................................................\n4033\nFigure 12 Algorithm for evaluation before initiation and follow-up\nof patients requiring sodium channel blocking agents ....................\n4038\nFigure 13 Algorithm for evaluation before initiation and follow-up\nof patients requiring drugs associated with QT prolongation ....\n4039\nFigure 14 Algorithm for the prevention and management of\nventricular arrhythmias in ST-elevation myocardial infarction .........\n4045\nFigure 15 Algorithm for risk stratiﬁcation and primary prevention\nof sudden cardiac death in patients with chronic coronary artery\ndisease and reduced ejection fraction ....................................................\n4048\nFigure 16 Algorithm for the management of sustained\nmonomorphic ventricular tachycardia in patients with chronic\ncoronary artery disease ................................................................................\n4049\nFigure 17 Algorithm for the management of patients with\nidiopathic premature ventricular complexes/ventricular\ntachycardia and non-apparent structural heart disease .................\n4051\nFigure 18 Algorithm for the management of patients with\npremature ventricular complex-induced/-aggravated\ncardiomyopathy ...............................................................................................\n4053\nFigure 19 Algorithm for risk stratiﬁcation and primary prevention\nof sudden cardiac death in patients with dilated cardiomyopathy/\nhypokinetic non-dilated cardiomyopathy .............................................\n4055\nESC Guidelines\n4001\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026\n\n\nFigure 20 Typical features of dilated cardiomyopathy associated\nwith lamin A/C gene mutation with ventricular arrhythmias ......\n4056\nFigure 21 Typical features of arrhythmogenic right\nventricular cardiomyopathy associated with ventricular\narrhythmias ................................................................................................ 4059\nFigure 22 Typical features of hypertrophic cardiomyopathy\nassociated with sustained monomorphic ventricular\ntachycardia ................................................................................................. 4061\nFigure 23 Algorithm for risk stratiﬁcation, sudden cardiac death\nprevention, and treatment of ventricular arrhythmia in myotonic\ndystrophy .......................................................................................................................... 4064\nFigure 24 Algorithm for sudden cardiac death prevention and\ntreatment of ventricular arrhythmia in patients with cardiac\nsarcoidosis ..........................................................................................................\n4068\nFigure 25 Typical features of cardiac sarcoidosis associated with\nsustained monomorphic ventricular tachycardia ..............................\n4069\nFigure 26 Algorithm for the management of sustained ventricular\narrhythmia in patients with congenital heart disease ......................\n4071\nFigure 27 Algorithm for the management of patients with\nidiopathic ventricular ﬁbrillation ...............................................................\n4074\nFigure 28 Idiopathic ventricular ﬁbrillation triggered by\nshort-coupled premature ventricular complexes .............................\n4075\nFigure 29 Long QT syndrome electrocardiograms and\ntorsade-de-pointes ventricular tachycardia .........................................\n4076\nFigure 30 Brisk standing electrocardiogram changes and T wave\nalternans in Long QT syndrome patients .............................................\n4077\nFigure 31 Algorithm for the management of patients with long\nQT syndrome ...................................................................................................\n4078\nFigure 32 Typical examples of (A) Brugada type 1\nelectrocardiogram, and (B) early repolarization pattern\nelectrocardiogram ...........................................................................................\n4080\nFigure 33 Part One. Algorithm for the management of patients\nwith Brugada pattern electrocardiogram .............................................\n4082\nFigure 33 Part Two. Algorithm for the management of patients\nwith Brugada pattern electrocardiogram .............................................\n4083\nFigure 34 Management of patients with early repolarization\npattern/syndrome ...........................................................................................\n4084\nFigure 35 Management of patients with catecholaminergic\npolymorphic ventricular tachycardia ......................................................\n4085\nFigure 36 Exercise test of a patient with catecholaminergic\npolymorphic ventricular tachycardia ......................................................\n4086\nFigure 37 Short QT syndrome .................................................................\n4087\nAbbreviations and acronyms\nAAD\nAnti-arrhythmic drug\nACE-I\nAngiotensin-converting enzyme inhibitor\nACS\nAcute coronary syndrome\nAED\nAutomated external deﬁbrillator\nAF\nAtrial ﬁbrillation\nAH\nAtrial–His interval\nALS\nAdvanced life support\nARB\nAngiotensin receptor blocker\nARNI\nAngiotensin receptor neprilysin inhibitor\nARVC\nArrhythmogenic right ventricular cardiomyopathy\nATP\nAnti-tachycardia pacing\nAV\nAtrioventricular\nAVRT\nAV re-entry tachycardia\nBBR-VT\nBundle branch re-entrant ventricular tachycardia\nBrS\nBrugada syndrome\nCA\nCardiac arrest\ncAMP\nCyclic adenosine monophosphate\nCAD\nCoronary artery disease\nCAG\nCoronary angiogram\nCCB\nCalcium channel blocker\nCHD\nCongenital heart disease\nCIED\nCardiac implantable electronic devices\nCMR\nCardiac magnetic resonance\nCPR\nCardiopulmonary resuscitation\nCPVT\nCatecholaminergic polymorphic ventricular tachycardia\nCRT\nCardiac resynchronization therapy\nCT/CTA\nComputed tomography/Computed tomography\nangiography\nDCM\nDilated cardiomyopathy\nDNA\nDeoxyribonucleic acid\nECG\nElectrocardiogram\nEF\nEjection fraction\nERP\nEarly repolarization pattern\nERS\nEarly repolarization syndrome\nFBI\nFast, broad, irregular\nHCM\nHypertrophic cardiomyopathy\nHFrEF\nHeart failure with reduced ejection fraction\nHNDCM\nHypokinetic non-dilated cardiomyopathy\nHTX\nHeart transplantation\nHV\nHis–ventricular interval\nICD\nImplantable cardioverter deﬁbrillator\nILR\nImplantable loop recorder\nIVF\nIdiopathic ventricular ﬁbrillation\nLBBB\nLeft bundle branch block\nLCSD\nLeft cardiac sympathetic denervation\nLGE\nLate gadolinium enhancement\nLMNA\nLamin A/C\nLQTS\nLong QT syndrome\nLV\nLeft ventricular\nLVAD\nLeft ventricular assist device\nLVEF\nLeft ventricular ejection fraction\nLVH\nLeft ventricular hypertrophy\nLVNC\nLeft ventricular non-compaction\nLVOT\nLeft ventricle outﬂow tract\nMI\nMyocardial infarction\nMRA\nMineralocorticoid receptor antagonist\nMVP\nMitral valve prolapse\nMVT\nMonomorphic ventricular tachycardia\nNSVT\nNon-sustained ventricular tachycardia\nNYHA\nNew York Heart Association\nOHCA\nOut-of-hospital cardiac arrest\nOMT\nOptimal medical treatment\nPCI\nPercutaneous coronary intervention\nPCR\nPolymerase chain reaction\nPES\nProgrammed electrical stimulation\nPET-CT\nPositron emission tomography computed\ntomography\nPPCM\nPeri-partum cardiomyopathy\nPVC\nPremature ventricular complex\nPVT\nPolymorphic ventricular tachycardia\nQI\nQuality indicators\nRBBB\nRight bundle branch block\n4002\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026",
      "keywords": [
        "heart failure",
        "patients",
        "age",
        "cardiomyopathy",
        "genetic",
        "angiography",
        "nyha",
        "coronary artery",
        "sudden",
        "death",
        "arrhythmias",
        "calcium channel",
        "secondary prevention",
        "management",
        "primary prevention",
        "arrhythmia",
        "syncope",
        "ventricular tachycardia",
        "lvef",
        "icd",
        "arb",
        "sudden cardiac death",
        "exercise",
        "ecg",
        "ejection fraction",
        "elderly",
        "tachycardia",
        "guidelines",
        "electrocardiogram",
        "ventricular"
      ],
      "tables": [
        {
          "title": "3998 ESC Guidelines",
          "page_number": 1,
          "content": " |  | urheartj/article/43/40/399\n | Keywords Guidelines • Anti-arrhythmic drugs • Cardiac magnetic resonance • Cardiomyopathies • Catheter ablation •\nChronic coronary artery disease • Genetic testing • Implantable cardioverter defibrillator • Premature ventricular\ncomplex • Primary electrical disease • Recommendations • Risk calculator • Risk stratification • Sudden cardiac\ndeath • Sudden death • Ventricular arrhythmia • Ventricular fibrillation • Ventricular tachycardia | \n |  | ",
          "bbox": [
            0.0,
            362.61419067382815,
            595.260009765625,
            449.9440002441406
          ],
          "function_potential": "raw"
        },
        {
          "title": "ESC Guidelines 4003",
          "page_number": 6,
          "content": "Class I | Evidence and/or general agreement\nthat a given treatment or procedure is\nbeneficial, useful, effective. | Is recommended or is indicated",
          "bbox": [
            112.47159729003906,
            515.9000244140625,
            493.71000501844617,
            568.9190063476562
          ],
          "function_potential": "auto_generate"
        },
        {
          "title": "ESC Guidelines 4003",
          "page_number": 6,
          "content": "Class II | Conflicting evidence and/or a divergence of opinion about the usefulness/\neffcacy of the given treatment or procedure. |  |  | \n |  |  |  | \nClass IIa |  | Weight of evidence/opinion is in\nfavour of usefulness/effcacy. | Should be considered | \n |  |  |  | \nClass IIb |  | Usefulness/efficacy is less well\nestablished by evidence/opinion. | May be considered | ",
          "bbox": [
            112.47159729003906,
            575.0289916992188,
            493.71000501844617,
            676.1503092447916
          ],
          "function_potential": "auto_generate"
        },
        {
          "title": "ESC Guidelines 4003",
          "page_number": 6,
          "content": "Class III | Evidence or general agreement that the\ngiven treatment or procedure is not\nuseful/effective, and in some cases\nmay be harmful. | Is not recommended",
          "bbox": [
            112.47159729003906,
            681.6900024414062,
            493.71000501844617,
            735.8457763671875
          ],
          "function_potential": "auto_generate"
        }
      ]
    },
    {
      "number": "2",
      "title": "Abbreviations and acronyms",
      "start_page": 5,
      "end_page": 9,
      "content": "Figure 20 Typical features of dilated cardiomyopathy associated\nwith lamin A/C gene mutation with ventricular arrhythmias ......\n4056\nFigure 21 Typical features of arrhythmogenic right\nventricular cardiomyopathy associated with ventricular\narrhythmias ................................................................................................ 4059\nFigure 22 Typical features of hypertrophic cardiomyopathy\nassociated with sustained monomorphic ventricular\ntachycardia ................................................................................................. 4061\nFigure 23 Algorithm for risk stratiﬁcation, sudden cardiac death\nprevention, and treatment of ventricular arrhythmia in myotonic\ndystrophy .......................................................................................................................... 4064\nFigure 24 Algorithm for sudden cardiac death prevention and\ntreatment of ventricular arrhythmia in patients with cardiac\nsarcoidosis ..........................................................................................................\n4068\nFigure 25 Typical features of cardiac sarcoidosis associated with\nsustained monomorphic ventricular tachycardia ..............................\n4069\nFigure 26 Algorithm for the management of sustained ventricular\narrhythmia in patients with congenital heart disease ......................\n4071\nFigure 27 Algorithm for the management of patients with\nidiopathic ventricular ﬁbrillation ...............................................................\n4074\nFigure 28 Idiopathic ventricular ﬁbrillation triggered by\nshort-coupled premature ventricular complexes .............................\n4075\nFigure 29 Long QT syndrome electrocardiograms and\ntorsade-de-pointes ventricular tachycardia .........................................\n4076\nFigure 30 Brisk standing electrocardiogram changes and T wave\nalternans in Long QT syndrome patients .............................................\n4077\nFigure 31 Algorithm for the management of patients with long\nQT syndrome ...................................................................................................\n4078\nFigure 32 Typical examples of (A) Brugada type 1\nelectrocardiogram, and (B) early repolarization pattern\nelectrocardiogram ...........................................................................................\n4080\nFigure 33 Part One. Algorithm for the management of patients\nwith Brugada pattern electrocardiogram .............................................\n4082\nFigure 33 Part Two. Algorithm for the management of patients\nwith Brugada pattern electrocardiogram .............................................\n4083\nFigure 34 Management of patients with early repolarization\npattern/syndrome ...........................................................................................\n4084\nFigure 35 Management of patients with catecholaminergic\npolymorphic ventricular tachycardia ......................................................\n4085\nFigure 36 Exercise test of a patient with catecholaminergic\npolymorphic ventricular tachycardia ......................................................\n4086\nFigure 37 Short QT syndrome .................................................................\n4087\nAbbreviations and acronyms\nAAD\nAnti-arrhythmic drug\nACE-I\nAngiotensin-converting enzyme inhibitor\nACS\nAcute coronary syndrome\nAED\nAutomated external deﬁbrillator\nAF\nAtrial ﬁbrillation\nAH\nAtrial–His interval\nALS\nAdvanced life support\nARB\nAngiotensin receptor blocker\nARNI\nAngiotensin receptor neprilysin inhibitor\nARVC\nArrhythmogenic right ventricular cardiomyopathy\nATP\nAnti-tachycardia pacing\nAV\nAtrioventricular\nAVRT\nAV re-entry tachycardia\nBBR-VT\nBundle branch re-entrant ventricular tachycardia\nBrS\nBrugada syndrome\nCA\nCardiac arrest\ncAMP\nCyclic adenosine monophosphate\nCAD\nCoronary artery disease\nCAG\nCoronary angiogram\nCCB\nCalcium channel blocker\nCHD\nCongenital heart disease\nCIED\nCardiac implantable electronic devices\nCMR\nCardiac magnetic resonance\nCPR\nCardiopulmonary resuscitation\nCPVT\nCatecholaminergic polymorphic ventricular tachycardia\nCRT\nCardiac resynchronization therapy\nCT/CTA\nComputed tomography/Computed tomography\nangiography\nDCM\nDilated cardiomyopathy\nDNA\nDeoxyribonucleic acid\nECG\nElectrocardiogram\nEF\nEjection fraction\nERP\nEarly repolarization pattern\nERS\nEarly repolarization syndrome\nFBI\nFast, broad, irregular\nHCM\nHypertrophic cardiomyopathy\nHFrEF\nHeart failure with reduced ejection fraction\nHNDCM\nHypokinetic non-dilated cardiomyopathy\nHTX\nHeart transplantation\nHV\nHis–ventricular interval\nICD\nImplantable cardioverter deﬁbrillator\nILR\nImplantable loop recorder\nIVF\nIdiopathic ventricular ﬁbrillation\nLBBB\nLeft bundle branch block\nLCSD\nLeft cardiac sympathetic denervation\nLGE\nLate gadolinium enhancement\nLMNA\nLamin A/C\nLQTS\nLong QT syndrome\nLV\nLeft ventricular\nLVAD\nLeft ventricular assist device\nLVEF\nLeft ventricular ejection fraction\nLVH\nLeft ventricular hypertrophy\nLVNC\nLeft ventricular non-compaction\nLVOT\nLeft ventricle outﬂow tract\nMI\nMyocardial infarction\nMRA\nMineralocorticoid receptor antagonist\nMVP\nMitral valve prolapse\nMVT\nMonomorphic ventricular tachycardia\nNSVT\nNon-sustained ventricular tachycardia\nNYHA\nNew York Heart Association\nOHCA\nOut-of-hospital cardiac arrest\nOMT\nOptimal medical treatment\nPCI\nPercutaneous coronary intervention\nPCR\nPolymerase chain reaction\nPES\nProgrammed electrical stimulation\nPET-CT\nPositron emission tomography computed\ntomography\nPPCM\nPeri-partum cardiomyopathy\nPVC\nPremature ventricular complex\nPVT\nPolymorphic ventricular tachycardia\nQI\nQuality indicators\nRBBB\nRight bundle branch block\n4002\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026\n\n\nRCM\nRestrictive cardiomyopathy\nRCT\nRandomized control trial\nRV\nRight ventricular\nRVOT\nRight ventricle outﬂow tract\nSADS\nSudden arrhythmic death syndrome\nSaECG\nSignal-averaged ECG\nSCA\nSudden cardiac arrest\nSCD\nSudden cardiac death\nSD\nSudden death\nSGLT2\nSodium–glucose co-transporter 2\nSHD\nStructural heart disease\nS-ICD\nSubcutaneous implantable cardioverter\ndeﬁbrillator\nSMVT\nSustained monomorphic ventricular tachycardia\nSPTV\nSustained polymorphic ventricular tachycardia\nSQTS\nShort QT syndrome\nSTEMI\nST elevation myocardial infarction\nSVT\nSupraventricular tachycardia\nTAVI\nTranscatheter aortic valve implantation\nTdP\nTorsades de pointes\nTOF\nTetralogy of Fallot\nVA\nVentricular arrhythmia\nVF\nVentricular ﬁbrillation\nVT\nVentricular tachycardia\nWCD\nWearable cardioverter deﬁbrillator\nWPW\nWolff–Parkinson–White\n1. Preamble\nGuidelines summarize and evaluate available evidence with the aim of\nassisting health professionals in proposing the best management\nstrategies for an individual patient with\na given\ncondition.\nGuidelines and their recommendations should facilitate decision\nmaking of health professionals in their daily practice. However, guide-\nlines are not a substitute for the patient’s relationship with their prac-\ntitioner. The ﬁnal decisions concerning an individual patient must be\nmade by the responsible health professional(s), based on what they\nconsider to be the most appropriate in the circumstances. These de-\ncisions are made in consultation with the patient and caregiver as\nappropriate.\nGuidelines are intended for use by health professionals. To ensure\nthat all users have access to the most recent recommendations, the\nESC makes its guidelines freely available. The ESC warns readers that\nthe technical language may be misinterpreted and declines any re-\nsponsibility in this respect.\nA great number of guidelines have been issued in recent years by\nthe ESC. Because of their impact on clinical practice, quality criteria\nfor the development of guidelines have been established to make all\ndecisions transparent to the user. The recommendations for formu-\nlating and issuing ESC Guidelines can be found on the ESC website\n(https://www.escardio.org/Guidelines). The ESC Guidelines re-\npresent the ofﬁcial position of the ESC on a given topic and are regu-\nlarly updated.\nIn addition to the publication of Clinical Practice Guidelines, the\nESC carries out the EURObservational Research Programme of\ninternational registries of cardiovascular diseases and interventions\nthat are essential to assess diagnostic/therapeutic processes, use of\nresources, and adherence to guidelines. These registries aim at pro-\nviding a better understanding of medical practice in Europe and\naround the world, based on high-quality data collected during rou-\ntine clinical practice.\nFurthermore, the ESC develops sets of quality indicators (QIs),\nwhich are tools to evaluate the level of implementation of the guide-\nlines and may be used by the ESC, hospitals, healthcare providers,\nand professionals to measure clinical practice, and in educational\nTable 1\nClasses of recommendations\n©ESC 2022\nClasses of recommendations\nClass I \nEvide\nbeneficial, useful, effective.\neffcacy of the given treatment or procedure.\nnce and/or general agreement\nthat a given treatment or procedure is\nConﬂicting evidence and/or a divergence of opinion about the usefulness/ \nIs recommended or is indicated\nWording to use\nDeﬁnition\nClass III \nEvidence or general agreement that the\ngiven tr\nuseful/effective, and in some cases\neatment or procedure is not\nmay be harmful. \nIs not recommended\nClass IIb\nestablished by evidence/opinion.\nMay be considered\nClass IIa\nW\nfavour of usefulness/effcacy.\neight of \nUsefulness/efficacy is less well\nevidence/opinion is in\nShould be considered\nClass II \n© ESC 2022\nESC Guidelines\n4003\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026\n\n\nprogrammes, alongside the key messages from the guidelines, to im-\nprove quality of care and clinical outcomes.\nThe Members of this task force were selected by the ESC to re-\npresent professionals involved with the medical care of patients\nwith this pathology. The selection procedure aimed to ensure that\nthere is a representative mix of members predominantly from across\nthe whole of the ESC region and from relevant ESC Subspecialty\nCommunities. Consideration was given to diversity and inclusion,\nnotably with respect to gender and country of origin. A critical evalu-\nation of diagnostic and therapeutic procedures was performed, in-\ncluding assessment of the risk–beneﬁt ratio. The level of evidence\nand the strength of the recommendation of particular management\noptions were weighed and scored according to predeﬁned scales, as\noutlined below. The task force followed the ESC voting procedures.\nAll recommendations subject to a vote achieved at least 75% among\nvoting members.\nThe experts of the writing and reviewing panels provided declar-\nation of interest forms for all relationships that might be perceived as\nreal or potential sources of conﬂicts of interest. Their declarations of\ninterest were reviewed according to the ESC declaration of interest\nrules and can be found on the ESC website (http://www.escardio.org/\nGuidelines) and have been compiled in a report and published in a\nsupplementary document simultaneously to the guidelines.\nThis process ensures transparency and prevents potential biases in\nthe development and review processes. Any changes in declarations of\ninterest that arise during the writing period were notiﬁed to the ESC\nand updated. The task force received its entire ﬁnancial support from\nthe ESC without any involvement from the healthcare industry.\nThe ESC CPG Committee supervises and coordinates the prepar-\nation of new guidelines. The Committee is also responsible for the\napproval process of these guidelines. The ESC Guidelines undergo\nextensive review by the CPG Committee and external experts, in-\ncluding a mix of members from across the whole of the ESC region\nand from relevant ESC Subspecialty Communities and National\nCardiac Societies. After appropriate revisions, the guidelines are\nsigned off by all the experts involved in the task force. The ﬁnalized\ndocument is signed off by the CPG Committee for publication in the\nEuropean Heart Journal. The guidelines were developed after careful\nconsideration of the scientiﬁc and medical knowledge and the evi-\ndence available at the time of their writing.\nThe task of developing ESC Guidelines also includes the creation\nof educational tools and implementation programmes for the re-\ncommendations, including condensed pocket guideline versions,\nsummary slides, summary cards for non-specialists, and an electronic\nversion for digital applications (smartphones, etc.). These versions\nare abridged and thus, for more detailed information, the user\nshould always access the full-text version of the guidelines, which\nis freely available via the ESC website and the European Heart\nJournal. The National Cardiac Societies of the ESC are encouraged\nto endorse, adopt, translate, and implement all ESC Guidelines.\nImplementation programmes are needed because it has been shown\nthat the outcome of disease may be favourably inﬂuenced by the\nthorough application of clinical recommendations.\nHealth professionals are encouraged to take the ESC Guidelines\nfully into account when exercising their clinical judgement, as well\nas in the determination and the implementation of preventive,\ndiagnostic, or therapeutic medical strategies. However, the ESC\nGuidelines do not override in any way whatsoever the individual re-\nsponsibility of health professionals to make appropriate and accurate\ndecisions in consideration of each patient‘s health condition and in\nconsultation with that patient or the patient’s caregiver where ap-\npropriate and/or necessary. It is also the health professional’s re-\nsponsibility to verify the rules and regulations applicable in each\ncountry to drugs and devices at the time of prescription and, where\nappropriate, to respect the ethical rules of their profession.\nOff-label use of medication may be presented in this guideline if\nsufﬁcient level of evidence shows that it can be considered medically\nappropriate to a given condition and if patients could beneﬁt from\nthe recommended therapy. However, the ﬁnal decisions concerning\nan individual patient must be made by the responsible health profes-\nsional giving special consideration to:\n(1) the speciﬁc situation of the patient. In this respect, it is speciﬁed\nthat, unless otherwise provided for by national regulations, off-\nTable 2\nLevels of evidence\nLevel of\nevidence A\nLevel of\nevidence B\nLevel of\nevidence C\nData derived from multiple randomized clinical trials\nor meta-analyses.\nData derived from a single randomized clinical trial\nor large non-randomized studies.\nConsensus of opinion of the experts and/or small studies,\nretrospective studies, registries.\n©ESC 2022\n4004\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026\n\n\nlabel use of medication should be limited to situations where it is\nin the patient’s interest to do so, with regard to the quality,\nsafety, and efﬁcacy of care, and only after the patient has been\ninformed and has provided consent;\n(2) country-speciﬁc health regulations, indications by governmental\ndrug regulatory agencies, and the ethical rules to which health\nprofessionals are subject, where applicable.\n2. Introduction\nThis document presents an update of the 2015 ESC Guidelines\nfor the management of patients with ventricular arrhythmias (VA)\nand the prevention of sudden cardiac death (SCD). New insights\ninto the epidemiology of SCD, new evidence on genetics, imaging,\nand clinical ﬁndings for risk stratiﬁcation for VA and SCD, and ad-\nvances in diagnostic evaluation and therapeutic strategies made this\nrevision necessary. The committee was composed of 25 members\nincluding 23 expert physicians, one methodologist, and one patient\nrepresentative. Experts were selected to cover all areas of VA and\nSCD as well as subspecialties of cardiology with the assistance of re-\nlated ESC working groups.\nAll 25 members of the task force committee approved the guide-\nline\nrecommendations\nafter\nan\nanonymous\nvoting\nprocess.\nNinety-nine peer reviewers reviewed the document. A systematic\nliterature survey was conducted, after instructions by the method-\nologist in the group, that led to the incorporation of 1155 references,\nof which 485 were selected to support the recommendations and\nfurther speciﬁed in the table of evidence (Supplementary data).\n2.1. What is new\nThe diagnostic and management parts of the guidelines have been\nadapted to facilitate their use in everyday clinical decision-making.\nThe ﬁrst general part has new sections on diagnostic evaluation,\nincluding pharmacologic provocative tests, genetic testing, and a sys-\ntematic work-up of probands and relatives with primary electrical\ndiseases. Comprehensive ﬂowcharts and recommendations for the\ndiagnostic evaluation at ﬁrst presentation with a VA of patients with-\nout a previously known cardiac disease are provided for ﬁve fre-\nquently encountered clinical scenarios. Practical recommendations\nfor optimization of implantable cardioverter deﬁbrillator (ICD) pro-\ngramming and algorithms for management of patients experiencing\nregular wide complex tachycardia and electrical storm are presented\n(Table 3).\nTable 3\nNew sections and concepts\nNew sections and concepts\nSection\nProvocative diagnostic tests\n5.1.3.5\nGenetic testing\n5.1.4\nDiagnostic evaluation at ﬁrst presentation with VA in\npatients without known cardiac disease\n5.2\nManagement of patients with electrical storm\n6.1.3\nSpecial aspects of device therapy\n6.2.3\n© ESC 2022\nTable 4\nNew recommendations in 2022\nRecommendations\nClass\nPublic basic life support and access to AEDs\nIt is recommended that public-access deﬁbrillation be available\nat sites where cardiac arrest is more likely to occur.a\nI\nPrompt CPR by bystanders is recommended at OHCA.\nI\nIt is recommended to promote community training in basic life\nsupport to increase bystander CPR rate and AED use.\nI\nMobile phone-based alerting of basic life support-trained\nbystander volunteers to assist nearby OHCA victims should be\nconsidered.\nIIa\nTreatment of VA. General aspects\nDC cardioversion is recommended as the ﬁrst-line treatment\nfor patients presenting with tolerated SMVT provided that the\nanaesthetic/sedation risk is low.\nI\nOptimal medical treatment including ACE-I/ARB/ARNIs,\nMRAs, beta-blockers, and SGLT2 inhibitors is indicated in all\nheart failure patients with reduced EF.\nI\nImplantation of a cardioverter deﬁbrillator is only\nrecommended in patients who have an expectation of\ngood-quality survival .1 year.\nI\nIn patients presenting with a haemodynamically tolerated\nSMVT and known or suspected SHD, intravenous\nprocainamide should be considered.\nIIa\nIn patients presenting with a haemodynamically tolerated\nSMVT in the absence of an established diagnosis, intravenous\namiodarone may be considered.\nIIb\nIn patients with SMVT or SPVT/VF triggered by a PVC with\nsimilar morphology and an indication for ICD, catheter ablation\nmay be considered when an ICD is not available,\ncontraindicated for concurrent medical reasons, or declined by\nthe patient.\nIIb\nThe WCD may be considered in the early phase after MI in\nselected patients.\nIIb\nCoronary artery disease\nIn patients with CAD and recurrent, symptomatic SMVT, or\nICD shocks for SMVT despite chronic amiodarone therapy,\ncatheter ablation is recommended in preference to escalating\nAAD therapy.\nI\nCardiac stress imaging during physical exercise is\nrecommended in addition to cardiopulmonary exercise test\nafter surgery in patients with anomalous aortic origin of a\ncoronary artery with a history of aborted CA.\nI\nIn SCA survivors with coronary artery spasm, implantation of\nan ICD should be considered.\nIIa\nICD therapy should be considered in patients with CAD,\nNYHA class I, and LVEF ≤30% despite ≥3 months of OMT.\nIIa\nICD implantation should be considered in patients with CAD,\nLVEF ≤40% despite ≥3 months of OMT and NSVT, if they are\ninducible for SMVT by PES.\nIIa\nContinued\nESC Guidelines\n4005\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026",
      "keywords": [
        "heart failure",
        "class ii",
        "guideline",
        "recommended",
        "cardiomyopathy",
        "genetic",
        "angiography",
        "nyha",
        "coronary artery",
        "class i",
        "abbreviations",
        "calcium channel",
        "sglt2",
        "arrhythmia",
        "ventricular tachycardia",
        "lvef",
        "icd",
        "arb",
        "aortic",
        "sudden cardiac death",
        "tavi",
        "exercise",
        "ecg",
        "ejection fraction",
        "gender",
        "tachycardia",
        "class iii",
        "acronyms",
        "glucose",
        "electrocardiogram"
      ],
      "tables": [
        {
          "title": "ESC Guidelines 4005",
          "page_number": 8,
          "content": "Recommendations |  | Class | \n | Public basic life support and access to AEDs |  | \nIt is recommended that public-access defibrillation be available\nat sites where cardiac arrest is more likely to occur.a |  | I | \nPrompt CPR by bystanders is recommended at OHCA. |  | I | \nIt is recommended to promote community training in basic life\nsupport to increase bystander CPR rate and AED use. |  | I | \nMobile phone-based alerting of basic life support-trained\nbystander volunteers to assist nearby OHCA victims should be\nconsidered. |  | IIa | \n | Treatment of VA. General aspects |  | \nDC cardioversion is recommended as the first-line treatment\nfor patients presenting with tolerated SMVT provided that the\nanaesthetic/sedation risk is low. |  | I | \nOptimal medical treatment including ACE-I/ARB/ARNIs,\nMRAs, beta-blockers, and SGLT2 inhibitors is indicated in all\nheart failure patients with reduced EF. |  | I | \nImplantation of a cardioverter defibrillator is only\nrecommended in patients who have an expectation of\ngood-quality survival .1 year. |  | I | \nIn patients presenting with a haemodynamically tolerated\nSMVT and known or suspected SHD, intravenous\nprocainamide should be considered. |  | IIa | \nIn patients presenting with a haemodynamically tolerated\nSMVT in the absence of an established diagnosis, intravenous\namiodarone may be considered. |  | IIb | \nIn patients with SMVT or SPVT/VF triggered by a PVC with\nsimilar morphology and an indication for ICD, catheter ablation\nmay be considered when an ICD is not available,\ncontraindicated for concurrent medical reasons, or declined by\nthe patient. |  | IIb | \nThe WCD may be considered in the early phase after MI in\nselected patients. |  | IIb | \n | Coronary artery disease |  | \nIn patients with CAD and recurrent, symptomatic SMVT, or\nICD shocks for SMVT despite chronic amiodarone therapy,\ncatheter ablation is recommended in preference to escalating\nAAD therapy. |  | I | \nCardiac stress imaging during physical exercise is\nrecommended in addition to cardiopulmonary exercise test\nafter surgery in patients with anomalous aortic origin of a\ncoronary artery with a history of aborted CA. |  | I | \nIn SCA survivors with coronary artery spasm, implantation of\nan ICD should be considered. |  | IIa | \nICD therapy should be considered in patients with CAD,\nNYHA class I, and LVEF ≤30% despite ≥3 months of OMT. |  | IIa | \nICD implantation should be considered in patients with CAD,\nLVEF ≤40% despite ≥3 months of OMT and NSVT, if they are\ninducible for SMVT by PES. |  | IIa | ",
          "bbox": [
            312.2799987792969,
            74.0,
            552.2800505264946,
            699.7085460316051
          ],
          "function_potential": "auto_generate"
        },
        {
          "title": "ESC Guidelines 4005",
          "page_number": 8,
          "content": "New sections and concepts | Section\nProvocative diagnostic tests | 5.1.3.5\nGenetic testing | 5.1.4\nDiagnostic evaluation at first presentation with VA in\npatients without known cardiac disease | 5.2\nManagement of patients with electrical storm | 6.1.3\nSpecial aspects of device therapy | 6.2.3",
          "bbox": [
            48.0,
            613.0989990234375,
            288.0,
            709.7059936523438
          ],
          "function_potential": "raw"
        },
        {
          "title": "4006 ESC Guidelines",
          "page_number": 9,
          "content": "In patients with CAD and haemodynamically well-tolerated\nSMVT and LVEF ≥40%, catheter ablation in experienced\ncentres should be considered as an alternative to ICD therapy,\nprovided that established endpoints have been reached.b |  | IIa | \nCatheter ablation should be considered in patients with CAD\nand recurrent, symptomatic SMVT, or ICD shocks for SMVT\ndespite beta-blocker or sotalol treatment. |  | IIa | \n | Idiopathic PVC/VT and PVC-induced cardiomyopathy |  | \nCatheter ablation as first-line treatment is recommended for\nsymptomatic idiopathic VT/PVCs from the RVOT or the left\nfascicles. |  | I | \nBeta-blockers or non-dihydropyridine CCBs are indicated in\nsymptomatic patients with idiopathic VT/PVCs from an origin\nother than the RVOT or the left fascicles. |  | I | \nIn patients with PVCs/VT and a presentation not typical for an\nidiopathic origin,c CMR should be considered, despite a normal\nechocardiogram. |  | IIa | \nBeta-blockers, non-dihydropyridine CCBs or flecainide should\nbe considered when catheter ablation is not available, not\ndesired, or is particularly risky in symptomatic patients with\nidiopathic VT/PVCs from the RVOT or the left fascicles. |  | IIa | \nCatheter ablation or flecainide should be considered in\nsymptomatic patients with idiopathic VT/PVCs from an origin\nother than the RVOT or the left fascicles. |  | IIa | \nIn patients with an unexplained reduced EF and a PVC burden\nof at least 10%, PVC-induced cardiomyopathy should be\nconsidered. |  | IIa | \nIn patients with suspected PVC-induced cardiomyopathy, CMR\nshould be considered. |  | IIa | \nIn non-responders to CRT with frequent, predominately\nmonomorphic PVCs limiting optimal biventricular pacing\ndespite pharmacological therapy, catheter ablation or AADs\nshould be considered. |  | IIa | \nCatheter ablation may be considered for idiopathic VT/PVCs in\nasymptomatic patients with repeatedly more than 20% of\nPVCs per day at follow-up. |  | IIb | \nAmiodarone as a first-line treatment is not recommended in\npatients with idiopathic VTs/PVCs. |  | III | \nDCM/HNDCM |  |  | \nGenetic testing (including at least LMNA, PLN, RBM20, and\nFLNC genes) is recommended in patients with DCM/HNDCM\nand AV conduction delay at ,50 years, or who have a family\nhistory of DCM/HNDCM or SCD in a first-degree relative (at\nage ,50 years). |  | I | \nIn a first-degree relative of a DCM/HNDCM patient, an ECG,\nand an echocardiogram are recommended if:\n• the index patient was diagnosed ,50 years of age or has\nclinical features suggestive of an inherited cause, or\n• there is a family history of DCM/HNDCM, or premature\nunexpected SD. |  | I | \nCMR with LGE should be considered in DCM/HNDCM\npatients for assessing the aetiology and the risk of VA/SCD. |  | IIa | ",
          "bbox": [
            43.0,
            59.5,
            283.00001373291013,
            707.6460361480713
          ],
          "function_potential": "raw"
        },
        {
          "title": "4006 ESC Guidelines",
          "page_number": 9,
          "content": "Genetic testing (including at least LMNA, PLN, RBM20, and\nFLNC genes) should be considered for risk stratification in\npatients with apparently sporadic DCM/HNDCM, who\npresent at young age or with signs suspicious for an inherited\naetiology. |  | IIa | \nICD implantation should be considered in DCM/HNDCM\npatients with an LVEF ,50% and ≥2 risk factors (syncope, LGE\non CMR, inducible SMVT at PES, pathogenic mutations in\nLMNA, PLN, FLNC, and RBM20 genes). |  | IIa | \nICD implantation should be considered in patients with DCM/\nHNDCM and haemodynamically tolerated SMVT. |  | IIa | \nIn a first-degree relative of a patient with apparently sporadic\nDCM/HNDCM, an ECG, and an echocardiogram may be\nconsidered. |  | IIb | \nParticipation in high-intensity exercise including competitive\nsports is not recommended for individuals with DCM/\nHNDCM and a LMNA mutation. |  | III | \n | ARVC |  | \nIn patients with suspected ARVC, CMR is recommended. |  | I | \nIn patients with a suspected or definite diagnosis of ARVC,\ngenetic counselling and testing are recommended. |  | I | \nICD implantation should be considered in symptomaticd\npatients with definite ARVC, moderate right or left ventricular\ndysfunction, and either NSVT or inducibility of SMVT at PES. |  | IIa | \nIn ARVC patients with indication for ICDs, a device with the\ncapability of ATP programming for SMVT up to high rates\nshould be considered. |  | IIa | \nAvoidance of high-intensitye exercise may be considered in\ncarriers of ARVC-related pathogenic mutations and no\nphenotype. |  | IIb | \nBeta-blocker therapy may be considered in all patients with a\ndefinite diagnosis of ARVC. |  | IIb | \nIn patients with ARVC and symptoms highly suspicious for VA,\nPES may be considered for risk stratification. |  | IIb | \n | HCM |  | \nCMR with LGE is recommended in HCM patients for\ndiagnostic work-up. |  | I | \nGenetic counselling and testing are recommended in HCM\npatients. |  | I | \nIn a first-degree relative of a patient with HCM, ECG, and\nechocardiogram are recommended. |  | I | \nICD implantation should be considered in HCM patients aged\n16 years or more with an intermediate 5-year risk of SCD (≥4\nto ,6%)f, and with (a) significant LGE at CMR (usually ≥15% of\nLV mass); or (b) LVEF ,50%; or (c) abnormal blood pressure\nresponse during exercise testg; or (d) LV apical aneurysm; or\n(e) presence of sarcomeric pathogenic mutation. |  | IIa | \nIn children ,16 years of age with HCM and an estimated\n5-year risk of SD ≥6% (based on HCM Risk-Kids scoreh), ICD\nimplantation should be considered. |  | IIa | \nIn patients with HCM presenting with haemodynamically\ntolerated SMVT, ICD implantation should be considered. |  | IIa | ",
          "bbox": [
            307.2799987792969,
            59.5,
            547.2800452190896,
            707.6460361480713
          ],
          "function_potential": "auto_generate"
        }
      ]
    },
    {
      "number": "2",
      "title": "4. Epidemiology of sudden cardiac death, public awareness, and risk stratification",
      "start_page": 14,
      "end_page": 15,
      "content": "3. Deﬁnitions\n3.1. Ventricular arrhythmia subtypes\nPremature ventricular complex (PVC): Premature occurrence of an ab-\nnormal QRS complex (duration typically ≥120 ms, corresponding\nT-wave typically broad and in the opposite direction of the major\nQRS deﬂection, no preceding P-wave).\nUnifocal or monomorphic PVCs: PVCs with a single QRS morphology.\nMultifocal, multiform, or polymorphic PVCs: PVCs with different QRS\nmorphologies.\nShort-coupled PVC: A PVC that interrupts the T-wave of the pre-\nceding conducted beat.\nVentricular tachycardia (VT): ≥3 consecutive beats with a rate\n.100 b.p.m. originating from the ventricles, independent from atrial\nand atrioventricular (AV) nodal conduction.\nNon-sustained ventricular tachycardia (NSVT): Run of consecutive\nventricular beats persisting for 3 beats to 30 s.\nMonomorphic ventricular tachycardia (MVT): Same QRS morph-\nology from beat to beat.\nPolymorphic ventricular tachycardia (PVT): Continually changing QRS\nmorphology.\nSustained monomorphic/polymorphic ventricular tachycardia (SMVT/\nSPVT): Continuous VT for at least 30 s, or which requires an interven-\ntion for termination.\nBidirectional ventricular tachycardia: Beat to beat alternation of the\nfrontal QRS axis (e.g. in catecholaminergic polymorphic ventricular\ntachycardia\n[CPVT],\nAndersen–Tawil,\ndigoxin\ntoxicity,\nacute\nmyocarditis).\nTorsades de pointes ventricular tachycardia (TdP): Subtype of a poly-\nmorphic VT in the context of QT prolongation with continually\nchanging QRS complexes that appear to spiral around the baseline\nof the electrocardiogram (ECG) lead in a sinusoidal pattern.\nVentricular ﬁbrillation (VF): A chaotic rhythm with undulations that\nare irregular in timing and morphology, without discrete QRS com-\nplexes on the surface ECG.\nElectrical storm: VA that occurs 3 or more times within 24 h (sepa-\nrated by at least 5 min), each requiring termination by an\nintervention.\nIncessant VT: Continuous sustained VT that recurs promptly des-\npite repeated intervention for termination over several hours.\n3.2. Sudden cardiac death\nSudden cardiac arrest (SCA): Sudden cessation of normal cardiac activ-\nity with haemodynamic collapse.\nSudden cardiac death (SCD): Sudden natural death presumed to be\nof cardiac cause that occurs within 1 h of onset of symptoms in wit-\nnessed cases, and within 24 h of last being seen alive when it is unwit-\nnessed. SCD in autopsied cases is deﬁned as the natural unexpected\ndeath of unknown or cardiac cause.\nSudden unexplained death: Unexplained sudden death occurring in\nan individual older than 1 year.\nSudden infant death syndrome (SIDS): Unexplained sudden death\noccurring in an individual younger than 1 year with negative patho-\nlogical and toxicological assessment and negative forensic examin-\nation of the circumstances of death.\nSudden arrhythmic death syndrome (SADS): Unexplained sudden\ndeath occurring in an individual older than 1 year with negative\npathological and toxicological assessment. Note: Synonymous with\n‘autopsy-negative sudden unexplained death’.\n3.3. Syncope\nUnexplained syncope: Transient loss of consciousness due to cerebral\nhypoperfusion, characterized by a rapid onset, short duration, and\nspontaneous complete recovery, but unexplained after conventional\nworkup. Work-up and differential diagnosis are provided in the 2018\nESC Guidelines for the diagnosis and management of syncope.1\nArrhythmic syncope: as above, but highly suspicious for intermittent\nbradycardia, rapid supraventricular tachycardia (SVT), or VA.\n3.4. Specialized centres\nMultidisciplinary teams: A multidisciplinary team across specialties is\ncharacterized by open communication, positive management and\nleadership,\nappropriate\nresources,\nand\na\nmix\nof\nskills.\nDecision-making should be shared in the team.\nSpecialized centre for catheter ablation of VA: Patient and procedural\ncomplexity vary widely. Some patients require a more experienced\noperator and a centre with more capabilities, which is more likely\nin patients with a non-ischaemic aetiology. A specialized centre has\nat least one operator with appropriate experience in interventions\nthat may be required for a successful procedure (e.g. percutaneous\nepicardial access). The centre performs catheter ablation of VT in\nstructural heart disease (SHD) on a regular basis. In addition, the cen-\ntre has the required resources to manage medical conditions, co-\nmorbidities, and potential complications in patients undergoing\ncomplex VA ablation; this includes interventional cardiology expert-\nise, acute placement of mechanical circulatory assist devices, and car-\ndiothoracic surgical back-up. Considering the variable availability\nacross European countries, it is preferable to treat complex patients\nin the most experienced centre within reasonable distance.\n3.5. Genetics\nPathogenic variant and likely pathogenic variant: The American College\nof Medical Genetics has provided a framework for the interpretation\nof disease causation by genetic variants standardized into classes. The\ngenetic variants most likely to cause an associated disease are termed\nV, ‘pathogenic’, and IV, ‘likely pathogenic’.\nMutation: This term is used in this document to mean a Class IV or\nV variant.\nVariant of uncertain signiﬁcance: A change in a gene’s deoxyribo-\nnucleic acid (DNA) sequence that has an unknown effect on a per-\nson’s health.\n4. Epidemiology of sudden cardiac\ndeath, public awareness, and risk\nstratiﬁcation\n4.1. Incidence of sudden cardiac death\nSCD accounts for approximately 50% of all cardiovascular deaths,\nwith up to 50% being the ﬁrst manifestation of cardiac disease.19–24\nIdeally, cases suspicious of SCD should be identiﬁed from multiple\nESC Guidelines\n4011\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026",
      "keywords": [
        "genetic",
        "sudden",
        "death",
        "epidemiology",
        "risk",
        "awareness",
        "arrhythmia",
        "syncope",
        "ventricular tachycardia",
        "public",
        "sudden cardiac death",
        "bradycardia",
        "older",
        "ecg",
        "tachycardia",
        "electrocardiogram",
        "ablation",
        "cardiac",
        "transient loss of consciousness",
        "scd",
        "stratification"
      ],
      "tables": []
    },
    {
      "number": "2",
      "title": "5. Evaluation and treatment. General aspects",
      "start_page": 17,
      "end_page": 18,
      "content": "OHCA victims.101–103 Education of public ofﬁcials and community\nmembers regarding the importance of increasing rates of bystander\nCPR and promoting the use of early deﬁbrillation by lay and profes-\nsional rescuers is critical to increasing survival rates.\n5. Evaluation and treatment.\nGeneral aspects\n5.1. Diagnostic tools\n5.1.1. History and physical examination\nHistory should focus on ‘red ﬂags’, including features of arrhythmic\nsyncope, e.g. absence of vagal prodrome, and family history of pre-\nmature or SCD including, e.g. drowning or car accident in long QT\nsyndrome (LQTS), and CPVT.1,106 Subtle features to suggest inher-\nited causes include a family history of epilepsy, sudden infant death\nsyndrome, deafness (LQTS), heart failure, or pacemaker implantation\nat ,50 years old. Features of diseases related to pro-arrhythmic con-\nditions include mid-systolic click in mitral valve prolapse (MVP) and\noutﬂow tract murmurs with Valsalva in HCM. Speciﬁc skin features\nmay be relevant, e.g. Lupus pernio, erythema nodosum in sarcoidosis,\nangiokeratoma in Fabry’s disease, xanthelasma/xanthoma, and palmo-\nplantar keratosis in ARVC.\n5.1.2. Laboratory testing\nNatriuretic peptides (b-type-natriuretic peptide, or N-terminal\npro-b-type-natriuretic peptide) may have a role in the identiﬁcation\nof individuals at increased risk of SCD in the general population107,108\nor in patients with CAD.109 There is not sufﬁcient evidence to use\nb-type-natriuretic peptide as a method to select the need for an\nICD.110,111\n5.1.3. Non-invasive and invasive tests\n5.1.3.1. Electrocardiogram and ambulatory electrocardiographic\nmonitoring2\nThe 12-lead ECG is an important tool for the diagnosis of underlying\ndisease, for risk stratiﬁcation in selected populations, and for the\ndiagnosis of the VA subtype, if captured. Documentation of arrhyth-\nmias related to symptoms is clinically pivotal but may be challenging\nwith sporadic events. The type of ECG-monitoring device and the re-\ncording time should therefore match the frequency of clinical events.\nMonitoring over a period of 24–48 h (typically ‘Holter recording’) is\nappropriate for daily arrhythmias,112 while intermittent monitoring\nover a longer period, with patient-activated ECG recorders (or\nmobile-health/smartphones), should be preferred for infrequent\nevents.113 Implantable loop recorders (ILR) can be useful in diagnos-\ning arrhythmias in patients with potentially life-threatening symp-\ntoms, such as unexplained syncope.114\n5.1.3.2. Signal-averaged electrocardiogram\nSignal-averaged electrocardiogram (SaECG) can detect very low\namplitude signals (‘late potentials’) in the terminal QRS segment115\nusing three time-domain measurements: QRS duration, low-amplitude\n(,40 µV) signal duration and root mean square voltage of terminal\n40 ms QRS.112 Abnormalities in the SaECG can also be assessed by\nfrequency-domain analysis.112 SaECG can contribute to the diagno-\nsis of ARVC.116\n5.1.3.3. Exercise testing\nExercise testing is useful for the diagnosis and for evaluating response\nto therapy in patients with suspected/proven adrenergic-dependent\nrhythm disturbances, such as exercise-induced idiopathic MVT, PVT,\nor bidirectional VT in CPVT.117,118 The 4-minute recovery QTc after\nexercise testing can contribute to the diagnosis LQTS.119\n5.1.3.4. Imaging\nImaging is crucial to assess cardiac function and detect cardiomy-\nopathies (\nESC CardioMed chapter 10).120 A negative imaging\nstudy supports primary electrical disease in a patient with VA.\nEchocardiography is a readily available and ﬁrst-line diagnostic and risk\nstratiﬁcation tool for valve diseases, CAD and DCM, HCM, ARVC,121\nand left ventricular non-compaction (LVNC). Echocardiographic strain-\nrate imaging allows differentiation between active and passive move-\nment of myocardial segments and early detection of myocardial dys-\nfunction. Wall motion abnormalities can indicate previous infarcts,\ncardiomyopathies, or inﬂammatory disease. Global longitudinal strain\nis a robust measure of left ventricular (LV) function and can detect sub-\ntle changes in LV function while LVEF is still preserved.122 Strain imaging\ncan assess mechanical dispersion reﬂecting inhomogeneous contraction\nthat could be associated with increased risk of VA.122–125\nCMR currently provides the most accurate and reproducible meas-\nurement of atrial, biventricular global and regional systolic function,\nand can detect myocardial oedema, ﬁbrosis, inﬁltration, and\nRecommendation Table 1 — Recommendations for\npublic basic life support and access to automated ex-\nternal deﬁbrillators\nRecommendations\nClassa\nLevelb\nIt is recommended that public access deﬁbrillation\nbe available at sites where cardiac arrest is more\nlikely to occur.c,90–92\nI\nB\nPrompt CPR by bystanders is recommended at\nOHCA.93–95\nI\nB\nIt is recommended to promote community\ntraining in basic life support to increase bystander\nCPR rate and AED use.93,97,104\nI\nB\nMobile phone-based alerting of basic life\nsupport-trained bystander volunteers to\nassist nearby OHCA victims should be\nconsidered.101–103,105\nIIa\nB\n© ESC 2022\nAED, automated external deﬁbrillator; CPR, cardiopulmonary resuscitation; OHCA,\nout-of-hospital cardiac arrest.\naClass of recommendation.\nbLevel of evidence.\ncShopping centres, stadiums, public transport stations, casinos.\n4014\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026",
      "keywords": [
        "heart failure",
        "lvef",
        "treatment",
        "icd",
        "pacemaker",
        "aspects",
        "recommended",
        "echocardiography",
        "exercise",
        "ecg",
        "evaluation",
        "general",
        "systolic",
        "electrocardiogram",
        "scd",
        "syncope",
        "family history"
      ],
      "tables": [
        {
          "title": "4014 ESC Guidelines",
          "page_number": 17,
          "content": "Recommendations | Classa | Levelb\nIt is recommended that public access defibrillation\nbe available at sites where cardiac arrest is more\nlikely to occur.c,90–92 | I | B\nPrompt CPR by bystanders is recommended at\nOHCA.93–95 | I | B\nIt is recommended to promote community\ntraining in basic life support to increase bystander\nCPR rate and AED use.93,97,104 | I | B\nMobile phone-based alerting of basic life\nsupport-trained bystander volunteers to\nassist nearby OHCA victims should be\nconsidered.101–103,105 | IIa | B",
          "bbox": [
            43.0,
            170.5009765625,
            283.0,
            340.5
          ],
          "function_potential": "raw"
        }
      ]
    },
    {
      "number": "2",
      "title": "6. Therapies for ventricular arrhythmias. General aspects",
      "start_page": 30,
      "end_page": 31,
      "content": "Where they diverged was the frequency of usage of additional\ntests such as high-lead ECGs, Holter monitoring, signal-averaged\nECG, CMR, and provocative testing.135 Sodium channel blocker\ndrug challenge and high-lead ECGs systematically performed in\nSADS relatives provided a yield of 28% BrS diagnoses in one\nstudy281; however, there are concerns about false positives.139\nFurthermore, epinephrine challenge has not been studied sys-\ntematically in SADS families but, in the opinion of this panel,\nmay be of utility in CPVT-suspected patients who are unable\nto exercise.137\nRecent data indicated at least a 13% genetic yield in SADS\ncases.135,178,183,276,283 Routine follow-up of families without a diag-\nnosis yields little in new diagnoses,284 although children of decedents\nmay be followed for age-penetrant disease until adulthood.181\nIf an autopsy is ambiguous, or if an autopsy was not undertaken in\na young SCD case with family or personal history suspicious for in-\nherited heart disease, then the yield of familial evaluation was similar\nto that in clear SADS cases.223,253,271\n6. Therapies for ventricular\narrhythmias. General aspects\n6.1. Acute management\n6.1.1. Treatment of reversible causes\nReversible causes may account for up to 50% of SCA.285,286 However,\nmost of the time it is difﬁcult to determine the exact underlying cause of\nSCA and whether it is reversible. A comprehensive evaluation of pa-\ntients with SCA is mandatory if the underlying cardiac disease is un-\nknown or disease progression is suspected (Section 5.2.3, scenario 3).\nElectrolyte imbalances, such as hypokalaemia, may trigger VA, and a ra-\npid rise in extracellular potassium may lead to asystole.287–289 Other fac-\ntors such as bradycardia, ischaemia, coronary spasm, thrombosis, fever,\nacute starvation, and dieting may contribute to the occurrence of VA.\n290–292 Acute correction of these reversible factors is recommended.\nDrug-induced arrhythmias should be suspected in patients being\ntreated with agents known to alter the electrical properties of the heart\n(e.g. inducing QRS and/or QT prolongation) or causing electrolyte ab-\nnormalities (e.g. thiazide and loop diuretics). When drug-induced ar-\nrhythmias are presumed, any offending drug needs to be withdrawn\nand substances that are known to prolong QT (e.g. sotalol) should\nbe avoided.293,294 Hypomagnesaemia and/or hypokalaemia may be as-\nsociated with Torsades de pointes (TdP). Intravenous magnesium is an\neffective therapy for TdP even in the absence of hypomagnesaemia.295\nIn refractory cases of recurrent TdP in the setting of acquired long QT,\nthe arrhythmia can be suppressed by increasing the underlying heart\nrate using isoproterenol (isoprenaline) or transvenous pacing.\nPatients who survive SCA in the context of a presumed reversible\ncause may have a high mortality rate.286 In a recent large observational\nstudy296 on survivors of SCA attributed to a reversible and correctable\ncause, subsequent ICD implantation was associated with lower all-cause\nmortality except for aborted CA occurring in the presence of acute\nmyocardial infarction (MI). Thus, the need for prophylactic ICD implant-\nation should be considered based on the underlying cardiac disease and\nan individual evaluation of the future risk of life-threatening VA.\nRecommendation Table 7 — Recommendations for\nevaluation of relatives of sudden arrhythmic death\nsyndrome decedents\nRecommendations\nClassa\nLevelb\nFamilial evaluation of SADS decedents is\nrecommended:\n• for ﬁrst-degree relatives\n• for relatives who must carry a mutation based\non analysis of the family history\n• for relatives with suspicious symptoms\n• when the decedent’s age is ,50 years, or if\nthere is other circumstantial data or family\nhistory to suggest heritable\ndisease.223,252,253,277,281\nI\nB\nFamilial evaluation of SADS decedents is\nrecommended to include genetic testing when\npost-mortem genetic testing in a SADS decedent\ndetects a pathogenic mutation.183,253,277,281\nI\nB\nBaseline familial evaluation of SADS decedents is\nrecommended to include taking a medical history\nand performing physical examination, standard and\nhigh precordial lead ECG, echocardiography, and\nexercise testing.223,252,253,277,281\nI\nB\nIn SADS families without a diagnosis after clinical\nevaluation, follow-up is recommended for\nchildren of decedents until they reach\nadulthood.181,284\nI\nC\nPharmacological testing with a sodium channel\nblocker should be considered in relatives of SADS\ndecedents who are 16 years or older when\nbaseline testing and/or proband ﬁndings increase\nthe suspicion of BrS.277,281\nIIa\nB\nContinued\nAmbulatory cardiac rhythm monitoring and CMR\nmay be considered in relatives of SADS\ndecedents.223,253,277,281\nIIb\nC\nPharmacological testing including epinephrine\nchallenge (if exercise testing is impractical) and\nsodium channel blocker challenge may be\nconsidered in ﬁrst-degree relatives of SADS\ndecedents with normal baseline testing.223,281\nIIb\nB\nIn SADS families without a diagnosis after clinical\nevaluation, follow-up is not recommended for\nasymptomatic adults who can be discharged with\nadvice to return if they develop symptoms or if\nthe family history changes.181,284\nIII\nC\n© ESC 2022\nBrS, Brugada syndrome; CMR, cardiac magnetic resonance; ECG, electrocardiogram;\nSADS, sudden arrhythmic death syndrome.\naClass of recommendation.\nbLevel of evidence.\nESC Guidelines\n4027\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026",
      "keywords": [
        "aspects",
        "age",
        "recommended",
        "echocardiography",
        "genetic",
        "family history",
        "arrhythmias",
        "arrhythmia",
        "icd",
        "bradycardia",
        "therapies",
        "older",
        "exercise",
        "ecg",
        "electrocardiogram",
        "should be considered",
        "ventricular",
        "general",
        "scd",
        "may be considered"
      ],
      "tables": [
        {
          "title": "ESC Guidelines 4027",
          "page_number": 30,
          "content": "Ambulatory cardiac rhythm monitoring and CMR\nmay be considered in relatives of SADS\ndecedents.223,253,277,281 | IIb | C\nPharmacological testing including epinephrine\nchallenge (if exercise testing is impractical) and\nsodium channel blocker challenge may be\nconsidered in first-degree relatives of SADS\ndecedents with normal baseline testing.223,281 | IIb | B\nIn SADS families without a diagnosis after clinical\nevaluation, follow-up is not recommended for\nasymptomatic adults who can be discharged with\nadvice to return if they develop symptoms or if\nthe family history changes.181,284 | III | C",
          "bbox": [
            312.27500406901044,
            59.5372314453125,
            552.2750244140625,
            217.53666178385416
          ],
          "function_potential": "raw"
        },
        {
          "title": "ESC Guidelines 4027",
          "page_number": 30,
          "content": "Recommendations | Classa | Levelb\nFamilial evaluation of SADS decedents is\nrecommended:\n• for first-degree relatives\n• for relatives who must carry a mutation based\non analysis of the family history\n• for relatives with suspicious symptoms\n• when the decedent’s age is ,50 years, or if\nthere is other circumstantial data or family\nhistory to suggest heritable\ndisease.223,252,253,277,281 | I | B\nFamilial evaluation of SADS decedents is\nrecommended to include genetic testing when\npost-mortem genetic testing in a SADS decedent\ndetects a pathogenic mutation.183,253,277,281 | I | B\nBaseline familial evaluation of SADS decedents is\nrecommended to include taking a medical history\nand performing physical examination, standard and\nhigh precordial lead ECG, echocardiography, and\nexercise testing.223,252,253,277,281 | I | B\nIn SADS families without a diagnosis after clinical\nevaluation, follow-up is recommended for\nchildren of decedents until they reach\nadulthood.181,284 | I | C\nPharmacological testing with a sodium channel\nblocker should be considered in relatives of SADS\ndecedents who are 16 years or older when\nbaseline testing and/or proband findings increase\nthe suspicion of BrS.277,281 | IIa | B",
          "bbox": [
            48.0,
            334.5,
            288.0,
            698.1525268554688
          ],
          "function_potential": "raw"
        }
      ]
    },
    {
      "number": "2",
      "title": "7. Diagnostic evaluation, management, and risk stratification according to clinical presentation and known (likely) \u0006disease",
      "start_page": 47,
      "end_page": 48,
      "content": "6.2.4.1.2. Patients without apparent structural heart disease.\n‘Idiopathic VTs’ is the term for VTs that are not associated with\nSHD or a genetic arrhythmic syndrome. Most idiopathic VTs are\nmediated by triggered activity, but a re-entrant mechanism (involving\nthe LV Purkinje network) explains verapamil-sensitive fascicular\nVTs.523 Three important key features distinguish idiopathic VTs\nfrom VTs associated with SHD. First, idiopathic VTs mostly originate\nfrom a single site and speciﬁc region of the heart (namely the right or\nleft ventricular outﬂow tracts,524,525 along the valve annuli,526–528\npapillary muscle,529 or the LV Purkinje network).523 Second, no de-\ntectable scar is found in idiopathic VTs.530 Finally, idiopathic VTs have\na benign prognosis so that ICD implantation is generally not\nrecommended.466\nThe earliest site of activation during VT is the ablation target for\nfocal sources, while abnormal Purkinje tissue (with diastolic activity\nduring VT) is the ablation target of left fascicular VTs.531,532\nCatheter ablation is curative in most idiopathic VT patients and\nperi-procedural complications are rare.533–537\n6.2.4.2. Autonomic modulation\nThe role of the autonomic nervous system in promoting arrhythmias\nhas long been recognized, leading to the concept of Coumel’s triangle\nof arrhythmogenesis.538\nSympathetic activation has been demonstrated as playing a key\nrole in inducing VAs in some entities, such as congenital LQTS and\nCPVT,539,540 and left cardiac sympathetic denervation was shown\nto be associated with a decrease in the frequency of arrhythmo-\ngenic syncope in congenital LQTS.541,542 The efﬁcacy of cardiac\nsympathetic blockade by different approaches (thoracic epidural\nanaesthesia, percutaneous stellate ganglion anaesthesia, or surgical\nstellate ganglion resection) in reducing the arrhythmia burden in\nrefractory VT/VF has been recognized in several small observation-\nal studies.326,328,340 Further studies are needed to assess which pa-\ntients may beneﬁt from a modulation of the autonomic nervous\nsystem to better control VT/VF.\n7. Diagnostic evaluation,\nmanagement, and risk\nstratiﬁcation according to clinical\npresentation and known (likely)\ndisease\n7.1. Speciﬁc structural heart diseases\n7.1.1. Coronary artery disease\n7.1.1.1. Acute coronary syndromes and vasospasm\n7.1.1.1.1. Acute coronary syndromes. SCD is a major cause of\nmortality in ACS, mostly caused by sustained VAs, in particular\nVF. The majority of studies have reported on patients with\nSTEMI. Of patients with STEMI, 4–12% develop VA within the\nﬁrst 48 h after the onset of symptoms.69,543,544 Pre-reperfusion\nVAs are more common than reperfusion-induced or post-\nreperfusion arrhythmias in STEMI.545 Haemodynamic instability,\ncardiogenic shock, LVEF , 40%, and the sum of ST-segment de-\nviations in all leads are independent predictors of VA both in\nSTEMI and non-STEMI.69,546 In addition, an early repolarization\npattern has been associated with increased risk of VAs and\nSCD in ACS.547\nPrevention of ventricular arrhythmias in ST elevation myocardial\ninfarction\nUrgent reperfusion is the most important therapy,292,548 as acute\nischaemia triggers arrhythmias. Beta-blocker treatment is also\nrecommended to prevent VA.3,549 In a recent randomized trial of pa-\ntients with STEMI, early intravenous metoprolol before percutan-\neous coronary intervention reduced the incidence of arrhythmias\nin the acute phase and was not associated with an increase in adverse\nevents.550 Prophylactic treatment with AADs has not proven bene-\nﬁcial, and may even be harmful.322 Correction of electrolyte imbal-\nances is strongly recommended.289\nManagement of sustained ventricular tachycardia and ventricular\nﬁbrillation in acute coronary syndrome\nElectrical cardioversion or deﬁbrillation is the intervention of\nchoice to acutely terminate VAs in ACS patients (Figure 14).205,339\nRecurrent sustained VT, especially when polymorphic, or recurrent\nVF can indicate incomplete reperfusion or recurrence of acute is-\nchaemia. In this case, immediate coronary angiography is indicated.3\nFor recurrent PVT degenerating into VF, beta-blockers are recom-\nmended.551,552 In addition, deep sedation may be helpful to reduce\nepisodes of VT or VF.553 Intravenous amiodarone should be consid-\nered to acutely suppress recurrent haemodynamically relevant VAs,\nalthough there is a paucity of controlled studies for amiodarone dur-\ning STEMI554 and the evidence in this setting is mainly extrapolated\nfrom studies of OHCA.555 If treatment with beta-blockers and amio-\ndarone is not effective, lidocaine may be considered.322 The use of\nother AADs in ACS is not recommended.549,556 In haemodynamic-\nally unstable patients with refractory VA, mechanical circulatory sup-\nport may be considered.336,557 For VA in the context of relative\nbradycardia or pause-related, pacing may be effective to prevent\nre-initiation.\nThe prognostic signiﬁcance of early ventricular arrhythmias\nEarly VAs are deﬁned as VT/VF occurring within 48 h after a\nSTEMI. In the contemporary percutaneous coronary intervention\n(PCI)-based revascularization era, almost all VA occur within the ﬁrst\n24 h.558 Early VA have been associated with an up to six-fold increase\nin in-hospital mortality, whereas long-term prognosis seems not to\nbe signiﬁcantly affected.543,559,560 In a prospective cohort study, pa-\ntients with VF during the acute STEMI phase had low and very similar\nincidence of late SCD as compared with VF-free patients during\n5-year observation.560 Of note, early monomorphic VT was asso-\nciated with signiﬁcantly higher incidence of adequate ICD interven-\ntions compared with early VF, and was an independent predictor\nof death during long-term follow-up.561 Thus, the prognostic signiﬁ-\ncance of VT and VF occurring in the acute phase of MI may be differ-\nent. The impact of VA occurring late after reperfusion (.48 h) on\nlate SCD is less clear.\nPodolecki et al.559 recently demonstrated that long-term all-cause\nmortality after STEMI was predicted by VA occurring late after re-\nperfusion (.48 h after reperfusion), while early reperfusion VAs\ndid not affect 5-year outcome. Further studies are required to clarify\n4044\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026",
      "keywords": [
        "known",
        "according",
        "recommended",
        "genetic",
        "angiography",
        "clinical",
        "coronary artery",
        "presentation",
        "risk",
        "diagnostic",
        "management",
        "arrhythmia",
        "syncope",
        "ventricular tachycardia",
        "lvef",
        "diastolic",
        "disease",
        "icd",
        "bradycardia",
        "evaluation",
        "tachycardia",
        "ablation",
        "likely",
        "scd",
        "may be considered",
        "stratification"
      ],
      "tables": []
    },
    {
      "number": "2",
      "title": "8. Special aspects in selected populations",
      "start_page": 91,
      "end_page": 92,
      "content": "8. Special aspects in selected\npopulations\n8.1. Pregnant patients and peri-partum\ncardiomyopathy\nPregnancy and the post-partum period contribute a signiﬁcant risk in\nwomen with arrhythmic heart disease and is covered in the 2018\nESC Guidelines for the management of cardiovascular diseases during\npregnancy.1076–1080 New-onset VT may present during pregnancy and\nrisk of recurrent VT is higher in patients with previous VT and SHD.1081\nPeri-partum cardiomyopathy (PPCM) should be ruled out in the case\nof new-onset VT during the last 6 weeks of pregnancy or in the early\npost-partum period.1082 A genetic contribution may be present in up\nto 20% of patients with PPCM (in particular titin-truncating var-\niants)1083 and future studies should reveal if genetic testing plays a\nrole in PPCM patients with a positive family history.\n8.1.1. Electrocardioversion and implantable\ncardioverter deﬁbrillator therapy in pregnancy\nCardioversion seems safe in all phases of pregnancy and case reports\nshow neither compromise in fetal blood ﬂow nor initiation of pre-\nterm labour.1084 Foetal heart rate should be routinely controlled\nafter cardioversion.1085 If an ICD is indicated, ICD implantation\nshould be performed beyond 8 weeks of gestation with radiation\nprotection by experienced operator teams.1086 Echocardiographic\nguidance or a 3D mapping system may be helpful in ICD implantation\nto avoid radiation.1087,1088 In pregnant patients with existing ICD,\nroutine ICD interrogation is recommended prior to delivery. In pa-\ntients with PPCM, thresholds for early ICD implantations are higher\nthan in other conditions because of a high rate of spontaneous recov-\nery after delivery.1089 WCD have been suggested to temporarily\nprevent SCD during the ﬁrst 3–6 months after diagnosis of PPCM\nwith LVEF ≤35%, while awaiting recovery.1090,1091\n8.1.2. Pharmacological treatment\nPharmacological treatment of arrhythmias and heart failure in pregnant\nwomen should follow treatment in non-pregnant patients with avoid-\nance of drugs contraindicated in pregnancy, such as ACE inhibitors,\nARB inhibitors/ARNI and renin inhibitors.1080,1082,1092,1093 The ﬁrst tri-\nmester is associated with the greatest teratogenic risk. Start of pharma-\ncological therapy is advised to begin at the latest possible point in the\npregnancy and with the lowest effective dose. Drug exposure in the se-\ncond and third trimestera may confer adverse effects on foetal growth\nand development as well as increasing the risk of pro-arrhythmia.\nIt is recommended to check drugs and safety data before initiation of\na new drug during pregnancy, according to the 2018 ESC Guidelines for\nthe management of cardiovascular diseases during pregnancy.1080 From\nthis list, AADs can be summarized as followed:\n• Well tolerated: sotalol, oral verapamil\n• Use only if potential beneﬁt outweighs potential risk: bi-\nsoprolol, carvedilol, digoxin, diltiazem (possible teratogenic ef-\nfects), disopyramide (uterine contractions), ﬂecainide, lidocaine,\nmetoprolol, nadolol, propranolol, verapamil IV, quinidine\n• Inadequate\ndata:\nIvabradine,\nmexiletine,\nproprafenone,\nvernakalant\n• Contraindicated: amiodarone, atenolol, dronedarone.\nIn LQTS (LQT2 in particular), risk of cardiac events increases sub-\nstantially in the post-partum period (up to one year after deliv-\nery).1094 Therefore, it is important to continue beta-blocker\ntherapy\nthroughout\npregnancy\nand\npost-partum.955,1094,1095\nContinuation of beta-blocker treatment is recommended in LQTS\nand CPVT1096 and should be considered in ARVC.1097–1099 No add-\nitional risk by pregnancy is known in women with BrS1100,1101\n(\nESC CardioMed chapter 53.6).1102\nIn patients with PPCM, use of bromocriptine as disease-speciﬁc\ntherapy in addition to standard heart failure therapy has shown\npromising results in two clinical trials.1103,1104\n8.1.3. Catheter ablation\nIn planned pregnancies, symptomatic tachyarrhythmia should be\ntreated by catheter ablation before pregnancy. If catheter ablation\nis indicated in a pregnant patient, one should avoid the procedure\nin the ﬁrst trimester, and electroanatomical mapping-guided proce-\ndures should be preferred.1105,1106\nRecommendation Table 47 — Recommendations for\nthe prevention of sudden cardiac death and manage-\nment of ventricular arrhythmia during pregnancy\nRecommendations\nClassa\nLevelb\nAcute management of VA\nDuring pregnancy, electrical cardioversion is\nrecommended for sustained VT.1084\nI\nC\nFor acute conversion of haemodynamically\ntolerated SMVT during pregnancy, a beta-blocker,\nsotalol, ﬂecainide, procainamide, or overdrive\nventricular pacing should be considered.\nIIa\nC\nLong-term management of VA\nIf ICD implantation is indicated during pregnancy,\nimplantation is recommended with optimal\nradiation protection.1087,1107\nI\nC\nContinuation of beta-blockers is recommended\nduring pregnancy and post-partum in women with\nLQTS or CPVT.955,1094–1096\nI\nC\nContinuation of beta-blockers should be\nconsidered during pregnancy in women with\nARVC.1097–1099\nIIa\nC\nOral metoprolol, propranolol, or verapamil\nshould be considered for long-term management\nof idiopathic sustained VT during pregnancy.\nIIa\nC\nCatheter ablation using non-ﬂuoroscopic mapping\nsystems should be considered, preferably after the\nﬁrst trimester, in women with highly symptomatic\nrecurrent SMVT refractory or who are intolerant\nto AADs.1105\nIIa\nC\n© ESC 2022\nAAD, anti-arrhythmic drug; ARVC, arrhythmogenic right ventricular cardiomyopathy;\nCPVT, catecholaminergic polymorphic ventricular tachycardia; ICD, implantable\ncardioverter deﬁbrillator; LQTS, long QT syndrome; SMVT, sustained monomorphic\nVT; VA, ventricular arrhythmia; VT, ventricular tachycardia.\naClass of recommendation.\nbLevel of evidence.\n4088\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026",
      "keywords": [
        "heart failure",
        "aspects",
        "recommended",
        "cardiomyopathy",
        "genetic",
        "family history",
        "selected",
        "special",
        "arrhythmia",
        "ventricular tachycardia",
        "lvef",
        "icd",
        "arb",
        "sudden cardiac death",
        "tachycardia",
        "populations",
        "should be considered",
        "ablation",
        "scd"
      ],
      "tables": [
        {
          "title": "4088 ESC Guidelines",
          "page_number": 91,
          "content": " | ",
          "bbox": [
            308.98903369903564,
            143.6029815673828,
            322.6054962158203,
            153.00099182128906
          ],
          "function_potential": "raw"
        },
        {
          "title": "4088 ESC Guidelines",
          "page_number": 91,
          "content": "Recommendations | Classa | Levelb | \nAcute management of VA |  |  | \nDuring pregnancy, electrical cardioversion is\nrecommended for sustained VT.1084 | I | C | \nFor acute conversion of haemodynamically\ntolerated SMVT during pregnancy, a beta-blocker,\nsotalol, flecainide, procainamide, or overdrive\nventricular pacing should be considered. | IIa | C | \nLong-term management of VA |  |  | \nIf ICD implantation is indicated during pregnancy,\nimplantation is recommended with optimal\nradiation protection.1087,1107 | I | C | \nContinuation of beta-blockers is recommended\nduring pregnancy and post-partum in women with\nLQTS or CPVT.955,1094–1096 | I | C | \nContinuation of beta-blockers should be\nconsidered during pregnancy in women with\nARVC.1097–1099 | IIa | C | \nOral metoprolol, propranolol, or verapamil\nshould be considered for long-term management\nof idiopathic sustained VT during pregnancy. | IIa | C | \nCatheter ablation using non-fluoroscopic mapping\nsystems should be considered, preferably after the\nfirst trimester, in women with highly symptomatic\nrecurrent SMVT refractory or who are intolerant\nto AADs.1105 | IIa | C | ",
          "bbox": [
            308.98903369903564,
            354.552001953125,
            547.2750150240385,
            691.5505065917969
          ],
          "function_potential": "raw"
        },
        {
          "title": "ESC Guidelines 4089",
          "page_number": 92,
          "content": "Recommendations |  | Classa | Levelb | \n | Prior to heart transplant |  |  | \nIn patients awaiting heart transplantation, ICD\nimplantation for primary prevention should be\nconsidered.1108,1111,1112 |  | IIa | C | \nIn patients awaiting heart transplantation, WCD\nmay be considered.1109,1113,1119 |  | IIb | C | \n | Post heart transplant |  |  | \nIn selected transplanted patients with cardiac\nallograft vasculopathy or treated rejection, ICD\nimplantation may be considered.1114,1116 |  | IIb | C | ",
          "bbox": [
            48.0,
            290.4129943847656,
            287.9996566772461,
            443.4119873046875
          ],
          "function_potential": "raw"
        },
        {
          "title": "ESC Guidelines 4089",
          "page_number": 92,
          "content": "Recommendations | Classa | Levelb\nIn athletes with positive medical history, abnormal\nphysical examination, or ECG alterations, further\ninvestigations including echocardiography and/or\nCMR to confirm (or exclude) an underlying\ndisease are recommended.1123,1133,1135 | I | C\nIt is recommended that athletes diagnosed with a\ncardiovascular disease associated with SCD are\nmanaged according to current guidelines for\nsports eligibility. | I | C\nIt is recommended that staff at sporting facilities\nare trained in CPR and in the use of AED.93,1137 | I | C\nPre-participation cardiovascular evaluation of\ncompetitive athletes should be\nconsidered.46,1122,1123,1127 | IIa | C\nIt should be considered that cardiovascular\nevaluation of young (,35 years) competitive\nathletes includes history, physical examination,\nand 12-lead ECG.1123,1126,1130,1140 | IIa | C\nThe cardiovascular risk of middle-aged and elderly\nindividuals should be evaluated before engaging in\nstrenuous sports through established scores such\nas the SCORE2 risk chart.46,1141,1142 | IIa | C",
          "bbox": [
            312.27542550223217,
            392.17332356770834,
            552.2750244140625,
            685.5506795247396
          ],
          "function_potential": "auto_generate"
        }
      ]
    },
    {
      "number": "2",
      "title": "9. Key messages",
      "start_page": 93,
      "end_page": 94,
      "content": "8.4. Wolff–Parkinson–White syndrome\nIn patients with Wolff–Parkinson–White (WPW) syndrome, the\nmost common arrhythmia is AV re-entry tachycardia (AVRT;\n80%), followed by AF (20–30%). SCD secondary to pre-excited AF\nresulting in VF is the most feared manifestation of WPW syndrome.\nThe risk of CA/VF in untreated WPW patients has been estimated at\n0.9–2.4 per 1000 person-year.1143,1144 The management of WPW\npatients has recently been reviewed in the 2019 ESC Guidelines\nfor the management of patients with SVT302 and updated with a par-\nticular focus on athletes in 2020.1145 In patients with ventricular\npre-excitation and symptomatic AVRT, catheter ablation is recom-\nmended (class I). In asymptomatic patients with ventricular\npre-excitation, both invasive (class IIa) and non-invasive (class IIb)\nassessment are options for risk stratiﬁcation for SCD. While cath-\neter ablation is recommended for asymptomatic accessory pathways\nwith high-risk features (class I), clinical follow-up (class IIa), or cath-\neter ablations (class IIb) are options based on informed patient\nchoice. This decision should take into account the location of the ac-\ncessory pathway, the local ablation experience and the fact that\nsymptomatic arrhythmias will frequently develop during follow-\nup.1146 For the paediatric population, SVT due to WPW can usually\nbe managed pharmacologically, and accessory pathways often lose\nantegrade conduction in the ﬁrst years of life.1147 In children with\nasymptomatic accessory pathways, risk stratiﬁcation is not recom-\nmend before the age of 8 years.1148\n8.5. Prevention of sudden cardiac death\nin the elderly\nAge is a strong risk factor for death. In several studies, advanced\nage was one of the factors associated with a reduced expected\nbeneﬁt from ICD treatment. In patients with ischaemic cardiomy-\nopathy enrolled in MADIT-II trial, a risk scheme composed of 5\nclinical factors including age .70 years was predictive of the ab-\nsence of long-term beneﬁt conferred by the ICD.1149 In a recent\nanalysis of ICD patients enrolled in four MADIT studies, age ,75\nyears was a predictor of VT/VF whereas age ≥75 years was a pre-\ndictor of non-arrhythmic mortality.365 Consistently, in the recent\nrandomized DANISH trial in patients with non-ischaemic heart\nfailure, the association between the ICD and survival decreased\nlinearly with increasing age, while an age cut-off at ≤70 years\nyielded the highest survival.647 Contemporary non-randomized\ndata corroborate these ﬁndings. In the EU-CERT-ICD prospect-\nive cohort study in patients with CAD or cardiomyopathies\nwith indication for primary prevention ICD implantation, no\nICD beneﬁt was observed in patients aged ≥75 years.357 In con-\ntrast, there was a signiﬁcant survival beneﬁt in patients aged\n,75 years. Further retrospective data are in line with this\nobservation.1150\nBiological age may vary in part according to comorbidities.\nIndeed, comorbidities signiﬁcantly inﬂuence survival of ICD recipi-\nents and a high comorbidity index is associated with less survival\ngain in primary or secondary prevention ICD patients.1149,1151\nTherefore, a simple age cut-off cannot guide the decision on ICD\nimplantation adequately and the ICD indication in elderly patients\nshould be based on a personalized assessment considering the\noverall condition and comorbidities.\n9. Key messages\n9.1. General aspects\n• Increased availability of public access deﬁbrillators and community\ntraining in basic life support are key elements to improve survival of\nout-of-hospital cardiac arrest victims.\n• Risk calculators for SCD and VA implemented in clinical practice\nneed to meet agreed high standards for the development, external\nvalidation, and reporting of prediction models.\n• Patients with genetic cardiomyopathies and arrhythmia syndromes\nrequire genetic testing as a routine part of their care.\n• Genetic testing and counselling require access to an expert multi-\ndisciplinary team.\n• A systematic workup of cardiac arrest survivors requires a multi-\nmodal approach.\n• A comprehensive autopsy is recommended in all cases of sudden\ndeath under 50 years and is desirable in all sudden death victims.\n• Clinical and genetic evaluation of SADS decedents and their fam-\nilies leads to a diagnosis of genetic heart disease in a substantial\nproportion of families.\n• An electrical storm refractory to drug treatment requires the avail-\nability of advanced catheter ablation techniques, mechanical circu-\nlatory support, and autonomic modulation.\n• When considering ICD therapy beneﬁt, competing risk factors for\nnon-arrhythmic death and the patient’s wishes and quality of life\nneed to be taken into account.\n9.2. Structural heart disease\n• Catheter ablation is recommended in CAD patients with recurrent\nsymptomatic SMVT despite chronic amiodarone therapy.\n• Catheter ablation is the ﬁrst-line treatment for PVC-induced\ncardiomyopathy.\n• In HNDCM/DCM patients, indication for primary prevention\nICD implantation should not be restricted to an LVEF ≤35%.\nAdditional risk factors (e.g. CMR and genetics) are important to\nconsider.\n• Patients with an LMNA mutation require speciﬁc risk stratiﬁcation\nfor SCD.\n• ARVC patients have a high rate of appropriate ICD interventions\nwhich may not necessarily be classiﬁed as lifesaving.\nRecommendation Table 50 — Recommendations for\nimplantable cardioverter deﬁbrillator implantation in\nthe elderly\nRecommendations\nClassa\nLevelb\nIn elderly patients in whom a beneﬁt from the\ndeﬁbrillator is not expected due to the patient’s\nage and comorbidities, omission of ICD\nimplantation for primary prevention may be\nconsidered.647,1150,1152\nIIb\nB\n© ESC 2022\nICD, implantable cardioverter deﬁbrillator.\naClass of recommendation.\nbLevel of evidence.\n4090\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026",
      "keywords": [
        "indication",
        "lvef",
        "scd",
        "risk factor",
        "messages",
        "icd",
        "sudden cardiac death",
        "ablation",
        "age",
        "recommended",
        "cardiomyopathy",
        "genetic",
        "secondary prevention",
        "elderly",
        "tachycardia",
        "primary prevention",
        "arrhythmia",
        "class i"
      ],
      "tables": [
        {
          "title": "4090 ESC Guidelines",
          "page_number": 93,
          "content": "Recommendations | Classa | Levelb\nIn elderly patients in whom a benefit from the\ndefibrillator is not expected due to the patient’s\nage and comorbidities, omission of ICD\nimplantation for primary prevention may be\nconsidered.647,1150,1152 | IIb | B",
          "bbox": [
            307.2750015258789,
            94.0009765625,
            547.2749633789062,
            176.99999237060547
          ],
          "function_potential": "raw"
        }
      ]
    },
    {
      "number": "2",
      "title": "10. Gaps in evidence",
      "start_page": 94,
      "end_page": 95,
      "content": "• A validated risk calculator (HCM Risk-Kids score) is useful to assess\nthe risk for SCD in HCM patients younger than 16 years.\n• Myotonic dystrophy patients with palpitations suspected of ar-\nrhythmia, syncope or aborted sudden death need to be evaluated\nby invasive electrophysiological study.\n• In patients with repaired tetralogy of Fallot and monomorphic VT,\ncatheter ablation is the preferred treatment.\n9.3. Primary electrical disease\n• Nadolol or propranolol are the preferred beta-blockers in LQTS\nand CPVT patients.\n• In asymptomatic LQTS patients the arrhythmic risk (1-2-3 Risk cal-\nculator) may be useful to calculate.\n• A type 1 Brugada ECG pattern provoked by sodium channel\nblocker test in the absence of other ﬁndings does not diagnose\nthe BrS.\n• SCD risk stratiﬁcation in asymptomatic BrS patients with a spon-\ntaneous type 1 pattern remains controversial.\n• Routine catheter ablation is not recommended in asymptomatic\nBrS patients.\n• The diagnosis of idiopathic VF requires exclusion of an\nunderlying\nstructural,\nchannelopathic,\nor\nmetabolic\naetiology.\n• ERP can be a benign ﬁnding and is distinct from ERS.\n• Left cardiac denervation plays an important role in the manage-\nment of CPVT and LQTS patients.\n10. Gaps in evidence\n10.1. General aspects\n• Accurate screening tests to detect heart conditions associated\nwith SCD in asymptomatic individuals in the general population\nare required.\n• In patients with SHD, the optimal time interval between repeated\nnon-invasive and invasive prognostic tests, in case of a negative\ntest, is unknown.\n• Improved assessment of genetic variants of uncertain signiﬁcance\nand likely pathogenic variants is needed.\n• The utility of polygenic risk scores in patients at risk of SCD re-\nquires investigation.\n10.2. Structural heart disease—general\n• The long-term safety and efﬁcacy of S-ICDs is unknown.\n• The role of primary preventive ICD therapy in patients with SHD\nand mildly reduced or preserved ejection fraction has not been\nstudied systematically.\n• The optimal techniques to undertake VT substrate mapping and\nablation in SHD remain to be determined.\n• The role of ICD implantation in end-stage heart failure patients\nsupported by current-generation, continuous-ﬂow LVADs is\nunclear.\n10.3. Idiopathic premature ventricular\ncomplexes/ventricular tachycardia\n• The beneﬁcial role of catheter ablation or anti-arrhythmic drug\ntreatment in patients with asymptomatic, frequent PVCs and pre-\nserved cardiac function needs to be determined.\n10.4. Coronary artery disease\n• It is unknown which patients with chronic CAD and severely im-\npaired LVEF are at low risk for SCD.\n• The role of LGE-CMR for risk stratiﬁcation for SCD in chronic\nCAD is unclear.\n• RCTs are needed to determine the role of ICDs after successful\nVT ablation in chronic CAD with mildly reduced or preserved\nLVEF.\n10.5. Cardiomyopathies\n• It is unknown if PVC-induced cardiomyopathy is a diagnosis on its\nown or if an underlying predisposition is needed.\n• The predictive value of LGE-CMR ﬁndings (e.g. pattern and\namount of LGE) for individual risk stratiﬁcation for SCD in patients\nwith cardiac sarcoidosis, HCM, and DCM/HNDC is unclear.\n• Studies are needed to determine the role of PES in patients with\ncardiac sarcoidosis and DCM/HNDC who have a mildly reduced\nor preserved cardiac function and LGE on CMR.\n• Prospective data on the association between intensity and dur-\nation of exercise and manifestation and severity of the phenotype\nin healthy ARVC mutation carriers are lacking.\n• The beneﬁcial role of ICDs after successful ablation in ARVC pa-\ntients who present with haemodynamically tolerated VT needs\nto be studied.\n• Data on clinical outcome, predictors for arrhythmic events, and in-\ndication for treatment, including ICD therapy, in patients with bi-\nventricular and left-dominant arrhythmogenic cardiomyopathy are\nrequired.\n10.6. Valvular heart disease\n• There is a lack of knowledge to identify patients with MVP at risk\nfor VA and SCD.\n10.7. Congenital heart disease\n• There is a lack of knowledge regarding the absolute risk for VA and\nSCD in CHD that have undergone repair with contemporary sur-\ngical approaches.\n10.8. Primary electrical disease\n• Robust evidence is required to support the prophylactic use of the\nICD on top of medical therapy with beta-blockers and gene-\nspeciﬁc therapy in LQTS patients.\n• More data are required to determine the role of LCSD and ICD in\nhigh-risk LQTS patients who do not tolerate medical therapy.\nESC Guidelines\n4091\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026",
      "keywords": [
        "heart failure",
        "lvef",
        "evidence",
        "icd",
        "ablation",
        "recommended",
        "cardiomyopathy",
        "genetic",
        "exercise",
        "ecg",
        "ejection fraction",
        "risk calculator",
        "tachycardia",
        "coronary artery",
        "scd",
        "syncope",
        "gaps",
        "ventricular tachycardia"
      ],
      "tables": [
        {
          "title": "4092 ESC Guidelines",
          "page_number": 95,
          "content": "Recommendations |  | Classa | Levelb | \n | Recommendations for public basic life support and access to automated external defibrillator |  |  | \nIt is recommended that public access defibrillation be available at sites where cardiac arrest is more likely to occur.c |  | I | B | \nPrompt CPR by bystanders is recommended at OHCA. |  | I | B | \nIt is recommended to promote community training in basic life support to increase bystander CPR rate and AED use. |  | I | B | \n | Recommendations for genetic testing |  |  | \nGenetic testing is recommended when a condition is diagnosed in a living or deceased individual with a likely genetic basis and a risk of VA\nand SCD. |  | I | B | \nWhen a putative causative variant is first identified, evaluation for pathogenicity is recommended using an internationally accepted\nframework. |  | I | C | \nWhen a Class IV or Class V variant has been identified in a living or deceased individual with a condition that carries a risk of VA and SCD,\ngenetic testing of first-degree and symptomatic relatives and obligate carriers is recommended. |  | I | C | \nIt is recommended that genetic testing and counselling on its potential consequences should be undertaken by an expert\nmultidisciplinary team. |  | I | C | \nIt is recommended that Class III variants (of uncertain significance) and Class IV variants should be evaluated for segregation in families\nwhere possible, and the variant re-evaluated periodically. |  | I | C | \nIt is not recommended to undertake genetic testing in index patients with insufficient evidence of a genetic disease. |  | III | C | \n | Recommendations for evaluation of patients presenting with newly documented ventricular arrhythmia |  |  | \nIn patients with newly documented VA (frequent PVCs, NSVT, SMVT), a baseline 12-lead ECG, recording of the VA on 12-lead ECG,\nwhenever possible, and an echocardiogram are recommended as first-line evaluation. |  | I | C | \n | Recommendations for evaluation of sudden cardiac arrest survivors |  |  | \nThe investigation of a SCA survivor without obvious extra-cardiac cause is recommended to be overseen by a multidisciplinary team. |  | I | B | \nIn electrically unstable patients after SCA, with suspicion of ongoing myocardial ischaemia, a coronary angiogram is indicated. |  | I | C | \nIn SCA survivors, collection of blood samples at presentation is recommended for potential toxicology and genetic testing. |  | I | B | \nRetrieval of recordings from CIEDs and wearable monitors is recommended for all SCA survivors. |  | I | B | \nIn SCA survivors, repeated 12-lead ECGs during stable rhythm (including high precordial lead ECG) as well as continuous cardiac\nmonitoring are recommended. |  | I | B | \nEchocardiography is recommended for evaluation of cardiac structure and function in all SCA survivors. |  | I | C | \nCoronary imaging and CMR with LGE are recommended for evaluation of cardiac structure and function in all SCA survivors without a\nclear underlying cause. |  | I | B | \nSodium channel blocker test and exercise testing is recommended in SCA survivors without a clear underlying cause. |  | I | B | ",
          "bbox": [
            43.0,
            174.5,
            547.2750004359654,
            711.1517278497869
          ],
          "function_potential": "auto_generate"
        }
      ]
    },
    {
      "number": "2",
      "title": "11. ‘What to do’ and ‘what not to do’ messages from the Guidelines",
      "start_page": 95,
      "end_page": 103,
      "content": "• Improved diagnostic and risk stratiﬁcation tools for asymptomatic\nBrugada patients and suspected early repolarization syndrome are\nneeded.\n• The role of endo-epicardial mapping to identify localized structural\nalterations potentially related to IVF and targeted catheter ablation\nneeds to be further studied.\n• Long-term data are required on the efﬁcacy of the ICD vs. no ICD\nin CPVT survivors of cardiac arrest.\n• It is poorly understood why women are at low risk of\nsport-related SCD.\n11. ‘What to do’ and ‘what not to do’ messages from the Guidelines\nRecommendations\nClassa\nLevelb\nRecommendations for public basic life support and access to automated external deﬁbrillator\nIt is recommended that public access deﬁbrillation be available at sites where cardiac arrest is more likely to occur.c\nI\nB\nPrompt CPR by bystanders is recommended at OHCA.\nI\nB\nIt is recommended to promote community training in basic life support to increase bystander CPR rate and AED use.\nI\nB\nRecommendations for genetic testing\nGenetic testing is recommended when a condition is diagnosed in a living or deceased individual with a likely genetic basis and a risk of VA\nand SCD.\nI\nB\nWhen a putative causative variant is ﬁrst identiﬁed, evaluation for pathogenicity is recommended using an internationally accepted\nframework.\nI\nC\nWhen a Class IV or Class V variant has been identiﬁed in a living or deceased individual with a condition that carries a risk of VA and SCD,\ngenetic testing of ﬁrst-degree and symptomatic relatives and obligate carriers is recommended.\nI\nC\nIt is recommended that genetic testing and counselling on its potential consequences should be undertaken by an expert\nmultidisciplinary team.\nI\nC\nIt is recommended that Class III variants (of uncertain signiﬁcance) and Class IV variants should be evaluated for segregation in families\nwhere possible, and the variant re-evaluated periodically.\nI\nC\nIt is not recommended to undertake genetic testing in index patients with insufﬁcient evidence of a genetic disease.\nIII\nC\nRecommendations for evaluation of patients presenting with newly documented ventricular arrhythmia\nIn patients with newly documented VA (frequent PVCs, NSVT, SMVT), a baseline 12-lead ECG, recording of the VA on 12-lead ECG,\nwhenever possible, and an echocardiogram are recommended as ﬁrst-line evaluation.\nI\nC\nRecommendations for evaluation of sudden cardiac arrest survivors\nThe investigation of a SCA survivor without obvious extra-cardiac cause is recommended to be overseen by a multidisciplinary team.\nI\nB\nIn electrically unstable patients after SCA, with suspicion of ongoing myocardial ischaemia, a coronary angiogram is indicated.\nI\nC\nIn SCA survivors, collection of blood samples at presentation is recommended for potential toxicology and genetic testing.\nI\nB\nRetrieval of recordings from CIEDs and wearable monitors is recommended for all SCA survivors.\nI\nB\nIn SCA survivors, repeated 12-lead ECGs during stable rhythm (including high precordial lead ECG) as well as continuous cardiac\nmonitoring are recommended.\nI\nB\nEchocardiography is recommended for evaluation of cardiac structure and function in all SCA survivors.\nI\nC\nCoronary imaging and CMR with LGE are recommended for evaluation of cardiac structure and function in all SCA survivors without a\nclear underlying cause.\nI\nB\nSodium channel blocker test and exercise testing is recommended in SCA survivors without a clear underlying cause.\nI\nB\nContinued\n4092\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026\n\n\nRecommendations for evaluation of sudden death victims\nInvestigation of unexpected SD, especially in case of suspicion of inherited disease, should be made a public health priority.\nI\nB\nIn cases of SD, it is recommended to collect a detailed description of circumstances of death, symptoms prior to death, the family\nhistory, and to review prior medical ﬁles.\nI\nB\nA comprehensive autopsy is recommended, ideally, in all cases of unexpected SD, and always in those under 50 years of age.\nI\nB\nIn cases of SCD, it is recommended to retain samples suitable for DNA extraction and consult a cardiac pathologist when an inherited\ncause is suspected or the cause of death unexplained.\nI\nB\nToxicology screens are recommended in SD cases with uncertain cause of death.\nI\nB\nFor SCD where the cause is known or suspected to be heritable, genetic testing targeted to the cause is recommended.\nI\nB\nFollowing SADS, post-mortem genetic testing targeted to primary electrical disease is recommended when the decedent is young (,50\nyears of age) and/or the circumstances and/or family history support a primary electrical disease.\nI\nB\nWhen an autopsy diagnoses possible heritable cardiac disease, it is recommended to refer ﬁrst-degree relatives for cardiac assessment in\na specialized clinic.\nI\nB\nIn non-autopsied cases of SD where inherited cardiac disease is suspected, it is recommended to refer ﬁrst-degree relatives for cardiac\nassessment in a specialized clinic.\nI\nB\nRecommendations for evaluation of relatives of sudden arrhythmic death syndrome decedents\nFollowing SADS, hypothesis-free post-mortem genetic testing using exome or genome sequencing is not recommended.\nIII\nB\nFamilial evaluation of SADS decedents is recommended:\n• for ﬁrst-degree relatives\n• for relatives who must carry a mutation based on analysis of the family history\n• for relatives with suspicious symptoms\n• when the decedent’s age is ,50 years or if there are other circumstantial data or family history to suggest heritable disease.\nI\nB\nFamilial evaluation of SADS decedents is recommended to include genetic testing when post-mortem genetic testing in a SADS\ndecedent detects a pathogenic mutation.\nI\nB\nBaseline familial evaluation of SADS decedents is recommended to include taking a medical history and performing physical examination,\nstandard- and high-precordial lead ECG, echocardiography, and exercise testing.\nI\nB\nIn SADS families without a diagnosis after clinical evaluation, follow-up is recommended for children of decedents until they reach\nadulthood.\nI\nC\nIn SADS families without a diagnosis after clinical evaluation, follow-up is not recommended for asymptomatic adults who can be\ndischarged with advice to return if they develop symptoms or if the family history changes.\nIII\nC\nRecommendations for treatment of reversible conditions\nWithdrawal of offending agents is recommended whenever drug-induced VA are suspected.\nI\nB\nInvestigation for reversible causes (e.g. electrolyte imbalances, ischaemia, hypoxaemia, fever)d is recommended in patients with VA.\nI\nC\nRecommendations for the acute treatment of sustained ventricular tachycardia and electrical storm\nDC cardioversion is recommended as the ﬁrst-line treatment for patients with haemodynamically not-tolerated SMVT.\nI\nB\nDC cardioversion is recommended as the ﬁrst-line treatment for patients presenting with tolerated SMVT provided that the\nanaesthetic/sedation risk is low.\nI\nC\nIn patients presenting with a haemodynamically tolerated idiopathic VT, treatment with intravenous beta-blocker (RVOT VT) or\nverapamil (fascicular VT) is recommended.\nI\nC\nIntravenous verapamil is not recommended in broad QRS complex tachycardia of unknown mechanism.\nIII\nB\nMild to moderate sedation is recommended in patients with electrical storm to alleviate psychological distress and reduce sympathetic\ntone.\nI\nC\nAntiarrhythmic therapy with beta-blockers (non-selective preferred) in combination with intravenous amiodarone is recommended in\npatients with SHD and electrical storm unless contraindicated.\nI\nB\nContinued\nESC Guidelines\n4093\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026\n\n\nIntravenous magnesium with supplementation of potassium is recommended in patients with TdP.\nI\nC\nIsoproterenol or transvenous pacing to increase heart rate is recommended in patients with acquired LQT syndrome and recurrent\nTdP despite correction of precipitating conditions and magnesium.\nI\nC\nCatheter ablation is recommended in patients presenting with incessant VT or electrical storm due to SMVT refractory to AADs.\nI\nB\nRecommendations for treatment with heart failure medication\nOptimal medical treatment including ACE-I/ARB/ARNIs, MRAs, beta-blockers, and SGLT2 inhibitors is indicated in all heart failure\npatients with reduced EF.\nI\nA\nRecommendations for implantable cardioverter deﬁbrillation implantation (general aspects)\nImplantation of a cardioverter deﬁbrillator is only recommended in patients who have an expectation of good quality survival .1 year.\nI\nC\nIt is not recommended to implant an ICD in patients with incessant VAs until the VA is controlled.\nIII\nC\nRecommendations for secondary prevention of sudden cardiac death\nICD implantation is recommended in patients with documented VF or haemodynamically not-tolerated VT in the absence of reversible\ncauses.\nI\nA\nRecommendations for adding cardiac resynchronization therapy to implantable cardioverter deﬁbrillator\nWhen an ICD is indicated, it is recommended to evaluate whether the patient could beneﬁt from CRT-deﬁbrillator.\nI\nC\nRecommendations for optimization of device programming\nOptimization of ICD programming is indicated to avoid inappropriate and unnecessary therapies and to reduce mortality.\nI\nA\nIn single- or dual-chamber ICD patients without bradycardia pacing indications, it is recommended to minimize ventricular pacing.\nI\nA\nProgramming of prolonged detection settings is indicated (duration criteria of at least 6–12 s or 30 intervals).\nI\nA\nIt is recommended to program the slowest tachycardia therapy zone limit ≥188 b.p.m. in primary prevention ICD patients.\nI\nA\nIn patients with SHD, programming of at least one ATP therapy is recommended in all tachyarrhythmias zones.\nI\nA\nIt is recommended to program algorithms for SVT vs. VT discrimination for tachycardias with rates up to 230 b.p.m.\nI\nB\nIt is recommended to activate lead failure alerts.\nI\nB\nRemote monitoring is recommended to reduce the incidence of inappropriate shocks.\nI\nB\nProgramming of burst ATP as a ﬁrst attempt is recommended over ramp ATP.\nI\nB\nFor S-ICDs, a dual detection zone conﬁguration is recommended with activation of discrimination algorithm in the lower conditional\nshock zone\nI\nB\nRecommendations for concomitant treatment to avoid inappropriate implantable cardioverter deﬁbrillator therapy\nCatheter ablation is recommended for ICD patients with recurrent SVT resulting in inappropriate ICD therapies.\nI\nC\nPharmacological treatment or catheter ablation is recommended in patients with AF-related inappropriate ICD therapies despite\noptimal ICD programming.\nI\nC\nRecommendation for psychosocial management after implantable cardioverter deﬁbrillator implantation\nAssessment of psychological status and treatment of distress is recommended in ICD patients.\nI\nC\nCommunication between patient and physician/healthcare professional is recommended to address ICD-related concerns and to\ndiscuss quality-of-life issues before ICD implantation and during disease progression.\nI\nC\nContinued\n4094\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026\n\n\nRecommendations for prevention of implantable cardioverter deﬁbrillator complications\nSingle-chamber ICD is recommended over dual-chamber ICD in primary prevention patients without current or expected indication\nfor atrial or AV sequential pacing due to a lower risk of device-related complications.\nI\nA\nRecommendations for end-of-life issues in implantable cardioverter deﬁbrillator carriers\nInformed discussion with patient and family about ICD deactivation options and shared decision-making is indicated prior to\nimplantation and in case of signiﬁcant health status deterioration.\nI\nC\nRecommendations for treatment of ventricular arrhythmia in acute coronary syndrome and vasospasm\nIntravenous beta-blocker treatment is indicated for patients with recurrent PVT/VF during STEMI unless contraindicated.\nI\nB\nProphylactic treatment with AADs (other than beta-blockers) is not recommended in ACS.\nIII\nB\nRecommendations for risk stratiﬁcation and treatment of ventricular arrhythmia early after myocardial infarction\nEarly (before discharge) assessment of LVEF is recommended in all patients with acute MI.\nI\nB\nIn patients with pre-discharge LVEF ≤40%, re-evaluation of LVEF 6–12 weeks after MI is recommended to assess the potential need for\nprimary prevention ICD implantation.\nI\nC\nRecommendations for risk stratiﬁcation, sudden cardiac death prevention, and treatment of ventricular arrhythmia in chronic\ncoronary artery disease\nIn patients with syncope and previous STEMI, PES is indicated when syncope remains unexplained after non-invasive evaluation.\nI\nC\nICD therapy is recommended in patients with CAD, symptomatic heart failure (NYHA class II–III), and LVEF ≤35% despite ≥3 months\nof OMT.\nI\nA\nIn patients with CAD, prophylactic treatment with AADs other than beta-blockers is not recommended.\nIII\nA\nICD implantation is recommended in patients without ongoing ischaemia with documented VF or haemodynamically not-tolerated VT\noccurring later than 48 h after MI.\nI\nA\nIn patients with CAD and recurrent, symptomatic SMVT or ICD shocks for SMVT despite chronic amiodarone therapy, catheter\nablation is recommended in preference to escalating AAD therapy.\nI\nB\nRecommendations for sudden cardiac death prevention in patients with coronary anomalies\nCardiac stress imaging during physical exercise is recommended in addition to cardiopulmonary exercise test in patients with anomalous\naortic origin of a coronary artery with an interarterial course to conﬁrm/exclude myocardial ischaemia.\nI\nC\nCardiac stress imaging during physical exercise is recommended in addition to cardiopulmonary exercise test after surgery in patients\nwith anomalous aortic origin of a coronary artery with a history of aborted CA.\nI\nC\nSurgery is recommended in patients with anomalous aortic origin of a coronary artery with CA, syncope suspected to be due to VAs or\nangina when other causes have been excluded.\nI\nC\nRecommendations for the management of patients with idiopathic premature ventricular complexes/ventricular tachycardia\nRegular assessment of ventricular function of patients with PVC burden .10% and normal ventricular function is indicated.\nI\nC\nCatheter ablation as ﬁrst-line treatment is recommended for symptomatic idiopathic VT/PVCs from the RVOT or the left fascicles.e\nI\nB\nBeta-blockers or non-dihydropyridine CCB are indicated in symptomatic patients with idiopathic VT/PVCs from an origin other than\nthe RVOT or the left fascicles.\nI\nC\nCatheter ablation is not recommended in children ,5 years of age or ,10 kg weight except when previous medical therapy fails or\nwhen VT is not haemodynamically tolerated.\nIII\nC\nAmiodarone as a ﬁrst-line treatment is not recommended in patients with idiopathic VTs/PVCs.\nIII\nC\nVerapamil is not recommended in children ,1 year of age with PVC/VT, particularly if they have signs of heart failure or concurrent use\nof other AADs.\nIII\nC\nRecommendations for the management of patients with premature ventricular complex-induced or aggravated cardiomyopathy\nIn patients with a cardiomyopathy suspected to be caused by frequent and predominately monomorphic PVCs, catheter ablation is\nrecommended.\nI\nC\nContinued\nESC Guidelines\n4095\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026\n\n\nRecommendations for risk stratiﬁcation, sudden cardiac death prevention, and treatment of ventricular arrhythmia in dilated\ncardiomyopathy/hypokinetic non-dilated cardiomyopathy\nGenetic testing (including at least LMNA, PLN, RBM20, and FLNC genes) is recommended in patients with DCM/HNDCM and AV\nconduction delay at ,50 years, or who have a family history of DCM/HNDCM or SCD in a ﬁrst-degree relative (at age ,50 years).\nI\nB\nParticipation in high-intensity exercise including competitive sports is not recommended for individuals with DCM/HNDCM and a\nLMNA mutation.\nIII\nC\nICD implantation is recommended in patients with DCM/HNDCM, who survive SCA due to VT/VF or experience haemodynamically\nnot-tolerated SMVT.\nI\nB\nIn a ﬁrst-degree relative of a DCM/HNDCM patient, an ECG, and an echocardiogram are recommended if:\n• the index patient was diagnosed ,50 years of age or has clinical features suggestive of an inherited cause, or\n• there is family history of DCM/HNDCM, or premature unexpected SD.\nI\nC\nRecommendations for diagnostic, risk stratiﬁcation, sudden cardiac death prevention and treatment of ventricular arrhythmia in\narrhythmogenic right ventricular cardiomyopathy\nIn patients with suspected ARVC, CMR is recommended.\nI\nB\nIn patients with a suspected or deﬁnite diagnosis of ARVC, genetic counselling and testing are recommended.\nI\nB\nAvoidance of high-intensity exercise is recommended in patients with a deﬁnite diagnosis of ARVC.\nI\nB\nICD implantation is recommended in ARVC patients with haemodynamically not-tolerated VT or VF.\nI\nC\nIn patients with ARVC and non-sustained or sustained VAs, beta-blocker therapy is recommended.\nI\nC\nIn a ﬁrst-degree relative of a patient with ARVC, ECG, and echocardiogram are recommended.\nI\nC\nRecommendations for risk stratiﬁcation, sudden cardiac death prevention, and treatment of ventricular arrhythmia in hypertrophic\ncardiomyopathy\nCMR with LGE is recommended in HCM patients for diagnostic work-up.\nI\nB\nGenetic counselling and testing are recommended in HCM patients.\nI\nB\nIt is recommended that the 5-year risk of SCD is assessed at ﬁrst evaluation and at 1–3-year intervals or when there is a change in clinical\nstatus.\nI\nC\nICD implantation is recommended in HCM patients with haemodynamically not-tolerated VT or VF.\nI\nB\nIn a ﬁrst-degree relative of a patient with HCM, ECG, and echocardiogram are recommended.\nI\nC\nRecommendations for risk stratiﬁcation, sudden cardiac death prevention, and treatment of ventricular arrhythmia in\nneuromuscular diseases\nAnnual follow-up with at least a 12-lead ECG is recommended in patients with muscular dystrophies, even in the concealed phase of the\ndisease.\nI\nC\nIt is recommended that patients with neuromuscular disorders who have VAs or ventricular dysfunction are treated in the same way for\narrhythmia as patients without neuromuscular disorders.\nI\nC\nInvasive electrophysiological evaluation is recommended in patients with myotonic dystrophy and palpitations or syncope suggestive of\nVA, VT, or surviving a CA.\nI\nC\nICD implantation is recommended in patients with myotonic dystrophy and SMVT or aborted CA not caused by BBR-VT.\nI\nC\nIn myotonic dystrophy patients, serial electrophysiological evaluation of AV conduction and arrhythmia induction is not recommended\nwithout arrhythmia suspicion or progression of ECG conduction disorders.\nIII\nC\nIn symptomatic patients with BBR-VT, catheter ablation is recommended.\nI\nC\nIn patients with myotonic dystrophy undergoing ablation for BBR-VT, pacemaker/ICD implantation is recommended.\nI\nC\nContinued\n4096\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026\n\n\nRecommendations for sudden cardiac death prevention, and treatment of ventricular arrhythmia in myocarditis\nIn conﬁrmed or clinically suspected acute myocarditis, it is recommended that patients who present with life-threatening VA are\nreferred to a specialized centre.\nI\nC\nIn patients with haemodynamically not-tolerated SMVT occurring in the chronic phase of myocarditis, an ICD implantation is\nrecommended.\nI\nC\nRecommendations for risk stratiﬁcation, sudden cardiac death prevention, and treatment of ventricular arrhythmia in cardiac\nsarcoidosis\nICD implantation is recommended in patients with cardiac sarcoidosis who have an LVEF ≤35%.\nI\nB\nICD implantation is recommended in patients with cardiac sarcoidosis who (a) have documented sustained VT, or (2) aborted CA.\nI\nB\nRecommendations for sudden cardiac death prevention, and treatment of ventricular arrhythmia in valvular heart disease\nPES with standby catheter ablation is recommended in patients with aortic valve disease and SMVT to identify and ablate BBR-VT,\nespecially if it occurs following a valve intervention.\nI\nC\nIn patients with valvular heart disease and persistent LV dysfunction after surgical correction (if possible) it is recommended that ICD\nimplantation for primary prevention follows DCM/HNDCM recommendations.\nI\nC\nRecommendations for sudden cardiac death prevention, and treatment of ventricular arrhythmia in congenital heart disease\nIn adults with CHD with biventricular physiology and a left systemic ventricle presenting with symptomatic heart failure (NYHA II/III)\nand EF ≤35% despite ≥3 months of OMT, ICD implantation is indicated.\nI\nC\nIn patients with CHD presenting with sustained VAs, evaluation for residual or new anatomical abnormalities is recommended.\nI\nB\nIn patients with CHD with not-tolerated VT/aborted CA due to VF, ICD implantation is indicated after exclusion of reversible causes.\nI\nC\nIn patients with repaired TOF who present with SMVT or recurrent, symptomatic appropriate ICD therapy for SMVT, catheter ablation\nperformed in specialized centres is recommended.\nI\nC\nRecommendations for management of patients with idiopathic ventricular ﬁbrillation\nIt is recommended that idiopathic VF is diagnosed in a SCA survivor, preferably with documentation of VF, after exclusion of an\nunderlying structural, channelopathic, metabolic, or toxicological aetiology.\nI\nB\nICD implantation is recommended in idiopathic VF.\nI\nB\nRecommendations for management of patients with long QT syndrome\nIt is recommended that LQTS is diagnosed with either QTc ≥480 ms in repeated 12-lead ECGs with or without symptoms or LQTS\ndiagnostic score .3.\nI\nC\nIn patients with clinically diagnosed long QT syndrome, genetic testing, and genetic counselling are recommended.\nI\nC\nIt is recommended that LQTS is diagnosed in the presence of a pathogenic mutation, irrespective of the QT duration.\nI\nC\nRoutine diagnostic testing with epinephrine challenge is not recommended in LQTS.\nIII\nC\nThe following is recommended in LQTS:\n• Avoid QT-prolonging drugs.f\n• Avoid and correct electrolyte abnormalities.\n• Avoid genotype-speciﬁc triggers for arrhythmias.\nI\nC\nBeta-blockers, ideally non-selective beta-blockers (nadolol or propranolol), are recommended in LQTS patients with documented QT\ninterval prolongation, to reduce risk of arrhythmic events.\nI\nB\nMexiletine is indicated in LQT3 patients with a prolonged QT interval.\nI\nC\nICD implantation in addition to beta-blockers is recommended in LQTS patients with CA.\nI\nB\nICD implantation is recommended in patients with LQTS who are symptomaticg while receiving beta-blockers and genotype-speciﬁc\ntherapies.\nI\nC\nContinued\nESC Guidelines\n4097\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026\n\n\nLCSD is indicated in patients with symptomaticg LQTS when: (a) ICD therapy is contraindicated or declined; (b) patient is on\nbeta-blockers and genotype-speciﬁc therapies with an ICD and experiences multiple shocks or syncope due to VA.\nI\nC\nInvasive electrophysiologic study is not recommended in LQTS.\nIII\nC\nRecommendations for management of patients with Andersen–Tawil syndrome\nGenetic testing is recommended in patients with suspected Andersen–Tawil syndrome.\nI\nC\nICD implantation is recommended in patients with Andersen–Tawil syndrome after aborted CA not tolerated sustained VT.\nI\nC\nRecommendations for management of patients with Brugada syndrome\nIt is recommended that BrS is diagnosed in patients with no other heart disease and a spontaneous type 1 Brugada ECG pattern.\nI\nC\nIt is recommended that BrS is diagnosed in patients with no other heart disease who have survived a CA due to VF or PVT and exhibit a\ntype 1 Brugada ECG induced by sodium channel blocker challenge or during fever.\nI\nC\nGenetic testing for SCN5A gene is recommended for probands with BrS.\nI\nC\nSodium channel blocker test is not recommended in patients with a prior type I Brugada pattern.\nIII\nC\nThe following is recommended in all patients with BrS:\n(a) Avoidance of drugs that may induce ST-segment elevation in right precordial leads (http://www.brugadadrugs.org).\n(b) Avoidance of cocaine, cannabis, and excessive alcohol intake.\n(c) Treatment of fever with antipyretic drugs.\nI\nC\nICD implantation is recommended in patients with BrS who:\n(a) Are survivors of an aborted CA, and/or\n(b) Have documented spontaneous sustained VT.\nI\nC\nCatheter ablation in asymptomatic BrS patients is not recommended.\nIII\nC\nRecommendations for management of patients with early repolarizaton pattern/syndrome\nIt is recommended that the ERP is diagnosed as J-point elevation of ≥1 mm in two adjacent inferior and/or lateral ECG leads.\nI\nC\nIt is recommended that the ERS is diagnosed in a patient resuscitated from unexplained VF/PVT in the presence of ERP.\nI\nC\nClinical evaluation is not recommended routinely in asymptomatic subjects with ERP.\nIII\nC\nICD implantation is recommended in patients with a diagnosis of ERS who have survived a CA.\nI\nB\nICD implantation is not recommended in asymptomatic patients with an isolated ERP.\nIII\nC\nRecommendations for management of patients with catecholaminergic polymorphic ventricular tachycardia\nIt is recommended that CPVT is diagnosed in the presence of a structurally normal heart, normal ECG, and exercise- or\nemotion-induced bidirectional or PVT.\nI\nC\nIt is recommended that CPVT is diagnosed in patients who are carriers of a mutation in disease-causing genes.\nI\nC\nGenetic testing and genetic counselling are indicated in patients with clinical suspicion or clinical diagnosis of CPVT.\nI\nC\nAvoidance of competitive sports, strenuous exercise, and exposure to stressful environments is recommended in all patients with\nCPVT.\nI\nC\nBeta-blockers, ideally non-selective (nadolol or propranolol), are recommended in all patients with a clinical diagnosis of CPVT.\nI\nC\nICD implantation combined with beta-blockers and ﬂecainide is recommended in CPVT patients after aborted CA.\nI\nC\nPES is not recommended for stratiﬁcation of SCD risk.\nIII\nC\nContinued\n4098\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026\n\n\n12. Quality indicators\nQuality indicators (QIs) are tools that may be used to evaluate care qual-\nity, including structural aspects, process, and outcomes of care.1153 They\nserve as a mechanism for enhancing adherence to guideline recommen-\ndations, through associated quality improvement initiatives and the\nbenchmarking of care providers.1154,1155 As such, the role of QIs in im-\nproving care and outcomes is increasingly recognized by healthcare au-\nthorities, professional organizations, payers, and the public.1153\nThe ESC understands the need for measuring and reporting qual-\nity and outcomes of cardiovascular care, and has established meth-\nods for the development of the ESC QIs for the quantiﬁcation of\ncare and outcomes for cardiovascular disease.1153 In parallel with\nthe writing of this Clinical Practice Guideline document, a process\nhas been initiated to develop QIs for patients with, or at risk of,\nVA or SCD using the ESC methodology and through the collabor-\nation with domain experts and the European Heart Rhythm\nAssociation. These QIs, alongside their speciﬁcations and develop-\nment process, will be published separately.\n13. Supplementary data\nSupplementary data is available at European Heart Journal online.\n14. Data availability statement\nNo new data were generated or analysed in support of this research.\n15. Author information\nAuthor/task force Member Afﬁliations:\nMarta de Riva, Cardiology, Leiden University Medical Centre,\nLeiden,\nNetherlands;\nBo\nGregers\nWinkel,\nCardiology,\nRecommendations for management of patients with short QT syndrome\nIt is recommended that SQTS is diagnosed in the presence of a QTc ≤360 ms and one or more of the following: (a) a pathogenic\nmutation, (b) a family history of SQTS, (c) survival from a VT/VF episode in the absence of heart disease.\nI\nC\nGenetic testing is indicated in patients diagnosed with SQTS.\nI\nC\nICD implantation is recommended in patients with a diagnosis of SQTS who: (a) are survivors of an aborted CA, and/or (b) have\ndocumented spontaneous sustained VT.\nI\nC\nPES is not recommended for SCD risk stratiﬁcation in SQTS patients.\nIII\nC\nRecommendations for the prevention of sudden cardiac death and management of ventricular arrhythmia during pregnancy\nDuring pregnancy, electrical cardioversion is recommended for sustained VT.\nI\nC\nIf ICD implantation is indicated during pregnancy, implantation is recommended with optimal radiation protection.\nI\nC\nContinuation of beta-blockers is recommended during pregnancy and post-partum in patients with LQTS or CPVT.\nI\nC\nRecommendations for risk stratiﬁcation and prevention of sudden cardiac death in athletes\nIn athletes with positive medical history, abnormal physical examination, or ECG alterations, further investigations including\nechocardiography and/or CMR to conﬁrm (or exclude) an underlying disease are recommended.\nI\nC\nIt is recommended that athletes diagnosed with a cardiovascular disease associated with SCD are managed according to current\nguidelines for sports eligibility.\nI\nC\nIt is recommended that staff at sporting facilities are trained in CPR and in the use of AED.\nI\nC\n© ESC 2022\nAAD, anti-arrhythmic drug; ACE-I, angiotensin-converting-enzyme inhibitor; AED, automated external deﬁbrillator; ARB, angiotensin receptor blockers; ARNIs, angiotensin receptor\nneprilysin\ninhibitor;\nARVC,\narrhythmogenic\nright\nventricular\ncardiomyopathy;\nATP,\nanti-tachycardia\npacing;\nAV,\natrioventricular;\nBBR-VT,\nbundle\nbranch\nre-entry;\nBrS, Brugada syndrome; CA, cardiac arrest; CAD, coronary artery disease; CCB, calcium channel blocker; CHD, congenital heart disease; CIED, cardiac implantable electronic\ndevices; CMR, cardiac magnetic resonance; CPR, cardiopulmonary resuscitation; CPVT, catecholaminergic polymorphic ventricular tachycardia; CRT, cardiac resynchronization\ntherapy; DC, direct current; DCM, dilated cardiomyopathy; ECG, electrocardiogram; EF, ejection fraction; ERP, early repolarization pattern; ERS, early repolarization syndrome;\nHCM, hypertrophic cardiomyopathy; HNDCM, hypokinetic non-dilated cardiomyopathy; ICD, implantable cardioverter deﬁbrillator; CAD, coronary artery disease; ILR, implantable\nloop recorder; LCSD, left cardiac sympathetic denervation; LGE, late gadolinium enhancement; LQTS, long QT syndrome; LV, left ventricular; LVEF, left ventricular ejection fraction;\nMRA, mineralocorticoid receptor antagonist; NSVT, non-sustained ventricular tachycardia; NYHA, New York Heart Association; OHCA, out-of-hospital cardiac arrest; OMT,\noptimal medical therapy; PES, programmed electrical stimulation; PVC, premature ventricular complex; PVT, polymorphic ventricular tachycardia; RVOT, right ventricular outﬂow\ntract; SADS, sudden arrhythmic death syndrome; SCA, sudden cardiac arrest; SCD, sudden cardiac death; SD, sudden death; SGLT2, sodium–glucose co-transporter 2; SHD,\nstructural heart disease; SMVT, sustained monomorphic ventricular tachycardia; SQT, short QT syndrome; STEMI, ST-elevation myocardial infarction; SVT, supraventricular\ntachycardia; VA, ventricular arrhythmia; VF, ventricular ﬁbrillation; VT, ventricular tachycardia.\naClass of recommendation.\nbLevel of evidence.\ncShopping malls, stadiums, public transport stations, casinos.\ndList not exhaustive.\neLOE C for VT/PVCs from left fascicles.\nfhttp://www.crediblemeds.org\ngArrhythmic syncope or haemodynamically non-tolerated VA\nESC Guidelines\n4099\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026",
      "keywords": [
        "heart failure",
        "alcohol",
        "class ii",
        "guideline",
        "what",
        "age",
        "recommended",
        "cardiomyopathy",
        "genetic",
        "echocardiography",
        "nyha",
        "coronary artery",
        "family history",
        "calcium channel",
        "secondary prevention",
        "sglt2",
        "primary prevention",
        "arrhythmia",
        "syncope",
        "ventricular tachycardia",
        "lvef",
        "icd",
        "arb",
        "pacemaker",
        "bradycardia",
        "sudden cardiac death",
        "aortic",
        "exercise",
        "ecg",
        "ejection fraction"
      ],
      "tables": [
        {
          "title": "ESC Guidelines 4093",
          "page_number": 96,
          "content": " | Recommendations for evaluation of sudden death victims |  |  | \nInvestigation of unexpected SD, especially in case of suspicion of inherited disease, should be made a public health priority. |  | I | B | \nIn cases of SD, it is recommended to collect a detailed description of circumstances of death, symptoms prior to death, the family\nhistory, and to review prior medical files. |  | I | B | \nA comprehensive autopsy is recommended, ideally, in all cases of unexpected SD, and always in those under 50 years of age. |  | I | B | \nIn cases of SCD, it is recommended to retain samples suitable for DNA extraction and consult a cardiac pathologist when an inherited\ncause is suspected or the cause of death unexplained. |  | I | B | \nToxicology screens are recommended in SD cases with uncertain cause of death. |  | I | B | \nFor SCD where the cause is known or suspected to be heritable, genetic testing targeted to the cause is recommended. |  | I | B | \nFollowing SADS, post-mortem genetic testing targeted to primary electrical disease is recommended when the decedent is young (,50\nyears of age) and/or the circumstances and/or family history support a primary electrical disease. |  | I | B | \nWhen an autopsy diagnoses possible heritable cardiac disease, it is recommended to refer first-degree relatives for cardiac assessment in\na specialized clinic. |  | I | B | \nIn non-autopsied cases of SD where inherited cardiac disease is suspected, it is recommended to refer first-degree relatives for cardiac\nassessment in a specialized clinic. |  | I | B | \n | Recommendations for evaluation of relatives of sudden arrhythmic death syndrome decedents |  |  | \nFollowing SADS, hypothesis-free post-mortem genetic testing using exome or genome sequencing is not recommended. |  | III | B | \nFamilial evaluation of SADS decedents is recommended:\n• for first-degree relatives\n• for relatives who must carry a mutation based on analysis of the family history\n• for relatives with suspicious symptoms\n• when the decedent’s age is ,50 years or if there are other circumstantial data or family history to suggest heritable disease. |  | I | B | \nFamilial evaluation of SADS decedents is recommended to include genetic testing when post-mortem genetic testing in a SADS\ndecedent detects a pathogenic mutation. |  | I | B | \nBaseline familial evaluation of SADS decedents is recommended to include taking a medical history and performing physical examination,\nstandard- and high-precordial lead ECG, echocardiography, and exercise testing. |  | I | B | \nIn SADS families without a diagnosis after clinical evaluation, follow-up is recommended for children of decedents until they reach\nadulthood. |  | I | C | \nIn SADS families without a diagnosis after clinical evaluation, follow-up is not recommended for asymptomatic adults who can be\ndischarged with advice to return if they develop symptoms or if the family history changes. |  | III | C | \n | Recommendations for treatment of reversible conditions |  |  | \nWithdrawal of offending agents is recommended whenever drug-induced VA are suspected. |  | I | B | \nInvestigation for reversible causes (e.g. electrolyte imbalances, ischaemia, hypoxaemia, fever)d is recommended in patients with VA. |  | I | C | \n | Recommendations for the acute treatment of sustained ventricular tachycardia and electrical storm |  |  | \nDC cardioversion is recommended as the first-line treatment for patients with haemodynamically not-tolerated SMVT. |  | I | B | \nDC cardioversion is recommended as the first-line treatment for patients presenting with tolerated SMVT provided that the\nanaesthetic/sedation risk is low. |  | I | C | \nIn patients presenting with a haemodynamically tolerated idiopathic VT, treatment with intravenous beta-blocker (RVOT VT) or\nverapamil (fascicular VT) is recommended. |  | I | C | \nIntravenous verapamil is not recommended in broad QRS complex tachycardia of unknown mechanism. |  | III | B | \nMild to moderate sedation is recommended in patients with electrical storm to alleviate psychological distress and reduce sympathetic\ntone. |  | I | C | \nAntiarrhythmic therapy with beta-blockers (non-selective preferred) in combination with intravenous amiodarone is recommended in\npatients with SHD and electrical storm unless contraindicated. |  | I | B | ",
          "bbox": [
            43.0,
            61.00001220703125,
            547.2749996185303,
            734.1515502929688
          ],
          "function_potential": "raw"
        },
        {
          "title": "4094 ESC Guidelines",
          "page_number": 97,
          "content": "Intravenous magnesium with supplementation of potassium is recommended in patients with TdP. |  | I | C | \nIsoproterenol or transvenous pacing to increase heart rate is recommended in patients with acquired LQT syndrome and recurrent\nTdP despite correction of precipitating conditions and magnesium. |  | I | C | \nCatheter ablation is recommended in patients presenting with incessant VT or electrical storm due to SMVT refractory to AADs. |  | I | B | \n | Recommendations for treatment with heart failure medication |  |  | \nOptimal medical treatment including ACE-I/ARB/ARNIs, MRAs, beta-blockers, and SGLT2 inhibitors is indicated in all heart failure\npatients with reduced EF. |  | I | A | \n | Recommendations for implantable cardioverter defibrillation implantation (general aspects) |  |  | \nImplantation of a cardioverter defibrillator is only recommended in patients who have an expectation of good quality survival .1 year. |  | I | C | \nIt is not recommended to implant an ICD in patients with incessant VAs until the VA is controlled. |  | III | C | \n | Recommendations for secondary prevention of sudden cardiac death |  |  | \nICD implantation is recommended in patients with documented VF or haemodynamically not-tolerated VT in the absence of reversible\ncauses. |  | I | A | \n | Recommendations for adding cardiac resynchronization therapy to implantable cardioverter defibrillator |  |  | \nWhen an ICD is indicated, it is recommended to evaluate whether the patient could benefit from CRT-defibrillator. |  | I | C | \n | Recommendations for optimization of device programming |  |  | \nOptimization of ICD programming is indicated to avoid inappropriate and unnecessary therapies and to reduce mortality. |  | I | A | \nIn single- or dual-chamber ICD patients without bradycardia pacing indications, it is recommended to minimize ventricular pacing. |  | I | A | \nProgramming of prolonged detection settings is indicated (duration criteria of at least 6–12 s or 30 intervals). |  | I | A | \nIt is recommended to program the slowest tachycardia therapy zone limit ≥188 b.p.m. in primary prevention ICD patients. |  | I | A | \nIn patients with SHD, programming of at least one ATP therapy is recommended in all tachyarrhythmias zones. |  | I | A | \nIt is recommended to program algorithms for SVT vs. VT discrimination for tachycardias with rates up to 230 b.p.m. |  | I | B | \nIt is recommended to activate lead failure alerts. |  | I | B | \nRemote monitoring is recommended to reduce the incidence of inappropriate shocks. |  | I | B | \nProgramming of burst ATP as a first attempt is recommended over ramp ATP. |  | I | B | \nFor S-ICDs, a dual detection zone configuration is recommended with activation of discrimination algorithm in the lower conditional\nshock zone |  | I | B | \n | Recommendations for concomitant treatment to avoid inappropriate implantable cardioverter defibrillator therapy |  |  | \nCatheter ablation is recommended for ICD patients with recurrent SVT resulting in inappropriate ICD therapies. |  | I | C | \nPharmacological treatment or catheter ablation is recommended in patients with AF-related inappropriate ICD therapies despite\noptimal ICD programming. |  | I | C | \n | Recommendation for psychosocial management after implantable cardioverter defibrillator implantation |  |  | \nAssessment of psychological status and treatment of distress is recommended in ICD patients. |  | I | C | \nCommunication between patient and physician/healthcare professional is recommended to address ICD-related concerns and to\ndiscuss quality-of-life issues before ICD implantation and during disease progression. |  | I | C | ",
          "bbox": [
            43.0,
            59.5,
            547.2750145164696,
            721.1515502929688
          ],
          "function_potential": "raw"
        },
        {
          "title": "ESC Guidelines 4095",
          "page_number": 98,
          "content": " | Recommendations for prevention of implantable cardioverter defibrillator complications |  |  | \nSingle-chamber ICD is recommended over dual-chamber ICD in primary prevention patients without current or expected indication\nfor atrial or AV sequential pacing due to a lower risk of device-related complications. |  | I | A | \n | Recommendations for end-of-life issues in implantable cardioverter defibrillator carriers |  |  | \nInformed discussion with patient and family about ICD deactivation options and shared decision-making is indicated prior to\nimplantation and in case of significant health status deterioration. |  | I | C | \n | Recommendations for treatment of ventricular arrhythmia in acute coronary syndrome and vasospasm |  |  | \nIntravenous beta-blocker treatment is indicated for patients with recurrent PVT/VF during STEMI unless contraindicated. |  | I | B | \nProphylactic treatment with AADs (other than beta-blockers) is not recommended in ACS. |  | III | B | \n | Recommendations for risk stratification and treatment of ventricular arrhythmia early after myocardial infarction |  |  | \nEarly (before discharge) assessment of LVEF is recommended in all patients with acute MI. |  | I | B | \nIn patients with pre-discharge LVEF ≤40%, re-evaluation of LVEF 6–12 weeks after MI is recommended to assess the potential need for\nprimary prevention ICD implantation. |  | I | C | \n | Recommendations for risk stratification, sudden cardiac death prevention, and treatment of ventricular arrhythmia in chronic\ncoronary artery disease |  |  | \nIn patients with syncope and previous STEMI, PES is indicated when syncope remains unexplained after non-invasive evaluation. |  | I | C | \nICD therapy is recommended in patients with CAD, symptomatic heart failure (NYHA class II–III), and LVEF ≤35% despite ≥3 months\nof OMT. |  | I | A | \nIn patients with CAD, prophylactic treatment with AADs other than beta-blockers is not recommended. |  | III | A | \nICD implantation is recommended in patients without ongoing ischaemia with documented VF or haemodynamically not-tolerated VT\noccurring later than 48 h after MI. |  | I | A | \nIn patients with CAD and recurrent, symptomatic SMVT or ICD shocks for SMVT despite chronic amiodarone therapy, catheter\nablation is recommended in preference to escalating AAD therapy. |  | I | B | \n | Recommendations for sudden cardiac death prevention in patients with coronary anomalies |  |  | \nCardiac stress imaging during physical exercise is recommended in addition to cardiopulmonary exercise test in patients with anomalous\naortic origin of a coronary artery with an interarterial course to confirm/exclude myocardial ischaemia. |  | I | C | \nCardiac stress imaging during physical exercise is recommended in addition to cardiopulmonary exercise test after surgery in patients\nwith anomalous aortic origin of a coronary artery with a history of aborted CA. |  | I | C | \nSurgery is recommended in patients with anomalous aortic origin of a coronary artery with CA, syncope suspected to be due to VAs or\nangina when other causes have been excluded. |  | I | C | \n | Recommendations for the management of patients with idiopathic premature ventricular complexes/ventricular tachycardia |  |  | \nRegular assessment of ventricular function of patients with PVC burden .10% and normal ventricular function is indicated. |  | I | C | \nCatheter ablation as first-line treatment is recommended for symptomatic idiopathic VT/PVCs from the RVOT or the left fascicles.e |  | I | B | \nBeta-blockers or non-dihydropyridine CCB are indicated in symptomatic patients with idiopathic VT/PVCs from an origin other than\nthe RVOT or the left fascicles. |  | I | C | \nCatheter ablation is not recommended in children ,5 years of age or ,10 kg weight except when previous medical therapy fails or\nwhen VT is not haemodynamically tolerated. |  | III | C | \nAmiodarone as a first-line treatment is not recommended in patients with idiopathic VTs/PVCs. |  | III | C | \nVerapamil is not recommended in children ,1 year of age with PVC/VT, particularly if they have signs of heart failure or concurrent use\nof other AADs. |  | III | C | \n | Recommendations for the management of patients with premature ventricular complex-induced or aggravated cardiomyopathy |  |  | \nIn patients with a cardiomyopathy suspected to be caused by frequent and predominately monomorphic PVCs, catheter ablation is\nrecommended. |  | I | C | ",
          "bbox": [
            48.0,
            61.00001220703125,
            552.2750533254523,
            724.1515502929688
          ],
          "function_potential": "auto_generate"
        },
        {
          "title": "4096 ESC Guidelines",
          "page_number": 99,
          "content": " | Recommendations for risk stratification, sudden cardiac death prevention, and treatment of ventricular arrhythmia in dilated\ncardiomyopathy/hypokinetic non-dilated cardiomyopathy |  |  | \nGenetic testing (including at least LMNA, PLN, RBM20, and FLNC genes) is recommended in patients with DCM/HNDCM and AV\nconduction delay at ,50 years, or who have a family history of DCM/HNDCM or SCD in a first-degree relative (at age ,50 years). |  | I | B | \nParticipation in high-intensity exercise including competitive sports is not recommended for individuals with DCM/HNDCM and a\nLMNA mutation. |  | III | C | \nICD implantation is recommended in patients with DCM/HNDCM, who survive SCA due to VT/VF or experience haemodynamically\nnot-tolerated SMVT. |  | I | B | \nIn a first-degree relative of a DCM/HNDCM patient, an ECG, and an echocardiogram are recommended if:\n• the index patient was diagnosed ,50 years of age or has clinical features suggestive of an inherited cause, or\n• there is family history of DCM/HNDCM, or premature unexpected SD. |  | I | C | \n | Recommendations for diagnostic, risk stratification, sudden cardiac death prevention and treatment of ventricular arrhythmia in\narrhythmogenic right ventricular cardiomyopathy |  |  | \nIn patients with suspected ARVC, CMR is recommended. |  | I | B | \nIn patients with a suspected or definite diagnosis of ARVC, genetic counselling and testing are recommended. |  | I | B | \nAvoidance of high-intensity exercise is recommended in patients with a definite diagnosis of ARVC. |  | I | B | \nICD implantation is recommended in ARVC patients with haemodynamically not-tolerated VT or VF. |  | I | C | \nIn patients with ARVC and non-sustained or sustained VAs, beta-blocker therapy is recommended. |  | I | C | \nIn a first-degree relative of a patient with ARVC, ECG, and echocardiogram are recommended. |  | I | C | \n | Recommendations for risk stratification, sudden cardiac death prevention, and treatment of ventricular arrhythmia in hypertrophic\ncardiomyopathy |  |  | \nCMR with LGE is recommended in HCM patients for diagnostic work-up. |  | I | B | \nGenetic counselling and testing are recommended in HCM patients. |  | I | B | \nIt is recommended that the 5-year risk of SCD is assessed at first evaluation and at 1–3-year intervals or when there is a change in clinical\nstatus. |  | I | C | \nICD implantation is recommended in HCM patients with haemodynamically not-tolerated VT or VF. |  | I | B | \nIn a first-degree relative of a patient with HCM, ECG, and echocardiogram are recommended. |  | I | C | \n | Recommendations for risk stratification, sudden cardiac death prevention, and treatment of ventricular arrhythmia in\nneuromuscular diseases |  |  | \nAnnual follow-up with at least a 12-lead ECG is recommended in patients with muscular dystrophies, even in the concealed phase of the\ndisease. |  | I | C | \nIt is recommended that patients with neuromuscular disorders who have VAs or ventricular dysfunction are treated in the same way for\narrhythmia as patients without neuromuscular disorders. |  | I | C | \nInvasive electrophysiological evaluation is recommended in patients with myotonic dystrophy and palpitations or syncope suggestive of\nVA, VT, or surviving a CA. |  | I | C | \nICD implantation is recommended in patients with myotonic dystrophy and SMVT or aborted CA not caused by BBR-VT. |  | I | C | \nIn myotonic dystrophy patients, serial electrophysiological evaluation of AV conduction and arrhythmia induction is not recommended\nwithout arrhythmia suspicion or progression of ECG conduction disorders. |  | III | C | \nIn symptomatic patients with BBR-VT, catheter ablation is recommended. |  | I | C | \nIn patients with myotonic dystrophy undergoing ablation for BBR-VT, pacemaker/ICD implantation is recommended. |  | I | C | ",
          "bbox": [
            43.0,
            61.00001220703125,
            547.2750007875504,
            733.1515558416194
          ],
          "function_potential": "raw"
        },
        {
          "title": "ESC Guidelines 4097",
          "page_number": 100,
          "content": " | Recommendations for sudden cardiac death prevention, and treatment of ventricular arrhythmia in myocarditis |  |  | \nIn confirmed or clinically suspected acute myocarditis, it is recommended that patients who present with life-threatening VA are\nreferred to a specialized centre. |  | I | C | \nIn patients with haemodynamically not-tolerated SMVT occurring in the chronic phase of myocarditis, an ICD implantation is\nrecommended. |  | I | C | \n | Recommendations for risk stratification, sudden cardiac death prevention, and treatment of ventricular arrhythmia in cardiac\nsarcoidosis |  |  | \nICD implantation is recommended in patients with cardiac sarcoidosis who have an LVEF ≤35%. |  | I | B | \nICD implantation is recommended in patients with cardiac sarcoidosis who (a) have documented sustained VT, or (2) aborted CA. |  | I | B | \n | Recommendations for sudden cardiac death prevention, and treatment of ventricular arrhythmia in valvular heart disease |  |  | \nPES with standby catheter ablation is recommended in patients with aortic valve disease and SMVT to identify and ablate BBR-VT,\nespecially if it occurs following a valve intervention. |  | I | C | \nIn patients with valvular heart disease and persistent LV dysfunction after surgical correction (if possible) it is recommended that ICD\nimplantation for primary prevention follows DCM/HNDCM recommendations. |  | I | C | \n | Recommendations for sudden cardiac death prevention, and treatment of ventricular arrhythmia in congenital heart disease |  |  | \nIn adults with CHD with biventricular physiology and a left systemic ventricle presenting with symptomatic heart failure (NYHA II/III)\nand EF ≤35% despite ≥3 months of OMT, ICD implantation is indicated. |  | I | C | \nIn patients with CHD presenting with sustained VAs, evaluation for residual or new anatomical abnormalities is recommended. |  | I | B | \nIn patients with CHD with not-tolerated VT/aborted CA due to VF, ICD implantation is indicated after exclusion of reversible causes. |  | I | C | \nIn patients with repaired TOF who present with SMVT or recurrent, symptomatic appropriate ICD therapy for SMVT, catheter ablation\nperformed in specialized centres is recommended. |  | I | C | \n | Recommendations for management of patients with idiopathic ventricular fibrillation |  |  | \nIt is recommended that idiopathic VF is diagnosed in a SCA survivor, preferably with documentation of VF, after exclusion of an\nunderlying structural, channelopathic, metabolic, or toxicological aetiology. |  | I | B | \nICD implantation is recommended in idiopathic VF. |  | I | B | \n | Recommendations for management of patients with long QT syndrome |  |  | \nIt is recommended that LQTS is diagnosed with either QTc ≥480 ms in repeated 12-lead ECGs with or without symptoms or LQTS\ndiagnostic score .3. |  | I | C | \nIn patients with clinically diagnosed long QT syndrome, genetic testing, and genetic counselling are recommended. |  | I | C | \nIt is recommended that LQTS is diagnosed in the presence of a pathogenic mutation, irrespective of the QT duration. |  | I | C | \nRoutine diagnostic testing with epinephrine challenge is not recommended in LQTS. |  | III | C | \nThe following is recommended in LQTS:\n• Avoid QT-prolonging drugs.f\n• Avoid and correct electrolyte abnormalities.\n• Avoid genotype-specific triggers for arrhythmias. |  | I | C | \nBeta-blockers, ideally non-selective beta-blockers (nadolol or propranolol), are recommended in LQTS patients with documented QT\ninterval prolongation, to reduce risk of arrhythmic events. |  | I | B | \nMexiletine is indicated in LQT3 patients with a prolonged QT interval. |  | I | C | \nICD implantation in addition to beta-blockers is recommended in LQTS patients with CA. |  | I | B | \nICD implantation is recommended in patients with LQTS who are symptomaticg while receiving beta-blockers and genotype-specific\ntherapies. |  | I | C | ",
          "bbox": [
            48.0,
            61.00001220703125,
            552.2750459558823,
            716.1515447443181
          ],
          "function_potential": "auto_generate"
        },
        {
          "title": "4098 ESC Guidelines",
          "page_number": 101,
          "content": "LCSD is indicated in patients with symptomaticg LQTS when: (a) ICD therapy is contraindicated or declined; (b) patient is on\nbeta-blockers and genotype-specific therapies with an ICD and experiences multiple shocks or syncope due to VA. |  | I | C | \nInvasive electrophysiologic study is not recommended in LQTS. |  | III | C | \n | Recommendations for management of patients with Andersen–Tawil syndrome |  |  | \nGenetic testing is recommended in patients with suspected Andersen–Tawil syndrome. |  | I | C | \nICD implantation is recommended in patients with Andersen–Tawil syndrome after aborted CA not tolerated sustained VT. |  | I | C | \n | Recommendations for management of patients with Brugada syndrome |  |  | \nIt is recommended that BrS is diagnosed in patients with no other heart disease and a spontaneous type 1 Brugada ECG pattern. |  | I | C | \nIt is recommended that BrS is diagnosed in patients with no other heart disease who have survived a CA due to VF or PVT and exhibit a\ntype 1 Brugada ECG induced by sodium channel blocker challenge or during fever. |  | I | C | \nGenetic testing for SCN5A gene is recommended for probands with BrS. |  | I | C | \nSodium channel blocker test is not recommended in patients with a prior type I Brugada pattern. |  | III | C | \nThe following is recommended in all patients with BrS:\n(a) Avoidance of drugs that may induce ST-segment elevation in right precordial leads (http://www.brugadadrugs.org).\n(b) Avoidance of cocaine, cannabis, and excessive alcohol intake.\n(c) Treatment of fever with antipyretic drugs. |  | I | C | \nICD implantation is recommended in patients with BrS who:\n(a) Are survivors of an aborted CA, and/or\n(b) Have documented spontaneous sustained VT. |  | I | C | \nCatheter ablation in asymptomatic BrS patients is not recommended. |  | III | C | \n | Recommendations for management of patients with early repolarizaton pattern/syndrome |  |  | \nIt is recommended that the ERP is diagnosed as J-point elevation of ≥1 mm in two adjacent inferior and/or lateral ECG leads. |  | I | C | \nIt is recommended that the ERS is diagnosed in a patient resuscitated from unexplained VF/PVT in the presence of ERP. |  | I | C | \nClinical evaluation is not recommended routinely in asymptomatic subjects with ERP. |  | III | C | \nICD implantation is recommended in patients with a diagnosis of ERS who have survived a CA. |  | I | B | \nICD implantation is not recommended in asymptomatic patients with an isolated ERP. |  | III | C | \n | Recommendations for management of patients with catecholaminergic polymorphic ventricular tachycardia |  |  | \nIt is recommended that CPVT is diagnosed in the presence of a structurally normal heart, normal ECG, and exercise- or\nemotion-induced bidirectional or PVT. |  | I | C | \nIt is recommended that CPVT is diagnosed in patients who are carriers of a mutation in disease-causing genes. |  | I | C | \nGenetic testing and genetic counselling are indicated in patients with clinical suspicion or clinical diagnosis of CPVT. |  | I | C | \nAvoidance of competitive sports, strenuous exercise, and exposure to stressful environments is recommended in all patients with\nCPVT. |  | I | C | \nBeta-blockers, ideally non-selective (nadolol or propranolol), are recommended in all patients with a clinical diagnosis of CPVT. |  | I | C | \nICD implantation combined with beta-blockers and flecainide is recommended in CPVT patients after aborted CA. |  | I | C | \nPES is not recommended for stratification of SCD risk. |  | III | C | ",
          "bbox": [
            43.0,
            59.5,
            547.274995803833,
            734.1515502929688
          ],
          "function_potential": "raw"
        },
        {
          "title": "ESC Guidelines 4099",
          "page_number": 102,
          "content": " | Recommendations for management of patients with short QT syndrome |  |  | \nIt is recommended that SQTS is diagnosed in the presence of a QTc ≤360 ms and one or more of the following: (a) a pathogenic\nmutation, (b) a family history of SQTS, (c) survival from a VT/VF episode in the absence of heart disease. |  | I | C | \nGenetic testing is indicated in patients diagnosed with SQTS. |  | I | C | \nICD implantation is recommended in patients with a diagnosis of SQTS who: (a) are survivors of an aborted CA, and/or (b) have\ndocumented spontaneous sustained VT. |  | I | C | \nPES is not recommended for SCD risk stratification in SQTS patients. |  | III | C | \n | Recommendations for the prevention of sudden cardiac death and management of ventricular arrhythmia during pregnancy |  |  | \nDuring pregnancy, electrical cardioversion is recommended for sustained VT. |  | I | C | \nIf ICD implantation is indicated during pregnancy, implantation is recommended with optimal radiation protection. |  | I | C | \nContinuation of beta-blockers is recommended during pregnancy and post-partum in patients with LQTS or CPVT. |  | I | C | \n | Recommendations for risk stratification and prevention of sudden cardiac death in athletes |  |  | \nIn athletes with positive medical history, abnormal physical examination, or ECG alterations, further investigations including\nechocardiography and/or CMR to confirm (or exclude) an underlying disease are recommended. |  | I | C | \nIt is recommended that athletes diagnosed with a cardiovascular disease associated with SCD are managed according to current\nguidelines for sports eligibility. |  | I | C | \nIt is recommended that staff at sporting facilities are trained in CPR and in the use of AED. |  | I | C | ",
          "bbox": [
            48.0,
            61.00001220703125,
            552.275053136489,
            344.4989929199219
          ],
          "function_potential": "raw"
        }
      ]
    },
    {
      "number": "2",
      "title": "12. Quality indicators",
      "start_page": 102,
      "end_page": 103,
      "content": "12. Quality indicators\nQuality indicators (QIs) are tools that may be used to evaluate care qual-\nity, including structural aspects, process, and outcomes of care.1153 They\nserve as a mechanism for enhancing adherence to guideline recommen-\ndations, through associated quality improvement initiatives and the\nbenchmarking of care providers.1154,1155 As such, the role of QIs in im-\nproving care and outcomes is increasingly recognized by healthcare au-\nthorities, professional organizations, payers, and the public.1153\nThe ESC understands the need for measuring and reporting qual-\nity and outcomes of cardiovascular care, and has established meth-\nods for the development of the ESC QIs for the quantiﬁcation of\ncare and outcomes for cardiovascular disease.1153 In parallel with\nthe writing of this Clinical Practice Guideline document, a process\nhas been initiated to develop QIs for patients with, or at risk of,\nVA or SCD using the ESC methodology and through the collabor-\nation with domain experts and the European Heart Rhythm\nAssociation. These QIs, alongside their speciﬁcations and develop-\nment process, will be published separately.\n13. Supplementary data\nSupplementary data is available at European Heart Journal online.\n14. Data availability statement\nNo new data were generated or analysed in support of this research.\n15. Author information\nAuthor/task force Member Afﬁliations:\nMarta de Riva, Cardiology, Leiden University Medical Centre,\nLeiden,\nNetherlands;\nBo\nGregers\nWinkel,\nCardiology,\nRecommendations for management of patients with short QT syndrome\nIt is recommended that SQTS is diagnosed in the presence of a QTc ≤360 ms and one or more of the following: (a) a pathogenic\nmutation, (b) a family history of SQTS, (c) survival from a VT/VF episode in the absence of heart disease.\nI\nC\nGenetic testing is indicated in patients diagnosed with SQTS.\nI\nC\nICD implantation is recommended in patients with a diagnosis of SQTS who: (a) are survivors of an aborted CA, and/or (b) have\ndocumented spontaneous sustained VT.\nI\nC\nPES is not recommended for SCD risk stratiﬁcation in SQTS patients.\nIII\nC\nRecommendations for the prevention of sudden cardiac death and management of ventricular arrhythmia during pregnancy\nDuring pregnancy, electrical cardioversion is recommended for sustained VT.\nI\nC\nIf ICD implantation is indicated during pregnancy, implantation is recommended with optimal radiation protection.\nI\nC\nContinuation of beta-blockers is recommended during pregnancy and post-partum in patients with LQTS or CPVT.\nI\nC\nRecommendations for risk stratiﬁcation and prevention of sudden cardiac death in athletes\nIn athletes with positive medical history, abnormal physical examination, or ECG alterations, further investigations including\nechocardiography and/or CMR to conﬁrm (or exclude) an underlying disease are recommended.\nI\nC\nIt is recommended that athletes diagnosed with a cardiovascular disease associated with SCD are managed according to current\nguidelines for sports eligibility.\nI\nC\nIt is recommended that staff at sporting facilities are trained in CPR and in the use of AED.\nI\nC\n© ESC 2022\nAAD, anti-arrhythmic drug; ACE-I, angiotensin-converting-enzyme inhibitor; AED, automated external deﬁbrillator; ARB, angiotensin receptor blockers; ARNIs, angiotensin receptor\nneprilysin\ninhibitor;\nARVC,\narrhythmogenic\nright\nventricular\ncardiomyopathy;\nATP,\nanti-tachycardia\npacing;\nAV,\natrioventricular;\nBBR-VT,\nbundle\nbranch\nre-entry;\nBrS, Brugada syndrome; CA, cardiac arrest; CAD, coronary artery disease; CCB, calcium channel blocker; CHD, congenital heart disease; CIED, cardiac implantable electronic\ndevices; CMR, cardiac magnetic resonance; CPR, cardiopulmonary resuscitation; CPVT, catecholaminergic polymorphic ventricular tachycardia; CRT, cardiac resynchronization\ntherapy; DC, direct current; DCM, dilated cardiomyopathy; ECG, electrocardiogram; EF, ejection fraction; ERP, early repolarization pattern; ERS, early repolarization syndrome;\nHCM, hypertrophic cardiomyopathy; HNDCM, hypokinetic non-dilated cardiomyopathy; ICD, implantable cardioverter deﬁbrillator; CAD, coronary artery disease; ILR, implantable\nloop recorder; LCSD, left cardiac sympathetic denervation; LGE, late gadolinium enhancement; LQTS, long QT syndrome; LV, left ventricular; LVEF, left ventricular ejection fraction;\nMRA, mineralocorticoid receptor antagonist; NSVT, non-sustained ventricular tachycardia; NYHA, New York Heart Association; OHCA, out-of-hospital cardiac arrest; OMT,\noptimal medical therapy; PES, programmed electrical stimulation; PVC, premature ventricular complex; PVT, polymorphic ventricular tachycardia; RVOT, right ventricular outﬂow\ntract; SADS, sudden arrhythmic death syndrome; SCA, sudden cardiac arrest; SCD, sudden cardiac death; SD, sudden death; SGLT2, sodium–glucose co-transporter 2; SHD,\nstructural heart disease; SMVT, sustained monomorphic ventricular tachycardia; SQT, short QT syndrome; STEMI, ST-elevation myocardial infarction; SVT, supraventricular\ntachycardia; VA, ventricular arrhythmia; VF, ventricular ﬁbrillation; VT, ventricular tachycardia.\naClass of recommendation.\nbLevel of evidence.\ncShopping malls, stadiums, public transport stations, casinos.\ndList not exhaustive.\neLOE C for VT/PVCs from left fascicles.\nfhttp://www.crediblemeds.org\ngArrhythmic syncope or haemodynamically non-tolerated VA\nESC Guidelines\n4099\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026",
      "keywords": [
        "guideline",
        "recommended",
        "cardiomyopathy",
        "genetic",
        "echocardiography",
        "nyha",
        "coronary artery",
        "family history",
        "calcium channel",
        "sglt2",
        "arrhythmia",
        "syncope",
        "ventricular tachycardia",
        "lvef",
        "icd",
        "arb",
        "sudden cardiac death",
        "indicators",
        "ecg",
        "ejection fraction",
        "quality",
        "tachycardia",
        "glucose",
        "electrocardiogram",
        "crt",
        "scd"
      ],
      "tables": []
    },
    {
      "number": "2",
      "title": "13. Supplementary data",
      "start_page": 102,
      "end_page": 103,
      "content": "12. Quality indicators\nQuality indicators (QIs) are tools that may be used to evaluate care qual-\nity, including structural aspects, process, and outcomes of care.1153 They\nserve as a mechanism for enhancing adherence to guideline recommen-\ndations, through associated quality improvement initiatives and the\nbenchmarking of care providers.1154,1155 As such, the role of QIs in im-\nproving care and outcomes is increasingly recognized by healthcare au-\nthorities, professional organizations, payers, and the public.1153\nThe ESC understands the need for measuring and reporting qual-\nity and outcomes of cardiovascular care, and has established meth-\nods for the development of the ESC QIs for the quantiﬁcation of\ncare and outcomes for cardiovascular disease.1153 In parallel with\nthe writing of this Clinical Practice Guideline document, a process\nhas been initiated to develop QIs for patients with, or at risk of,\nVA or SCD using the ESC methodology and through the collabor-\nation with domain experts and the European Heart Rhythm\nAssociation. These QIs, alongside their speciﬁcations and develop-\nment process, will be published separately.\n13. Supplementary data\nSupplementary data is available at European Heart Journal online.\n14. Data availability statement\nNo new data were generated or analysed in support of this research.\n15. Author information\nAuthor/task force Member Afﬁliations:\nMarta de Riva, Cardiology, Leiden University Medical Centre,\nLeiden,\nNetherlands;\nBo\nGregers\nWinkel,\nCardiology,\nRecommendations for management of patients with short QT syndrome\nIt is recommended that SQTS is diagnosed in the presence of a QTc ≤360 ms and one or more of the following: (a) a pathogenic\nmutation, (b) a family history of SQTS, (c) survival from a VT/VF episode in the absence of heart disease.\nI\nC\nGenetic testing is indicated in patients diagnosed with SQTS.\nI\nC\nICD implantation is recommended in patients with a diagnosis of SQTS who: (a) are survivors of an aborted CA, and/or (b) have\ndocumented spontaneous sustained VT.\nI\nC\nPES is not recommended for SCD risk stratiﬁcation in SQTS patients.\nIII\nC\nRecommendations for the prevention of sudden cardiac death and management of ventricular arrhythmia during pregnancy\nDuring pregnancy, electrical cardioversion is recommended for sustained VT.\nI\nC\nIf ICD implantation is indicated during pregnancy, implantation is recommended with optimal radiation protection.\nI\nC\nContinuation of beta-blockers is recommended during pregnancy and post-partum in patients with LQTS or CPVT.\nI\nC\nRecommendations for risk stratiﬁcation and prevention of sudden cardiac death in athletes\nIn athletes with positive medical history, abnormal physical examination, or ECG alterations, further investigations including\nechocardiography and/or CMR to conﬁrm (or exclude) an underlying disease are recommended.\nI\nC\nIt is recommended that athletes diagnosed with a cardiovascular disease associated with SCD are managed according to current\nguidelines for sports eligibility.\nI\nC\nIt is recommended that staff at sporting facilities are trained in CPR and in the use of AED.\nI\nC\n© ESC 2022\nAAD, anti-arrhythmic drug; ACE-I, angiotensin-converting-enzyme inhibitor; AED, automated external deﬁbrillator; ARB, angiotensin receptor blockers; ARNIs, angiotensin receptor\nneprilysin\ninhibitor;\nARVC,\narrhythmogenic\nright\nventricular\ncardiomyopathy;\nATP,\nanti-tachycardia\npacing;\nAV,\natrioventricular;\nBBR-VT,\nbundle\nbranch\nre-entry;\nBrS, Brugada syndrome; CA, cardiac arrest; CAD, coronary artery disease; CCB, calcium channel blocker; CHD, congenital heart disease; CIED, cardiac implantable electronic\ndevices; CMR, cardiac magnetic resonance; CPR, cardiopulmonary resuscitation; CPVT, catecholaminergic polymorphic ventricular tachycardia; CRT, cardiac resynchronization\ntherapy; DC, direct current; DCM, dilated cardiomyopathy; ECG, electrocardiogram; EF, ejection fraction; ERP, early repolarization pattern; ERS, early repolarization syndrome;\nHCM, hypertrophic cardiomyopathy; HNDCM, hypokinetic non-dilated cardiomyopathy; ICD, implantable cardioverter deﬁbrillator; CAD, coronary artery disease; ILR, implantable\nloop recorder; LCSD, left cardiac sympathetic denervation; LGE, late gadolinium enhancement; LQTS, long QT syndrome; LV, left ventricular; LVEF, left ventricular ejection fraction;\nMRA, mineralocorticoid receptor antagonist; NSVT, non-sustained ventricular tachycardia; NYHA, New York Heart Association; OHCA, out-of-hospital cardiac arrest; OMT,\noptimal medical therapy; PES, programmed electrical stimulation; PVC, premature ventricular complex; PVT, polymorphic ventricular tachycardia; RVOT, right ventricular outﬂow\ntract; SADS, sudden arrhythmic death syndrome; SCA, sudden cardiac arrest; SCD, sudden cardiac death; SD, sudden death; SGLT2, sodium–glucose co-transporter 2; SHD,\nstructural heart disease; SMVT, sustained monomorphic ventricular tachycardia; SQT, short QT syndrome; STEMI, ST-elevation myocardial infarction; SVT, supraventricular\ntachycardia; VA, ventricular arrhythmia; VF, ventricular ﬁbrillation; VT, ventricular tachycardia.\naClass of recommendation.\nbLevel of evidence.\ncShopping malls, stadiums, public transport stations, casinos.\ndList not exhaustive.\neLOE C for VT/PVCs from left fascicles.\nfhttp://www.crediblemeds.org\ngArrhythmic syncope or haemodynamically non-tolerated VA\nESC Guidelines\n4099\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026",
      "keywords": [
        "guideline",
        "recommended",
        "cardiomyopathy",
        "genetic",
        "echocardiography",
        "nyha",
        "coronary artery",
        "family history",
        "calcium channel",
        "sglt2",
        "arrhythmia",
        "syncope",
        "ventricular tachycardia",
        "lvef",
        "icd",
        "arb",
        "sudden cardiac death",
        "ecg",
        "ejection fraction",
        "tachycardia",
        "glucose",
        "electrocardiogram",
        "crt",
        "data",
        "supplementary",
        "scd"
      ],
      "tables": []
    },
    {
      "number": "2",
      "title": "14. Data availability statement",
      "start_page": 102,
      "end_page": 103,
      "content": "12. Quality indicators\nQuality indicators (QIs) are tools that may be used to evaluate care qual-\nity, including structural aspects, process, and outcomes of care.1153 They\nserve as a mechanism for enhancing adherence to guideline recommen-\ndations, through associated quality improvement initiatives and the\nbenchmarking of care providers.1154,1155 As such, the role of QIs in im-\nproving care and outcomes is increasingly recognized by healthcare au-\nthorities, professional organizations, payers, and the public.1153\nThe ESC understands the need for measuring and reporting qual-\nity and outcomes of cardiovascular care, and has established meth-\nods for the development of the ESC QIs for the quantiﬁcation of\ncare and outcomes for cardiovascular disease.1153 In parallel with\nthe writing of this Clinical Practice Guideline document, a process\nhas been initiated to develop QIs for patients with, or at risk of,\nVA or SCD using the ESC methodology and through the collabor-\nation with domain experts and the European Heart Rhythm\nAssociation. These QIs, alongside their speciﬁcations and develop-\nment process, will be published separately.\n13. Supplementary data\nSupplementary data is available at European Heart Journal online.\n14. Data availability statement\nNo new data were generated or analysed in support of this research.\n15. Author information\nAuthor/task force Member Afﬁliations:\nMarta de Riva, Cardiology, Leiden University Medical Centre,\nLeiden,\nNetherlands;\nBo\nGregers\nWinkel,\nCardiology,\nRecommendations for management of patients with short QT syndrome\nIt is recommended that SQTS is diagnosed in the presence of a QTc ≤360 ms and one or more of the following: (a) a pathogenic\nmutation, (b) a family history of SQTS, (c) survival from a VT/VF episode in the absence of heart disease.\nI\nC\nGenetic testing is indicated in patients diagnosed with SQTS.\nI\nC\nICD implantation is recommended in patients with a diagnosis of SQTS who: (a) are survivors of an aborted CA, and/or (b) have\ndocumented spontaneous sustained VT.\nI\nC\nPES is not recommended for SCD risk stratiﬁcation in SQTS patients.\nIII\nC\nRecommendations for the prevention of sudden cardiac death and management of ventricular arrhythmia during pregnancy\nDuring pregnancy, electrical cardioversion is recommended for sustained VT.\nI\nC\nIf ICD implantation is indicated during pregnancy, implantation is recommended with optimal radiation protection.\nI\nC\nContinuation of beta-blockers is recommended during pregnancy and post-partum in patients with LQTS or CPVT.\nI\nC\nRecommendations for risk stratiﬁcation and prevention of sudden cardiac death in athletes\nIn athletes with positive medical history, abnormal physical examination, or ECG alterations, further investigations including\nechocardiography and/or CMR to conﬁrm (or exclude) an underlying disease are recommended.\nI\nC\nIt is recommended that athletes diagnosed with a cardiovascular disease associated with SCD are managed according to current\nguidelines for sports eligibility.\nI\nC\nIt is recommended that staff at sporting facilities are trained in CPR and in the use of AED.\nI\nC\n© ESC 2022\nAAD, anti-arrhythmic drug; ACE-I, angiotensin-converting-enzyme inhibitor; AED, automated external deﬁbrillator; ARB, angiotensin receptor blockers; ARNIs, angiotensin receptor\nneprilysin\ninhibitor;\nARVC,\narrhythmogenic\nright\nventricular\ncardiomyopathy;\nATP,\nanti-tachycardia\npacing;\nAV,\natrioventricular;\nBBR-VT,\nbundle\nbranch\nre-entry;\nBrS, Brugada syndrome; CA, cardiac arrest; CAD, coronary artery disease; CCB, calcium channel blocker; CHD, congenital heart disease; CIED, cardiac implantable electronic\ndevices; CMR, cardiac magnetic resonance; CPR, cardiopulmonary resuscitation; CPVT, catecholaminergic polymorphic ventricular tachycardia; CRT, cardiac resynchronization\ntherapy; DC, direct current; DCM, dilated cardiomyopathy; ECG, electrocardiogram; EF, ejection fraction; ERP, early repolarization pattern; ERS, early repolarization syndrome;\nHCM, hypertrophic cardiomyopathy; HNDCM, hypokinetic non-dilated cardiomyopathy; ICD, implantable cardioverter deﬁbrillator; CAD, coronary artery disease; ILR, implantable\nloop recorder; LCSD, left cardiac sympathetic denervation; LGE, late gadolinium enhancement; LQTS, long QT syndrome; LV, left ventricular; LVEF, left ventricular ejection fraction;\nMRA, mineralocorticoid receptor antagonist; NSVT, non-sustained ventricular tachycardia; NYHA, New York Heart Association; OHCA, out-of-hospital cardiac arrest; OMT,\noptimal medical therapy; PES, programmed electrical stimulation; PVC, premature ventricular complex; PVT, polymorphic ventricular tachycardia; RVOT, right ventricular outﬂow\ntract; SADS, sudden arrhythmic death syndrome; SCA, sudden cardiac arrest; SCD, sudden cardiac death; SD, sudden death; SGLT2, sodium–glucose co-transporter 2; SHD,\nstructural heart disease; SMVT, sustained monomorphic ventricular tachycardia; SQT, short QT syndrome; STEMI, ST-elevation myocardial infarction; SVT, supraventricular\ntachycardia; VA, ventricular arrhythmia; VF, ventricular ﬁbrillation; VT, ventricular tachycardia.\naClass of recommendation.\nbLevel of evidence.\ncShopping malls, stadiums, public transport stations, casinos.\ndList not exhaustive.\neLOE C for VT/PVCs from left fascicles.\nfhttp://www.crediblemeds.org\ngArrhythmic syncope or haemodynamically non-tolerated VA\nESC Guidelines\n4099\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026",
      "keywords": [
        "guideline",
        "recommended",
        "availability",
        "cardiomyopathy",
        "genetic",
        "echocardiography",
        "nyha",
        "coronary artery",
        "family history",
        "calcium channel",
        "sglt2",
        "arrhythmia",
        "syncope",
        "ventricular tachycardia",
        "lvef",
        "icd",
        "arb",
        "sudden cardiac death",
        "ecg",
        "ejection fraction",
        "statement",
        "tachycardia",
        "glucose",
        "electrocardiogram",
        "crt",
        "data",
        "scd"
      ],
      "tables": []
    },
    {
      "number": "2",
      "title": "15. Author information",
      "start_page": 102,
      "end_page": 130,
      "content": "12. Quality indicators\nQuality indicators (QIs) are tools that may be used to evaluate care qual-\nity, including structural aspects, process, and outcomes of care.1153 They\nserve as a mechanism for enhancing adherence to guideline recommen-\ndations, through associated quality improvement initiatives and the\nbenchmarking of care providers.1154,1155 As such, the role of QIs in im-\nproving care and outcomes is increasingly recognized by healthcare au-\nthorities, professional organizations, payers, and the public.1153\nThe ESC understands the need for measuring and reporting qual-\nity and outcomes of cardiovascular care, and has established meth-\nods for the development of the ESC QIs for the quantiﬁcation of\ncare and outcomes for cardiovascular disease.1153 In parallel with\nthe writing of this Clinical Practice Guideline document, a process\nhas been initiated to develop QIs for patients with, or at risk of,\nVA or SCD using the ESC methodology and through the collabor-\nation with domain experts and the European Heart Rhythm\nAssociation. These QIs, alongside their speciﬁcations and develop-\nment process, will be published separately.\n13. Supplementary data\nSupplementary data is available at European Heart Journal online.\n14. Data availability statement\nNo new data were generated or analysed in support of this research.\n15. Author information\nAuthor/task force Member Afﬁliations:\nMarta de Riva, Cardiology, Leiden University Medical Centre,\nLeiden,\nNetherlands;\nBo\nGregers\nWinkel,\nCardiology,\nRecommendations for management of patients with short QT syndrome\nIt is recommended that SQTS is diagnosed in the presence of a QTc ≤360 ms and one or more of the following: (a) a pathogenic\nmutation, (b) a family history of SQTS, (c) survival from a VT/VF episode in the absence of heart disease.\nI\nC\nGenetic testing is indicated in patients diagnosed with SQTS.\nI\nC\nICD implantation is recommended in patients with a diagnosis of SQTS who: (a) are survivors of an aborted CA, and/or (b) have\ndocumented spontaneous sustained VT.\nI\nC\nPES is not recommended for SCD risk stratiﬁcation in SQTS patients.\nIII\nC\nRecommendations for the prevention of sudden cardiac death and management of ventricular arrhythmia during pregnancy\nDuring pregnancy, electrical cardioversion is recommended for sustained VT.\nI\nC\nIf ICD implantation is indicated during pregnancy, implantation is recommended with optimal radiation protection.\nI\nC\nContinuation of beta-blockers is recommended during pregnancy and post-partum in patients with LQTS or CPVT.\nI\nC\nRecommendations for risk stratiﬁcation and prevention of sudden cardiac death in athletes\nIn athletes with positive medical history, abnormal physical examination, or ECG alterations, further investigations including\nechocardiography and/or CMR to conﬁrm (or exclude) an underlying disease are recommended.\nI\nC\nIt is recommended that athletes diagnosed with a cardiovascular disease associated with SCD are managed according to current\nguidelines for sports eligibility.\nI\nC\nIt is recommended that staff at sporting facilities are trained in CPR and in the use of AED.\nI\nC\n© ESC 2022\nAAD, anti-arrhythmic drug; ACE-I, angiotensin-converting-enzyme inhibitor; AED, automated external deﬁbrillator; ARB, angiotensin receptor blockers; ARNIs, angiotensin receptor\nneprilysin\ninhibitor;\nARVC,\narrhythmogenic\nright\nventricular\ncardiomyopathy;\nATP,\nanti-tachycardia\npacing;\nAV,\natrioventricular;\nBBR-VT,\nbundle\nbranch\nre-entry;\nBrS, Brugada syndrome; CA, cardiac arrest; CAD, coronary artery disease; CCB, calcium channel blocker; CHD, congenital heart disease; CIED, cardiac implantable electronic\ndevices; CMR, cardiac magnetic resonance; CPR, cardiopulmonary resuscitation; CPVT, catecholaminergic polymorphic ventricular tachycardia; CRT, cardiac resynchronization\ntherapy; DC, direct current; DCM, dilated cardiomyopathy; ECG, electrocardiogram; EF, ejection fraction; ERP, early repolarization pattern; ERS, early repolarization syndrome;\nHCM, hypertrophic cardiomyopathy; HNDCM, hypokinetic non-dilated cardiomyopathy; ICD, implantable cardioverter deﬁbrillator; CAD, coronary artery disease; ILR, implantable\nloop recorder; LCSD, left cardiac sympathetic denervation; LGE, late gadolinium enhancement; LQTS, long QT syndrome; LV, left ventricular; LVEF, left ventricular ejection fraction;\nMRA, mineralocorticoid receptor antagonist; NSVT, non-sustained ventricular tachycardia; NYHA, New York Heart Association; OHCA, out-of-hospital cardiac arrest; OMT,\noptimal medical therapy; PES, programmed electrical stimulation; PVC, premature ventricular complex; PVT, polymorphic ventricular tachycardia; RVOT, right ventricular outﬂow\ntract; SADS, sudden arrhythmic death syndrome; SCA, sudden cardiac arrest; SCD, sudden cardiac death; SD, sudden death; SGLT2, sodium–glucose co-transporter 2; SHD,\nstructural heart disease; SMVT, sustained monomorphic ventricular tachycardia; SQT, short QT syndrome; STEMI, ST-elevation myocardial infarction; SVT, supraventricular\ntachycardia; VA, ventricular arrhythmia; VF, ventricular ﬁbrillation; VT, ventricular tachycardia.\naClass of recommendation.\nbLevel of evidence.\ncShopping malls, stadiums, public transport stations, casinos.\ndList not exhaustive.\neLOE C for VT/PVCs from left fascicles.\nfhttp://www.crediblemeds.org\ngArrhythmic syncope or haemodynamically non-tolerated VA\nESC Guidelines\n4099\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026\n\n\nRigshospitalet,\nCopenhagen,\nDenmark,\nEuropean\nReference\nNetworks for rare, low prevalence and complex diseases of the\nheart, ERN-GUARD HEART; Elijah R. Behr, Cardiovascular\nClinical\nAcademic\nGroup,\nCardiology\nSection,\nSt\nGeorge’s,\nUniversity of London, London, United Kingdom, Department of\nCardiology, St George’s University Hospitals NHS Foundation\nTrust, London, United Kingdom, and Cardiology, Mayo Clinic\nHealthcare, London, United Kingdom; Nico A. Blom, Paediatric\nCardiology,\nLeiden\nUniversity\nMedical\nCentre,\nLeiden,\nNetherlands, and Paediatric Cardiology, Amsterdam University\nMedical Center, Amsterdam, Netherlands; Philippe Charron,\nAPHP, Centre de Référence des Maladies Cardiaques Héréditaires\nou Rares, Hôpital Pitié-Salpêtrière, Paris, France, UMR_S 1166, and\nICAN Institute for Cardiometabolism, and Nutrition, Sorbonne\nUniversité, Paris, France, and European Reference Networks for\nrare,\nlow\nprevalence\nand\ncomplex\ndiseases\nof\nthe\nheart,\nERN-Guard\nHEART,\nParis,\nFrance;\nDomenico\nCorrado,\nDepartment of Cardiac, Thoracic and Vascular Sciences and Public\nHealth, University of Padova, Padova, Italy; Nikolaos Dagres,\nDepartment\nof\nElectrophysiology,\nHeart\nCenter\nLeipzig\nat\nUniversity of Leipzig, Leipzig, Germany; Christian de Chillou,\nDepartment of Cardiology, CHRU-Nancy, Nancy, France, and\nIADI, INSERM U1254, Université de Lorraine, Nancy, France; Lars\nEckardt,\nDepartment\nof\nCardiology\nII—Electrophysiology,\nUniversity Hospital Münster, Münster, Germany; Tim Friede,\nDepartment of Medical Statistics, University Medical Center\nGoettingen, Goettingen, Germany, and Partner Site Goettingen,\nDZHK (German Center for Cardiovascular Research), Goettingen,\nGermany; Kristina H. Haugaa, Department of Cardiology, Oslo\nUniversity Hospital, Rikshospitalet, Oslo, Norway, and Faculty of\nMedicine, University of Oslo, Oslo, Norway; Mélèze Hocini,\nCardiology Department, Liryc Institute, Pessac, France, Hopital\nCardiologique du Haut Lévêque, Pessac, France, and Université de\nBordeaux, Bordeaux, France; Pier D. Lambiase, Institute of\nCardiovascular\nScience,\nUniversity\nCollege,\nLondon,\nUnited\nKingdom, Barts Heart Centre, St Bartholomews Hospital, London,\nUnited Kingdom, and Heart, Vascular and Thoracic Institute,\nCleveland\nClinic,\nLondon,\nUnited\nKingdom;\nEloi\nMarijon,\nCardiology Department, European Georges Pompidou Hospital,\nParis, France; Jose L. Merino, Arrhythmia and Electrophysiology\nRobotic Unit, La Paz University Hospital, Universidad Autonoma,\nIdiPaz, Madrid, Spain, Cardiology Department, Hospital Ruber Juan\nBravo, Madrid, Spain, and Cardiac Electrophysiology, Hospital\nViamed Santa Elena, Madrid, Spain; Petr Peichl, Cardiology\nDepartment, IKEM, Prague, Czech Republic; Silvia G. Priori,\nMolecular Medicine Department, University of Pavia, Pavia, Italy,\nMolecular\nCardiology\nDepartment,\nIstituti\nClinici\nScientiﬁci\nMaugeri\nSpA\nSB,\nPavia,\nItaly,\nand\nMolecular\nCardiology\nDepartment, Centro Nacional de Investigaciones Cardiovasculares\nCarlos III (CNIC), Madrid, Spain, European Reference Networks\nfor rare, low prevalence and complex diseases of the heart, ERN-\nGUARD HEART; Tobias Reichlin, Department of Cardiology,\nInselspital—University Hospital Bern, University of Bern, Bern,\nSwitzerland;\nJeanette\nSchulz-Menger,\nCardiology,\nECRC,\nCharité—Universitätsmedizin Berlin, corporate member of Freie\nUniversität Berlin and Humboldt-Universität zu Berlin, Berlin,\nGermany, Cardiology, Helios Clinics Berlin-Buch, Berlin, Germany,\nand DZHK Partnersite Berlin, Charité, Berlin, Germany; Christian\nSticherling, Department of Cardiology, University Hospital Basel,\nUniversity of Basel, Basel, Switzerland; Stylianos Tzeis, Cardiology\nDepartment, Mitera Hospital, Hygeia Group, Athens, Greece; Axel\nVerstrael (Belgium), ESC Patient Forum, Sophia Antipolis, France;\nand Maurizio Volterrani, Department of Cardiology, IRCCS San\nRaffaele Roma, Rome, Italy, and Professor of Exercise Science and\nMedicine, San Raffaele Telematic University of Rome, Rome.\n16. Appendix\nESC Scientiﬁc Document Group\nIncludes Document Reviewers and ESC National Cardiac\nSocieties.\nDocument Reviewers: Maja Cikes (CPG Review Coordinator)\n(Croatia), Paulus Kirchhof (CPG Review Coordinator) (Germany),\nMagdy Abdelhamid (Egypt), Victor Aboyans (France), Elena Arbelo\n(Spain), Fernando Arribas (Spain), Riccardo Asteggiano (Italy), Cristina\nBasso (Italy), Axel Bauer (Austria), Emanuele Bertaglia (Italy), Tor\nBiering-Sørensen (Denmark), Carina Blomström-Lundqvist (Sweden),\nMichael A. Borger (Germany), Jelena Čelutkienė (Lithuania), Bernard\nCosyns\n(Belgium),\nVolkmar\nFalk\n(Germany),\nLaurent\nFauchier\n(France), Bulent Gorenek (Turkey), Sigrun Halvorsen (Norway),\nRobert Hatala (Slovakia), Hein Heidbuchel (Belgium), Stefan Kaab\n(Germany), Aleksandra Konradi (Russian Federation), Konstantinos\nC. Koskinas (Switzerland), Dipak Kotecha (United Kingdom), Ulf\nLandmesser (Germany), Basil S. Lewis (Israel), Ales Linhart (Czech\nRepublic), Maja-Lisa Løchen (Norway), Lars H. Lund (Sweden),\nAndreas Metzner (Germany), Richard Mindham (United Kingdom),\nJens Cosedis Nielsen (Denmark), Tone M. Norekvål (Norway),\nMonica Patten (Germany), Eva Prescott (Denmark), Amina Rakisheva\n(Kazakhstan), Carol Ann Remme (Netherlands), Ivo Roca-Luque\n(Spain), Andrea Sarkozy (Belgium), Daniel Scherr (Austria), Marta\nSitges (Spain), Rhian M. Touyz (Canada/United Kingdom), Nicolas Van\nMieghem (Netherlands), Vedran Velagic (Croatia), Sami Viskin (Israel),\nand Paul G. A. Volders (Netherlands).\nESC National Cardiac Societies actively involved in the re-\nview process of the 2022 ESC Guidelines for the management of pa-\ntients with ventricular arrhythmias and the prevention of sudden\ncardiac death.\nAlgeria: Algerian Society of Cardiology, Brahim Kichou; Armenia:\nArmenian Cardiologists Association, Mihran Martirosyan; Austria:\nAustrian\nSociety\nof\nCardiology,\nDaniel\nScherr;\nAzerbaijan:\nAzerbaijan Society of Cardiology, Farid Aliyev; Belgium: Belgian\nSociety of Cardiology, Rik Willems; Bosnia and Herzegovina:\nAssociation of Cardiologists of Bosnia and Herzegovina, Nabil Naser;\nBulgaria: Bulgarian Society of Cardiology, Tchavdar Shalganov;\nCroatia: Croatian Cardiac Society, Davor Milicic; Cyprus: Cyprus\nSociety of Cardiology, Theodoros Christophides; Czech Republic:\nCzech Society of Cardiology, Josef Kautzner; Denmark: Danish\nSociety of Cardiology, Jim Hansen; Egypt: Egyptian Society of\nCardiology, Lamyaa Allam; Estonia: Estonian Society of Cardiology,\nPriit Kampus; Finland: Finnish Cardiac Society, Juhani Junttila;\nFrance:\nFrench\nSociety\nof\nCardiology,\nChristophe\nLeclercq;\nGeorgia: Georgian Society of Cardiology, Kakhaber Etsadashvili;\nGermany: German Cardiac Society, Daniel Steven; Greece:\nHellenic Society of Cardiology, Konstantinos Gatzoulis; Hungary:\n4100\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026\n\n\nHungarian Society of Cardiology, László Gellér; Iceland: Icelandic\nSociety of Cardiology, David O. Arnar; Ireland: Irish Cardiac Society,\nJoseph Galvin, European Reference Networks for rare, low prevalence\nand complex diseases of the heart, ERN-GUARD HEART; Israel: Israel\nHeart Society, Moti Haim; Italy: Italian Federation of Cardiology, Carlo\nPappone; Kosovo (Republic of): Kosovo Society of Cardiology,\nShpend Elezi; Kyrgyzstan: Kyrgyz Society of Cardiology, Alina\nKerimkulova; Latvia: Latvian Society of Cardiology, Oskars Kalejs;\nLebanon: Lebanese Society of Cardiology, Ali Rabah; Lithuania:\nLithuanian Society of Cardiology, Aras Puodziukynas; Luxembourg:\nLuxembourg Society of Cardiology, Carlo Dimmer; Malta: Maltese\nCardiac Society, Mark Adrian Sammut; Moldova (Republic of):\nMoldavian Society of Cardiology, Lilia David; Montenegro:\nMontenegro Society of Cardiology, Aneta Boskovic; Morocco:\nMoroccan\nSociety\nof\nCardiology,\nAbdelhamid\nMoustaghﬁr;\nNetherlands: Netherlands Society of Cardiology, Alexander\nH. Maass; North Macedonia: North Macedonian Society of\nCardiology,\nLidija\nPoposka;\nNorway:\nNorwegian\nSociety\nof\nCardiology, Ole Christian Mjolstad; Poland: Polish Cardiac Society,\nPrzemysław Mitkowski; Portugal: Portuguese Society of Cardiology,\nLeonor Parreira; Romania: Romanian Society of Cardiology, Dragos\nCozma; Russian Federation: Russian Society of Cardiology, Elena\nGolukhova; San Marino: San Marino Society of Cardiology,\nRoberto Bini; Serbia: Cardiology Society of Serbia, Sinisa Stojkovic;\nSlovakia: Slovak Society of Cardiology, Peter Hlivak; Slovenia:\nSlovenian Society of Cardiology, Andrej Pernat; Spain: Spanish\nSociety of Cardiology, Nicasio Perez Castellano; Sweden: Swedish\nSociety of Cardiology, Pyotr G. Platonov; Switzerland: Swiss\nSociety of Cardiology, Firat Duru; Syrian Arab Republic: Syrian\nCardiovascular Association, Ahmad Rasheed Al Saadi; Tunisia:\nTunisian Society of Cardiology and Cardio-Vascular Surgery, Sana\nOuali; Turkey: Turkish Society of Cardiology, Sabri Demircan;\nUkraine: Ukrainian Association of Cardiology, Oleg Sychov; and\nUnited Kingdom of Great Britain and Northern Ireland:\nBritish Cardiovascular Society, Alistair Slade.\nESC Clinical Practice Guidelines (CPG) Committee:\nColin Baigent (Chairperson) (United Kingdom), Magdy Abdelhamid\n(Egypt),\nVictor\nAboyans\n(France),\nSotiris\nAntoniou\n(United\nKingdom), Elena Arbelo (Spain), Riccardo Asteggiano (Italy), Andreas\nBaumbach (United Kingdom), Michael A. Borger (Germany), Jelena\nČelutkienė (Lithuania), Maja Cikes (Croatia), Jean-Philippe Collet\n(France), Volkmar Falk (Germany), Laurent Fauchier (France), Chris\nP. Gale (United Kingdom), Sigrun Halvorsen (Norway), Bernard Iung\n(France), Tiny Jaarsma (Sweden), Aleksandra Konradi (Russian\nFederation), Konstantinos C. Koskinas (Switzerland), Dipak Kotecha\n(United Kingdom), Ulf Landmesser (Germany), Basil S. Lewis (Israel),\nAles Linhart (Czech Republic), Maja-Lisa Løchen (Norway), Richard\nMindham (United Kingdom), Jens Cosedis Nielsen (Denmark),\nSteffen E. Petersen (United Kingdom), Eva Prescott (Denmark),\nAmina Rakisheva (Kazakhstan), Marta Sitges (Spain), and Rhian\nM. Touyz (Canada/United Kingdom).\n17. References\n1. Brignole M, Moya A, de Lange FJ, Deharo J-C, Elliott PM, Fanciulli A, et al. 2018 ESC\nGuidelines for the diagnosis and management of syncope. Eur Heart J 2018;39:\n1883–1948.\n2. Glikson M, Nielsen JC, Kronborg MB, Michowitz Y, Auricchio A, Barbash IM, et al.\n2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. Eur\nHeart J 2021;42:3427–3520.\n3. Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, et al. 2017\nESC Guidelines for the management of acute myocardial infarction in patients pre-\nsenting with ST-segment elevation: the task force for the management of acute\nmyocardial infarction in patients presenting with ST-segment elevation of the\nEuropean Society of Cardiology (ESC). Eur Heart J 2018;39:119–177.\n4. Pelliccia A, Sharma S, Gati S, Bäck M, Börjesson M, Caselli S, et al. 2020 ESC\nGuidelines on sports cardiology and exercise in patients with cardiovascular dis-\nease. Eur Heart J 2021;42:17–96.\n5. Wahbi K, Babuty D, Probst V, Wissocque L, Labombarda F, Porcher R, et al.\nIncidence and predictors of sudden death, major conduction defects and sustained\nventricular tachyarrhythmias in 1388 patients with myotonic dystrophy type 1. Eur\nHeart J 2017;38:751–758.\n6. Bucci E, Testa M, Licchelli L, Frattari A, El Halabieh NA, Gabriele E, et al. A 34-year\nlongitudinal study on long-term cardiac outcomes in DM1 patients with normal\nECG at baseline at an Italian clinical centre. J Neurol 2018;265:885–895.\n7. Chong-Nguyen C, Wahbi K, Algalarrondo V, Bécane HM, Radvanyi-Hoffman H,\nArnaud P, et al. Association between mutation size and cardiac involvement in\nmyotonic dystrophy type 1: an analysis of the DM1-heart registry. Circ Cardiovasc\nGenet 2017;10:e001526.\n8. Sabovic M, Medica I, Logar N, Mandić E, Zidar J, Peterlin B. Relation of CTG expan-\nsion and clinical variables to electrocardiogram conduction abnormalities and sud-\nden death in patients with myotonic dystrophy. Neuromuscul Disord 2003;13:\n822–826.\n9. Clarke\nNR,\nKelion\nAD,\nNixon\nJ,\nHilton-Jones\nD,\nForfar\nJC.\nDoes\ncytosine-thymine-guanine (CTG) expansion size predict cardiac events and elec-\ntrocardiographic progression in myotonic dystrophy? Heart 2001;86:411–416.\n10. Melacini P, Villanova C, Menegazzo E, Novelli G, Danieli G, Rizzoli G, et al.\nCorrelation between cardiac involvement and CTG trinucleotide repeat length\nin myotonic dystrophy. J Am Coll Cardiol 1995;25:239–245.\n11. Lazarus A, Varin J, Ounnoughene Z, Radvanyi H, Junien C, Coste J, et al.\nRelationships among electrophysiological ﬁndings and clinical status, heart function,\nand extent of DNA mutation in myotonic dystrophy. Circulation 1999;99:\n1041–1046.\n12. Sansone VA, Brigonzi E, Schoser B, Villani S, Gaeta M, De Ambroggi G, et al. The\nfrequency and severity of cardiac involvement in myotonic dystrophy type 2\n(DM2): long-term outcomes. Int J Cardiol 2013;168:1147–1153.\n13. Breton R, Mathieu J. Usefulness of clinical and electrocardiographic data for pre-\ndicting adverse cardiac events in patients with myotonic dystrophy. Can J Cardiol\n2009;25:e23–e27.\n14. Hermans MCE, Faber CG, Bekkers SCAM, de Die-Smulders CEM, Gerrits MM,\nMerkies ISJ, et al. Structural and functional cardiac changes in myotonic dystrophy\ntype1: a cardiovascular magnetic resonance study.J Cardiovasc Magn Reson 2012;14:48.\n15. Schmacht L, Traber J, Grieben U, Utz W, Dieringer MA, Kellman P, et al. Cardiac\ninvolvement in myotonic dystrophy type 2 patients with preserved ejection frac-\ntion: detection by cardiovascular magnetic resonance. Circ Cardiovasc Imaging\n2016;9:e004615.\n16. Groh WJ, Groh MR, Saha C, Kincaid JC, Simmons Z, Ciafaloni E, et al.\nElectrocardiographic abnormalities and sudden death in myotonic dystrophy\ntype 1. N Engl J Med 2008;358:2688–2697.\n17. Bhakta D, Groh MR, Shen C, Pascuzzi RM, Groh WJ. Increased mortality with left\nventricular systolic dysfunction and heart failure in adults with myotonic dystrophy\ntype 1. Am Heart J 2010;160:1137–1141.\n18. Petri H, Ahtarovski KA, Vejlstrup N, Vissing J, Witting N, Køber L, et al. Myocardial\nﬁbrosis in patients with myotonic dystrophy type 1: a cardiovascular magnetic res-\nonance study. J Cardiovasc Magn Reson 2014;16:59.\n19. Myerburg RJ, Junttila MJ. Sudden cardiac death caused by coronary heart disease.\nCirculation 2012;125:1043–1052.\n20. Stecker EC, Reinier K, Marijon E, Narayanan K, Teodorescu C, Uy-Evanado A, et al.\nPublic health burden of sudden cardiac death in the United States. Circ Arrhythm\nElectrophysiol 2014;7:212–217.\n21. Chen LY, Sotoodehnia N, Bůžková P, Lopez FL, Yee LM, Heckbert SR, et al. Atrial\nﬁbrillation and the risk of sudden cardiac death: the atherosclerosis risk in commu-\nnities study and cardiovascular health study. JAMA Intern Med 2013;173:29–35.\n22. Marijon E, Uy-Evanado A, Dumas F, Karam N, Reinier K, Teodorescu C, et al.\nWarning symptoms are associated with survival from sudden cardiac arrest. Ann\nIntern Med 2016;164:23–29.\n23. Glinge C, Jabbari R, Risgaard B, Lynge TH, Engstrøm T, Albert CM, et al. Symptoms\nbefore sudden arrhythmic death syndrome: a nationwide study among the young in\nDenmark. J Cardiovasc Electrophysiol 2015;26:761–767.\n24. Ågesen FN, Lynge TH, Blanche P, Banner J, Prescott E, Jabbari R, et al. Temporal\ntrends and sex differences in sudden cardiac death in the Copenhagen City\nHeart Study. Heart 2021;107:1303–1309.\nESC Guidelines\n4101\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026\n\n\n25. Winkel BG, Holst AG, Theilade J, Kristensen IB, Thomsen JL, Ottesen GL, et al.\nNationwide study of sudden cardiac death in persons aged 1–35 years. Eur Heart\nJ 2011;32:983–990.\n26. Pilmer CM, Kirsh JA, Hildebrandt D, Krahn AD, Gow RM. Sudden cardiac death in\nchildren and adolescents between 1 and 19 years of age. Heart Rhythm 2014;11:\n239–245.\n27. Risgaard B, Winkel BG, Jabbari R, Behr ER, Ingemann-Hansen O, Thomsen JL, et al.\nBurden of sudden cardiac death in persons aged 1 to 49 years: nationwide study in\nDenmark. Circ Arrhythm Electrophysiol 2014;7:205–211.\n28. Fishman GI, Chugh SS, DiMarco JP, Albert CM, Anderson ME, Bonow RO, et al.\nSudden cardiac death prediction and prevention report from a national heart,\nlung, and blood institute and heart rhythm society workshop. Circulation 2010;\n122:2335–2348.\n29. Wong CX, Brown A, Lau DH, Chugh SS, Albert CM, Kalman JM, et al. Epidemiology\nof sudden cardiac death: global and regional perspectives. Heart Lung Circ 2019;28:\n6–14.\n30. Bougouin W, Lamhaut L, Marijon E, Jost D, Dumas F, Deye N, et al. Characteristics\nand prognosis of sudden cardiac death in Greater Paris: population-based approach\nfrom the Paris Sudden Death Expertise Center (Paris-SDEC). Intensive Care Med\n2014;40:846–854.\n31. Deo R, Albert CM. Epidemiology and genetics of sudden cardiac death. Circulation\n2012;125:620–637.\n32. Gerber Y, Jacobsen SJ, Frye RL, Weston SA, Killian JM, Roger VL. Secular trends in\ndeaths from cardiovascular diseases: a 25-year community study. Circulation 2006;\n113:2285–2292.\n33. Krahn AD, Connolly SJ, Roberts RS, Gent M, ATMA Investigators. Diminishing pro-\nportional risk of sudden death with advancing age: implications for prevention of\nsudden death. Am Heart J 2004;147:837–840.\n34. Becker LB, Han BH, Meyer PM, Wright FA, Rhodes KV, Smith DW, et al. Racial dif-\nferences in the incidence of cardiac arrest and subsequent survival. The CPR\nChicago Project. N Engl J Med 1993;329:600–606.\n35. Zhao D, Post WS, Blasco-Colmenares E, Cheng A, Zhang Y, Deo R, et al. Racial\ndifferences in sudden cardiac death. Circulation 2019;139:1688–1697.\n36. de Vreede-Swagemakers JJ, Gorgels AP, Dubois-Arbouw WI, van Ree JW, Daemen\nMJ, Houben LG, et al. Out-of-hospital cardiac arrest in the 1990’s: a population-\nbased study in the Maastricht area on incidence, characteristics and survival. J Am\nColl Cardiol 1997;30:1500–1505.\n37. Lynge TH, Risgaard B, Banner J, Nielsen JL, Jespersen T, Stampe NK, et al.\nNationwide burden of sudden cardiac death: a study of 54,028 deaths in\nDenmark. Heart Rhythm 2021;18:1657–1665.\n38. Atwood C, Eisenberg MS, Herlitz J, Rea TD. Incidence of EMS-treated\nout-of-hospital cardiac arrest in Europe. Resuscitation 2005;67:75–80.\n39. Empana J-P, Blom MT, Böttiger BW, Dagres N, Dekker JM, Gislason G, et al.\nDeterminants of occurrence and survival after sudden cardiac arrest—a\nEuropean perspective: The ESCAPE-NET project. Resuscitation 2018;124:7–13.\n40. Fox CS, Evans JC, Larson MG, Kannel WB, Levy D. Temporal trends in coronary\nheart disease mortality and sudden cardiac death from 1950 to 1999: the\nFramingham Heart Study. Circulation 2004;110:522–527.\n41. Niemeijer MN, van den Berg ME, Leening MJG, Hofman A, Franco OH, Deckers\nJW, et al. Declining incidence of sudden cardiac death from 1990–2010 in a general\nmiddle-aged and elderly population: the Rotterdam Study. Heart Rhythm 2015;12:\n123–129.\n42. Lynge TH, Nielsen JL, Blanche P, Gislason G, Torp-Pedersen C, Winkel BG, et al.\nDecline in incidence of sudden cardiac death in the young: a 10-year nationwide\nstudy of 8756 deaths in Denmark. Europace 2019;21:909–917.\n43. Zheng ZJ, Croft JB, Giles WH, Mensah GA. Sudden cardiac death in the United\nStates, 1989 to 1998. Circulation 2001;104:2158–2163.\n44. Dudas K, Lappas G, Stewart S, Rosengren A. Trends in out-of-hospital deaths due\nto coronary heart disease in Sweden (1991 to 2006). Circulation 2011;123:46–52.\n45. Harmon KG, Asif IM, Maleszewski JJ, Owens DS, Prutkin JM, Salerno JC, et al.\nIncidence, cause, and comparative frequency of sudden cardiac death in national\ncollegiate athletic association athletes: a decade in review. Circulation 2015;132:\n10–19.\n46. Risgaard B, Winkel BG, Jabbari R, Glinge C, Ingemann-Hansen O, Thomsen JL, et al.\nSports-related sudden cardiac death in a competitive and a noncompetitive athlete\npopulation aged 12 to 49 years: data from an unselected nationwide study in\nDenmark. Heart Rhythm 2014;11:1673–1681.\n47. Holst AG, Winkel BG, Theilade J, Kristensen IB, Thomsen JL, Ottesen GL, et al.\nIncidence and etiology of sports-related sudden cardiac death in Denmark—impli-\ncations for preparticipation screening. Heart Rhythm 2010;7:1365–1371.\n48. Maron BJ, Doerer JJ, Haas TS, Tierney DM, Mueller FO. Sudden deaths in young\ncompetitive athletes: analysis of 1866 deaths in the United States, 1980–2006.\nCirculation 2009;119:1085–1092.\n49. Corrado D, Basso C, Thiene G. Sudden cardiac death in athletes: what is the role of\nscreening? Curr Opin Cardiol 2012;27:41–48.\n50. Albert CM, Mittleman MA, Chae CU, Lee IM, Hennekens CH, Manson JE.\nTriggering of sudden death from cardiac causes by vigorous exertion. N Engl J\nMed 2000;343:1355–1361.\n51. Siscovick DS, Weiss NS, Fletcher RH, Lasky T. The incidence of primary cardiac ar-\nrest during vigorous exercise. N Engl J Med 1984;311:874–877.\n52. Marijon E, Tafﬂet M, Celermajer DS, Dumas F, Perier M-C, Mustaﬁc H, et al.\nSports-related sudden death in the general population. Circulation 2011;124:\n672–681.\n53. Heidbuchel H, Willems R, Jordaens L, Olshansky B, Carre F, Lozano IF, et al.\nIntensive recreational athletes in the prospective multinational ICD sports safety\nregistry: results from the European cohort. Eur J Prev Cardiol 2019;26:764–775.\n54. Marijon E, Bougouin W, Périer M-C, Celermajer DS, Jouven X. Incidence of sports-\nrelated sudden death in France by speciﬁc sports and sex. JAMA 2013;310:642–643.\n55. Marijon E, Uy-Evanado A, Reinier K, Teodorescu C, Narayanan K, Jouven X, et al.\nSudden cardiac arrest during sports activity in middle age. Circulation 2015;131:\n1384–1391.\n56. Bagnall RD, Weintraub RG, Ingles J, Duﬂou J, Yeates L, Lam L, et al. A prospective\nstudy of sudden cardiac death among children and young adults. N Engl J Med 2016;\n374:2441–2452.\n57. Wisten A, Forsberg H, Krantz P, Messner T. Sudden cardiac death in 15-35-year\nolds in Sweden during 1992-99. J Intern Med 2002;252:529–536.\n58. Chugh SS, Jui J, Gunson K, Stecker EC, John BT, Thompson B, et al. Current burden\nof sudden cardiac death: multiple source surveillance versus retrospective death\ncertiﬁcate-based review in a large US. community. J Am Coll Cardiol 2004;44:\n1268–1275.\n59. Winkel BG, Risgaard B, Sadjadieh G, Bundgaard H, Haunsø S, Tfelt-Hansen J.\nSudden cardiac death in children (1–18 years): symptoms and causes of death in\na nationwide setting. Eur Heart J 2014;35:868–875.\n60. Byrne R, Constant O, Smyth Y, Callagy G, Nash P, Daly K, et al. Multiple source\nsurveillance incidence and aetiology of out-of-hospital sudden cardiac death in a\nrural population in the West of Ireland. Eur Heart J 2008;29:1418–1423.\n61. Eckart RE, Shry EA, Burke AP, McNear JA, Appel DA, Castillo-Rojas LM, et al.\nSudden death in young adults an autopsy-based series of a population undergoing\nactive surveillance. J Am Coll Cardiol 2011;58:1254–1261.\n62. Waldmann V, Karam N, Bougouin W, Sharifzadehgan A, Dumas F, Narayanan K,\net al. Burden of coronary artery disease as a cause of sudden cardiac arrest in\nthe young. J Am Coll Cardiol 2019;73:2118–2120.\n63. Waldmann V, Karam N, Rischard J, Bougouin W, Sharifzadehgan A, Dumas F, et al.\nLow rates of immediate coronary angiography among young adults resuscitated\nfrom sudden cardiac arrest. Resuscitation 2020;147:34–42.\n64. Lloyd-Jones DM, Wilson PWF, Larson MG, Beiser A, Leip EP, D’Agostino RB, et al.\nFramingham risk score and prediction of lifetime risk for coronary heart disease.\nAm J Cardiol 2004;94:20–24.\n65. Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, et al. 2021\nESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J\n2021;42:3227–3337.\n66. Jouven X, Desnos M, Guerot C, Ducimetière P. Predicting sudden death in the\npopulation: the Paris Prospective Study I. Circulation 1999;99:1978–1983.\n67. Dekker LRC, Bezzina CR, Henriques JPS, Tanck MW, Koch KT, Alings MW, et al.\nFamilial sudden death is an important risk factor for primary ventricular ﬁbrillation:\na case-control study in acute myocardial infarction patients. Circulation 2006;114:\n1140–1145.\n68. Kaikkonen KS, Kortelainen M-L, Linna E, Huikuri HV. Family history and the risk of\nsudden cardiac death as a manifestation of an acute coronary event. Circulation\n2006;114:1462–1467.\n69. Jabbari R, Engstrøm T, Glinge C, Risgaard B, Jabbari J, Winkel BG, et al. Incidence\nand risk factors of ventricular ﬁbrillation before primary angioplasty in patients\nwith ﬁrst ST-elevation myocardial infarction: a nationwide study in Denmark. J\nAm Heart Assoc 2015;4:e001399.\n70. Friedlander Y, Siscovick DS, Weinmann S, Austin MA, Psaty BM, Lemaitre RN, et al.\nFamily history as a risk factor for primary cardiac arrest. Circulation 1998;97:\n155–160.\n71. Deo R, Norby FL, Katz R, Sotoodehnia N, Adabag S, DeFilippi CR, et al.\nDevelopment and validation of a sudden cardiac death prediction model for the\ngeneral population. Circulation 2016;134:806–816.\n72. Aro AL, Reinier K, Rusinaru C, Uy-Evanado A, Darouian N, Phan D, et al. Electrical\nrisk score beyond the left ventricular ejection fraction: prediction of sudden cardiac\ndeath in the Oregon Sudden Unexpected Death Study and the Atherosclerosis\nRisk in Communities Study. Eur Heart J 2017;38:3017–3025.\n73. Waks JW, Sitlani CM, Soliman EZ, Kabir M, Ghafoori E, Biggs ML, et al. Global elec-\ntric heterogeneity risk score for prediction of sudden cardiac death in the general\npopulation: the Atherosclerosis Risk in Communities (ARIC) and Cardiovascular\nHealth (CHS) studies. Circulation 2016;133:2222–2234.\n4102\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026\n\n\n74. Yoshinaga M, Ushinohama H, Sato S, Tauchi N, Horigome H, Takahashi H, et al.\nElectrocardiographic screening of 1-month-old infants for identifying prolonged\nQT intervals. Circ Arrhythm Electrophysiol 2013;6:932–938.\n75. Yoshinaga M, Kucho Y, Sarantuya J, Ninomiya Y, Horigome H, Ushinohama H, et al.\nGenetic characteristics of children and adolescents with long-QT syndrome diag-\nnosed by school-based electrocardiographic screening programs. Circ Arrhythm\nElectrophysiol 2014;7:107–112.\n76. Jørgensen T, Jacobsen RK, Toft U, Aadahl M, Glümer C, Pisinger C. Effect of screen-\ning and lifestyle counselling on incidence of ischaemic heart disease in general popu-\nlation: Inter99 randomised trial. BMJ 2014;348:g3617.\n77. Boas R, Sappler N, von Stülpnagel L, Klemm M, Dixen U, Thune JJ, et al. Periodic\nrepolarization dynamics identiﬁes ICD-responders in non-ischemic cardiomyop-\nathy: a DANISH substudy. Circulation 2022;145:754–764.\n78. Spirito P, Bellone P, Harris KM, Bernabo P, Bruzzi P, Maron BJ. Magnitude of left\nventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy.\nN Engl J Med 2000;342:1778–1785.\n79. Barsheshet A, Goldenberg I, O-Uchi J, Moss AJ, Jons C, Shimizu W, et al. Mutations\nin cytoplasmic loops of the KCNQ1 channel and the risk of life-threatening events:\nimplications for mutation-speciﬁc response to β-blocker therapy in type 1 long-QT\nsyndrome. Circulation 2012;125:1988–1996.\n80. Wahbi K, Ben Yaou R, Gandjbakhch E, Anselme F, Gossios T, Lakdawala NK, et al.\nDevelopment and validation of a new risk prediction score for life-threatening ven-\ntricular tachyarrhythmias in laminopathies. Circulation 2019;140:293–302.\n81. Cadrin-Tourigny J, Bosman LP, Nozza A, Wang W, Tadros R, Bhonsale A, et al. A\nnew prediction model for ventricular arrhythmias in arrhythmogenic right ventricu-\nlar cardiomyopathy. Eur Heart J 2019;40:1850–1858.\n82. Priori SG, Schwartz PJ, Napolitano C, Bloise R, Ronchetti E, Grillo M, et al. Risk\nstratiﬁcation in the long-QT syndrome. N Engl J Med 2003;348:1866–1874.\n83. Miron A, Lafreniere-Roula M, Steve Fan C-P, Armstrong KR, Dragulescu A, Papaz\nT, et al. A validated model for sudden cardiac death risk prediction in pediatric\nhypertrophic cardiomyopathy. Circulation 2020;142:217–229.\n84. Norrish G, Ding T, Field E, Ziólkowska L, Olivotto I, Limongelli G, et al.\nDevelopment of a novel risk prediction model for sudden cardiac death in child-\nhood hypertrophic cardiomyopathy (HCM risk-kids). JAMA Cardiol 2019;4:\n918–927.\n85. O’Mahony C, Jichi F, Pavlou M, Monserrat L, Anastasakis A, Rapezzi C, et al. A novel\nclinical risk prediction model for sudden cardiac death in hypertrophic cardiomy-\nopathy (HCM risk-SCD). Eur Heart J 2014;35:2010–2020.\n86. Steyerberg EW, Vergouwe Y. Towards better clinical prediction models: seven\nsteps for development and an ABCD for validation. Eur Heart J 2014;35:\n1925–1931.\n87. Collins GS, Reitsma JB, Altman DG, Moons KGM, TRIPOD Group. Transparent re-\nporting of a multivariable prediction model for individual prognosis or diagnosis\n(TRIPOD): the TRIPOD statement. Circulation 2015;131:211–219.\n88. Alba AC, Agoritsas T, Walsh M, Hanna S, Iorio A, Devereaux PJ, et al.\nDiscrimination and calibration of clinical prediction models: users’ guides to the\nmedical literature. JAMA 2017;318:1377–1384.\n89. Yan S, Gan Y, Jiang N, Wang R, Chen Y, Luo Z, et al. The global survival rate among\nadult out-of-hospital cardiac arrest patients who received cardiopulmonary resus-\ncitation: a systematic review and meta-analysis. Crit Care 2020;24:61.\n90. Hallstrom AP, Ornato JP, Weisfeldt M, Travers A, Christenson J, McBurnie MA,\net al. Public-access deﬁbrillation and survival after out-of-hospital cardiac arrest.\nN Engl J Med 2004;351:637–646.\n91. Nakashima T, Noguchi T, Tahara Y, Nishimura K, Yasuda S, Onozuka D, et al.\nPublic-access\ndeﬁbrillation\nand\nneurological\noutcomes\nin\npatients\nwith\nout-of-hospital cardiac arrest in Japan: a population-based cohort study. Lancet\n2019;394:2255–2262.\n92. Pollack RA, Brown SP, Rea T, Aufderheide T, Barbic D, Buick JE, et al. Impact of\nbystander automated external deﬁbrillator use on survival and functional outcomes\nin shockable observed public cardiac arrests. Circulation 2018;137:2104–2113.\n93. Kragholm K, Wissenberg M, Mortensen RN, Hansen SM, Malta Hansen C,\nThorsteinsson K, et al. Bystander efforts and 1-year outcomes in out-of-hospital\ncardiac arrest. N Engl J Med 2017;376:1737–1747.\n94. Kitamura T, Kiyohara K, Sakai T, Matsuyama T, Hatakeyama T, Shimamoto T, et al.\nPublic-access deﬁbrillation and out-of-hospital cardiac arrest in Japan. N Engl J Med\n2016;375:1649–1659.\n95. Hasselqvist-Ax I, Riva G, Herlitz J, Rosenqvist M, Hollenberg J, Nordberg P, et al.\nEarly cardiopulmonary resuscitation in out-of-hospital cardiac arrest. N Engl J\nMed 2015;372:2307–2315.\n96. Marijon E, Bougouin W, Celermajer DS, Perier M-C, Benameur N, Lamhaut L, et al.\nMajor regional disparities in outcomes after sudden cardiac arrest during sports.\nEur Heart J 2013;34:3632–3640.\n97. Karam N, Narayanan K, Bougouin W, Benameur N, Beganton F, Jost D, et al. Major\nregional differences in Automated External Deﬁbrillator placement and Basic Life\nSupport training in France: further needs for coordinated implementation.\nResuscitation 2017;118:49–54.\n98. Mpotos N, De Wever B, Cleymans N, Raemaekers J, Loeys T, Herregods L, et al.\nRepetitive sessions of formative self-testing to refresh CPR skills: a randomised\nnon-inferiority trial. Resuscitation 2014;85:1282–1286.\n99. Gundry JW, Comess KA, DeRook FA, Jorgenson D, Bardy GH. Comparison of na-\nive sixth-grade children with trained professionals in the use of an automated ex-\nternal deﬁbrillator. Circulation 1999;100:1703–1707.\n100. Blewer AL, Putt ME, Becker LB, Riegel BJ, Li J, Leary M, et al. Video-only cardiopul-\nmonary resuscitation education for high-risk families before hospital discharge: a\nmulticenter pragmatic trial. Circ Cardiovasc Qual Outcomes 2016;9:740–748.\n101. Ringh M, Rosenqvist M, Hollenberg J, Jonsson M, Fredman D, Nordberg P, et al.\nMobile-phone dispatch of laypersons for CPR in out-of-hospital cardiac arrest. N\nEngl J Med 2015;372:2316–2325.\n102. Stroop R, Kerner T, Strickmann B, Hensel M. Mobile phone-based alerting of\nCPR-trained volunteers simultaneously with the ambulance can reduce the\nresuscitation-free interval and improve outcome after out-of-hospital cardiac ar-\nrest: a German, population-based cohort study. Resuscitation 2020;147:57–64.\n103. Lee SY, Shin SD, Lee YJ, Song KJ, Hong KJ, Ro YS, et al. Text message alert system\nand resuscitation outcomes after out-of-hospital cardiac arrest: a before-and-after\npopulation-based study. Resuscitation 2019;138:198–207.\n104. Fordyce CB, Hansen CM, Kragholm K, Dupre ME, Jollis JG, Roettig ML, et al.\nAssociation of public health initiatives with outcomes for out-of-hospital cardiac ar-\nrest at home and in public locations. JAMA Cardiol 2017;2:1226–1235.\n105. Andelius L, Malta Hansen C, Lippert FK, Karlsson L, Torp-Pedersen C, Kjær Ersbøll\nA, et al. Smartphone activation of citizen responders to facilitate deﬁbrillation in\nout-of-hospital cardiac arrest. J Am Coll Cardiol 2020;76:43–53.\n106. Ranthe MF, Winkel BG, Andersen EW, Risgaard B, Wohlfahrt J, Bundgaard H, et al.\nRisk of cardiovascular disease in family members of young sudden cardiac death vic-\ntims. Eur Heart J 2013;34:503–511.\n107. Patton KK, Sotoodehnia N, DeFilippi C, Siscovick DS, Gottdiener JS, Kronmal RA.\nN-terminal pro-B-type natriuretic peptide is associated with sudden cardiac death\nrisk: the Cardiovascular Health Study. Heart Rhythm 2011;8:228–233.\n108. Everett BM, Moorthy MV, Tikkanen JT, Cook NR, Albert CM. Markers of myocar-\ndial stress, myocardial injury, and subclinical inﬂammation and the risk of sudden\ndeath. Circulation 2020;142:1148–1158.\n109. Berger R, Huelsman M, Strecker K, Bojic A, Moser P, Stanek B, et al. B-type natri-\nuretic peptide predicts sudden death in patients with chronic heart failure.\nCirculation 2002;105:2392–2397.\n110. Scott PA, Barry J, Roberts PR, Morgan JM. Brain natriuretic peptide for the predic-\ntion of sudden cardiac death and ventricular arrhythmias: a meta-analysis. Eur J\nHeart Fail 2009;11:958–966.\n111. Ahmad T, Fiuzat M, Neely B, Neely ML, Pencina MJ, Kraus WE, et al. Biomarkers of\nmyocardial stress and ﬁbrosis as predictors of mode of death in patients with\nchronic heart failure. JACC Heart Fail 2014;2:260–268.\n112. Goldberger JJ, Cain ME, Hohnloser SH, Kadish AH, Knight BP, Lauer MS, et al.\nAmerican Heart Association/American College of Cardiology Foundation/Heart\nRhythm Society scientiﬁc statement on noninvasive risk stratiﬁcation techniques\nfor identifying patients at risk for sudden cardiac death: a scientiﬁc statement\nfrom\nthe\nAmerican\nHeart\nAssociation\nCouncil\non\nClinical\nCardiology\nCommittee\non\nElectrocardiography\nand\nArrhythmias\nand\nCouncil\non\nEpidemiology and Prevention. Circulation 2008;118:1497–1518.\n113. Varma N, Cygankiewicz I, Turakhia MP, Heidbuchel H, Hu Y-F, Chen LY, et al. 2021\nISHNE/HRS/EHRA/APHRS expert collaborative statement on mHealth in arrhyth-\nmia management: digital medical tools for heart rhythm professionals: from the\ninternational society for holter and noninvasive electrocardiology/heart rhythm so-\nciety/European heart rhythm association/Asia-Paciﬁc heart rhythm society. Circ\nArrhythm Electrophysiol 2021;14:e009204.\n114. Solbiati M, Casazza G, Dipaola F, Barbic F, Caldato M, Montano N, et al. The diag-\nnostic yield of implantable loop recorders in unexplained syncope: a systematic re-\nview and meta-analysis. Int J Cardiol 2017;231:170–176.\n115. Gatzoulis KA, Arsenos P, Trachanas K, Dilaveris P, Antoniou C, Tsiachris D, et al.\nSignal-averaged electrocardiography: past, present, and future. J Arrhythmia 2018;\n34:222–229.\n116. Marcus FI, McKenna WJ, Sherrill D, Basso C, Bauce B, Bluemke DA, et al. Diagnosis\nof arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modiﬁca-\ntion of the task force criteria. Eur Heart J 2010;31:806–814.\n117. Giudicessi JR, Ackerman MJ. Exercise testing oversights underlie missed and delayed\ndiagnosis of catecholaminergic polymorphic ventricular tachycardia in young sud-\nden cardiac arrest survivors. Heart Rhythm 2019;16:1232–1239.\n118. Roston TM, Kallas D, Davies B, Franciosi S, De Souza AM, Laksman ZW, et al. Burst\nexercise testing can unmask arrhythmias in patients with incompletely penetrant\ncatecholaminergic polymorphic ventricular tachycardia. JACC Clin Electrophysiol\n2021;7:437–441.\nESC Guidelines\n4103\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026\n\n\n119. Sy RW, van der Werf C, Chattha IS, Chockalingam P, Adler A, Healey JS, et al.\nDerivation and validation of a simple exercise-based algorithm for prediction of\ngenetic testing in relatives of LQTS probands. Circulation 2011;124:2187–2194.\n120. Binder T. Transthoracic echocardiography and the standard examination of\nspeciﬁc cardiac structures. ESC CardioMed. 3rd ed. Oxford University Press;\n2022. p425–431.\n121. Haugaa KH, Basso C, Badano LP, Bucciarelli-Ducci C, Cardim N, Gaemperli O, et al.\nComprehensive multi-modality imaging approach in arrhythmogenic cardiomyop-\nathy—an\nexpert\nconsensus\ndocument\nof\nthe\nEuropean\nAssociation\nof\nCardiovascular Imaging. Eur Heart J Cardiovasc Imaging 2017;18:237–253.\n122. Haugaa KH, Grenne BL, Eek CH, Ersboll M, Valeur N, Svendsen JH, et al. Strain\nechocardiography improves risk prediction of ventricular arrhythmias after myo-\ncardial infarction. JACC Cardiovasc Imaging 2013;6:841–850.\n123. Haugaa KH, Hasselberg NE, Edvardsen T. Mechanical dispersion by strain echocar-\ndiography: a predictor of ventricular arrhythmias in subjects with lamin A/C muta-\ntions. JACC Cardiovasc Imaging 2015;8:104–106.\n124. Ersboll M, Valeur N, Andersen MJ, Mogensen UM, Vinther M, Svendsen JH, et al.\nEarly echocardiographic deformation analysis for the prediction of sudden cardiac\ndeath and life-threatening arrhythmias after myocardial infarction. JACC Cardiovasc\nImaging 2013;6:851–860.\n125. Biering-Sørensen T, Knappe D, Pouleur A-C, Claggett B, Wang PJ, Moss AJ, et al.\nRegional longitudinal deformation improves prediction of ventricular tachyarrhyth-\nmias in patients with heart failure with reduced ejection fraction: a MADIT-CRT\nsubstudy\n(Multicenter\nAutomatic\nDeﬁbrillator\nImplantation\nTrial-Cardiac\nResynchronization Therapy). Circ Cardiovasc Imaging 2017;10:e005096.\n126. Garg R, Friedrich MG. Cardiomyopathies. ESC CardioMed. 3rd ed. Oxford\nUniversity Press; 2022, p510–515.\n127. Borgquist R, Haugaa KH, Gilljam T, Bundgaard H, Hansen J, Eschen O, et al. The\ndiagnostic performance of imaging methods in ARVC using the 2010 task force cri-\nteria. Eur Heart J Cardiovasc Imaging 2014;15:1219–1225.\n128. Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, Charron P, et al. 2014\nESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy:\nthe\ntask\nforce\nfor\nthe\nDiagnosis\nand\nManagement\nof\nHypertrophic\nCardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J 2014;\n35:2733–2779.\n129. Di Marco A, Anguera I, Schmitt M, Klem I, Neilan TG, White JA, et al. Late gado-\nlinium enhancement and the risk for ventricular arrhythmias or sudden death in di-\nlated cardiomyopathy: systematic review and meta-analysis. JACC Heart Fail 2017;5:\n28–38.\n130. Dejgaard LA, Skjølsvik ET, Lie ØH, Ribe M, Stokke MK, Hegbom F, et al. The mitral\nannulus disjunction arrhythmic syndrome. J Am Coll Cardiol 2018;72:1600–1609.\n131. Basso C, Iliceto S, Thiene G, Perazzolo Marra M. Mitral valve prolapse, ventricular\narrhythmias, and sudden death. Circulation 2019;140:952–964.\n132. Achenbach S. Technology of cardiac computed tomography. ESC CardioMed. 3rd\ned. Oxford University Press; 2022, p537–541.\n133. Meijboom WB, van Mieghem CAG, Mollet NR, Pugliese F, Weustink AC, van Pelt\nN, et al. 64-Slice computed tomography coronary angiography in patients with high,\nintermediate, or low pretest probability of signiﬁcant coronary artery disease. J Am\nColl Cardiol 2007;50:1469–1475.\n134. Douglas PS, Hoffmann U, Patel MR, Mark DB, Al-Khalidi HR, Cavanaugh B, et al.\nOutcomes of anatomical versus functional testing for coronary artery disease. N\nEngl J Med 2015;372:1291–1300.\n135. Priori SG, Wilde AA, Horie M, Cho Y, Behr ER, Berul C, et al. Executive summary:\nHRS/EHRA/APHRS expert consensus statement on the diagnosis and management\nof patients with inherited primary arrhythmia syndromes. Europace 2013;15:\n1389–1406.\n136. Govindan M, Batchvarov VN, Raju H, Shanmugam N, Bizrah M, Bastiaenen R, et al.\nUtility of high and standard right precordial leads during ajmaline testing for the\ndiagnosis of Brugada syndrome. Heart 2010;96:1904–1908.\n137. Churet M, Luttoo K, Hocini M, Haïssaguerre M, Sacher F, Duchateau J. Diagnostic\nreproducibility of epinephrine drug challenge interpretation in suspected long QT\nsyndrome. J Cardiovasc Electrophysiol 2019;30:896–901.\n138. Rolf S. The ajmaline challenge in Brugada syndrome: diagnostic impact, safety, and\nrecommended protocol. Eur Heart J 2003;24:1104–1112.\n139. Tadros R, Nannenberg EA, Lieve KV, Škorić-Milosavljević D, Lahrouchi N, Lekanne\nDeprez RH, et al. Yield and pitfalls of ajmaline testing in the evaluation of unex-\nplained cardiac arrest and sudden unexplained death: single-center experience\nwith 482 families. JACC Clin Electrophysiol 2017;3:1400–1408.\n140. Meregalli PG, Ruijter JM, Hofman N, Bezzina CR, Wilde AAM, Tan HL. Diagnostic\nvalue of ﬂecainide testing in unmasking SCN5A-related Brugada syndrome.\nJ Cardiovasc Electrophysiol 2006;17:857–864.\n141. Krahn AD, Healey JS, Chauhan VS, Birnie DH, Champagne J, Sanatani S, et al.\nEpinephrine infusion in the evaluation of unexplained cardiac arrest and familial sud-\nden death: from the cardiac arrest survivors with preserved Ejection Fraction\nRegistry. Circ Arrhythm Electrophysiol 2012;5:933–940.\n142. Sueda S, Kohno H, Ochi T, Uraoka T. Overview of the acetylcholine spasm provo-\ncation test. Clin Cardiol 2015;38:430–438.\n143. Takagi Y, Yasuda S, Takahashi J, Tsunoda R, Ogata Y, Seki A, et al. Clinical implica-\ntions of provocation tests for coronary artery spasm: safety, arrhythmic complica-\ntions, and prognostic impact: multicentre registry study of the Japanese Coronary\nSpasm Association. Eur Heart J 2013;34:258–267.\n144. Garratt CJ, Antoniou A, Grifﬁth MJ, Ward DE, Camm AJ. Use of intravenous ad-\nenosine in sinus rhythm as a diagnostic test for latent preexcitation. Am J Cardiol\n1990;65:868–873.\n145. Bourke JP, Richards DA, Ross DL, Wallace EM, McGuire MA, Uther JB. Routine\nprogrammed electrical stimulation in survivors of acute myocardial infarction for\nprediction of spontaneous ventricular tachyarrhythmias during follow-up: results,\noptimal stimulation protocol and cost-effective screening. J Am Coll Cardiol 1991;\n18:780–788.\n146. Gatzoulis KA, Tsiachris D, Arsenos P, Archontakis S, Dilaveris P, Vouliotis A, et al.\nPrognostic value of programmed ventricular stimulation for sudden death in se-\nlected high risk patients with structural heart disease and preserved systolic func-\ntion. Int J Cardiol 2014;176:1449–1451.\n147. Gatzoulis KA, Vouliotis A-I, Tsiachris D, Salourou M, Archontakis S, Dilaveris P,\net al. Primary prevention of sudden cardiac death in a nonischemic dilated cardio-\nmyopathy population: reappraisal of the role of programmed ventricular stimula-\ntion. Circ Arrhythm Electrophysiol 2013;6:504–512.\n148. Brilakis ES, Shen WK, Hammill SC, Hodge DO, Rea RF, Lexvold NY, et al. Role of\nprogrammed ventricular stimulation and implantable cardioverter deﬁbrillators in\npatients with idiopathic dilated cardiomyopathy and syncope. Pacing Clin\nElectrophysiol 2001;24:1623–1630.\n149. Brembilla-Perrot B, Suty-Selton C, Beurrier D, Houriez P, Nippert M, de la Chaise\nAT, et al. Differences in mechanisms and outcomes of syncope in patients with cor-\nonary disease or idiopathic left ventricular dysfunction as assessed by electrophy-\nsiologic testing. J Am Coll Cardiol 2004;44:594–601.\n150. Schmitt C, Barthel P, Ndrepepa G, Schreieck J, Plewan A, Schömig A, et al. Value of\nprogrammed ventricular stimulation for prophylactic internal cardioverter-\ndeﬁbrillator implantation in postinfarction patients preselected by noninvasive\nrisk stratiﬁers. J Am Coll Cardiol 2001;37:1901–1907.\n151. Gatzoulis KA, Tsiachris D, Arsenos P, Antoniou C-K, Dilaveris P, Sideris S, et al.\nArrhythmic risk stratiﬁcation in post-myocardial infarction patients with preserved\nejection fraction: the PRESERVE EF study. Eur Heart J 2019;40:2940–2949.\n152. Denis A, Sacher F, Derval N, Lim HS, Cochet H, Shah AJ, et al. Diagnostic value of\nisoproterenol testing in arrhythmogenic right ventricular cardiomyopathy. Circ\nArrhythm Electrophysiol 2014;7:590–597.\n153. Merino JL, Carmona JR, Fernández-Lozano I, Peinado R, Basterra N, Sobrino JA.\nMechanisms of sustained ventricular tachycardia in myotonic dystrophy: implica-\ntions for catheter ablation. Circulation 1998;98:541–546.\n154. Pezawas T, Stix G, Kastner J, Wolzt M, Mayer C, Moertl D, et al. Unexplained syn-\ncope in patients with structural heart disease and no documented ventricular ar-\nrhythmias:\nvalue\nof\nelectrophysiologically\nguided\nimplantable\ncardioverter\ndeﬁbrillator therapy. Europace 2003;5:305–312.\n155. Sroubek J, Probst V, Mazzanti A, Delise P, Hevia JC, Ohkubo K, et al. Programmed\nventricular stimulation for risk stratiﬁcation in the Brugada syndrome: a pooled ana-\nlysis. Circulation 2016;133:622–630.\n156. Nayyar S, Downar E, Bhaskaran AP, Massé S, Nanthakumar K. Signature signal\nstrategy: electrogram-based ventricular tachycardia mapping. Heart Rhythm 2020;\n17:2000–2009.\n157. Lazarus A, Varin J, Babuty D, Anselme F, Coste J, Duboc D. Long-term follow-up of\narrhythmias in patients with myotonic dystrophy treated by pacing: a multicenter\ndiagnostic pacemaker study. J Am Coll Cardiol 2002;40:1645–1652.\n158. Tandri H, Asimaki A, Abraham T, Dalal D, Tops L, Jain R, et al. Prolonged RV endo-\ncardial activation duration: a novel marker of arrhythmogenic right ventricular dys-\nplasia/cardiomyopathy. Heart Rhythm 2009;6:769–775.\n159. Gomes J, Finlay M, Ahmed AK, Ciaccio EJ, Asimaki A, Safﬁtz JE, et al.\nElectrophysiological abnormalities precede overt structural changes in arrhythmo-\ngenic right ventricular cardiomyopathy due to mutations in desmoplakin-A com-\nbined murine and human study. Eur Heart J 2012;33:1942–1953.\n160. Orini M, Graham AJ, Srinivasan NT, Campos FO, Hanson BM, Chow A, et al.\nEvaluation of the reentry vulnerability index to predict ventricular tachycardia cir-\ncuits using high-density contact mapping. Heart Rhythm 2020;17:576–583.\n161. Jackson N, Gizurarson S, Viswanathan K, King B, Massé S, Kusha M, et al.\nDecrement evoked potential mapping: basis of a mechanistic strategy for ventricu-\nlar tachycardia ablation. Circ Arrhythm Electrophysiol 2015;8:1433–1442.\n162. Avella A, d’Amati G, Pappalardo A, Re F, Silenzi PF, Laurenzi F, et al. Diagnostic va-\nlue of endomyocardial biopsy guided by electroanatomic voltage mapping in ar-\nrhythmogenic\nright\nventricular\ncardiomyopathy/dysplasia.\nJ\nCardiovasc\nElectrophysiol 2008;19:1127–1134.\n163. Wilde AAM, Behr ER. Genetic testing for inherited cardiac disease. Nat Rev Cardiol\n2013;10:571–583.\n4104\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026\n\n\n164. Hosseini SM, Kim R, Udupa S, Costain G, Jobling R, Liston E, et al. Reappraisal of\nreported genes for sudden arrhythmic death: evidence-based evaluation of gene\nvalidity for Brugada syndrome. Circulation 2018;138:1195–1205.\n165. Ingles J, Goldstein J, Thaxton C, Caleshu C, Corty EW, Crowley SB, et al. Evaluating\nthe clinical validity of hypertrophic cardiomyopathy genes. Circ Genom Precis Med\n2019;12:e002460.\n166. Adler A, Novelli V, Amin AS, Abiusi E, Care M, Nannenberg EA, et al. An inter-\nnational, multicentered, evidence-based reappraisal of genes reported to cause\ncongenital long QT syndrome. Circulation 2020;141:418–428.\n167. Risgaard B, Jabbari R, Refsgaard L, Holst AG, Haunsø S, Sadjadieh A, et al. High\nprevalence of genetic variants previously associated with Brugada syndrome in\nnew exome data. Clin Genet 2013;84:489–495.\n168. James CA, Jongbloed JDH, Hershberger RE, Morales A, Judge DP, Syrris P, et al. An\ninternational evidence based reappraisal of genes associated with arrhythmogenic\nright ventricular cardiomyopathy (ARVC) using the ClinGen framework. Circ\nGenom Precis Med 2021;14:e003273.\n169. Lahrouchi N, Tadros R, Crotti L, Mizusawa Y, Postema PG, Beekman L, et al.\nTransethnic genome-wide association study provides insights in the genetic archi-\ntecture and heritability of long QT syndrome. Circulation 2020;142:324–338.\n170. Wijeyeratne YD, Tanck MW, Mizusawa Y, Batchvarov V, Barc J, Crotti L, et al.\nSCN5A mutation type and a genetic risk score associate variably with Brugada syn-\ndrome phenotype in SCN5A families. Circ Genom Precis Med 2020;13:e002911.\n171. Harper AR, Goel A, Grace C, Thomson KL, Petersen SE, Xu X, et al. Common gen-\netic variants and modiﬁable risk factors underpin hypertrophic cardiomyopathy\nsusceptibility and expressivity. Nat Genet 2021;53:135–142.\n172. Tadros R, Francis C, Xu X, Vermeer AMC, Harper AR, Huurman R, et al. Shared\ngenetic pathways contribute to risk of hypertrophic and dilated cardiomyopathies\nwith opposite directions of effect. Nat Genet 2021;53:128–134.\n173. Tadros R, Tan HL, ESCAPE-NET Investigators, El Mathari S, Kors JA, Postema PG,\net al. Predicting cardiac electrical response to sodium-channel blockade and\nBrugada syndrome using polygenic risk scores. Eur Heart J 2019;40:3097–3107.\n174. Ware JS, Roberts AM, Cook SA. Next generation sequencing for clinical diagnostics\nand personalised medicine: implications for the next generation cardiologist. Heart\n2012;98:276–281.\n175. Ashar FN, Mitchell RN, Albert CM, Newton-Cheh C, Brody JA, Müller-Nurasyid M,\net al. A comprehensive evaluation of the genetic architecture of sudden cardiac ar-\nrest. Eur Heart J 2018;39:3961–3969.\n176. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guide-\nlines for the interpretation of sequence variants: a joint consensus recommenda-\ntion of the American College of Medical Genetics and Genomics and the\nAssociation for Molecular Pathology. Genet Med 2015;17:405–424.\n177. Ingles J, Lind JM, Phongsavan P, Semsarian C. Psychosocial impact of specialized car-\ndiac genetic clinics for hypertrophic cardiomyopathy. Genet Med 2008;10:117–120.\n178. Ackerman MJ, Priori SG, Willems S, Berul C, Brugada R, Calkins H, et al. HRS/EHRA\nexpert consensus statement on the state of genetic testing for the channelopathies\nand cardiomyopathies: this document was developed as a partnership between the\nHeart Rhythm Society (HRS) and the European Heart Rhythm Association\n(EHRA). Europace 2011;13:1077–1109.\n179. Conte G, Wilde A, Behr ER, Scherr D, Lenarczyk R, Gandjbachkh E, et al.\nImportance of dedicated units for the management of patients with inherited ar-\nrhythmia syndromes. Circ Genom Precis Med 2021;14:e003313.\n180. Minier M, Probst V, Berthome P, Tixier R, Briand J, Geoffroy O, et al. Age at diag-\nnosis of Brugada syndrome: inﬂuence on clinical characteristics and risk of arrhyth-\nmia. Heart Rhythm 2020;17:743–749.\n181. Wong LCH, Roses-Noguer F, Till JA, Behr ER. Cardiac evaluation of pediatric re-\nlatives in sudden arrhythmic death syndrome: a 2-center experience. Circ\nArrhythm Electrophysiol 2014;7:800–806.\n182. Mellor GJ, Blom LJ, Groeneveld SA, Winkel BG, Ensam B, Bargehr J, et al. Familial\nevaluation in idiopathic ventricular ﬁbrillation: diagnostic yield and signiﬁcance of J\nWave Syndromes. Circ Arrhythm Electrophysiol 2021;14:e009089.\n183. Lahrouchi N, Raju H, Lodder EM, Papatheodorou E, Ware JS, Papadakis M, et al.\nUtility of post-mortem genetic testing in cases of sudden arrhythmic death syn-\ndrome. J Am Coll Cardiol 2017;69:2134–2145.\n184. Faber TS, Gradinger R, Treusch S, Morkel C, Brachmann J, Bode C, et al. Incidence\nof ventricular tachyarrhythmias during permanent pacemaker therapy in low-risk\npatients results from the German multicentre EVENTS study. Eur Heart J 2007;\n28:2238–2242.\n185. Middlekauff HR, Stevenson WG, Stevenson LW, Saxon LA. Syncope in advanced\nheart failure: high risk of sudden death regardless of origin of syncope. J Am Coll\nCardiol 1993;21:110–116.\n186. Noda T, Shimizu W, Taguchi A, Aiba T, Satomi K, Suyama K, et al. Malignant entity\nof idiopathic ventricular ﬁbrillation and polymorphic ventricular tachycardia in-\nitiated by premature extrasystoles originating from the right ventricular outﬂow\ntract. J Am Coll Cardiol 2005;46:1288–1294.\n187. Belhassen B, Viskin S. Idiopathic ventricular tachycardia and ﬁbrillation. J Cardiovasc\nElectrophysiol 1993;4:356–368.\n188. Zareba W, Platonov P. ECG patterns related to arrhythmias and sudden death:\nchannelopathies, early repolarization, and pre-excitation. ESC CardioMed. 3rd\ned. Oxford University Press; 2022, p382–389.\n189. Voigt J-U. Left ventricular function, heart failure, and resynchronization therapy.\nESC CardioMed. 3rd ed. Oxford University Press; 2022, p450–454.\n190. Edvardsen T. Cardiomyopathies, myocarditis, and the transplanted heart. ESC\nCardioMed. 3rd ed. Oxford University Press; 2022, p456–460.\n191. Cygankiewicz I. Ambulatory ECG monitoring. ESC CardioMed. 3rd ed. Oxford\nUniversity Press; 2022, p393–400.\n192. Gray B, Kirby A, Kabunga P, Freedman SB, Yeates L, Kanthan A, et al. Twelve-lead\nambulatory electrocardiographic monitoring in Brugada syndrome: potential diag-\nnostic and prognostic implications. Heart Rhythm 2017;14:866–874.\n193. Karogiannis N, Senior R. Stress echocardiography. ESC CardioMed. 3rd ed. Oxford\nUniversity Press; 2022, p431–434.\n194. Nucifora G, Muser D, Masci PG, Barison A, Rebellato L, Piccoli G, et al. Prevalence\nand prognostic value of concealed structural abnormalities in patients with appar-\nently idiopathic ventricular arrhythmias of left versus right ventricular origin: a mag-\nnetic resonance imaging study. Circ Arrhythm Electrophysiol 2014;7:456–462.\n195. Muser D, Nucifora G, Muser D, Nucifora G, Pieroni M, Castro SA, et al. Prognostic\nvalue of nonischemic ringlike left ventricular scar in patients with apparently idio-\npathic nonsustained ventricular arrhythmias. Circulation 2021;143:1359–1373.\n196. Josephson ME, Callans DJ. Using the twelve-lead electrocardiogram to localize the\nsite of origin of ventricular tachycardia. Heart Rhythm 2005;2:443–446.\n197. Corrado D, Basso C, Leoni L, Tokajuk B, Bauce B, Frigo G, et al. Three-dimensional\nelectroanatomic voltage mapping increases accuracy of diagnosing arrhythmogenic\nright ventricular cardiomyopathy/dysplasia. Circulation 2005;111:3042–3050.\n198. Casella M, Dello Russo A, Bergonti M, Catto V, Conte E, Sommariva E, et al.\nDiagnostic yield of electroanatomic voltage mapping in guiding endomyocardial bi-\nopsies. Circulation 2020;142:1249–1260.\n199. Haanschoten DM, Adiyaman A, ‘t Hart NA, Jager PL, Elvan A. Value of 3D mapping-\nguided endomyocardial biopsy in cardiac sarcoidosis: case series and narrative re-\nview on the value of electro-anatomic mapping-guided endomyocardial biopsies.\nEur J Clin Invest 2021;51:e13497.\n200. Tung R, Bauer B, Schelbert H, Lynch JP, Auerbach M, Gupta P, et al. Incidence of\nabnormal positron emission tomography in patients with unexplained cardiomyop-\nathy and ventricular arrhythmias: the potential role of occult inﬂammation in ar-\nrhythmogenesis. Heart Rhythm 2015;12:2488–2498.\n201. Palmisano A, Vignale D, Peretto G, Busnardo E, Calcagno C, Campochiaro C, et al.\nHybrid FDG-PET/MR or FDG-PET/CT to detect disease activity in patients with\npersisting arrhythmias after myocarditis. JACC Cardiovasc Imaging 2021;14:\n288–292.\n202. Venlet J, Piers SRD, Jongbloed JDH, Androulakis AFA, Naruse Y, den Uijl DW, et al.\nIsolated subepicardial right ventricular outﬂow tract scar in athletes with ventricu-\nlar tachycardia. J Am Coll Cardiol 2017;69:497–507.\n203. Geri G, Dumas F, Bougouin W, Varenne O, Daviaud F, Pène F, et al. Immediate per-\ncutaneous coronary intervention is associated with improved short- and long-term\nsurvival after out-of-hospital cardiac arrest. Circ Cardiovasc Interv 2015;8:e002303.\n204. Vyas A, Chan PS, Cram P, Nallamothu BK, McNally B, Girotra S. Early coronary\nangiography and survival after out-of-hospital cardiac arrest. Circ Cardiovasc Interv\n2015;8:e002321.\n205. Kalarus Z, Svendsen JH, Capodanno D, Dan G-A, De Maria E, Gorenek B, et al.\nCardiac arrhythmias in the emergency settings of acute coronary syndrome and re-\nvascularization: an European Heart Rhythm Association (EHRA) consensus docu-\nment, endorsed by the European Association of Percutaneous Cardiovascular\nInterventions (EAPCI), and European Acute Cardiovascular Care Association\n(ACCA). Europace 2019;21:1603–1604.\n206. Noc M, Fajadet J, Lassen JF, Kala P, MacCarthy P, Olivecrona GK, et al. Invasive cor-\nonary treatment strategies for out-of-hospital cardiac arrest: a consensus state-\nment\nfrom\nthe\nEuropean\nassociation\nfor\npercutaneous\ncardiovascular\ninterventions (EAPCI)/stent for life (SFL) groups. EuroIntervention 2014;10:31–37.\n207. Verma BR, Sharma V, Shekhar S, Kaur M, Khubber S, Bansal A, et al. Coronary angi-\nography in patients with out-of-hospital cardiac arrest without ST-segment eleva-\ntion: a systematic review and meta-analysis. JACC Cardiovasc Interv 2020;13:\n2193–2205.\n208. Barbarawi M, Zayed Y, Kheiri B, Barbarawi O, Al-Abdouh A, Dhillon H, et al.\nOptimal timing of coronary intervention in patients resuscitated from cardiac ar-\nrest without ST-segment elevation myocardial infarction (NSTEMI): a systematic\nreview and meta-analysis. Resuscitation 2019;144:137–144.\n209. Meng-Chang Y, Meng-Jun W, Xiao-Yan X, Peng KL, Peng YG, RuRong W.\nCoronary angiography or not after cardiac arrest without ST segment elevation:\na systematic review and meta-analysis. Medicine (Baltimore) 2020;99:e22197.\n210. Khan MS, Shah SMM, Mubashir A, Khan AR, Fatima K, Schenone AL, et al. Early cor-\nonary angiography in patients resuscitated from out of hospital cardiac arrest\nESC Guidelines\n4105\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026\n\n\nwithout ST-segment elevation: a systematic review and meta-analysis. Resuscitation\n2017;121:127–134.\n211. Welsford M, Bossard M, Shortt C, Pritchard J, Natarajan MK, Belley-Côté EP. Does\nearly coronary angiography improve survival after out-of-hospital cardiac arrest? A\nsystematic review with meta-analysis. Can J Cardiol 2018;34:180–194.\n212. Chelly J, Mongardon N, Dumas F, Varenne O, Spaulding C, Vignaux O, et al. Beneﬁt\nof an early and systematic imaging procedure after cardiac arrest: insights from the\nPROCAT (Parisian Region Out of Hospital Cardiac Arrest) registry. Resuscitation\n2012;83:1444–1450.\n213. Stiles MK, Wilde AAM, Abrams DJ, Ackerman MJ, Albert CM, Behr ER, et al. 2020\nAPHRS/HRS expert consensus statement on the investigation of decedents with\nsudden unexplained death and patients with sudden cardiac arrest, and of their\nfamilies. Heart Rhythm 2021;18:e1–e50.\n214. Tseng ZH, Olgin JE, Vittinghoff E, Ursell PC, Kim AS, Sporer K, et al. Prospective\ncountywide surveillance and autopsy characterization of sudden cardiac death:\nPOST SCD study. Circulation 2018;137:2689–2700.\n215. Fellmann F, van El CG, Charron P, Michaud K, Howard HC, Boers SN, et al.\nEuropean recommendations integrating genetic testing into multidisciplinary man-\nagement of sudden cardiac death. Eur J Hum Genet 2019;27:1763–1773.\n216. Yamamoto T, Takayama M, Sato N, Yodogawa K, Iwasaki Y-K, Kato K, et al.\nInappropriate analyses of automated external deﬁbrillators used during in-hospital\nventricular ﬁbrillation. Circ J 2008;72:679–681.\n217. Sweeney MO, Ruetz LL, Belk P, Mullen TJ, Johnson JW, Sheldon T. Bradycardia\npacing-induced short-long-short sequences at the onset of ventricular tachyar-\nrhythmias: a possible mechanism of proarrhythmia? J Am Coll Cardiol 2007;50:\n614–622.\n218. Tseng ZH, Hayward RM, Clark NM, Mulvanny CG, Colburn BJ, Ursell PC, et al.\nSudden death in patients with cardiac implantable electronic devices. JAMA Intern\nMed 2015;175:1342–1350.\n219. Lacour P, Buschmann C, Storm C, Nee J, Parwani AS, Huemer M, et al. Cardiac im-\nplantable electronic device interrogation at forensic autopsy: an underestimated re-\nsource? Circulation 2018;137:2730–2740.\n220. Curcio A, Mazzanti A, Bloise R, Monteforte N, IndolﬁC, Priori SG, et al. Clinical\npresentation and outcome of Brugada syndrome diagnosed with the new 2013 cri-\nteria. J Cardiovasc Electrophysiol 2016;27:937–943.\n221. Haïssaguerre M, Shah DC, Jaïs P, Shoda M, Kautzner J, Arentz T, et al. Role of\nPurkinje conducting system in triggering of idiopathic ventricular ﬁbrillation.\nLancet 2002;359:677–678.\n222. Krahn AD, Healey JS, Chauhan V, Birnie DH, Simpson CS, Champagne J, et al.\nSystematic assessment of patients with unexplained cardiac arrest: cardiac arrest\nsurvivors with preserved ejection fraction registry (CASPER). Circulation 2009;\n120:278–285.\n223. van der Werf C, Hofman N, Tan HL, van Dessel PF, Alders M, van der Wal AC, et al.\nDiagnostic yield in sudden unexplained death and aborted cardiac arrest in the\nyoung: the experience of a tertiary referral center in The Netherlands. Heart\nRhythm 2010;7:1383–1389.\n224. Eckart RE, Scoville SL, Campbell CL, Shry EA, Stajduhar KC, Potter RN, et al.\nSudden death in young adults: a 25-year review of autopsies in military recruits.\nAnn Intern Med 2004;141:829–834.\n225. Kunadian V, Chieffo A, Camici PG, Berry C, Escaned J, Maas AHEM, et al. An EAPCI\nexpert consensus document on ischaemia with non-obstructive coronary arteries\nin collaboration with European Society of Cardiology Working Group on\nCoronary\nPathophysiology\n&\nMicrocirculation\nEndorsed\nby\nCoronary\nVasomotor Disorders International Study Group. Eur Heart J 2020;41:3504–3520.\n226. Rodrigues P, Joshi A, Williams H, Westwood M, Petersen SE, Zemrak F, et al.\nDiagnosis and prognosis in sudden cardiac arrest survivors without coronary artery\ndisease: utility of a clinical approach using cardiac magnetic resonance imaging. Circ\nCardiovasc Imaging 2017;10:e006709.\n227. White JA, Fine NM, Gula L, Yee R, Skanes A, Klein G, et al. Utility of cardiovascular\nmagnetic resonance in identifying substrate for malignant ventricular arrhythmias.\nCirc Cardiovasc Imaging 2012;5:12–20.\n228. Basso C, Perazzolo Marra M, Rizzo S, De Lazzari M, Giorgi B, Cipriani A, et al.\nArrhythmic mitral valve prolapse and sudden cardiac death. Circulation 2015;132:\n556–566.\n229. Obeyesekere MN, Klein GJ, Modi S, Leong-Sit P, Gula LJ, Yee R, et al. How to per-\nform and interpret provocative testing for the diagnosis of Brugada syndrome,\nlong-QT syndrome, and catecholaminergic polymorphic ventricular tachycardia.\nCirc Arrhythm Electrophysiol 2011;4:958–964.\n230. Cheung CC, Mellor G, Deyell MW, Ensam B, Batchvarov V, Papadakis M, et al.\nComparison of ajmaline and procainamide provocation tests in the diagnosis of\nBrugada syndrome. JACC Clin Electrophysiol 2019;5:504–512.\n231. Antzelevitch C, Yan G-X, Ackerman MJ, Borggrefe M, Corrado D, Guo J, et al.\nJ-Wave syndromes expert consensus conference report: emerging concepts and\ngaps in knowledge. Europace 2017;19:665–694.\n232. Adler A, van der Werf C, Postema PG, Rosso R, Bhuiyan ZA, Kalman JM, et al. The\nphenomenon of ‘QT stunning’: the abnormal QT prolongation provoked by stand-\ning persists even as the heart rate returns to normal in patients with long QT syn-\ndrome. Heart Rhythm 2012;9:901–908.\n233. Dionne A, Fournier A, Dahdah N, Abrams D, Khairy P, Abadir S. Dynamic QT\ninterval changes from supine to standing in healthy children. Can J Cardiol 2018;\n34:66–72.\n234. Foo FS, Stiles MK, Heaven D. Unmasking latent preexcitation of a right-sided acces-\nsory pathway with intravenous adenosine after unexplained sudden cardiac arrest. J\nArrhythm 2020;36:939–941.\n235. Marjamaa A, Hiippala A, Arrhenius B, Lahtinen AM, Kontula K, Toivonen L, et al.\nIntravenous epinephrine infusion test in diagnosis of catecholaminergic polymorph-\nic ventricular tachycardia. J Cardiovasc Electrophysiol 2012;23:194–199.\n236. Ackerman MJ, Khositseth A, Tester DJ, Hejlik JB, Shen W-K, Porter CJ.\nEpinephrine-induced QT interval prolongation: a gene-speciﬁc paradoxical re-\nsponse in congenital long QT syndrome. Mayo Clin Proc 2002;77:413–421.\n237. Shimizu W, Noda T, Takaki H, Nagaya N, Satomi K, Kurita T, et al. Diagnostic value\nof epinephrine test for genotyping LQT1, LQT2, and LQT3 forms of congenital\nlong QT syndrome. Heart Rhythm 2004;1:276–283.\n238. Magnano AR, Talathoti N, Hallur R, Bloomﬁeld DM, Garan H. Sympathomimetic\ninfusion and cardiac repolarization: the normative effects of epinephrine and iso-\nproterenol in healthy subjects. J Cardiovasc Electrophysiol 2006;17:983–989.\n239. Vyas H, Hejlik J, Ackerman MJ. Epinephrine QT stress testing in the evaluation of\ncongenital long-QT syndrome: diagnostic accuracy of the paradoxical QT re-\nsponse. Circulation 2006;113:1385–1392.\n240. Waldmann V, Bougouin W, Karam N, Narayanan K, Sharifzadehgan A, Spaulding C,\net al. Coronary vasospasm-related sudden cardiac arrest in the community. J Am\nColl Cardiol 2018;72:814–815.\n241. Etienne P, Huchet F, Gaborit N, Barc J, Thollet A, Kyndt F, et al. Mental stress test: a\nrapid, simple, and efﬁcient test to unmask long QT syndrome. Europace 2018;20:\n2014–2020.\n242. Kop WJ, Krantz DS, Nearing BD, Gottdiener JS, Quigley JF, O’Callahan M, et al.\nEffects of acute mental stress and exercise on T-wave alternans in patients with im-\nplantable cardioverter deﬁbrillators and controls. Circulation 2004;109:1864–1869.\n243. Schwartz PJ, Lia C. QTc behavior during exercise and genetic testing for the\nlong-QT syndrome. Circulation 2011;124:2181–2184.\n244. Wang YS, Scheinman MM, Chien WW, Cohen TJ, Lesh MD, Grifﬁn JC. Patients\nwith supraventricular tachycardia presenting with aborted sudden death: incidence,\nmechanism and long-term follow-up. J Am Coll Cardiol 1991;18:1711–1719.\n245. Roberts JD, Gollob MH, Young C, Connors SP, Gray C, Wilton SB, et al. Bundle\nbranch re-entrant ventricular tachycardia: novel genetic mechanisms in a life-\nthreatening arrhythmia. JACC Clin Electrophysiol 2017;3:276–288.\n246. Santangeli P, Hamilton-Craig C, Dello Russo A, Pieroni M, Casella M, Pelargonio G,\net al. Imaging of scar in patients with ventricular arrhythmias of right ventricular ori-\ngin: cardiac magnetic resonance versus electroanatomic mapping. J Cardiovasc\nElectrophysiol 2011;22:1359–1366.\n247. Haïssaguerre M, Duchateau J, Dubois R, Hocini M, Cheniti G, Sacher F, et al.\nIdiopathic ventricular ﬁbrillation: role of Purkinje system and microstructural myo-\ncardial abnormalities. JACC Clin Electrophysiol 2020;6:591–608.\n248. Haïssaguerre M, Hocini M, Cheniti G, Duchateau J, Sacher F, Puyo S, et al. Localized\nstructural alterations underlying a subset of unexplained sudden cardiac death. Circ\nArrhythm Electrophysiol 2018;11:e006120.\n249. Mellor G, Laksman ZWM, Tadros R, Roberts JD, Gerull B, Simpson CS, et al.\nGenetic testing in the evaluation of unexplained cardiac arrest: from the\nCASPER (Cardiac Arrest Survivors With Preserved Ejection Fraction Registry).\nCirc Cardiovasc Genet 2017;10:e001686.\n250. Burns C, Bagnall RD, Lam L, Semsarian C, Ingles J. Multiple gene variants in hyper-\ntrophic cardiomyopathy in the era of next-generation sequencing. Circ Cardiovasc\nGenet 2017;10:e001666.\n251. Karam N, Jabre P, Narayanan K, Sharifzadehgan A, Perier M-C, Tennenbaum J, et al.\nPsychological support and medical screening of ﬁrst-degree relatives of sudden car-\ndiac arrest victims. JACC Clin Electrophysiol 2020;6:586–587.\n252. Behr E, Wood DA, Wright M, Syrris P, Sheppard MN, Casey A, et al. Cardiological\nassessment of ﬁrst-degree relatives in sudden arrhythmic death syndrome. Lancet\n2003;362:1457–1459.\n253. Tan HL, Hofman N, van Langen IM, van der Wal AC, Wilde AAM. Sudden unex-\nplained death: heritability and diagnostic yield of cardiological and genetic examin-\nation in surviving relatives. Circulation 2005;112:207–213.\n254. Lemkes JS, Janssens GN, van der Hoeven NW, Jewbali LSD, Dubois EA, Meuwissen\nM, et al. Coronary angiography after cardiac arrest without ST-segment elevation.\nN Engl J Med 2019;380:1397–1407.\n255. Kern KB, Radsel P, Jentzer JC, Seder DB, Lee KS, Lotun K, et al. Randomized pilot\nclinical trial of early coronary angiography versus no early coronary angiography\nafter cardiac arrest without ST-segment elevation: the PEARL study. Circulation\n2020;142:2002–2012.\n4106\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026\n\n\n256. Desch S, Freund A, Akin I, Behnes M, Preusch MR, Zelniker TA, et al. Angiography\nafter out-of-hospital cardiac arrest without ST-segment elevation. N Engl J Med\n2021;385:2544–2553.\n257. Arnaout M, Mongardon N, Deye N, Legriel S, Dumas F, Sauneuf B, et al.\nOut-of-hospital cardiac arrest from brain cause: epidemiology, clinical features,\nand outcome in a multicenter cohort. Crit Care Med 2015;43:453–460.\n258. Horner JM, Horner MM, Ackerman MJ. The diagnostic utility of recovery phase\nQTc during treadmill exercise stress testing in the evaluation of long QT syndrome.\nHeart Rhythm 2011;8:1698–1704.\n259. Perrin MJ, Angaran P, Laksman Z, Zhang H, Porepa LF, Rutberg J, et al. Exercise test-\ning in asymptomatic gene carriers exposes a latent electrical substrate of arrhyth-\nmogenic right ventricular cardiomyopathy. J Am Coll Cardiol 2013;62:1772–1779.\n260. Waldmann V, Bougouin W, Karam N, Dumas F, Sharifzadehgan A, Gandjbakhch E,\net al. Characteristics and clinical assessment of unexplained sudden cardiac arrest in\nthe real-world setting: focus on idiopathic ventricular ﬁbrillation. Eur Heart J 2018;\n39:1981–1987.\n261. Nakao K, Ohgushi M, Yoshimura M, Morooka K, Okumura K, Ogawa H, et al.\nHyperventilation as a speciﬁc test for diagnosis of coronary artery spasm. Am J\nCardiol 1997;80:545–549.\n262. Behr ER, Casey A, Sheppard M, Wright M, Bowker TJ, Davies MJ, et al. Sudden ar-\nrhythmic death syndrome: a national survey of sudden unexplained cardiac death.\nHeart 2007;93:601–605.\n263. Basso C, Aguilera B, Banner J, Cohle S, d’Amati G, de Gouveia RH, et al. Guidelines\nfor autopsy investigation of sudden cardiac death: 2017 update from the\nAssociation for European Cardiovascular Pathology. Virchows Arch 2017;471:\n691–705.\n264. de Noronha SV, Behr ER, Papadakis M, Ohta-Ogo K, Banya W, Wells J, et al. The\nimportance of specialist cardiac histopathological examination in the investigation\nof young sudden cardiac deaths. Europace 2014;16:899–907.\n265. Gulino SP, Burns K, Gunther WM, MacLeod H. Improving forensic pathologic in-\nvestigation of sudden death in the young. Acad Forensic Pathol 2018;8:347–391.\n266. Hansen BL, Jacobsen EM, Kjerrumgaard A, Tfelt-Hansen J, Winkel BG, Bundgaard\nH, et al. Diagnostic yield in victims of sudden cardiac death and their relatives.\nEuropace 2020;22:964–971.\n267. Bjune T, Risgaard B, Kruckow L, Glinge C, Ingemann-Hansen O, Leth PM, et al.\nPost-mortem toxicology in young sudden cardiac death victims: a nationwide co-\nhort study. Europace 2018;20:614–621.\n268. Allan KS, Morrison LJ, Pinter A, Tu JV, Dorian P, Rescu Epistry Investigators.\n‘Presumed cardiac’ arrest in children and young adults: a misnomer? Resuscitation\n2017;117:73–79.\n269. Lahrouchi N, Raju H, Lodder EM, Papatheodorou S, Miles C, Ware JS, et al. The\nyield of postmortem genetic testing in sudden death cases with structural ﬁndings\nat autopsy. Eur J Hum Genet 2020;28:17–22.\n270. Tester DJ, Medeiros-Domingo A, Will ML, Haglund CM, Ackerman MJ. Cardiac\nchannel molecular autopsy: insights from 173 consecutive cases of autopsy-\nnegative sudden unexplained death referred for postmortem genetic testing.\nMayo Clin Proc 2012;87:524–539.\n271. Papadakis M, Raju H, Behr ER, De Noronha SV, Spath N, Kouloubinis A, et al.\nSudden cardiac death with autopsy ﬁndings of uncertain signiﬁcance: potential\nfor erroneous interpretation. Circ Arrhythm Electrophysiol 2013;6:588–596.\n272. Jacobsen EM, Hansen BL, Kjerrumgaard A, Tfelt-Hansen J, Hassager C, Kjaergaard J,\net al. Diagnostic yield and long-term outcome of nonischemic sudden cardiac arrest\nsurvivors and their relatives: results from a tertiary referral center. Heart Rhythm\n2020;17:1679–1686.\n273. Kjerrumgaard A, Jacobsen EM, Hansen BL, Tfelt-Hansen J, Winkel BG, Christensen\nAH, et al. Diagnostic ﬁndings and follow-up outcomes in relatives to young non-\nautopsied sudden death victims. Int J Cardiol 2020;318:61–66.\n274. Shanks GW, Tester DJ, Ackerman JP, Simpson MA, Behr ER, White SM, et al.\nImportance of variant interpretation in whole-exome molecular autopsy:\npopulation-based case series. Circulation 2018;137:2705–2715.\n275. Narula N, Tester DJ, Paulmichl A, Maleszewski JJ, Ackerman MJ. Post-mortem\nWhole exome sequencing with gene-speciﬁc analysis for autopsy-negative sudden\nunexplained death in the young: a case series. Pediatr Cardiol 2015;36:768–778.\n276. Miles CJ, Behr ER. The role of genetic testing in unexplained sudden death. Transl\nRes 2016;168:59–73.\n277. Behr ER, Dalageorgou C, Christiansen M, Syrris P, Hughes S, Tome Esteban MT,\net al. Sudden arrhythmic death syndrome: familial evaluation identiﬁes inheritable\nheart disease in the majority of families. Eur Heart J 2008;29:1670–1680.\n278. Kumar S, Peters S, Thompson T, Morgan N, Maccicoca I, Trainer A, et al. Familial\ncardiological and targeted genetic evaluation: low yield in sudden unexplained death\nand high yield in unexplained cardiac arrest syndromes. Heart Rhythm 2013;10:\n1653–1660.\n279. McGorrian C, Constant O, Harper N, O’Donnell C, Codd M, Keelan E, et al.\nFamily-based cardiac screening in relatives of victims of sudden arrhythmic death\nsyndrome. Europace 2013;15:1050–1058.\n280. Mellor G, Raju H, de Noronha SV, Papadakis M, Sharma S, Behr ER, et al. Clinical\ncharacteristics and circumstances of death in the sudden arrhythmic death syn-\ndrome. Circ Arrhythm Electrophysiol 2014;7:1078–1083.\n281. Papadakis M, Papatheodorou E, Mellor G, Raju H, Bastiaenen R, Wijeyeratne Y,\net al. The diagnostic yield of Brugada syndrome after sudden death with normal aut-\nopsy. J Am Coll Cardiol 2018;71:1204–1214.\n282. Mellor G, Nelson CP, Robb C, Raju H, Wijeyeratne Y, Hengstenberg C, et al. The\nprevalence and signiﬁcance of the early repolarization pattern in sudden arrhythmic\ndeath syndrome families. Circ Arrhythm Electrophysiol 2016;9:e003960.\n283. Nunn LM, Lopes LR, Syrris P, Murphy C, Plagnol V, Firman E, et al. Diagnostic yield\nof molecular autopsy in patients with sudden arrhythmic death syndrome using tar-\ngeted exome sequencing. Europace 2016;18:888–896.\n284. van der Werf C, Stiekema L, Tan HL, Hofman N, Alders M, van der Wal AC, et al.\nLow rate of cardiac events in ﬁrst-degree relatives of diagnosis-negative young sud-\nden unexplained death syndrome victims during follow-up. Heart Rhythm 2014;11:\n1728–1732.\n285. Madhavan M, Friedman PA, Lennon RJ, Prasad A, White RD, Sriram CS, et al.\nImplantable cardioverter-deﬁbrillator therapy in patients with ventricular ﬁbrilla-\ntion out of hospital cardiac arrest secondary to acute coronary syndrome. J Am\nHeart Assoc 2015;4:e001255.\n286. Wyse DG, Friedman PL, Brodsky MA, Beckman KJ, Carlson MD, Curtis AB, et al.\nLife-threatening ventricular arrhythmias due to transient or correctable causes:\nhigh risk for death in follow-up. J Am Coll Cardiol 2001;38:1718–1724.\n287. Goyal A, Spertus JA, Gosch K, Venkitachalam L, Jones PG, Van den Berghe G, et al.\nSerum potassium levels and mortality in acute myocardial infarction. JAMA 2012;\n307:157–164.\n288. Hoppe LK, Muhlack DC, Koenig W, Carr PR, Brenner H, Schöttker B. Association\nof abnormal serum potassium levels with arrhythmias and cardiovascular mortality:\na systematic review and meta-analysis of observational studies. Cardiovasc Drugs\nTher 2018;32:197–212.\n289. Ravn Jacobsen M, Jabbari R, Glinge C, Kjær Stampe N, Butt JH, Blanche P, et al.\nPotassium disturbances and risk of ventricular ﬁbrillation among patients with\nST-segment-elevation myocardial infarction. J Am Heart Assoc 2020;9:e014160.\n290. Ahmed W, Flynn MA, Alpert MA. Cardiovascular complications of weight reduc-\ntion diets. Am J Med Sci 2001;321:280–284.\n291. Stephenson V. In pharmacy nursing—a dynamic new ﬁeld. Nurs RSA 1988;3:51–53.\n292. Dumas F, Cariou A, Manzo-Silberman S, Grimaldi D, Vivien B, Rosencher J, et al.\nImmediate percutaneous coronary intervention is associated with better survival\nafter out-of-hospital cardiac arrest: insights from the PROCAT (Parisian Region\nOut of hospital Cardiac ArresT) registry. Circ Cardiovasc Interv 2010;3:200–207.\n293. Gibbs C, Thalamus J, Heldal K, Holla ØL, Haugaa KH, Hysing J. Predictors of mor-\ntality in high-risk patients with QT prolongation in a community hospital. Europace\n2018;20:f99–f107.\n294. Simpson TF, Salazar JW, Vittinghoff E, Probert J, Iwahashi A, Olgin JE, et al.\nAssociation of QT-prolonging medications with risk of autopsy-deﬁned causes of\nsudden death. JAMA Intern Med 2020;180:698–706.\n295. Tzivoni D, Banai S, Schuger C, Benhorin J, Keren A, Gottlieb S, et al. Treatment of\ntorsade de pointes with magnesium sulfate. Circulation 1988;77:392–397.\n296. Ladejobi A, Pasupula DK, Adhikari S, Javed A, Durrani AF, Patil S, et al. Implantable\ndeﬁbrillator therapy in cardiac arrest survivors with a reversible cause. Circ Arrhythm\nElectrophysiol 2018;11:e005940.\n297. Postema PG, Wolpert C, Amin AS, Probst V, Borggrefe M, Roden DM, et al. Drugs\nand Brugada syndrome patients: review of the literature, recommendations, and an\nup-to-date website (www.brugadadrugs.org). Heart Rhythm 2009;6:1335–1341.\n298. Schupp T, Behnes M, von Zworowsky M, Kim S-H, Weidner K, Rusnak J, et al.\nHypokalemia but not hyperkalemia is associated with recurrences of ventricular ta-\nchyarrhythmias in ICD recipients. Clin Lab 2020;66.\n299. Gupta A, Pasupula DK, Bhonsale A, Kancharla K, Wang NC, Adelstein E, et al.\nImplantable cardioverter-deﬁbrillator therapy in device recipients who survived a\ncardiac arrest associated with a reversible cause. J Cardiovasc Electrophysiol 2018;\n29:1413–1417.\n300. Marill KA, Wolfram S, Desouza IS, Nishijima DK, Kay D, Setnik GS, et al. Adenosine\nfor wide-complex tachycardia: efﬁcacy and safety. Crit Care Med 2009;37:\n2512–2518.\n301. Lerman BB, Belardinelli L, West GA, Berne RM, DiMarco JP. Adenosine-sensitive\nventricular tachycardia: evidence suggesting cyclic AMP-mediated triggered activity.\nCirculation 1986;74:270–280.\n302. Brugada J, Katritsis DG, Arbelo E, Arribas F, Bax JJ, Blomström-Lundqvist C, et al.\n2019 ESC Guidelines for the management of patients with supraventricular\ntachycardiaThe task force for the management of patients with supraventricular\ntachycardia of the European Society of Cardiology (ESC). Eur Heart J 2020;41:\n655–720.\n303. Ortiz M, Martín A, Arribas F, Coll-Vinent B, Del Arco C, Peinado R, et al.\nRandomized comparison of intravenous procainamide vs. intravenous amiodarone\nESC Guidelines\n4107\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026\n\n\nfor the acute treatment of tolerated wide QRS tachycardia: the PROCAMIO study.\nEur Heart J 2017;38:1329–1335.\n304. Gill JS, Mehta D, Ward DE, Camm AJ. Efﬁcacy of ﬂecainide, sotalol, and verapamil in\nthe treatment of right ventricular tachycardia in patients without overt cardiac ab-\nnormality. Br Heart J 1992;68:392–397.\n305. Manz M, Mletzko R, Jung W, Lüderitz B. Electrophysiological and haemodynamic\neffects of lidocaine and ajmaline in the management of sustained ventricular tachy-\ncardia. Eur Heart J 1992;13:1123–1128.\n306. Buxton AE, Marchlinski FE, Doherty JU, Cassidy DM, Vassallo JA, Flores BT, et al.\nRepetitive, monomorphic ventricular tachycardia: clinical and electrophysiologic\ncharacteristics in patients with and patients without organic heart disease. Am J\nCardiol 1984;54:997–1002.\n307. Grifﬁth MJ, Garratt CJ, Rowland E, Ward DE, Camm AJ. Effects of intravenous ad-\nenosine on verapamil-sensitive ‘idiopathic’ ventricular tachycardia. Am J Cardiol\n1994;73:759–764.\n308. Buxton AE, Marchlinski FE, Doherty JU, Flores B, Josephson ME. Hazards of intra-\nvenous verapamil for sustained ventricular tachycardia. Am J Cardiol 1987;59:\n1107–1110.\n309. Rankin AC, Rae AP, Cobbe SM. Misuse of intravenous verapamil in patients with\nventricular tachycardia. Lancet 1987;2:472–474.\n310. Pedersen CT, Kay GN, Kalman J, Borggrefe M, Della-Bella P, Dickfeld T, et al.\nEHRA/HRS/APHRS expert consensus on ventricular arrhythmias. Europace 2014;\n16:1257–1283.\n311. Cronin EM, Bogun FM, Maury P, Peichl P, Chen M, Namboodiri N, et al. 2019 HRS/\nEHRA/APHRS/LAHRS expert consensus statement on catheter ablation of ven-\ntricular arrhythmias. Europace 2019;21:1143–1144.\n312. Kowlgi GN, Cha Y-M. Management of ventricular electrical storm: a contemporary\nappraisal. Europace 2020;22:1768–1780.\n313. Guerra F, Shkoza M, Scappini L, Flori M, Capucci A. Role of electrical storm as a\nmortality and morbidity risk factor and its clinical predictors: a meta-analysis.\nEuropace 2014;16:347–353.\n314. Noda T, Kurita T, Nitta T, Chiba Y, Furushima H, Matsumoto N, et al. Signiﬁcant\nimpact of electrical storm on mortality in patients with structural heart disease\nand an implantable cardiac deﬁbrillator. Int J Cardiol 2018;255:85–91.\n315. Soar J, Maconochie I, Wyckoff MH, Olasveengen TM, Singletary EM, Greif R, et al.\n2019 International consensus on cardiopulmonary resuscitation and emergency\ncardiovascular care science with treatment recommendations: summary from\nthe basic life support; advanced life support; pediatric life support; neonatal life sup-\nport; education, implementation, and teams; and ﬁrst aid task forces. Circulation\n2019;140:e826–e880.\n316. Eiﬂing M, Razavi M, Massumi A. The evaluation and management of electrical storm.\nTex Heart Inst J 2011;38:111–121.\n317. Chatzidou S, Kontogiannis C, Tsilimigras DI, Georgiopoulos G, Kosmopoulos M,\nPapadopoulou E, et al. Propranolol versus metoprolol for treatment of electrical\nstorm in patients with implantable cardioverter-deﬁbrillator. J Am Coll Cardiol\n2018;71:1897–1906.\n318. Connolly SJ, Dorian P, Roberts RS, Gent M, Bailin S, Fain ES, et al. Comparison of\nbeta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks\nfrom implantable cardioverter deﬁbrillators: the OPTIC Study: a randomized trial.\nJAMA 2006;295:165–171.\n319. Shiga T, Ikeda T, Shimizu W, Kinugawa K, Sakamoto A, Nagai R, et al. Efﬁcacy and\nsafety of landiolol in patients with ventricular tachyarrhythmias with or without re-\nnal impairment – subanalysis of the J-Land II study. Circ Rep 2020;2:440–445.\n320. Kanamori K, Aoyagi T, Mikamo T, Tsutsui K, Kunishima T, Inaba H, et al. Successful\ntreatment of refractory electrical storm with landiolol after more than 100 electric-\nal deﬁbrillations. Int Heart J 2015;56:555–557.\n321. Gorgels AP, van den Dool A, Hofs A, Mulleneers R, Smeets JL, Vos MA, et al.\nComparison of procainamide and lidocaine in terminating sustained monomorphic\nventricular tachycardia. Am J Cardiol 1996;78:43–46.\n322. Martí-Carvajal AJ, Simancas-Racines D, Anand V, Bangdiwala S. Prophylactic lido-\ncaine for myocardial infarction. Cochrane Database Syst Rev 2015;2015:CD008553.\n323. Viskin S, Chorin E, Viskin D, Hochstadt A, Halkin A, Tovia-Brodie O, et al.\nQuinidine-responsive polymorphic ventricular tachycardia in patients with coron-\nary heart disease. Circulation 2019;139:2304–2314.\n324. Viskin S, Hochstadt A, Chorin E, Viskin D, Havakuk O, Khoury S, et al.\nQuinidine-responsive out-of-hospital polymorphic ventricular tachycardia in pa-\ntients with coronary heart disease. Europace 2020;22:265–273.\n325. Martins RP, Urien J-M, Barbarot N, Rieul G, Sellal J-M, Borella L, et al. Effectiveness\nof deep sedation for patients with intractable electrical storm refractory to antiar-\nrhythmic drugs. Circulation 2020;142:1599–1601.\n326. Fudim M, Boortz-Marx R, Ganesh A, Waldron NH, Qadri YJ, Patel CB, et al. Stellate\nganglion blockade for the treatment of refractory ventricular arrhythmias: a sys-\ntematic review and meta-analysis. J Cardiovasc Electrophysiol 2017;28:1460–1467.\n327. Do DH, Bradﬁeld J, Ajijola OA, Vaseghi M, Le J, Rahman S, et al. Thoracic epidural\nanesthesia can be effective for the short-term management of ventricular tachycar-\ndia storm. J Am Heart Assoc 2017;6:e007080.\n328. Vaseghi M, Barwad P, Malavassi Corrales FJ, Tandri H, Mathuria N, Shah R, et al.\nCardiac sympathetic denervation for refractory ventricular arrhythmias. J Am Coll\nCardiol 2017;69:3070–3080.\n329. Gatzoulis KA, Andrikopoulos GK, Apostolopoulos T, Sotiropoulos E, Zervopoulos\nG, Antoniou J, et al. Electrical storm is an independent predictor of adverse long-\nterm outcome in the era of implantable deﬁbrillator therapy. Europace 2005;7:\n184–192.\n330. Carbucicchio C, Santamaria M, Trevisi N, Maccabelli G, Giraldi F, Fassini G, et al.\nCatheter ablation for the treatment of electrical storm in patients with implantable\ncardioverter-deﬁbrillators: short- and long-term outcomes in a prospective single-\ncenter study. Circulation 2008;117:462–469.\n331. Vergara P, Tung R, Vaseghi M, Brombin C, Frankel DS, Di Biase L, et al. Successful\nventricular tachycardia ablation in patients with electrical storm reduces recur-\nrences and improves survival. Heart Rhythm 2018;15:48–55.\n332. Komatsu Y, Hocini M, Nogami A, Maury P, Peichl P, Iwasaki Y, et al. Catheter ab-\nlation of refractory ventricular ﬁbrillation storm after myocardial infarction: a multi-\ncenter study. Circulation 2019;139:2315–2325.\n333. Knecht S, Sacher F, Wright M, Hocini M, Nogami A, Arentz T, et al. Long-term\nfollow-up of idiopathic ventricular ﬁbrillation ablation: a multicenter study. J Am\nColl Cardiol 2009;54:522–528.\n334. Peichl P, Cihák R, Kozeluhová M, Wichterle D, Vancura V, Kautzner J. Catheter ab-\nlation of arrhythmic storm triggered by monomorphic ectopic beats in patients\nwith coronary artery disease. J Interv Card Electrophysiol 2010;27:51–59.\n335. Le Pennec-Prigent S, Flecher E, Auffret V, Leurent G, Daubert J-C, Leclercq C, et al.\nEffectiveness of extracorporeal life support for patients with cardiogenic shock due\nto intractable arrhythmic storm. Crit Care Med 2017;45:e281–e289.\n336. Mariani S, Napp LC, Lo Coco V, Delnoij TSR, Luermans JGLM, Ter Bekke RMA,\net al. Mechanical circulatory support for life-threatening arrhythmia: a systematic\nreview. Int J Cardiol 2020;308:42–49.\n337. Muser D, Liang JJ, Castro SA, Hayashi T, Enriquez A, Troutman GS, et al. Outcomes\nwith prophylactic use of percutaneous left ventricular assist devices in high-risk pa-\ntients undergoing catheter ablation of scar-related ventricular tachycardia: a\npropensity-score matched analysis. Heart Rhythm 2018;15:1500–1506.\n338. Mathuria N, Wu G, Rojas-Delgado F, Shuraih M, Razavi M, Civitello A, et al.\nOutcomes of pre-emptive and rescue use of percutaneous left ventricular assist de-\nvice in patients with structural heart disease undergoing catheter ablation of ven-\ntricular tachycardia. J Interv Card Electrophysiol 2017;48:27–34.\n339. Patel KK, Spertus JA, Khariton Y, Tang Y, Curtis LH, Chan PS, et al. Association be-\ntween prompt deﬁbrillation and epinephrine treatment with long-term survival\nafter in-hospital cardiac arrest. Circulation 2018;137:2041–2051.\n340. Vaseghi M, Gima J, Kanaan C, Ajijola OA, Marmureanu A, Mahajan A, et al. Cardiac\nsympathetic denervation in patients with refractory ventricular arrhythmias or\nelectrical storm: Intermediate and long-term follow-up. Heart Rhythm 2014;11:\n360–366.\n341. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. 2016\nESC Guidelines for the diagnosis and treatment of acute and chronic heart failure:\nthe task force for the diagnosis and treatment of acute and chronic heart failure of\nthe European Society of Cardiology (ESC) Developed with the special contribution\nof the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016;37:2129–2200.\n342. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021\nESC Guidelines for the diagnosis and treatment of acute and chronic heart failure.\nEur Heart J 2021;42:3599–3726.\n343. AlJaroudi WA, Refaat MM, Habib RH, Al-Shaar L, Singh M, Gutmann R, et al. Effect\nof angiotensin-converting enzyme inhibitors and receptor blockers on appropriate\nimplantable cardiac deﬁbrillator shock in patients with severe systolic heart failure\n(from the GRADE Multicenter Study). Am J Cardiol 2015;115:924–931.\n344. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, et al. Eplerenone, a\nselective aldosterone blocker, in patients with left ventricular dysfunction after\nmyocardial infarction. N Engl J Med 2003;348:1309–1321.\n345. McMurray JJV, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al.\nAngiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med\n2014;371:993–1004.\n346. Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, et al.\nCardiovascular and renal outcomes with empagliﬂozin in heart failure. N Engl J\nMed 2020;383:1413–1424.\n347. Desai AS, McMurray JJV, Packer M, Swedberg K, Rouleau JL, Chen F, et al. Effect of\nthe angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on\nmode of death in heart failure patients. Eur Heart J 2015;36:1990–1997.\n348. Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, et al.\n2020 ESC Guidelines for the diagnosis and management of atrial ﬁbrillation devel-\noped in collaboration with the European Association for Cardio-Thoracic Surgery\n(EACTS): The task force for the diagnosis and management of atrial ﬁbrillation of\n4108\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026\n\n\nthe European Society of Cardiology (ESC) Developed with the special contribution\nof the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J 2021;\n42:373–498.\n349. Connolly SJ, Gent M, Roberts RS, Dorian P, Roy D, Sheldon RS, et al. Canadian im-\nplantable deﬁbrillator study (CIDS): a randomized trial of the implantable cardio-\nverter deﬁbrillator against amiodarone. Circulation 2000;101:1297–1302.\n350. Antiarrhythmics versus Implantable Deﬁbrillators (AVID) Investigators. A compari-\nson of antiarrhythmic-drug therapy with implantable deﬁbrillators in patients resus-\ncitated from near-fatal ventricular arrhythmias. N Engl J Med 1997;337:1576–1583.\n351. Kuck KH, Cappato R, Siebels J, Rüppel R. Randomized comparison of antiarrhyth-\nmic drug therapy with implantable deﬁbrillators in patients resuscitated from car-\ndiac arrest: the Cardiac Arrest Study Hamburg (CASH). Circulation 2000;102:\n748–754.\n352. Connolly SJ, Hallstrom AP, Cappato R, Schron EB, Kuck KH, Zipes DP, et al.\nMeta-analysis of the implantable cardioverter deﬁbrillator secondary prevention\ntrials.\nAVID,\nCASH\nand\nCIDS\nstudies.\nAntiarrhythmics\nvs\nImplantable\nDeﬁbrillator study. Cardiac Arrest Study Hamburg. Canadian Implantable\nDeﬁbrillator Study. Eur Heart J 2000;21:2071–2078.\n353. Moss AJ, Hall WJ, Cannom DS, Daubert JP, Higgins SL, Klein H, et al. Improved sur-\nvival with an implanted deﬁbrillator in patients with coronary disease at high risk for\nventricular arrhythmia. N Engl J Med 1996;335:1933–1940.\n354. Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, et al. Prophylactic\nimplantation of a deﬁbrillator in patients with myocardial infarction and reduced\nejection fraction. N Engl J Med 2002;346:877–883.\n355. Buxton AE, Lee KL, Fisher JD, Josephson ME, Prystowsky EN, Haﬂey G. A rando-\nmized study of the prevention of sudden death in patients with coronary artery dis-\nease. Multicenter Unsustained Tachycardia Trial Investigators. N Engl J Med 1999;\n341:1882–1890.\n356. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, et al. Amiodarone or\nan implantable cardioverter-deﬁbrillator for congestive heart failure. N Engl J Med\n2005;352:225–237.\n357. Zabel M, Willems R, Lubinski A, Bauer A, Brugada J, Conen D, et al. Clinical effect-\niveness of primary prevention implantable cardioverter-deﬁbrillators: results of the\nEU-CERT-ICD controlled multicentre cohort study. Eur Heart J 2020;41:\n3437–3447.\n358. Schrage B, Uijl A, Benson L, Westermann D, Ståhlberg M, Stolfo D, et al.\nAssociation between use of primary-prevention implantable cardioverter-\ndeﬁbrillators and mortality in patients with heart failure: a prospective propensity\nscore-matched analysis from the Swedish Heart Failure Registry. Circulation 2019;\n140:1530–1539.\n359. Køber L, Thune JJ, Nielsen JC, Haarbo J, Videbæk L, Korup E, et al. Deﬁbrillator im-\nplantation in patients with nonischemic systolic heart failure. N Engl J Med 2016;\n375:1221–1230.\n360. Jukema JW, Timal RJ, Rotmans JI, Hensen LCR, Buiten MS, de Bie MK, et al.\nProphylactic use of implantable cardioverter-deﬁbrillators in the prevention of sud-\nden cardiac death in dialysis patients. Circulation 2019;139:2628–2638.\n361. Sticherling C, Arendacka B, Svendsen JH, Wijers S, Friede T, Stockinger J, et al. Sex\ndifferences in outcomes of primary prevention implantable cardioverter-\ndeﬁbrillator therapy: combined registry data from eleven European countries.\nEuropace 2018;20:963–970.\n362. Junttila MJ, Pelli A, Kenttä TV, Friede T, Willems R, Bergau L, et al. Appropriate\nshocks and mortality in patients with versus without diabetes with prophylactic im-\nplantable cardioverter deﬁbrillators. Diabetes Care 2020;43:196–200.\n363. Koller MT, Schaer B, Wolbers M, Sticherling C, Bucher HC, Osswald S. Death with-\nout prior appropriate implantable cardioverter-deﬁbrillator therapy: a competing\nrisk study. Circulation 2008;117:1918–1926.\n364. Cleland JGF, Halliday BP, Prasad SK. Selecting patients with nonischemic dilated car-\ndiomyopathy for ICDs: myocardial function, ﬁbrosis, and what’s attached? J Am Coll\nCardiol 2017;70:1228–1231.\n365. Younis A, Goldberger JJ, Kutyifa V, Zareba W, Polonsky B, Klein H, et al. Predicted\nbeneﬁt of an implantable cardioverter-deﬁbrillator: the MADIT-ICD beneﬁt score.\nEur Heart J 2021;42:1676–1684.\n366. Knops RE, Olde Nordkamp LRA, Delnoy P-PHM, Boersma LVA, Kuschyk J,\nEl-Chami MF, et al. Subcutaneous or transvenous deﬁbrillator therapy. N Engl J\nMed 2020;383:526–536.\n367. Cleland JGF, Daubert J-C, Erdmann E, Freemantle N, Gras D, Kappenberger L, et al.\nThe effect of cardiac resynchronization on morbidity and mortality in heart failure.\nN Engl J Med 2005;352:1539–1549.\n368. Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, De Marco T, et al.\nCardiac-resynchronization therapy with or without an implantable deﬁbrillator in\nadvanced chronic heart failure. N Engl J Med 2004;350:2140–2150.\n369. Moss AJ, Hall WJ, Cannom DS, Klein H, Brown MW, Daubert JP, et al.\nCardiac-resynchronization therapy for the prevention of heart-failure events. N\nEngl J Med 2009;361:1329–1338.\n370. Masri A, Altibi AM, Erqou S, Zmaili MA, Saleh A, Al-Adham R, et al. Wearable\ncardioverter-deﬁbrillator therapy for the prevention of sudden cardiac death: a sys-\ntematic review and meta-analysis. JACC Clin Electrophysiol 2019;5:152–161.\n371. Garcia R, Combes N, Defaye P, Narayanan K, Guedon-Moreau L, Boveda S, et al.\nWearable cardioverter-deﬁbrillator in patients with a transient risk of sudden car-\ndiac death: the WEARIT-France cohort study. Europace 2021;23:73–81.\n372. Olgin JE, Pletcher MJ, Vittinghoff E, Wranicz J, Malik R, Morin DP, et al. Wearable\ncardioverter-deﬁbrillator after myocardial infarction. N Engl J Med 2018;379:\n1205–1215.\n373. Scott PA, Silberbauer J, McDonagh TA, Murgatroyd FD. Impact of prolonged im-\nplantable cardioverter-deﬁbrillator arrhythmia detection times on outcomes: a\nmeta-analysis. Heart Rhythm 2014;11:828–835.\n374. Tan VH, Wilton SB, Kuriachan V, Sumner GL, Exner DV. Impact of programming\nstrategies aimed at reducing nonessential implantable cardioverter deﬁbrillator\ntherapies on mortality: a systematic review and meta-analysis. Circ Arrhythm\nElectrophysiol 2014;7:164–170.\n375. Saeed M, Hanna I, Robotis D, Styperek R, Polosajian L, Khan A, et al. Programming\nimplantable cardioverter-deﬁbrillators in patients with primary prevention indica-\ntion to prolong time to ﬁrst shock: results from the PROVIDE study. J Cardiovasc\nElectrophysiol 2014;25:52–59.\n376. Wilkoff BL, Fauchier L, Stiles MK, Morillo CA, Al-Khatib SM, Almendral J, et al. 2015\nHRS/EHRA/APHRS/SOLAECE expert consensus statement on optimal implanta-\nble cardioverter-deﬁbrillator programming and testing. Europace 2016;18:\n159–183.\n377. Stiles MK, Fauchier L, Morillo CA, Wilkoff BL, ESC Scientiﬁc Document Group.\n2019 HRS/EHRA/APHRS/LAHRS focused update to 2015 expert consensus state-\nment on optimal implantable cardioverter-deﬁbrillator programming and testing.\nEuropace 2019;21:1442–1443.\n378. Barsheshet A, Moss AJ, McNitt S, Jons C, Glikson M, Klein HU, et al. Long-term im-\nplications of cumulative right ventricular pacing among patients with an implantable\ncardioverter-deﬁbrillator. Heart Rhythm 2011;8:212–218.\n379. Wilkoff BL, Cook JR, Epstein AE, Greene HL, Hallstrom AP, Hsia H, et al.\nDual-chamber pacing or ventricular backup pacing in patients with an implantable\ndeﬁbrillator: the Dual Chamber and VVI Implantable Deﬁbrillator (DAVID) Trial.\nJAMA 2002;288:3115–3123.\n380. Olshansky B, Day JD, Moore S, Gering L, Rosenbaum M, McGuire M, et al. Is dual-\nchamber programming inferior to single-chamber programming in an implantable\ncardioverter-deﬁbrillator?\nResults\nof\nthe\nINTRINSIC\nRV\n(Inhibition\nof\nUnnecessary RV Pacing With AVSH in ICDs) study. Circulation 2007;115:9–16.\n381. Hindricks G, Kühl M, Dagres N. The implantable cardioverter deﬁbrillator, conclu-\nsions on sudden cardiac death, and future perspective. ESC CardioMed. 3rd ed.\nOxford University Press; 2022, p2370–2376.\n382. Gasparini M, Proclemer A, Klersy C, Kloppe A, Ferrer JBM, Hersi A, et al. Effect of\nlong-detection interval vs standard-detection interval for implantable cardioverter-\ndeﬁbrillators on antitachycardia pacing and shock delivery: the ADVANCE III ran-\ndomized clinical trial. JAMA 2013;309:1903–1911.\n383. Moss AJ, Schuger C, Beck CA, Brown MW, Cannom DS, Daubert JP, et al.\nReduction in inappropriate therapy and mortality through ICD programming. N\nEngl J Med 2012;367:2275–2283.\n384. Wilkoff BL, Ousdigian KT, Sterns LD, Wang ZJ, Wilson RD, Morgan JM, et al. A\ncomparison of empiric to physician-tailored programming of implantable\ncardioverter-deﬁbrillators: results from the prospective randomized multicenter\nEMPIRIC trial. J Am Coll Cardiol 2006;48:330–339.\n385. Wilkoff BL, Williamson BD, Stern RS, Moore SL, Lu F, Lee SW, et al. Strategic pro-\ngramming of detection and therapy parameters in implantable cardioverter-\ndeﬁbrillators reduces shocks in primary prevention patients: results from the\nPREPARE (Primary Prevention Parameters Evaluation) study. J Am Coll Cardiol\n2008;52:541–550.\n386. Gilliam FR, Hayes DL, Boehmer JP, Day J, Heidenreich PA, Seth M, et al. Real world\nevaluation of dual-zone ICD and CRT-D programming compared to single-zone\nprogramming: the ALTITUDE REDUCES study. J Cardiovasc Electrophysiol 2011;\n22:1023–1029.\n387. Hernandez-Ojeda J, Arbelo E, Borras R, Berne P, Tolosana JM, Gomez-Juanatey A,\net al. Patients with Brugada syndrome and implanted cardioverter-deﬁbrillators:\nlong-term follow-up. J Am Coll Cardiol 2017;70:1991–2002.\n388. Gold MR, Weiss R, Theuns DAMJ, Smith W, Leon A, Knight BP, et al. Use of a dis-\ncrimination algorithm to reduce inappropriate shocks with a subcutaneous implan-\ntable cardioverter-deﬁbrillator. Heart Rhythm 2014;11:1352–1358.\n389. Mesquita J, Cavaco D, Ferreira A, Lopes N, Santos PG, Carvalho MS, et al.\nEffectiveness of subcutaneous implantable cardioverter-deﬁbrillators and determi-\nnants of inappropriate shock delivery. Int J Cardiol 2017;232:176–180.\n390. Gold MR, Lambiase PD, El-Chami MF, Knops RE, Aasbo JD, Bongiorni MG, et al.\nPrimary results from the understanding outcomes with the S-ICD in primary pre-\nvention patients with low ejection fraction (UNTOUCHED) trial. Circulation 2021;\n143:7–17.\nESC Guidelines\n4109\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026\n\n\n391. Wathen MS, DeGroot PJ, Sweeney MO, Stark AJ, Otterness MF, Adkisson WO,\net al. Prospective randomized multicenter trial of empirical antitachycardia pacing\nversus shocks for spontaneous rapid ventricular tachycardia in patients with im-\nplantable cardioverter-deﬁbrillators: Pacing Fast Ventricular Tachycardia Reduces\nShock Therapies (PainFREE Rx II) trial results. Circulation 2004;110:2591–2596.\n392. Gulizia MM, Piraino L, Scherillo M, Puntrello C, Vasco C, Scianaro MC, et al. A ran-\ndomized study to compare ramp versus burst antitachycardia pacing therapies to\ntreat fast ventricular tachyarrhythmias in patients with implantable cardioverter de-\nﬁbrillators: the PITAGORA ICD trial. Circ Arrhythm Electrophysiol 2009;2:146–153.\n393. Saxon LA, Hayes DL, Gilliam FR, Heidenreich PA, Day J, Seth M, et al. Long-term\noutcome after ICD and CRT implantation and inﬂuence of remote device follow-\nup: the ALTITUDE survival study. Circulation 2010;122:2359–2367.\n394. Varma N, Piccini JP, Snell J, Fischer A, Dalal N, Mittal S. The relationship between\nlevel of adherence to automatic wireless remote monitoring and survival in pace-\nmaker and deﬁbrillator patients. J Am Coll Cardiol 2015;65:2601–2610.\n395. Guédon-Moreau L, Kouakam C, Klug D, Marquié C, Brigadeau F, Boulé S, et al.\nDecreased delivery of inappropriate shocks achieved by remote monitoring of\nICD: a substudy of the ECOST trial. J Cardiovasc Electrophysiol 2014;25:763–770.\n396. Varma N, Michalski J, Epstein AE, Schweikert R. Automatic remote monitoring of\nimplantable cardioverter-deﬁbrillator lead and generator performance: the\nLumos-T Safely RedUceS RouTine Ofﬁce Device Follow-Up (TRUST) trial. Circ\nArrhythm Electrophysiol 2010;3:428–436.\n397. Ploux S, Swerdlow CD, Strik M, Welte N, Klotz N, Ritter P, et al. Towards eradi-\ncation of inappropriate therapies for ICD lead failure by combining comprehensive\nremote monitoring and lead noise alerts. J Cardiovasc Electrophysiol 2018;29:\n1125–1134.\n398. Ellenbogen KA, Gunderson BD, Stromberg KD, Swerdlow CD. Performance of\nLead Integrity Alert to assist in the clinical diagnosis of implantable cardioverter de-\nﬁbrillator lead failures: analysis of different implantable cardioverter deﬁbrillator\nleads. Circ Arrhythm Electrophysiol 2013;6:1169–1177.\n399. Swerdlow CD, Gunderson BD, Ousdigian KT, Abeyratne A, Sachanandani H,\nEllenbogen KA. Downloadable software algorithm reduces inappropriate shocks\ncaused by implantable cardioverter-deﬁbrillator lead fractures: a prospective study.\nCirculation 2010;122:1449–1455.\n400. Ruwald MH, Abu-Zeitone A, Jons C, Ruwald A-C, McNitt S, Kutyifa V, et al. Impact\nof\ncarvedilol\nand\nmetoprolol on\ninappropriate implantable\ncardioverter-\ndeﬁbrillator therapy: the MADIT-CRT trial (Multicenter Automatic Deﬁbrillator\nImplantation With Cardiac Resynchronization Therapy). J Am Coll Cardiol 2013;\n62:1343–1350.\n401. Miyazaki S, Taniguchi H, Kusa S, Komatsu Y, Ichihara N, Takagi T, et al. Catheter\nablation of atrial tachyarrhythmias causing inappropriate implantable cardioverter-\ndeﬁbrillator shocks. Europace 2015;17:289–294.\n402. Mainigi SK, Almuti K, Figueredo VM, Guttenplan NA, Aouthmany A, Smukler J, et al.\nUsefulness of radiofrequency ablation of supraventricular tachycardia to decrease\ninappropriate shocks from implantable cardioverter-deﬁbrillators. Am J Cardiol\n2012;109:231–237.\n403. Kosiuk J, Nedios S, Darma A, Rolf S, Richter S, Arya A, et al. Impact of single atrial\nﬁbrillation catheter ablation on implantable cardioverter deﬁbrillator therapies in\npatients with ischaemic and non-ischaemic cardiomyopathies. Europace 2014;16:\n1322–1326.\n404. Kirchhof P, Camm AJ, Goette A, Brandes A, Eckardt L, Elvan A, et al. Early rhythm-\ncontrol therapy in patients with atrial ﬁbrillation. N Engl J Med 2020;383:\n1305–1316.\n405. Gasparini M, Kloppe A, Lunati M, Anselme F, Landolina M, Martinez-Ferrer JB, et al.\nAtrioventricular junction ablation in patients with atrial ﬁbrillation treated with car-\ndiac resynchronization therapy: positive impact on ventricular arrhythmias, implan-\ntable cardioverter-deﬁbrillator therapies and hospitalizations: atrioventricular\njunction ablation in CRT patients with AF. Eur J Heart Fail 2018;20:1472–1481.\n406. Gasparini M, Galimberti P. Rate control: ablation and device therapy (ablate and\npace). ESC CardioMed. 3rd ed. Oxford University Press; 2022, p2159–2162.\n407. Kitamura T, Fukamizu S, Kawamura I, Hojo R, Aoyama Y, Komiyama K, et al.\nLong-term efﬁcacy of catheter ablation for paroxysmal atrial ﬁbrillation in patients\nwith Brugada syndrome and an implantable cardioverter-deﬁbrillator to prevent in-\nappropriate shock therapy. Heart Rhythm 2016;13:1455–1459.\n408. Magyar-Russell G, Thombs BD, Cai JX, Baveja T, Kuhl EA, Singh PP, et al. The preva-\nlence of anxiety and depression in adults with implantable cardioverter deﬁbrilla-\ntors: a systematic review. J Psychosom Res 2011;71:223–231.\n409. Tzeis S, Kolb C, Baumert J, Reents T, Zrenner B, Deisenhofer I, et al. Effect of de-\npression on mortality in implantable cardioverter deﬁbrillator recipients—ﬁndings\nfrom the prospective LICAD study. Pacing Clin Electrophysiol 2011;34:991–997.\n410. Andersen CM, Theuns DAMJ, Johansen JB, Pedersen SS. Anxiety, depression, ven-\ntricular arrhythmias and mortality in patients with an implantable cardioverter de-\nﬁbrillator: 7 years’ follow-up of the MIDAS cohort. Gen Hosp Psychiatry 2020;66:\n154–160.\n411. Berg SK, Thygesen LC, Svendsen JH, Christensen AV, Zwisler A-D. Anxiety pre-\ndicts mortality in ICD patients: results from the cross-sectional national\nCopenHeartICD survey with register follow-up. Pacing Clin Electrophysiol 2014;\n37:1641–1650.\n412. Thylén I, Moser DK, Strömberg A, Dekker RA, Chung ML. Concerns about implan-\ntable cardioverter-deﬁbrillator shocks mediate the relationship between actual\nshocks and psychological distress. Europace 2016;18:828–835.\n413. Pedersen SS, van Domburg RT, Theuns DAMJ, Jordaens L, Erdman RAM. Concerns\nabout the implantable cardioverter deﬁbrillator: a determinant of anxiety and de-\npressive symptoms independent of experienced shocks. Am Heart J 2005;149:\n664–669.\n414. Frizelle DJ, Lewin B, Kaye G, Moniz-Cook ED. Development of a measure of the\nconcerns held by people with implanted cardioverter deﬁbrillators: the ICDC. Br\nJ Health Psychol 2006;11:293–301.\n415. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr\nScand 1983;67:361–370.\n416. Frydensberg VS, Johansen JB, Möller S, Riahi S, Wehberg S, Haarbo J, et al. Anxiety\nand depression symptoms in Danish patients with an implantable cardioverter-\ndeﬁbrillator: prevalence and association with indication and sex up to 2 years of\nfollow-up (data from the national DEFIB-WOMEN study). Europace 2020;22:\n1830–1840.\n417. Hoogwegt MT, Kupper N, Theuns DAMJ, Zijlstra WP, Jordaens L, Pedersen SS.\nUndertreatment of anxiety and depression in patients with an implantable\ncardioverter-deﬁbrillator: impact on health status. Health Psychol 2012;31:\n745–753.\n418. Lane DA, Aguinaga L, Blomström-Lundqvist C, Boriani G, Dan G-A, Hills MT, et al.\nCardiac tachyarrhythmias and patient values and preferences for their manage-\nment: the European Heart Rhythm Association (EHRA) consensus document en-\ndorsed by the Heart Rhythm Society (HRS), Asia Paciﬁc Heart Rhythm Society\n(APHRS),\nand\nSociedad\nLatinoamericana\nde\nEstimulación\nCardíaca\ny\nElectroﬁsiología (SOLEACE). Europace 2015;17:1747–1769.\n419. Dunbar SB, Dougherty CM, Sears SF, Carroll DL, Goldstein NE, Mark DB, et al.\nEducational and psychological interventions to improve outcomes for recipients\nof implantable cardioverter deﬁbrillators and their families: a scientiﬁc statement\nfrom the American Heart Association. Circulation 2012;126:2146–2172.\n420. Sears SF, Sowell LDV, Kuhl EA, Kovacs AH, Serber ER, Handberg E, et al. The ICD\nshock and stress management program: a randomized trial of psychosocial treat-\nment to optimize quality of life in ICD patients. Pacing Clin Electrophysiol 2007;\n30:858–864.\n421. Berg SK, Rasmussen TB, Herning M, Svendsen JH, Christensen AV, Thygesen LC.\nCognitive behavioural therapy signiﬁcantly reduces anxiety in patients with im-\nplanted cardioverter deﬁbrillator compared with usual care: ﬁndings from the\nScreen-ICD randomised controlled trial. Eur J Prev Cardiol 2020;27:258–268.\n422. Schulz SM, Ritter O, Zniva R, Nordbeck P, Wacker C, Jack M, et al. Efﬁcacy of a\nweb-based intervention for improving psychosocial well-being in patients with im-\nplantable cardioverter-deﬁbrillators: the randomized controlled ICD-FORUM trial.\nEur Heart J 2020;41:1203–1211.\n423. van den Broek KC, Tekle FB, Habibović M, Alings M, van der Voort PH, Denollet J.\nEmotional distress, positive affect, and mortality in patients with an implantable car-\ndioverter deﬁbrillator. Int J Cardiol 2013;165:327–332.\n424. Hauptman PJ, Chibnall JT, Guild C, Armbrecht ES. Patient perceptions, physician\ncommunication, and the implantable cardioverter-deﬁbrillator. JAMA Intern Med\n2013;173:571–577.\n425. Cikes M, Jakus N, Claggett B, Brugts JJ, Timmermans P, Pouleur A-C, et al. Cardiac\nimplantable electronic devices with a deﬁbrillator component and all-cause mortal-\nity in left ventricular assist device carriers: results from the PCHF-VAD registry. Eur\nJ Heart Fail 2019;21:1129–1141.\n426. Galand V, Flécher E, Auffret V, Boulé S, Vincentelli A, Dambrin C, et al. Predictors\nand clinical impact of late ventricular arrhythmias in patients with continuous-ﬂow\nleft ventricular assist devices. JACC Clin Electrophysiol 2018;4:1166–1175.\n427. Nakahara S, Chien C, Gelow J, Dalouk K, Henrikson CA, Mudd J, et al. Ventricular\narrhythmias after left ventricular assist device. Circ Arrhythm Electrophysiol 2013;6:\n648–654.\n428. Clerkin KJ, Topkara VK, Demmer RT, Dizon JM, Yuzefpolskaya M, Fried JA, et al.\nImplantable cardioverter-deﬁbrillators in patients with a continuous-ﬂow left ven-\ntricular assist device: an analysis of the INTERMACS registry. JACC Heart Fail 2017;\n5:916–926.\n429. Oz MC, Rose EA, Slater J, Kuiper JJ, Catanese KA, Levin HR. Malignant ventricular\narrhythmias are well tolerated in patients receiving long-term left ventricular assist\ndevices. J Am Coll Cardiol 1994;24:1688–1691.\n430. Potapov EV, Antonides C, Crespo-Leiro MG, Combes A, Färber G, Hannan MM,\net al. 2019 EACTS Expert Consensus on long-term mechanical circulatory support.\nEur J Cardiothorac Surg 56:230–270.\n4110\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026\n\n\n431. Makki N, Mesubi O, Steyers C, Olshansky B, Abraham WT. Meta-analysis of the\nrelation of ventricular arrhythmias to all-cause mortality after implantation of a\nleft ventricular assist device. Am J Cardiol 2015;116:1385–1390.\n432. Yoruk A, Sherazi S, Massey HT, Kutyifa V, McNitt S, Hallinan W, et al. Predictors\nand clinical relevance of ventricular tachyarrhythmias in ambulatory patients with\na continuous ﬂow left ventricular assist device. Heart Rhythm 2016;13:1052–1056.\n433. Bedi M, Kormos R, Winowich S, McNamara DM, Mathier MA, Murali S. Ventricular\narrhythmias during left ventricular assist device support. Am J Cardiol 2007;99:\n1151–1153.\n434. Brenyo A, Rao M, Koneru S, Hallinan W, Shah S, Massey HT, et al. Risk of mortality\nfor ventricular arrhythmia in ambulatory LVAD patients. J Cardiovasc Electrophysiol\n2012;23:515–520.\n435. Vakil K, Kazmirczak F, Sathnur N, Adabag S, Cantillon DJ, Kiehl EL, et al. Implantable\ncardioverter-deﬁbrillator use in patients with left ventricular assist devices: a sys-\ntematic review and meta-analysis. JACC Heart Fail 2016;4:772–779.\n436. Refaat MM, Tanaka T, Kormos RL, McNamara D, Teuteberg J, Winowich S, et al.\nSurvival beneﬁt of implantable cardioverter-deﬁbrillators in left ventricular assist\ndevice-supported heart failure patients. J Card Fail 2012;18:140–145.\n437. Cantillon DJ, Tarakji KG, Kumbhani DJ, Smedira NG, Starling RC, Wilkoff BL.\nImproved survival among ventricular assist device recipients with a concomitant im-\nplantable cardioverter-deﬁbrillator. Heart Rhythm 2010;7:466–471.\n438. Joyce E, Starling RC. HFrEF other treatment: ventricular assist devices. ESC\nCardioMed. 3rd ed. Oxford University Press; 2022, p1884–1889.\n439. Younes A, Al-Kindi SG, Alajaji W, Mackall JA, Oliveira GH. Presence of implantable\ncardioverter-deﬁbrillators and wait-list mortality of patients supported with left\nventricular assist devices as bridge to heart transplantation. Int J Cardiol 2017;\n231:211–215.\n440. Agrawal S, Garg L, Nanda S, Sharma A, Bhatia N, Manda Y, et al. The role of implan-\ntable cardioverter-deﬁbrillators in patients with continuous ﬂow left ventricular as-\nsist devices – a meta-analysis. Int J Cardiol 2016;222:379–384.\n441. Blomström-Lundqvist C, Traykov V, Erba PA, Burri H, Nielsen JC, Bongiorni MG,\net al. European Heart Rhythm Association (EHRA) international consensus docu-\nment on how to prevent, diagnose, and treat cardiac implantable electronic device\ninfections-endorsed by the Heart Rhythm Society (HRS), the Asia Paciﬁc Heart\nRhythm Society (APHRS), the Latin American Heart Rhythm Society (LAHRS),\nInternational Society for Cardiovascular Infectious Diseases (ISCVID) and the\nEuropean Society of Clinical Microbiology and Infectious Diseases (ESCMID) in col-\nlaboration with the European Association for Cardio-Thoracic Surgery (EACTS).\nEuropace 2020;22:515–549.\n442. Burri H, Starck C, Auricchio A, BifﬁM, Burri M, D’Avila A, et al. EHRA expert con-\nsensus statement and practical guide on optimal implantation technique for con-\nventional pacemakers and implantable cardioverter-deﬁbrillators: endorsed by\nthe Heart Rhythm Society (HRS), the Asia Paciﬁc Heart Rhythm Society\n(APHRS), and the Latin-American Heart Rhythm Society (LAHRS). Europace\n2021;23:983–1008.\n443. Tarakji KG, Mittal S, Kennergren C, Corey R, Poole JE, Schloss E, et al. Antibacterial\nenvelope to prevent cardiac implantable device infection. N Engl J Med 2019;380:\n1895–1905.\n444. Atti V, Turagam MK, Garg J, Koerber S, Angirekula A, Gopinathannair R, et al.\nSubclavian and axillary vein access versus cephalic vein cutdown for cardiac implan-\ntable electronic device implantation: a meta-analysis. JACC Clin Electrophysiol 2020;6:\n661–671.\n445. Benz AP, Vamos M, Erath JW, Hohnloser SH. Cephalic vs. subclavian lead implant-\nation in cardiac implantable electronic devices: a systematic review and\nmeta-analysis. Europace 2019;21:121–129.\n446. Chan N-Y, Kwong N-P, Cheong A-P. Venous access and long-term pacemaker lead\nfailure: comparing contrast-guided axillary vein puncture with subclavian puncture\nand cephalic cutdown. Europace 2017;19:1193–1197.\n447. Defaye P, Boveda S, Klug D, Beganton F, Piot O, Narayanan K, et al. Dual- vs. single-\nchamber deﬁbrillators for primary prevention of sudden cardiac death: long-term\nfollow-up of the Déﬁbrillateur Automatique Implantable-Prévention Primaire\nregistry. Europace 2017;19:1478–1484.\n448. Dewland TA, Pellegrini CN, Wang Y, Marcus GM, Keung E, Varosy PD.\nDual-chamber implantable cardioverter-deﬁbrillator selection is associated with in-\ncreased complication rates and mortality among patients enrolled in the NCDR im-\nplantable cardioverter-deﬁbrillator registry. J Am Coll Cardiol 2011;58:1007–1013.\n449. Friedman PA, Bradley D, Koestler C, Slusser J, Hodge D, Bailey K, et al. A prospect-\nive randomized trial of single- or dual-chamber implantable cardioverter-\ndeﬁbrillators to minimize inappropriate shock risk in primary sudden cardiac death\nprevention. Europace 2014;16:1460–1468.\n450. Chen B-W, Liu Q, Wang X, Dang A-M. Are dual-chamber implantable\ncardioverter-deﬁbrillators really better than single-chamber ones? A systematic re-\nview and meta-analysis. J Interv Card Electrophysiol 2014;39:273–280.\n451. Epstein LM, Love CJ, Wilkoff BL, Chung MK, Hackler JW, Bongiorni MG, et al.\nSuperior vena cava deﬁbrillator coils make transvenous lead extraction more chal-\nlenging and riskier. J Am Coll Cardiol 2013;61:987–989.\n452. Larsen JM, Hjortshøj SP, Nielsen JC, Johansen JB, Petersen HH, Haarbo J, et al.\nSingle-coil and dual-coil deﬁbrillator leads and association with clinical outcomes\nin a complete Danish nationwide ICD cohort. Heart Rhythm 2016;13:706–712.\n453. Kumar KR, Mandleywala SN, Madias C, Weinstock J, Rowin EJ, Maron BJ, et al.\nSingle coil implantable cardioverter deﬁbrillator leads in patients with hypertrophic\ncardiomyopathy. Am J Cardiol 2020;125:1896–1900.\n454. Friedman PA, Rasmussen MJ, Grice S, Trusty J, Glikson M, Stanton MS. Deﬁbrillation\nthresholds are increased by right-sided implantation of totally transvenous implan-\ntable cardioverter deﬁbrillators. Pacing Clin Electrophysiol 1999;22:1186–1192.\n455. Stoevelaar R, Brinkman-Stoppelenburg A, Bhagwandien RE, van Bruchem-Visser\nRL, Theuns DA, van der Heide A, et al. The incidence and impact of implantable\ncardioverter deﬁbrillator shocks in the last phase of life: an integrated review.\nEur J Cardiovasc Nurs 2018;17:477–485.\n456. Kapa S, Mueller PS, Hayes DL, Asirvatham SJ. Perspectives on withdrawing pace-\nmaker and implantable cardioverter-deﬁbrillator therapies at end of life: results\nof a survey of medical and legal professionals and patients. Mayo Clin Proc 2010;\n85:981–990.\n457. Padeletti L, Arnar DO, Boncinelli L, Brachman J, Camm JA, Daubert JC, et al. EHRA\nExpert Consensus Statement on the management of cardiovascular implantable\nelectronic devices in patients nearing end of life or requesting withdrawal of ther-\napy. Europace 2010;12:1480–1489.\n458. Stoevelaar R, Brinkman-Stoppelenburg A, van Driel AG, Theuns DA, Bhagwandien\nRE, van Bruchem-Visser RL, et al. Trends in time in the management of the implan-\ntable cardioverter deﬁbrillator in the last phase of life: a retrospective study of med-\nical records. Eur J Cardiovasc Nurs 2019;18:449–457.\n459. Kirkpatrick JN, Gottlieb M, Sehgal P, Patel R, Verdino RJ. Deactivation of implanta-\nble cardioverter deﬁbrillators in terminal illness and end of life care. Am J Cardiol\n2012;109:91–94.\n460. Stevenson WG, Khan H, Sager P, Saxon LA, Middlekauff HR, Natterson PD, et al.\nIdentiﬁcation of reentry circuit sites during catheter mapping and radiofrequency\nablation of ventricular tachycardia late after myocardial infarction. Circulation\n1993;88:1647–1670.\n461. de Bakker JM, van Capelle FJ, Janse MJ, Tasseron S, Vermeulen JT, de Jonge N, et al.\nSlow conduction in the infarcted human heart. “Zigzag” course of activation.\nCirculation 1993;88:915–926.\n462. de Chillou C, Lacroix D, Klug D, Magnin-Poull I, Marquié C, Messier M, et al. Isthmus\ncharacteristics of reentrant ventricular tachycardia after myocardial infarction.\nCirculation 2002;105:726–731.\n463. Hsia HH, Callans DJ, Marchlinski FE. Characterization of endocardial electrophysio-\nlogical substrate in patients with nonischemic cardiomyopathy and monomorphic\nventricular tachycardia. Circulation 2003;108:704–710.\n464. Soejima K, Stevenson WG, Sapp JL, Selwyn AP, Couper G, Epstein LM. Endocardial\nand epicardial radiofrequency ablation of ventricular tachycardia associated with di-\nlated cardiomyopathy. J Am Coll Cardiol 2004;43:1834–1842.\n465. Miljoen H, State S, Dechillou C, Magninpoull I, Dotto P, Andronache M, et al.\nElectroanatomic mapping characteristics of ventricular tachycardia in patients\nwith arrhythmogenic right ventricular cardiomyopathy/dysplasia. Europace 2005;\n7:516–524.\n466. Priori SG, Blomström-Lundqvist C, Mazzanti A, Blom N, Borggrefe M, Camm J, et al.\n2015 ESC Guidelines for the management of patients with ventricular arrhythmias\nand the prevention of sudden cardiac death: The task force for the Management of\nPatients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death\nof the European Society of Cardiology (ESC). Endorsed by: Association for\nEuropean Paediatric and Congenital Cardiology (AEPC). Eur Heart J 2015;36:\n2793–2867.\n467. Al-Khatib SM, Stevenson WG, Ackerman MJ, Bryant WJ, Callans DJ, Curtis AB, et al.\n2017 AHA/ACC/HRS Guideline for management of patients with ventricular ar-\nrhythmias and the prevention of sudden cardiac death: executive summary. J Am\nColl Cardiol 2018;72:1677–1749.\n468. Towbin JA, McKenna WJ, Abrams DJ, Ackerman MJ, Calkins H, Darrieux FCC, et al.\n2019 HRS expert consensus statement on evaluation, risk stratiﬁcation, and man-\nagement of arrhythmogenic cardiomyopathy: executive summary. Heart Rhythm\n2019;16:e373–e407.\n469. Moss AJ, Greenberg H, Case RB, Zareba W, Hall WJ, Brown MW, et al. Long-term\nclinical course of patients after termination of ventricular tachyarrhythmia by an im-\nplanted deﬁbrillator. Circulation 2004;110:3760–3765.\n470. Poole JE, Johnson GW, Hellkamp AS, Anderson J, Callans DJ, Raitt MH, et al.\nPrognostic importance of deﬁbrillator shocks in patients with heart failure. N\nEngl J Med 2008;359:1009–1017.\n471. Sapp JL, Wells GA, Parkash R, Stevenson WG, Blier L, Sarrazin J-F, et al. Ventricular\ntachycardia ablation versus escalation of antiarrhythmic drugs. N Engl J Med 2016;\n375:111–121.\nESC Guidelines\n4111\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026\n\n\n472. Piccini JP, Berger JS, O’Connor CM. Amiodarone for the prevention of sudden car-\ndiac death: a meta-analysis of randomized controlled trials. Eur Heart J 2009;30:\n1245–1253.\n473. Palaniswamy C, Kolte D, Harikrishnan P, Khera S, Aronow WS, Mujib M, et al.\nCatheter ablation of postinfarction ventricular tachycardia: ten-year trends in util-\nization, in-hospital complications, and in-hospital mortality in the United States.\nHeart Rhythm 2014;11:2056–2063.\n474. Caceres J, Jazayeri M, McKinnie J, Avitall B, Denker ST, Tchou P, et al. Sustained bun-\ndle branch reentry as a mechanism of clinical tachycardia. Circulation 1989;79:\n256–270.\n475. Blanck Z, Dhala A, Deshpande S, Sra J, Jazayeri M, Akhtar M. Bundle branch re-\nentrant ventricular tachycardia: cumulative experience in 48 patients. J Cardiovasc\nElectrophysiol 1993;4:253–262.\n476. Chen H, Shi L, Yang B, Ju W, Zhang F, Yang G, et al. Electrophysiological character-\nistics of bundle branch reentry ventricular tachycardia in patients without structural\nheart disease. Circ Arrhythm Electrophysiol 2018;11:e006049.\n477. Pathak RK, Fahed J, Santangeli P, Hyman MC, Liang JJ, Kubala M, et al. Long-term\noutcome of catheter ablation for treatment of bundle branch re-entrant tachycar-\ndia. JACC Clin Electrophysiol 2018;4:331–338.\n478. Stevenson WG, Wilber DJ, Natale A, Jackman WM, Marchlinski FE, Talbert T, et al.\nIrrigated radiofrequency catheter ablation guided by electroanatomic mapping for\nrecurrent ventricular tachycardia after myocardial infarction: the multicenter ther-\nmocool ventricular tachycardia ablation trial. Circulation 2008;118:2773–2782.\n479. Della Bella P, Baratto F, Tsiachris D, Trevisi N, Vergara P, Bisceglia C, et al.\nManagement of ventricular tachycardia in the setting of a dedicated unit for the\ntreatment of complex ventricular arrhythmias: long-term outcome after ablation.\nCirculation 2013;127:1359–1368.\n480. Maury P, Baratto F, Zeppenfeld K, Klein G, Delacretaz E, Sacher F, et al.\nRadio-frequency ablation as primary management of well-tolerated sustained\nmonomorphic ventricular tachycardia in patients with structural heart disease\nand left ventricular ejection fraction over 30%. Eur Heart J 2014;35:1479–1485.\n481. Tung R, Vaseghi M, Frankel DS, Vergara P, Di Biase L, Nagashima K, et al. Freedom\nfrom recurrent ventricular tachycardia after catheter ablation is associated with im-\nproved survival in patients with structural heart disease: an International VT\nAblation Center Collaborative Group study. Heart Rhythm 2015;12:1997–2007.\n482. Santangeli P, Zado ES, Supple GE, Haqqani HM, Garcia FC, Tschabrunn CM, et al.\nLong-term outcome with catheter ablation of ventricular tachycardia in patients\nwith\narrhythmogenic\nright\nventricular\ncardiomyopathy.\nCirc\nArrhythm\nElectrophysiol 2015;8:1413–1421.\n483. Marchlinski FE, Haffajee CI, Beshai JF, Dickfeld T-ML, Gonzalez MD, Hsia HH, et al.\nLong-term success of irrigated radiofrequency catheter ablation of sustained ven-\ntricular tachycardia. J Am Coll Cardiol 2016;67:674–683.\n484. Reddy VY, Reynolds MR, Neuzil P, Richardson AW, Taborsky M, Jongnarangsin K,\net al. Prophylactic catheter ablation for the prevention of deﬁbrillator therapy. N\nEngl J Med 2007;357:2657–2665.\n485. Kuck K-H, Schaumann A, Eckardt L, Willems S, Ventura R, Delacrétaz E, et al.\nCatheter ablation of stable ventricular tachycardia before deﬁbrillator implantation\nin patients with coronary heart disease (VTACH): a multicentre randomised con-\ntrolled trial. Lancet 2010;375:31–40.\n486. Anter E, Kleber AG, Rottmann M, Leshem E, Barkagan M, Tschabrunn CM, et al.\nInfarct-related ventricular tachycardia. JACC Clin Electrophysiol 2018;4:1033–1048.\n487. Marchlinski FE, Callans DJ, Gottlieb CD, Zado E. Linear ablation lesions for control\nof unmappable ventricular tachycardia in patients with ischemic and nonischemic\ncardiomyopathy. Circulation 2000;101:1288–1296.\n488. de Chillou C, Groben L, Magnin-Poull I, Andronache M, Abbas MM, Zhang N, et al.\nLocalizing the critical isthmus of postinfarct ventricular tachycardia: the value of\npace-mapping during sinus rhythm. Heart Rhythm 2014;11:175–181.\n489. Jaïs P, Maury P, Khairy P, Sacher F, Nault I, Komatsu Y, et al. Elimination of local ab-\nnormal ventricular activities: a new end point for substrate modiﬁcation in patients\nwith scar-related ventricular tachycardia. Circulation 2012;125:2184–2196.\n490. Berruezo A, Fernandez-Armenta J. Lines, circles, channels, and clouds: looking for\nthe best design for substrate-guided ablation of ventricular tachycardia. Europace\n2014;16:943–945.\n491. Di Biase L, Burkhardt JD, Lakkireddy D, Carbucicchio C, Mohanty S, Mohanty P,\net al. Ablation of stable VTs versus substrate ablation in ischemic cardiomyopathy.\nJ Am Coll Cardiol 2015;66:2872–2882.\n492. Berruezo A, Fernández-Armenta J, Andreu D, Penela D, Herczku C, Evertz R, et al.\nScar dechanneling: new method for scar-related left ventricular tachycardia sub-\nstrate ablation. Circ Arrhythm Electrophysiol 2015;8:326–336.\n493. Haïssaguerre M, Shoda M, Jaïs P, Nogami A, Shah DC, Kautzner J, et al. Mapping and\nablation of idiopathic ventricular ﬁbrillation. Circulation 2002;106:962–967.\n494. Shirai Y, Liang JJ, Santangeli P, Arkles JS, Schaller RD, Supple GE, et al. Comparison\nof the ventricular tachycardia circuit between patients with ischemic and nonis-\nchemic cardiomyopathies: detailed characterization by entrainment. Circ Arrhythm\nElectrophysiol 2019;12:e007249.\n495. Bhaskaran A, Tung R, Stevenson WG, Kumar S. Catheter ablation of VT in non-\nischaemic cardiomyopathies: endocardial, epicardial and intramural approaches.\nHeart Lung Circ 2019;28:84–101.\n496. Tung R, Raiman M, Liao H, Zhan X, Chung FP, Nagel R, et al. Simultaneous endo-\ncardial and epicardial delineation of 3D reentrant ventricular tachycardia. J Am Coll\nCardiol 2020;75:884–897.\n497. Dinov B, Fiedler L, Schönbauer R, Bollmann A, Rolf S, Piorkowski C, et al.\nOutcomes in catheter ablation of ventricular tachycardia in dilated nonischemic\ncardiomyopathy compared with ischemic cardiomyopathy: results from the\nProspective Heart Centre of Leipzig VT (HELP-VT) Study. Circulation 2014;129:\n728–736.\n498. Proietti R, Essebag V, Beardsall J, Hache P, Pantano A, Wulffhart Z, et al.\nSubstrate-guided ablation of haemodynamically tolerated and untolerated ven-\ntricular tachycardia in patients with structural heart disease: effect of cardiomyop-\nathy type and acute success on long-term outcome. Europace 2015;17:461–467.\n499. Ebert M, Richter S, Dinov B, Zeppenfeld K, Hindricks G. Evaluation and manage-\nment of ventricular tachycardia in patients with dilated cardiomyopathy. Heart\nRhythm 2019;16:624–631.\n500. Proietti R, Lichelli L, Lellouche N, Dhanjal T. The challenge of optimising ablation\nlesions in catheter ablation of ventricular tachycardia. J Arrhythmia 2021;37:\n140–147.\n501. Tokuda M, Sobieszczyk P, Eisenhauer AC, Kojodjojo P, Inada K, Koplan BA, et al.\nTranscoronary ethanol ablation for recurrent ventricular tachycardia after failed\ncatheter ablation: an update. Circ Arrhythm Electrophysiol 2011;4:889–896.\n502. Kreidieh B, Rodríguez-Mañero M, Schurmann P, Ibarra-Cortez SH, Dave AS,\nValderrábano M. Retrograde coronary venous ethanol infusion for ablation of re-\nfractory ventricular tachycardia. Circ Arrhythm Electrophysiol 2016;9:e004352.\n503. Nguyen DT, Tzou WS, Sandhu A, Gianni C, Anter E, Tung R, et al. Prospective mul-\nticenter experience with cooled radiofrequency ablation using high impedance ir-\nrigant to target deep myocardial substrate refractory to standard ablation. JACC Clin\nElectrophysiol 2018;4:1176–1185.\n504. Stevenson WG, Tedrow UB, Reddy V, AbdelWahab A, Dukkipati S, John RM, et al.\nInfusion needle radiofrequency ablation for treatment of refractory ventricular ar-\nrhythmias. J Am Coll Cardiol 2019;73:1413–1425.\n505. Igarashi M, Nogami A, Fukamizu S, Sekiguchi Y, Nitta J, Sakamoto N, et al. Acute and\nlong-term results of bipolar radiofrequency catheter ablation of refractory ven-\ntricular arrhythmias of deep intramural origin. Heart Rhythm 2020;17:1500–1507.\n506. Della Bella P, Peretto G, Paglino G, Bisceglia C, Radinovic A, Sala S, et al. Bipolar\nradiofrequency ablation for ventricular tachycardias originating from the interven-\ntricular septum: safety and efﬁcacy in a pilot cohort study. Heart Rhythm 2020;17:\n2111–2118.\n507. Cuculich PS, Schill MR, Kashani R, Mutic S, Lang A, Cooper D, et al. Noninvasive\ncardiac radiation for ablation of ventricular tachycardia. N Engl J Med 2017;377:\n2325–2336.\n508. Robinson CG, Samson PP, Moore KMS, Hugo GD, Knutson N, Mutic S, et al. Phase\nI/II trial of electrophysiology-guided noninvasive cardiac radioablation for ventricu-\nlar tachycardia. Circulation 2019;139:313–321.\n509. Anter E, Hutchinson MD, Deo R, Haqqani HM, Callans DJ, Gerstenfeld EP, et al.\nSurgical ablation of refractory ventricular tachycardia in patients with nonischemic\ncardiomyopathy. Circ Arrhythm Electrophysiol 2011;4:494–500.\n510. Fernández-Armenta J, Berruezo A, Andreu D, Camara O, Silva E, Serra L, et al.\nThree-dimensional architecture of scar and conducting channels based on high\nresolution ce-CMR: insights for ventricular tachycardia ablation. Circ Arrhythm\nElectrophysiol 2013;6:528–537.\n511. Mahida S, Sacher F, Dubois R, Sermesant M, Bogun F, Haïssaguerre M, et al. Cardiac\nimaging in patients with ventricular tachycardia. Circulation 2017;136:2491–2507.\n512. Andreu D, Penela D, Acosta J, Fernández-Armenta J, Perea RJ, Soto-Iglesias D, et al.\nCardiac magnetic resonance–aided scar dechanneling: inﬂuence on acute and long-\nterm outcomes. Heart Rhythm 2017;14:1121–1128.\n513. Kuo L, Liang JJ, Nazarian S, Marchlinski FE. Multimodality imaging to guide ventricu-\nlar tachycardia ablation in patients with non-ischaemic cardiomyopathy. Arrhythm\nElectrophysiol Rev 2020;8:255–264.\n514. Roca-Luque I, Van Breukelen A, Alarcon F, Garre P, Tolosana JM, Borras R, et al.\nVentricular scar channel entrances identiﬁed by new wideband cardiac magnetic\nresonance sequence to guide ventricular tachycardia ablation in patients with car-\ndiac deﬁbrillators. Europace 2020;22:598–606.\n515. Betensky BP, Marchlinski FE. Outcomes of catheter ablation of ventricular tachy-\ncardia in the setting of structural heart disease. Curr Cardiol Rep 2016;18:68.\n516. Dukkipati SR, Koruth JS, Choudry S, Miller MA, Whang W, Reddy VY. Catheter ab-\nlation of ventricular tachycardia in structural heart disease. J Am Coll Cardiol 2017;\n70:2924–2941.\n517. Zeppenfeld K. Ventricular tachycardia ablation in nonischemic cardiomyopathy.\nJACC Clin Electrophysiol 2018;4:1123–1140.\n518. Guandalini GS, Liang JJ, Marchlinski FE. Ventricular tachycardia ablation. JACC Clin\nElectrophysiol 2019;5:1363–1383.\n4112\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026\n\n\n519. Peichl P, Wichterle D, Pavlu L, Cihak R, Aldhoon B, Kautzner J. Complications of\ncatheter ablation of ventricular tachycardia: a single-center experience. Circ\nArrhythm Electrophysiol 2014;7:684–690.\n520. Katz DF, Turakhia MP, Sauer WH, Tzou WS, Heath RR, Zipse MM, et al. Safety of\nventricular tachycardia ablation in clinical practice: ﬁndings from 9699 hospital dis-\ncharge records. Circ Arrhythm Electrophysiol 2015;8:362–370.\n521. Cheung JW, Yeo I, Ip JE, Thomas G, Liu CF, Markowitz SM, et al. Outcomes, costs,\nand 30-day readmissions after catheter ablation of myocardial infarct–associated\nventricular tachycardia in the real world: nationwide readmissions database 2010\nto 2015. Circ Arrhythm Electrophysiol 2018;11:e006754.\n522. Hendriks AA, Akca F, Dabiri Abkenari L, Khan M, Bhagwandien R, Yap S-C, et al.\nSafety and clinical outcome of catheter ablation of ventricular arrhythmias using\ncontact force sensing: consecutive case series. J Cardiovasc Electrophysiol 2015;26:\n1224–1229.\n523. Nogami A. Purkinje-related arrhythmias part I: monomorphic ventricular tachycar-\ndias. Pacing Clin Electrophysiol 2011;34:624–650.\n524. Lerman BB. Mechanism, diagnosis, and treatment of outﬂow tract tachycardia. Nat\nRev Cardiol 2015;12:597–608.\n525. Kobayashi Y. Idiopathic ventricular premature contraction and ventricular tachy-\ncardia: distribution of the origin, diagnostic algorithm, and catheter ablation. J\nNippon Med Sch 2018;85:87–94.\n526. Tada H, Ito S, Naito S, Kurosaki K, Kubota S, Sugiyasu A, et al. Idiopathic ventricular\narrhythmia arising from the mitral annulus: a distinct subgroup of idiopathic ven-\ntricular arrhythmias. J Am Coll Cardiol 2005;45:877–886.\n527. Wasmer K, Köbe J, Dechering DG, Bittner A, Pott C, Mönnig G, et al. Ventricular\narrhythmias from the mitral annulus: patient characteristics, electrophysiological\nﬁndings, ablation, and prognosis. Heart Rhythm 2013;10:783–788.\n528. Tada H, Tadokoro K, Ito S, Naito S, Hashimoto T, Kaseno K, et al. Idiopathic ven-\ntricular arrhythmias originating from the tricuspid annulus: prevalence, electrocar-\ndiographic characteristics, and results of radiofrequency catheter ablation. Heart\nRhythm 2007;4:7–16.\n529. Yamada T, Doppalapudi H, McElderry HT, Okada T, Murakami Y, Inden Y, et al.\nElectrocardiographic and electrophysiological characteristics in idiopathic ventricu-\nlar arrhythmias originating from the papillary muscles in the left ventricle: relevance\nfor catheter ablation. Circ Arrhythm Electrophysiol 2010;3:324–331.\n530. Macias C, Nakamura K, Tung R, Boyle NG, Kalyanam S, Bradﬁeld JS. Importance of\ndelayed enhanced cardiac MRI in idiopathic RVOT-VT: differentiating mimics in-\ncluding early stage ARVC and cardiac sarcoidosis. J Atr Fibrillation 2014;7:1097.\n531. Heeger C-H, Hayashi K, Kuck K-H, Ouyang F. Catheter ablation of idiopathic ven-\ntricular arrhythmias arising from the cardiac outﬂow tracts—recent insights and\ntechniques for the successful treatment of common and challenging cases. Circ J\n2016;80:1073–1086.\n532. Pathak RK, Ariyarathna N, Garcia FC, Sanders P, Marchlinski FE. Catheter ablation\nof idiopathic ventricular arrhythmias. Heart Lung Circ 2019;28:102–109.\n533. Yamada T, McElderry HT, Doppalapudi H, Murakami Y, Yoshida Y, Yoshida N, et al.\nIdiopathic ventricular arrhythmias originating from the aortic root prevalence, elec-\ntrocardiographic and electrophysiologic characteristics, and results of radiofre-\nquency catheter ablation. J Am Coll Cardiol 2008;52:139–147.\n534. Van Herendael H, Garcia F, Lin D, Riley M, Bala R, Cooper J, et al. Idiopathic right\nventricular arrhythmias not arising from the outﬂow tract: prevalence, electrocar-\ndiographic characteristics, and outcome of catheter ablation. Heart Rhythm 2011;8:\n511–518.\n535. Latchamsetty R, Yokokawa M, Morady F, Kim HM, Mathew S, Tilz R, et al.\nMulticenter outcomes for catheter ablation of idiopathic premature ventricular\ncomplexes. JACC Clin Electrophysiol 2015;1:116–123.\n536. Liu Y, Fang Z, Yang B, Kojodjojo P, Chen H, Ju W, et al. Catheter ablation of fasci-\ncular ventricular tachycardia: long-term clinical outcomes and mechanisms of re-\ncurrence. Circ Arrhythm Electrophysiol 2015;8:1443–1451.\n537. Hayashi T, Liang JJ, Shirai Y, Kuo L, Muser D, Kubala M, et al. Trends in successful\nablation sites and outcomes of ablation for idiopathic outﬂow tract ventricular ar-\nrhythmias. JACC Clin Electrophysiol 2020;6:221–230.\n538. Farré J, Wellens HJ. Philippe Coumel: a founding father of modern arrhythmology.\nEuropace 2004;6:464–465.\n539. Neira V, Enriquez A, Simpson C, Baranchuk A. Update on long QT syndrome. J\nCardiovasc Electrophysiol 2019;30:3068–3078.\n540. Winbo A, Paterson DJ. The brain-heart connection in sympathetically triggered in-\nherited arrhythmia syndromes. Heart Lung Circ 2020;29:529–537.\n541. Schwartz PJ, Priori SG, Cerrone M, Spazzolini C, Odero A, Napolitano C, et al. Left\ncardiac sympathetic denervation in the management of high-risk patients affected\nby the long-QT syndrome. Circulation 2004;109:1826–1833.\n542. Surman TL, Stuklis RG, Chan JC. Thoracoscopic sympathectomy for long QT syn-\ndrome. Literature review and case study. Heart Lung Circ 2019;28:486–494.\n543. Orvin K, Eisen A, Goldenberg I, Gottlieb S, Kornowski R, Matetzky S, et al.\nOutcome of contemporary acute coronary syndrome complicated by ventricular\ntachyarrhythmias. Europace 2016;18:219–226.\n544. Demirel F, Rasoul S, Elvan A, Ottervanger JP, Dambrink J-HE, Gosselink ATM, et al.\nImpact of out-of-hospital cardiac arrest due to ventricular ﬁbrillation in patients\nwith ST-elevation myocardial infarction admitted for primary percutaneous coron-\nary intervention: Impact of ventricular ﬁbrillation in STEMI patients. Eur Heart J\nAcute Cardiovasc Care 2015;4:16–23.\n545. Mehta RH, Starr AZ, Lopes RD, Hochman JS, Widimsky P, Pieper KS, et al.\nIncidence of and outcomes associated with ventricular tachycardia or ﬁbrillation\nin patients undergoing primary percutaneous coronary intervention. JAMA 2009;\n301:1779–1789.\n546. Demidova MM, Carlson J, Erlinge D, Platonov PG. Predictors of ventricular ﬁbrilla-\ntion at reperfusion in patients with acute ST-elevation myocardial infarction treated\nby primary percutaneous coronary intervention. Am J Cardiol 2015;115:417–422.\n547. Cheng Y-J, Li Z-Y, Yao F-J, Xu X-J, Ji C-C, Chen X-M, et al. Early repolarization is\nassociated with a signiﬁcantly increased risk of ventricular arrhythmias and sudden\ncardiac death in patients with structural heart diseases. Heart Rhythm 2017;14:\n1157–1164.\n548. Dumas F, Bougouin W, Geri G, Lamhaut L, Rosencher J, Pène F, et al. Emergency\npercutaneous coronary intervention in post-cardiac arrest patients without\nST-segment elevation pattern: insights from the PROCAT II registry. JACC\nCardiovasc Interv 2016;9:1011–1018.\n549. Chatterjee S, Chaudhuri D, Vedanthan R, Fuster V, Ibanez B, Bangalore S, et al. Early\nintravenous\nbeta-blockers\nin\npatients\nwith\nacute\ncoronary\nsyndrome–a\nmeta-analysis of randomized trials. Int J Cardiol 2013;168:915–921.\n550. Roolvink V, Ibáñez B, Ottervanger JP, Pizarro G, van Royen N, Mateos A, et al. Early\nintravenous beta-blockers in patients with ST-segment elevation myocardial infarc-\ntion before primary percutaneous coronary intervention. J Am Coll Cardiol 2016;67:\n2705–2715.\n551. Piccini JP, Hranitzky PM, Kilaru R, Rouleau J-L, White HD, Aylward PE, et al.\nRelation of mortality to failure to prescribe beta blockers acutely in patients with\nsustained ventricular tachycardia and ventricular ﬁbrillation following acute myo-\ncardial infarction (from the VALsartan In Acute myocardial iNfarcTion trial\n[VALIANT] Registry). Am J Cardiol 2008;102:1427–1432.\n552. Nademanee K, Taylor R, Bailey WE, Rieders DE, Kosar EM. Treating electrical\nstorm: sympathetic blockade versus advanced cardiac life support-guided therapy.\nCirculation 2000;102:742–747.\n553. Bundgaard JS, Jacobsen PK, Grand J, Lindholm MG, Hassager C, Pehrson S, et al.\nDeep sedation as temporary bridge to deﬁnitive treatment of ventricular arrhyth-\nmia storm. Eur Heart J Acute Cardiovasc Care 2020;9:657–664.\n554. Piccini JP, Schulte PJ, Pieper KS, Mehta RH, White HD, Van de Werf F, et al.\nAntiarrhythmic drug therapy for sustained ventricular arrhythmias complicating\nacute myocardial infarction. Crit Care Med 2011;39:78–83.\n555. Dorian P, Cass D, Schwartz B, Cooper R, Gelaznikas R, Barr A. Amiodarone as\ncompared with lidocaine for shock-resistant ventricular ﬁbrillation. N Engl J Med\n2002;346:884–890.\n556. Echt DS, Liebson PR, Mitchell LB, Peters RW, Obias-Manno D, Barker AH, et al.\nMortality and morbidity in patients receiving encainide, ﬂecainide, or placebo.\nThe Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991;324:781–788.\n557. Baudry G, Sonneville R, Waintraub X, Lebreton G, Deguillard C, Mertens E, et al.\nExtracorporeal membrane oxygenation to support life-threatening drug-refractory\nelectrical storm. Crit Care Med 2020;48:e856–e863.\n558. Demidova MM, Smith JG, Höijer C-J, Holmqvist F, Erlinge D, Platonov PG.\nPrognostic impact of early ventricular ﬁbrillation in patients with ST-elevation myo-\ncardial infarction treated with primary PCI. Eur Heart J Acute Cardiovasc Care 2012;\n1:302–311.\n559. Podolecki T, Lenarczyk R, Kowalczyk J, Jedrzejczyk-Patej E, Chodor P, Mazurek M,\net al. Prognostic signiﬁcance of complex ventricular arrhythmias complicating\nST-segment elevation myocardial infarction. Am J Cardiol 2018;121:805–809.\n560. Bougouin W, Marijon E, Puymirat E, Defaye P, Celermajer DS, Le Heuzey J-Y, et al.\nIncidence of sudden cardiac death after ventricular ﬁbrillation complicating acute\nmyocardial infarction: a 5-year cause-of-death analysis of the FAST-MI 2005 regis-\ntry. Eur Heart J 2014;35:116–122.\n561. Liang JJ, Hodge DO, Mehta RA, Russo AM, Prasad A, Cha Y-M. Outcomes in pa-\ntients with sustained ventricular tachyarrhythmias occurring within 48 h of acute\nmyocardial infarction: when is ICD appropriate? Europace 2014;16:1759–1766.\n562. Ahn J-M, Lee KH, Yoo S-Y, Cho Y-R, Suh J, Shin E-S, et al. Prognosis of variant angina\nmanifesting as aborted sudden cardiac death. J Am Coll Cardiol 2016;68:137–145.\n563. Sueda S, Kohno H. Optimal medications and appropriate implantable cardioverter-\ndeﬁbrillator shocks in aborted sudden cardiac death due to coronary spasm. Intern\nMed 2018;57:1361–1369.\n564. Rodríguez-Mañero M, Oloriz T, le Polain de Waroux J-B, Burri H, Kreidieh B, de\nAsmundis C, et al. Long-term prognosis of patients with life-threatening ventricular\narrhythmias induced by coronary artery spasm. Europace 2018;20:851–858.\n565. Solomon SD, Zelenkofske S, McMurray JJV, Finn PV, Velazquez E, Ertl G, et al.\nSudden death in patients with myocardial infarction and left ventricular dysfunction,\nheart failure, or both. N Engl J Med 2005;352:2581–2588.\nESC Guidelines\n4113\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026\n\n\n566. Busk M, Maeng M, Kristensen SD, Thuesen L, Krusell LR, Mortensen LS, et al.\nTiming, causes, and predictors of death after three years’ follow-up in the\nDanish Multicenter Randomized Study of Fibrinolysis versus Primary Angioplasty\nin Acute Myocardial Infarction (DANAMI-2) trial. Am J Cardiol 2009;104:210–215.\n567. St John Sutton M, Pfeffer MA, Plappert T, Rouleau JL, Moyé LA, Dagenais GR, et al.\nQuantitative two-dimensional echocardiographic measurements are major predic-\ntors of adverse cardiovascular events after acute myocardial infarction. The pro-\ntective effects of captopril. Circulation 1994;89:68–75.\n568. Søholm H, Lønborg J, Andersen MJ, Vejlstrup N, Engstrøm T, Møller JE, et al.\nRepeated echocardiography after ﬁrst ever ST-segment elevation myocardial in-\nfarction treated with primary percutaneous coronary intervention–is it necessary?\nEur Heart J Acute Cardiovasc Care 2015;4:528–536.\n569. Steinbeck G, Andresen D, Seidl K, Brachmann J, Hoffmann E, Wojciechowski D,\net al. Deﬁbrillator implantation early after myocardial infarction. N Engl J Med\n2009;361:1427–1436.\n570. Hohnloser SH, Kuck KH, Dorian P, Roberts RS, Hampton JR, Hatala R, et al.\nProphylactic use of an implantable cardioverter-deﬁbrillator after acute myocardial\ninfarction. N Engl J Med 2004;351:2481–2488.\n571. Exner DV, Kavanagh KM, Slawnych MP, Mitchell LB, Ramadan D, Aggarwal SG, et al.\nNoninvasive risk assessment early after a myocardial infarction the REFINE study. J\nAm Coll Cardiol 2007;50:2275–2284.\n572. Zaman S, Narayan A, Thiagalingam A, Sivagangabalan G, Thomas S, Ross DL, et al.\nLong-term arrhythmia-free survival in patients with severe left ventricular dysfunc-\ntion and no inducible ventricular tachycardia after myocardial infarction. Circulation\n2014;129:848–854.\n573. Daubert MA, White JA, Al-Khalidi HR, Velazquez EJ, Rao SV, Crowley AL, et al.\nCardiac remodeling after large ST-elevation myocardial infarction in the current\ntherapeutic era. Am Heart J 2020;223:87–97.\n574. Chew DS, Heikki H, Schmidt G, Kavanagh KM, Dommasch M, Bloch Thomsen PE,\net al. Change in left ventricular ejection fraction following ﬁrst myocardial infarction\nand outcome. JACC Clin Electrophysiol 2018;4:672–682.\n575. Bänsch D, Oyang F, Antz M, Arentz T, Weber R, Val-Mejias JE, et al. Successful cath-\neter ablation of electrical storm after myocardial infarction. Circulation 2003;108:\n3011–3016.\n576. Altmann DR, Mutschelknauss M, Ehl N, Koller M, Schaer B, Jörg L, et al. Prevalence\nof severely impaired left ventricular ejection fraction after reperfused ST-elevation\nmyocardial infarction. Swiss Med Wkly 2013;143:w13869.\n577. Shen L, Jhund PS, Petrie MC, Claggett BL, Barlera S, Cleland JGF, et al. Declining risk\nof sudden death in heart failure. N Engl J Med 2017;377:41–51.\n578. Cairns JA, Connolly SJ, Roberts R, Gent M. Randomised trial of outcome after myo-\ncardial infarction in patients with frequent or repetitive ventricular premature de-\npolarisations: CAMIAT. Canadian Amiodarone Myocardial Infarction Arrhythmia\nTrial Investigators. Lancet 1997;349:675–682.\n579. Julian DG, Camm AJ, Frangin G, Janse MJ, Munoz A, Schwartz PJ, et al. Randomised\ntrial of effect of amiodarone on mortality in patients with left-ventricular dysfunc-\ntion after recent myocardial infarction: EMIAT. European Myocardial Infarct\nAmiodarone Trial Investigators. Lancet 1997;349:667–674.\n580. Clemens M, Peichl P, Wichterle D, Pavlů L, Čihák R, Aldhoon B, et al. Catheter ab-\nlation of ventricular tachycardia as the ﬁrst-line therapy in patients with coronary\nartery disease and preserved left ventricular systolic function: long-term results:\nVT ablation in patients with preserved LV function. J Cardiovasc Electrophysiol\n2015;26:1105–1110.\n581. Paciﬁco A, Hohnloser SH, Williams JH, Tao B, Saksena S, Henry PD, et al.\nPrevention of implantable-deﬁbrillator shocks by treatment with sotalol.\nD,\nL-Sotalol Implantable Cardioverter-Deﬁbrillator Study Group. N Engl J Med 1999;\n340:1855–1862.\n582. Willems S, Tilz RR, Steven D, Kääb S, Wegscheider K, Gellér L, et al. Preventive or\ndeferred ablation of ventricular tachycardia in patients with ischemic cardiomyop-\nathy and implantable deﬁbrillator (BERLIN VT): a multicenter randomized trial.\nCirculation 2020;141:1057–1067.\n583. Kuck K-H, Tilz RR, Deneke T, Hoffmann BA, Ventura R, Hansen PS, et al. Impact of\nsubstrate modiﬁcation by catheter ablation on implantable cardioverter–deﬁbrilla-\ntor interventions in patients with unstable ventricular arrhythmias and coronary ar-\ntery disease: results from the multicenter randomized controlled SMS (substrate\nmodiﬁcation study). Circ Arrhythm Electrophysiol 2017;10:e004422.\n584. Olshansky B, Hahn EA, Hartz VL, Prater SP, Mason JW. Clinical signiﬁcance of syn-\ncope in the electrophysiologic study versus electrocardiographic monitoring\n(ESVEM) trial. The ESVEM Investigators. Am Heart J 1999;137:878–886.\n585. Molossi S, Agrawal H, Mery CM, Krishnamurthy R, Masand P, Sexson Tejtel SK,\net al. Outcomes in anomalous aortic origin of a coronary artery following a pro-\nspective standardized approach. Circ Cardiovasc Interv 2020;13:e008445.\n586. Krasuski RA, Magyar D, Hart S, Kalahasti V, Lorber R, Hobbs R, et al. Long-term\noutcome and impact of surgery on adults with coronary arteries originating from\nthe opposite coronary cusp. Circulation 2011;123:154–162.\n587. Jegatheeswaran A, Devlin PJ, McCrindle BW, Williams WG, Jacobs ML, Blackstone\nEH, et al. Features associated with myocardial ischemia in anomalous aortic origin\nof a coronary artery: a congenital heart surgeons’ society study. J Thorac Cardiovasc\nSurg 2019;158:822–834.\n588. Jegatheeswaran A, Devlin PJ, Williams WG, Brothers JA, Jacobs ML, DeCampli\nWM, et al. Outcomes after anomalous aortic origin of a coronary artery repair:\na congenital heart surgeons’ society study. J Thorac Cardiovasc Surg 2020;160:\n757–771.\n589. Hoffmayer KS, Bhave PD, Marcus GM, James CA, Tichnell C, Chopra N, et al. An\nelectrocardiographic scoring system for distinguishing right ventricular outﬂow\ntract arrhythmias in patients with arrhythmogenic right ventricular cardiomyopathy\nfrom idiopathic ventricular tachycardia. Heart Rhythm 2013;10:477–482.\n590. Yokokawa M, Siontis KC, Kim HM, Stojanovska J, Latchamsetty R, Crawford T, et al.\nValue of cardiac magnetic resonance imaging and programmed ventricular stimula-\ntion in patients with frequent premature ventricular complexes undergoing radio-\nfrequency ablation. Heart Rhythm 2017;14:1695–1701.\n591. Muser D, Santangeli P, Castro SA, Casado Arroyo R, Maeda S, Benhayon DA, et al.\nRisk stratiﬁcation of patients with apparently idiopathic premature ventricular con-\ntractions: a multicenter international CMR registry. JACC Clin Electrophysiol 2020;6:\n722–735.\n592. Kjekshus J, Bathen J, Orning OM, Storstein L. A double-blind, crossover comparison\nof ﬂecainide acetate and disopyramide phosphate in the treatment of ventricular\npremature complexes. Am J Cardiol 1984;53:72B–78B.\n593. Hamon D, Swid MA, Rajendran PS, Liu A, Boyle NG, Shivkumar K, et al. Premature\nventricular contraction diurnal proﬁles predict distinct clinical characteristics and\nbeta-blocker responses. J Cardiovasc Electrophysiol 2019;30:836–843.\n594. Primeau R, Agha A, Giorgi C, Shenasa M, Nadeau R. Long term efﬁcacy and toxicity\nof amiodarone in the treatment of refractory cardiac arrhythmias. Can J Cardiol\n1989;5:98–104.\n595. Ling Z, Liu Z, Su L, Zipunnikov V, Wu J, Du H, et al. Radiofrequency ablation versus\nantiarrhythmic medication for treatment of ventricular premature beats from the\nright ventricular outﬂow tract: prospective randomized study. Circ Arrhythm\nElectrophysiol 2014;7:237–243.\n596. Baksiene D, Sileikiene R, Sileikis V, Kazakevicius T, Zabiela V, Zebiene M, et al.\nIdiopathic ventricular tachycardia in children: curative therapy with radiofrequency\nablation. Medicina (Kaunas) 2007;43:803–807.\n597. Blaufox AD, Felix GL, Saul JP, Pediatric Catheter Ablation Registry. Radiofrequency\ncatheter ablation in infants ,/=18 months old: when is it done and how do they\nfare?: Short-term data from the pediatric ablation registry. Circulation 2001;104:\n2803–2808.\n598. Lapage MJ, Bradley DJ, Dick M. Verapamil in infants: an exaggerated fear? Pediatr\nCardiol 2013;34:1532–1534.\n599. Lee AKY, Andrade J, Hawkins NM, Alexander G, Bennett MT, Chakrabarti S, et al.\nOutcomes of untreated frequent premature ventricular complexes with normal\nleft ventricular function. Heart 2019;105:1408–1413.\n600. Baman TS, Lange DC, Ilg KJ, Gupta SK, Liu T-Y, Alguire C, et al. Relationship be-\ntween burden of premature ventricular complexes and left ventricular function.\nHeart Rhythm 2010;7:865–869.\n601. van Huls van Taxis CFB, Piers SRD, de Riva Silva M, Dekkers OM, Pijnappels DA,\nSchalij MJ, et al. Fatigue as presenting symptom and a high burden of premature ven-\ntricular contractions are independently associated with increased ventricular wall\nstress\nin\npatients\nwith\nnormal\nleft\nventricular\nfunction.\nCirc\nArrhythm\nElectrophysiol 2015;8:1452–1459.\n602. Sharma N, Cortez D, Imundo JR. High burden of premature ventricular contrac-\ntions in structurally normal hearts: to worry or not in pediatric patients? Ann\nNoninvasive Electrocardiol 2019;24:e12663.\n603. Niwano S, Wakisaka Y, Niwano H, Fukaya H, Kurokawa S, Kiryu M, et al. Prognostic\nsigniﬁcance of frequent premature ventricular contractions originating from the\nventricular outﬂow tract in patients with normal left ventricular function. Heart\n2009;95:1230–1237.\n604. Krittayaphong R, Sriratanasathavorn C, Dumavibhat C, Pumprueg S, Boonyapisit\nW, Pooranawattanakul S, et al. Electrocardiographic predictors of long-term out-\ncomes after radiofrequency ablation in patients with right-ventricular outﬂow tract\ntachycardia. Europace 2006;8:601–606.\n605. Komatsu Y, Nogami A, Kurosaki K, Morishima I, Masuda K, Ozawa T, et al.\nFascicular ventricular tachycardia originating from papillary muscles: Purkinje net-\nwork involvement in the reentrant circuit. Circ Arrhythm Electrophysiol 2017;10:\ne004549.\n606. Kirk CR, Gibbs JL, Thomas R, Radley-Smith R, Qureshi SA. Cardiovascular collapse\nafter verapamil in supraventricular tachycardia. Arch Dis Child 1987;62:1265–1266.\n607. Duffee DF, Shen WK, Smith HC. Suppression of frequent premature ventricular\ncontractions and improvement of left ventricular function in patients with pre-\nsumed idiopathic dilated cardiomyopathy. Mayo Clin Proc 1998;73:430–433.\n4114\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026\n\n\n608. Chugh SS, Shen WK, Luria DM, Smith HC. First evidence of premature ventricular\ncomplex-induced cardiomyopathy: a potentially reversible cause of heart failure. J\nCardiovasc Electrophysiol 2000;11:328–329.\n609. Penela D, Van Huls Van Taxis C, Van Huls Vans Taxis C, Aguinaga L,\nFernández-Armenta J, Mont L, et al. Neurohormonal, structural, and functional re-\ncovery pattern after premature ventricular complex ablation is independent of\nstructural heart disease status in patients with depressed left ventricular ejection\nfraction: a prospective multicenter study. J Am Coll Cardiol 2013;62:1195–1202.\n610. Penela D, Acosta J, Aguinaga L, Tercedor L, Ordoñez A, Fernández-Armenta J, et al.\nAblation of frequent PVC in patients meeting criteria for primary prevention ICD\nimplant: safety of withholding the implant. Heart Rhythm 2015;12:2434–2442.\n611. Voskoboinik A, Hadjis A, Alhede C, Im SI, Park H, Moss J, et al. Predictors of adverse\noutcome in patients with frequent premature ventricular complexes: the ABC-VT\nrisk score. Heart Rhythm 2020;17:1066–1074.\n612. Lee A, Denman R, Haqqani HM. Ventricular ectopy in the context of left ventricular\nsystolic dysfunction: risk factors and outcomes following catheter ablation. Heart\nLung Circ 2019;28:379–388.\n613. Sadron Blaye-Felice M, Hamon D, Sacher F, Pascale P, Rollin A, Duparc A, et al.\nPremature ventricular contraction-induced cardiomyopathy: related clinical and\nelectrophysiologic parameters. Heart Rhythm 2016;13:103–110.\n614. Penela D, Fernández-Armenta J, Aguinaga L, Tercedor L, Ordoñez A, Bisbal F, et al.\nClinical recognition of pure premature ventricular complex-induced cardiomyop-\nathy at presentation. Heart Rhythm 2017;14:1864–1870.\n615. Aquaro GD, Pingitore A, Strata E, Di Bella G, Molinaro S, Lombardi M. Cardiac\nmagnetic resonance predicts outcome in patients with premature ventricular com-\nplexes of left bundle branch block morphology. J Am Coll Cardiol 2010;56:\n1235–1243.\n616. Oebel S, Dinov B, Arya A, Hilbert S, Sommer P, Bollmann A, et al. ECG morphology\nof premature ventricular contractions predicts the presence of myocardial ﬁbrotic\nsubstrate on cardiac magnetic resonance imaging in patients undergoing ablation. J\nCardiovasc Electrophysiol 2017;28:1316–1323.\n617. Mountantonakis SE, Frankel DS, Gerstenfeld EP, Dixit S, Lin D, Hutchinson MD,\net al. Reversal of outﬂow tract ventricular premature depolarization–induced car-\ndiomyopathy with ablation: effect of residual arrhythmia burden and preexisting\ncardiomyopathy on outcome. Heart Rhythm 2011;8:1608–1614.\n618. Zang M, Zhang T, Mao J, Zhou S, He B. Beneﬁcial effects of catheter ablation of fre-\nquent premature ventricular complexes on left ventricular function. Heart 2014;\n100:787–793.\n619. Wijnmaalen AP, Delgado V, Schalij MJ, van Huls van Taxis CFB, Holman ER, Bax JJ,\net al. Beneﬁcial effects of catheter ablation on left ventricular and right ventricular\nfunction in patients with frequent premature ventricular contractions and pre-\nserved ejection fraction. Heart 2010;96:1275–1280.\n620. Bogun F, Crawford T, Reich S, Koelling TM, Armstrong W, Good E, et al.\nRadiofrequency ablation of frequent, idiopathic premature ventricular complexes:\ncomparison with a control group without intervention. Heart Rhythm 2007;4:\n863–867.\n621. Sarrazin J-F, Labounty T, Kuhne M, Crawford T, Armstrong WF, Desjardins B, et al.\nImpact of radiofrequency ablation of frequent post-infarction premature ventricu-\nlar complexes on left ventricular ejection fraction. Heart Rhythm 2009;6:\n1543–1549.\n622. El Kadri M, Yokokawa M, Labounty T, Mueller G, Crawford T, Good E, et al. Effect\nof ablation of frequent premature ventricular complexes on left ventricular func-\ntion in patients with nonischemic cardiomyopathy. Heart Rhythm 2015;12:\n706–713.\n623. Lakkireddy D, Di Biase L, Ryschon K, Biria M, Swarup V, Reddy YM, et al.\nRadiofrequency ablation of premature ventricular ectopy improves the efﬁcacy\nof cardiac resynchronization therapy in nonresponders. J Am Coll Cardiol 2012;\n60:1531–1539.\n624. Singh SN, Fletcher RD, Fisher SG, Singh BN, Lewis HD, Deedwania PC, et al.\nAmiodarone in patients with congestive heart failure and asymptomatic ventricular\narrhythmia. Survival trial of antiarrhythmic therapy in congestive heart failure. N\nEngl J Med 1995;333:77–82.\n625. Zhong L, Lee Y-H, Huang X-M, Asirvatham SJ, Shen W-K, Friedman PA, et al.\nRelative efﬁcacy of catheter ablation vs antiarrhythmic drugs in treating premature\nventricular contractions: a single-center retrospective study. Heart Rhythm 2014;\n11:187–193.\n626. Hyman MC, Mustin D, Supple G, Schaller RD, Santangeli P, Arkles J, et al. Class IC\nantiarrhythmic drugs for suspected premature ventricular contraction-induced car-\ndiomyopathy. Heart Rhythm 2018;15:159–163.\n627. Laurent G, Saal S, Amarouch MY, Béziau DM, Marsman RFJ, Faivre L, et al. Multifocal\nectopic Purkinje-related premature contractions: a new SCN5A-related cardiac\nchannelopathy. J Am Coll Cardiol 2012;60:144–156.\n628. Calloe K, Broendberg AK, Christensen AH, Pedersen LN, Olesen MS, de Los\nAngeles Tejada M, et al. Multifocal atrial and ventricular premature contractions\nwith an increased risk of dilated cardiomyopathy caused by a Nav1.5\ngain-of-function mutation (G213D). Int J Cardiol 2018;257:160–167.\n629. Mann SA, Castro ML, Ohanian M, Guo G, Zodgekar P, Sheu A, et al. R222Q\nSCN5A mutation is associated with reversible ventricular ectopy and dilated car-\ndiomyopathy. J Am Coll Cardiol 2012;60:1566–1573.\n630. Beckermann TM, McLeod K, Murday V, Potet F, George AL. Novel SCN5A muta-\ntion in amiodarone-responsive multifocal ventricular ectopy-associated cardiomy-\nopathy. Heart Rhythm 2014;11:1446–1453.\n631. Doisne N, Waldmann V, Redheuil A, Waintraub X, Fressart V, Ader F, et al. A novel\ngain-of-function\nmutation\nin\nSCN5A\nresponsible\nfor\nmultifocal\nectopic\nPurkinje-related premature contractions. Hum Mutat 2020;41:850–859.\n632. Elliott P, Andersson B, Arbustini E, Bilinska Z, Cecchi F, Charron P, et al.\nClassiﬁcation of the cardiomyopathies: a position statement from the European\nSociety Of Cardiology Working Group on Myocardial and Pericardial Diseases.\nEur Heart J 2008;29:270–276.\n633. Codd MB, Sugrue DD, Gersh BJ, Melton LJ. Epidemiology of idiopathic dilated and\nhypertrophic cardiomyopathy. A population-based study in Olmsted County,\nMinnesota, 1975–1984. Circulation 1989;80:564–572.\n634. Weintraub RG, Semsarian C, Macdonald P. Dilated cardiomyopathy. Lancet 2017;\n390:400–414.\n635. Beggs SAS, Jhund PS, Jackson CE, McMurray JJV, Gardner RS. Non-ischaemic car-\ndiomyopathy, sudden death and implantable deﬁbrillators: a review and\nmeta-analysis. Heart 2018;104:144–150.\n636. Towbin JA, Lowe AM, Colan SD, Sleeper LA, Orav EJ, Clunie S, et al. Incidence,\ncauses, and outcomes of dilated cardiomyopathy in children. JAMA 2006;296:\n1867–1876.\n637. Pahl E, Sleeper LA, Canter CE, Hsu DT, Lu M, Webber SA, et al. Incidence of and\nrisk factors for sudden cardiac death in children with dilated cardiomyopathy: a re-\nport from the Pediatric Cardiomyopathy Registry. J Am Coll Cardiol 2012;59:\n607–615.\n638. Bharucha T, Lee KJ, Daubeney PEF, Nugent AW, Turner C, Sholler GF, et al.\nSudden death in childhood cardiomyopathy: results from a long-term national\npopulation-based study. J Am Coll Cardiol 2015;65:2302–2310.\n639. Pinto YM, Elliott PM, Arbustini E, Adler Y, Anastasakis A, Böhm M, et al. Proposal\nfor a revised deﬁnition of dilated cardiomyopathy, hypokinetic non-dilated cardio-\nmyopathy, and its implications for clinical practice: a position statement of the ESC\nworking group on myocardial and pericardial diseases. Eur Heart J 2016;37:\n1850–1858.\n640. Asselbergs FW, Sammani A, Elliott P, Gimeno JR, Tavazzi L, Tendera M, et al.\nDifferences between familial and sporadic dilated cardiomyopathy: ESC EORP\nCardiomyopathy & Myocarditis registry. ESC Heart Fail 2021;8:95–105.\n641. Ader F, De Groote P, Réant P, Rooryck-Thambo C, Dupin-Deguine D, Rambaud C,\net al. FLNC pathogenic variants in patients with cardiomyopathies: prevalence and\ngenotype-phenotype correlations. Clin Genet 2019;96:317–329.\n642. Kayvanpour E, Sedaghat-Hamedani F, Amr A, Lai A, Haas J, Holzer DB, et al.\nGenotype-phenotype associations in dilated cardiomyopathy: meta-analysis on\nmore than 8000 individuals. Clin Res Cardiol 2017;106:127–139.\n643. Ortiz-Genga MF, Cuenca S, Dal Ferro M, Zorio E, Salgado-Aranda R, Climent V,\net al. Truncating FLNC mutations are associated with high-risk dilated and arrhyth-\nmogenic cardiomyopathies. J Am Coll Cardiol 2016;68:2440–2451.\n644. van den Hoogenhof MMG, Beqqali A, Amin AS, van der Made I, Auﬁero S, Khan\nMAF, et al. RBM20 mutations induce an arrhythmogenic dilated cardiomyopathy\nrelated to disturbed calcium handling. Circulation 2018;138:1330–1342.\n645. Gigli M, Merlo M, Graw SL, Barbati G, Rowland TJ, Slavov DB, et al. Genetic risk of\narrhythmic phenotypes in patients with dilated cardiomyopathy. J Am Coll Cardiol\n2019;74:1480–1490.\n646. Heliö T, Elliott P, Koskenvuo JW, Gimeno JR, Tavazzi L, Tendera M, et al. ESC EORP\ncardiomyopathy registry: real-life practice of genetic counselling and testing in adult\ncardiomyopathy patients. ESC Heart Fail 2020;7:3013–3021.\n647. Elming MB, Nielsen JC, Haarbo J, Videbæk L, Korup E, Signorovitch J, et al. Age and\noutcomes of primary prevention implantable cardioverter-deﬁbrillators in patients\nwith nonischemic systolic heart failure. Circulation 2017;136:1772–1780.\n648. Kristensen SL, Levy WC, Shadman R, Nielsen JC, Haarbo J, Videbæk L, et al. Risk\nmodels for prediction of implantable cardioverter-deﬁbrillator beneﬁt. JACC\nHeart Fail 2019;7:717–724.\n649. Wolff G, Lin Y, Karathanos A, Brockmeyer M, Wolters S, Nowak B, et al.\nImplantable cardioverter/deﬁbrillators for primary prevention in dilated cardiomy-\nopathy post-DANISH: an updated meta-analysis and systematic review of rando-\nmized controlled trials. Clin Res Cardiol 2017;106:501–513.\n650. Kadish A, Dyer A, Daubert JP, Quigg R, Estes NAM, Anderson KP, et al.\nProphylactic deﬁbrillator implantation in patients with nonischemic dilated cardio-\nmyopathy. N Engl J Med 2004;350:2151–2158.\n651. Klem I, Klein M, Khan M, Yang EY, Nabi F, Ivanov A, et al. Relationship of LVEF and\nmyocardial scar to long-term mortality risk and mode of death in patients with non-\nischemic cardiomyopathy. Circulation 2021;143:1343–1358.\nESC Guidelines\n4115\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026\n\n\n652. van Rijsingen IAW, Arbustini E, Elliott PM, Mogensen J, Hermans-van Ast JF, van der\nKooi AJ, et al. Risk factors for malignant ventricular arrhythmias in lamin a/c muta-\ntion carriers a European cohort study. J Am Coll Cardiol 2012;59:493–500.\n653. Thuillot M, Maupain C, Gandjbakhch E, Waintraub X, Hidden-Lucet F, Isnard R,\net al. External validation of risk factors for malignant ventricular arrhythmias in la-\nmin A/C mutation carriers. Eur J Heart Fail 2019;21:253–254.\n654. Pasotti M, Klersy C, Pilotto A, Marziliano N, Rapezzi C, Serio A, et al. Long-term\noutcome and risk stratiﬁcation in dilated cardiolaminopathies. J Am Coll Cardiol\n2008;52:1250–1260.\n655. Skjølsvik ET, Hasselberg NE, Dejgaard LA, Lie ØH, Andersen K, Holm T, et al.\nExercise is associated with impaired left ventricular systolic function in patients\nwith lamin A/C genotype. J Am Heart Assoc 2020;9:e012937.\n656. Verstraelen TE, van Lint FHM, Bosman LP, de Brouwer R, Proost VM, Abeln BGS,\net al. Prediction of ventricular arrhythmia in phospholamban p.Arg14del mutation\ncarriers-reaching the frontiers of individual risk prediction. Eur Heart J 2021;42:\n2842–2850.\n657. Knight BP, Goyal R, Pelosi F, Flemming M, Horwood L, Morady F, et al. Outcome of\npatients with nonischemic dilated cardiomyopathy and unexplained syncope trea-\nted with an implantable deﬁbrillator. J Am Coll Cardiol 1999;33:1964–1970.\n658. Desai AS, Fang JC, Maisel WH, Baughman KL. Implantable deﬁbrillators for the pre-\nvention of mortality in patients with nonischemic cardiomyopathy: a meta-analysis\nof randomized controlled trials. JAMA 2004;292:2874–2879.\n659. Merlo M, Gentile P, Artico J, Cannatà A, Paldino A, De Angelis G, et al. Arrhythmic\nrisk stratiﬁcation in patients with dilated cardiomyopathy and intermediate left ven-\ntricular dysfunction. J Cardiovasc Med (Hagerstown) 2019;20:343–350.\n660. Zecchin M, Di Lenarda A, Gregori D, Merlo M, Pivetta A, Vitrella G, et al. Are non-\nsustained ventricular tachycardias predictive of major arrhythmias in patients with\ndilated cardiomyopathy on optimal medical treatment? Pacing Clin Electro 2008;31:\n290–299.\n661. Link MS, Costeas XF, Grifﬁth JL, Colburn CD, Estes NA, Wang PJ. High incidence of\nappropriate implantable cardioverter-deﬁbrillator therapy in patients with syncope\nof unknown etiology and inducible ventricular arrhythmias. J Am Coll Cardiol 1997;\n29:370–375.\n662. Di Marco A, Brown PF, Bradley J, Nucifora G, Claver E, de Frutos F, et al. Improved\nrisk stratiﬁcation for ventricular arrhythmias and sudden death in patients with non-\nischemic dilated cardiomyopathy. J Am Coll Cardiol 2021;77:2890–2905.\n663. Kumar S, Romero J, Mehta NK, Fujii A, Kapur S, Baldinger SH, et al. Long-term out-\ncomes after catheter ablation of ventricular tachycardia in patients with and with-\nout structural heart disease. Heart Rhythm 2016;13:1957–1963.\n664. Muser D, Santangeli P, Castro SA, Pathak RK, Liang JJ, Hayashi T, et al. Long-term\noutcome after catheter ablation of ventricular tachycardia in patients with nonis-\nchemic dilated cardiomyopathy. Circ Arrhythm Electrophysiol 2016;9:e004328.\n665. Kumar S, Androulakis AFA, Sellal J-M, Maury P, Gandjbakhch E, Waintraub X, et al.\nMulticenter experience with catheter ablation for ventricular tachycardia in lamin\nA/C cardiomyopathy. Circ Arrhythm Electrophysiol 2016;9:e004357.\n666. Oloriz T, Silberbauer J, Maccabelli G, Mizuno H, Baratto F, Kirubakaran S, et al.\nCatheter ablation of ventricular arrhythmia in nonischemic cardiomyopathy: ante-\nroseptal versus inferolateral scar sub-types. Circ Arrhythm Electrophysiol 2014;7:\n414–423.\n667. Francone M. Role of cardiac magnetic resonance in the evaluation of dilated cardio-\nmyopathy: diagnostic contribution and prognostic signiﬁcance. ISRN Radiol 2014;\n2014:365404.\n668. Goldberger JJ, Subačius H, Patel T, Cunnane R, Kadish AH. Sudden cardiac death\nrisk stratiﬁcation in patients with nonischemic dilated cardiomyopathy. J Am Coll\nCardiol 2014;63:1879–1889.\n669. Ebert M, Wijnmaalen AP, de Riva M, Trines SA, Androulakis AFA, Glashan CA, et al.\nPrevalence and prognostic impact of pathogenic variants in patients with dilated\ncardiomyopathy\nreferred\nfor\nventricular\ntachycardia\nablation.\nJACC\nClin\nElectrophysiol 2020;6:1103–1114.\n670. Corrado D, Link MS, Calkins H. Arrhythmogenic right ventricular cardiomyopathy.\nN Engl J Med 2017;376:1489–1490.\n671. Quarta G, Muir A, Pantazis A, Syrris P, Gehmlich K, Garcia-Pavia P, et al. Familial\nevaluation in arrhythmogenic right ventricular cardiomyopathy: impact of genetics\nand revised task force criteria. Circulation 2011;123:2701–2709.\n672. Bhonsale A, Groeneweg JA, James CA, Dooijes D, Tichnell C, Jongbloed JDH, et al.\nImpact of genotype on clinical course in arrhythmogenic right ventricular dysplasia/\ncardiomyopathy-associated mutation carriers. Eur Heart J 2015;36:847–855.\n673. Rigato I, Bauce B, Rampazzo A, Zorzi A, Pilichou K, Mazzotti E, et al. Compound and\ndigenic heterozygosity predicts lifetime arrhythmic outcome and sudden cardiac\ndeath in desmosomal gene-related arrhythmogenic right ventricular cardiomyop-\nathy. Circ Cardiovasc Genet 2013;6:533–542.\n674. te Riele ASJM, James CA, Groeneweg JA, Sawant AC, Kammers K, Murray B, et al.\nApproach to family screening in arrhythmogenic right ventricular dysplasia/cardio-\nmyopathy. Eur Heart J 2016;37:755–763.\n675. Chivulescu M, Lie ØH, Popescu BA, Skulstad H, Edvardsen T, Jurcut RO, et al. High\npenetrance and similar disease progression in probands and in family members with\narrhythmogenic cardiomyopathy. Eur Heart J 2020;41:1401–1410.\n676. Rastegar N, Te Riele ASJM, James CA, Bhonsale A, Murray B, Tichnell C, et al.\nFibrofatty changes: incidence at cardiac MR imaging in patients with arrhythmogenic\nright ventricular dysplasia/cardiomyopathy. Radiology 2016;280:405–412.\n677. Aquaro GD, Barison A, Todiere G, Grigoratos C, Ait Ali L, Di Bella G, et al.\nUsefulness of combined functional assessment by cardiac magnetic resonance\nand tissue characterization versus task force criteria for diagnosis of arrhythmo-\ngenic right ventricular cardiomyopathy. Am J Cardiol 2016;118:1730–1736.\n678. te Riele ASJM, Bhonsale A, James CA, Rastegar N, Murray B, Burt JR, et al.\nIncremental value of cardiac magnetic resonance imaging in arrhythmic risk strati-\nﬁcation of arrhythmogenic right ventricular dysplasia/cardiomyopathy-associated\ndesmosomal mutation carriers. J Am Coll Cardiol 2013;62:1761–1769.\n679. Corrado D, van Tintelen PJ, McKenna WJ, Hauer RNW, Anastastakis A, Asimaki A,\net al. Arrhythmogenic right ventricular cardiomyopathy: evaluation of the current\ndiagnostic criteria and differential diagnosis. Eur Heart J 2020;41:1414–1429.\n680. Sen-Chowdhry S, Syrris P, Ward D, Asimaki A, Sevdalis E, McKenna WJ. Clinical\nand genetic characterization of families with arrhythmogenic right ventricular dys-\nplasia/cardiomyopathy provides novel insights into patterns of disease expression.\nCirculation 2007;115:1710–1720.\n681. Cipriani A, Bauce B, De Lazzari M, Rigato I, Bariani R, Meneghin S, et al.\nArrhythmogenic right ventricular cardiomyopathy: characterization of left ven-\ntricular phenotype and differential diagnosis with dilated cardiomyopathy. J Am\nHeart Assoc 2020;9:e014628.\n682. Corrado D, Perazzolo Marra M, Zorzi A, Beffagna G, Cipriani A, Lazzari MD, et al.\nDiagnosis of arrhythmogenic cardiomyopathy: the Padua criteria. Int J Cardiol 2020;\n319:106–114.\n683. Saberniak J, Hasselberg NE, Borgquist R, Platonov PG, Sarvari SI, Smith H, et al.\nVigorous physical activity impairs myocardial function in patients with arrhythmo-\ngenic right ventricular cardiomyopathy and in mutation positive family members.\nEur J Heart Fail 2014;16:1337–1344.\n684. Lie ØH, Dejgaard LA, Saberniak J, Rootwelt C, Stokke MK, Edvardsen T, et al.\nHarmful effects of exercise intensity and exercise duration in patients with arrhyth-\nmogenic cardiomyopathy. JACC Clin Electrophysiol 2018;4:744–753.\n685. James CA, Bhonsale A, Tichnell C, Murray B, Russell SD, Tandri H, et al. Exercise\nincreases age-related penetrance and arrhythmic risk in arrhythmogenic right ven-\ntricular dysplasia/cardiomyopathy-associated desmosomal mutation carriers. J Am\nColl Cardiol 2013;62:1290–1297.\n686. Ruwald A-C, Marcus F, Estes NAM, Link M, McNitt S, Polonsky B, et al. Association\nof competitive and recreational sport participation with cardiac events in patients\nwith arrhythmogenic right ventricular cardiomyopathy: results from the North\nAmerican multidisciplinary study of arrhythmogenic right ventricular cardiomyop-\nathy. Eur Heart J 2015;36:1735–1743.\n687. Sawant AC, te Riele ASJM, Tichnell C, Murray B, Bhonsale A, Tandri H, et al. Safety\nof American Heart Association-recommended minimum exercise for desmosomal\nmutation carriers. Heart Rhythm 2016;13:199–207.\n688. Thiene G, Nava A, Corrado D, Rossi L, Pennelli N. Right ventricular cardiomyop-\nathy and sudden death in young people. N Engl J Med 1988;318:129–133.\n689. Finocchiaro G, Papadakis M, Robertus J-L, Dhutia H, Steriotis AK, Tome M, et al.\nEtiology of sudden death in sports: insights from a United Kingdom Regional\nRegistry. J Am Coll Cardiol 2016;67:2108–2115.\n690. Marcus GM, Glidden DV, Polonsky B, Zareba W, Smith LM, Cannom DS, et al.\nEfﬁcacy of antiarrhythmic drugs in arrhythmogenic right ventricular cardiomyop-\nathy: a report from the North American ARVC Registry. J Am Coll Cardiol 2009;\n54:609–615.\n691. Hulot J-S, Jouven X, Empana J-P, Frank R, Fontaine G. Natural history and risk strati-\nﬁcation of arrhythmogenic right ventricular dysplasia/cardiomyopathy. Circulation\n2004;110:1879–1884.\n692. Wang W, Cadrin-Tourigny J, Bhonsale A, Tichnell C, Murray B, Monfredi O, et al.\nArrhythmic outcome of arrhythmogenic right ventricular cardiomyopathy patients\nwithout implantable deﬁbrillators. J Cardiovasc Electrophysiol 2018;29:1396–1402.\n693. Pinamonti B, Dragos AM, Pyxaras SA, Merlo M, Pivetta A, Barbati G, et al.\nPrognostic predictors in arrhythmogenic right ventricular cardiomyopathy: results\nfrom a 10-year registry. Eur Heart J 2011;32:1105–1113.\n694. Brun F, Groeneweg JA, Gear K, Sinagra G, van der Heijden J, Mestroni L, et al. Risk\nstratiﬁcation in arrhythmic right ventricular cardiomyopathy without implantable\ncardioverter-deﬁbrillators. JACC Clin Electrophysiol 2016;2:558–564.\n695. Bhonsale A, James CA, Tichnell C, Murray B, Gagarin D, Philips B, et al. Incidence\nand predictors of implantable cardioverter-deﬁbrillator therapy in patients with ar-\nrhythmogenic right ventricular dysplasia/cardiomyopathy undergoing implantable\ncardioverter-deﬁbrillator implantation for primary prevention. J Am Coll Cardiol\n2011;58:1485–1496.\n696. Corrado D, Calkins H, Link MS, Leoni L, Favale S, Bevilacqua M, et al. Prophylactic\nimplantable deﬁbrillator in patients with arrhythmogenic right ventricular\n4116\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026\n\n\ncardiomyopathy/dysplasia and no prior ventricular ﬁbrillation or sustained ven-\ntricular tachycardia. Circulation 2010;122:1144–1152.\n697. Platonov PG, Haugaa KH, Bundgaard H, Svensson A, Gilljam T, Hansen J, et al.\nPrimary prevention of sudden cardiac death with implantable cardioverter-\ndeﬁbrillator therapy in patients with arrhythmogenic right ventricular cardiomyop-\nathy. Am J Cardiol 2019;123:1156–1162.\n698. Link MS, Laidlaw D, Polonsky B, Zareba W, McNitt S, Gear K, et al. Ventricular ar-\nrhythmias in the North American multidisciplinary study of ARVC: predictors,\ncharacteristics, and treatment. J Am Coll Cardiol 2014;64:119–125.\n699. Schinkel AFL. Implantable cardioverter deﬁbrillators in arrhythmogenic right ven-\ntricular dysplasia/cardiomyopathy: patient outcomes, incidence of appropriate\nand inappropriate interventions, and complications. Circ Arrhythm Electrophysiol\n2013;6:562–568.\n700. Corrado D, Leoni L, Link MS, Della Bella P, Gaita F, Curnis A, et al. Implantable\ncardioverter-deﬁbrillator therapy for prevention of sudden death in patients\nwith arrhythmogenic right ventricular cardiomyopathy/dysplasia. Circulation 2003;\n108:3084–3091.\n701. Mazzanti A, Ng K, Faragli A, Maragna R, Chiodaroli E, Orphanou N, et al.\nArrhythmogenic right ventricular cardiomyopathy: clinical course and predictors\nof arrhythmic risk. J Am Coll Cardiol 2016;68:2540–2550.\n702. Cadrin-Tourigny J, Bosman LP, Wang W, Tadros R, Bhonsale A, Bourﬁss M, et al.\nSudden cardiac death prediction in arrhythmogenic right ventricular cardiomyop-\nathy: a multinational collaboration. Circ Arrhythm Electrophysiol 2021;14:e008509.\n703. Bosman LP, Sammani A, James CA, Cadrin-Tourigny J, Calkins H, van Tintelen JP,\net al. Predicting arrhythmic risk in arrhythmogenic right ventricular cardiomyop-\nathy: a systematic review and meta-analysis. Heart Rhythm 2018;15:1097–1107.\n704. Saguner AM, Vecchiati A, Baldinger SH, Rüeger S, Medeiros-Domingo A,\nMueller-Burri AS, et al. Different prognostic value of functional right ventricular\nparameters in arrhythmogenic right ventricular cardiomyopathy/dysplasia. Circ\nCardiovasc Imaging 2014;7:230–239.\n705. Saguner AM, Medeiros-Domingo A, Schwyzer MA, On C-J, Haegeli LM, Wolber T,\net al. Usefulness of inducible ventricular tachycardia to predict long-term adverse\noutcomes in arrhythmogenic right ventricular cardiomyopathy. Am J Cardiol\n2013;111:250–257.\n706. Orgeron GM, Te Riele A, Tichnell C, Wang W, Murray B, Bhonsale A, et al.\nPerformance of the 2015 international task force consensus statement risk strati-\nﬁcation algorithm for implantable cardioverter-deﬁbrillator placement in arrhyth-\nmogenic right ventricular dysplasia/cardiomyopathy. Circ Arrhythm Electrophysiol\n2018;11:e005593.\n707. Orgeron GM, James CA, Te Riele A, Tichnell C, Murray B, Bhonsale A, et al.\nImplantable cardioverter-deﬁbrillator therapy in arrhythmogenic right ventricular\ndysplasia/cardiomyopathy: predictors of appropriate therapy, outcomes, and com-\nplications. J Am Heart Assoc 2017;6:e006242.\n708. Wichter T, Borggrefe M, Haverkamp W, Chen X, Breithardt G. Efﬁcacy of antiar-\nrhythmic drugs in patients with arrhythmogenic right ventricular disease. Results in\npatients with inducible and noninducible ventricular tachycardia. Circulation 1992;\n86:29–37.\n709. Mahida S, Venlet J, Saguner AM, Kumar S, Baldinger SH, AbdelWahab A, et al.\nAblation compared with drug therapy for recurrent ventricular tachycardia in ar-\nrhythmogenic right ventricular cardiomyopathy: results from a multicenter study.\nHeart Rhythm 2019;16:536–543.\n710. Ermakov S, Gerstenfeld EP, Svetlichnaya Y, Scheinman MM. Use of ﬂecainide in\ncombination antiarrhythmic therapy in patients with arrhythmogenic right ven-\ntricular cardiomyopathy. Heart Rhythm 2017;14:564–569.\n711. Canpolat U, Kabakçi G, Aytemir K, Dural M, Şahiner L, Yorgun H, et al. Fragmented\nQRS complex predicts the arrhythmic events in patients with arrhythmogenic right\nventricular cardiomyopathy/dysplasia: frQRS and outcomes in ARVC/D. J\nCardiovasc Electrophysiol 2013;24:1260–1266.\n712. Martin A, Crawford J, Skinner JR, Smith W. High arrhythmic burden but low mor-\ntality during long-term follow-up in arrhythmogenic right ventricular cardiomyop-\nathy. Heart Lung Circ 2016;25:275–281.\n713. Santangeli P, Dello Russo A, Pieroni M, Casella M, Di Biase L, Burkhardt JD, et al.\nFragmented and delayed electrograms within ﬁbrofatty scar predict arrhythmic\nevents in arrhythmogenic right ventricular cardiomyopathy: Results from a pro-\nspective risk stratiﬁcation study. Heart Rhythm 2012;9:1200–1206.\n714. Berruezo A, Fernández-Armenta J, Mont L, Zeljko H, Andreu D, Herczku C, et al.\nCombined endocardial and epicardial catheter ablation in arrhythmogenic right\nventricular dysplasia incorporating scar dechanneling technique. Circ Arrhythm\nElectrophysiol 2012;5:111–121.\n715. Ommen SR, Mital S, Burke MA, Day SM, Deswal A, Elliott P, et al. 2020 AHA/ACC\nguideline for the diagnosis and treatment of patients with hypertrophic cardiomy-\nopathy: executive summary: a report of the American College of Cardiology/\nAmerican Heart Association Joint Committee on Clinical Practice Guidelines.\nCirculation 2020;142:e533–e557.\n716. Chan RH, Maron BJ, Olivotto I, Pencina MJ, Assenza GE, Haas T, et al. Prognostic\nvalue of quantitative contrast-enhanced cardiovascular magnetic resonance for the\nevaluation of sudden death risk in patients with hypertrophic cardiomyopathy.\nCirculation 2014;130:484–495.\n717. He D, Ye M, Zhang L, Jiang B. Prognostic signiﬁcance of late gadolinium enhance-\nment on cardiac magnetic resonance in patients with hypertrophic cardiomyop-\nathy. Heart Lung 2018;47:122–126.\n718. Weissler-Snir A, Dorian P, Rakowski H, Care M, Spears D. Primary prevention im-\nplantable cardioverter-deﬁbrillators in hypertrophic cardiomyopathy—are there\npredictors of appropriate therapy? Heart Rhythm 2021;18:63–70.\n719. Khanna S, Wen I, Bhat A, Chen HHL, Gan GCH, Pathan F, et al. The role of multi-\nmodality imaging in the diagnosis of cardiac amyloidosis: a focused update. Front\nCardiovasc Med 2020;7:590557.\n720. Pradella S, Grazzini G, De Amicis C, Letteriello M, Acquafresca M, Miele V. Cardiac\nmagnetic resonance in hypertrophic and dilated cardiomyopathies. Radiol Med\n2020;125:1056–1071.\n721. Rosmini S, Biagini E, O’Mahony C, Bulluck H, Ruozi N, Lopes LR, et al. Relationship\nbetween aetiology and left ventricular systolic dysfunction in hypertrophic cardio-\nmyopathy. Heart 2017;103:300–306.\n722. Ho CY, Day SM, Ashley EA, Michels M, Pereira AC, Jacoby D, et al. Genotype and\nlifetime burden of disease in hypertrophic cardiomyopathy: insights from the\nSarcomeric Human Cardiomyopathy Registry (SHaRe). Circulation 2018;138:\n1387–1398.\n723. Kim HY, Park JE, Lee S-C, Jeon E-S, On YK, Kim SM, et al. Genotype-related clinical\ncharacteristics and myocardial ﬁbrosis and their association with prognosis in\nhypertrophic cardiomyopathy. J Clin Med 2020;9:1671.\n724. Maron BJ, Maron MS, Semsarian C. Double or compound sarcomere mutations in\nhypertrophic cardiomyopathy: a potential link to sudden death in the absence of\nconventional risk factors. Heart Rhythm 2012;9:57–63.\n725. Wang J, Wang Y, Zou Y, Sun K, Wang Z, Ding H, et al. Malignant effects of multiple\nrare variants in sarcomere genes on the prognosis of patients with hypertrophic\ncardiomyopathy. Eur J Heart Fail 2014;16:950–957.\n726. Semsarian C, Ingles J, Maron MS, Maron BJ. New perspectives on the prevalence of\nhypertrophic cardiomyopathy. J Am Coll Cardiol 2015;65:1249–1254.\n727. Maron BJ, Rowin EJ, Casey SA, Link MS, Lesser JR, Chan RHM, et al. Hypertrophic\ncardiomyopathy in adulthood associated with low cardiovascular mortality with\ncontemporary management strategies. J Am Coll Cardiol 2015;65:1915–1928.\n728. O’Mahony C, Jichi F, Ommen SR, Christiaans I, Arbustini E, Garcia-Pavia P, et al.\nInternational External Validation Study of the 2014 European Society of\nCardiology Guidelines on Sudden Cardiac Death Prevention in Hypertrophic\nCardiomyopathy (EVIDENCE-HCM). Circulation 2018;137:1015–1023.\n729. Vriesendorp PA, Schinkel AFL, Liebregts M, Theuns DAMJ, van Cleemput J, ten\nCate FJ, et al. Validation of the 2014 European Society of Cardiology guidelines\nrisk prediction model for the primary prevention of sudden cardiac death in hyper-\ntrophic cardiomyopathy. Circ Arrhythm Electrophysiol 2015;8:829–835.\n730. Lorenzini M, Anastasiou Z, O’Mahony C, Guttman OP, Gimeno JR, Monserrat L,\net al. Mortality among referral patients with hypertrophic cardiomyopathy vs the\ngeneral European population. JAMA Cardiol 2020;5:73–80.\n731. Maron BJ, Rowin EJ, Casey SA, Haas TS, Chan RHM, Udelson JE, et al. Risk strati-\nﬁcation and outcome of patients with hypertrophic cardiomyopathy .=60 years\nof age. Circulation 2013;127:585–593.\n732. Gimeno JR, Tomé-Esteban M, Loﬁego C, Hurtado J, Pantazis A, Mist B, et al.\nExercise-induced ventricular arrhythmias and risk of sudden cardiac death in pa-\ntients with hypertrophic cardiomyopathy. Eur Heart J 2009;30:2599–2605.\n733. Pelliccia A, Lemme E, Maestrini V, Di Paolo FM, Pisicchio C, Di Gioia G, et al. Does\nsport participation worsen the clinical course of hypertrophic cardiomyopathy?\nClinical outcome of hypertrophic cardiomyopathy in athletes. Circulation 2018;\n137:531–533.\n734. Dejgaard LA, Haland TF, Lie OH, Ribe M, Bjune T, Leren IS, et al. Vigorous exercise\nin patients with hypertrophic cardiomyopathy. Int J Cardiol 2018;250:157–163.\n735. Monserrat L, Elliott PM, Gimeno JR, Sharma S, Penas-Lado M, McKenna WJ.\nNon-sustained ventricular tachycardia in hypertrophic cardiomyopathy: an inde-\npendent marker of sudden death risk in young patients. J Am Coll Cardiol 2003;\n42:873–879.\n736. Rowin EJ, Maron BJ, Carrick RT, Patel PP, Koethe B, Wells S, et al. Outcomes in\npatients with hypertrophic cardiomyopathy and left ventricular systolic dysfunc-\ntion. J Am Coll Cardiol 2020;75:3033–3043.\n737. Rowin EJ, Maron BJ, Haas TS, Garberich RF, Wang W, Link MS, et al. Hypertrophic\ncardiomyopathy with left ventricular apical aneurysm: implications for risk stratiﬁ-\ncation and management. J Am Coll Cardiol 2017;69:761–773.\n738. Sadoul N, Prasad K, Elliott PM, Bannerjee S, Frenneaux MP, McKenna WJ.\nProspective prognostic assessment of blood pressure response during exercise\nin patients with hypertrophic cardiomyopathy. Circulation 1997;96:2987–2991.\nESC Guidelines\n4117\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026\n\n\n739. Elliott PM, Poloniecki J, Dickie S, Sharma S, Monserrat L, Varnava A, et al. Sudden\ndeath in hypertrophic cardiomyopathy: identiﬁcation of high risk patients. J Am Coll\nCardiol 2000;36:2212–2218.\n740. Behr ER, Elliott P, McKenna WJ. Role of invasive EP testing in the evaluation and\nmanagement of hypertrophic cardiomyopathy. Card Electrophysiol Rev 2002;6:\n482–486.\n741. Gatzoulis KA, Georgopoulos S, Antoniou C-K, Anastasakis A, Dilaveris P, Arsenos\nP, et al. Programmed ventricular stimulation predicts arrhythmic events and survival\nin hypertrophic cardiomyopathy. Int J Cardiol 2018;254:175–181.\n742. Norrish G, Qu C, Field E, Cervi E, Khraiche D, Klaassen S, et al. External validation\nof the HCM Risk-Kids model for predicting sudden cardiac death in childhood\nhypertrophic cardiomyopathy. Eur J Prev Cardiol 2022;29:678–686.\n743. Petryka-Mazurkiewicz J, Ziolkowska L, Kowalczyk-Domagala M, Mazurkiewicz L,\nBoruc A, Spiewak M, et al. LGE for risk stratiﬁcation in primary prevention in chil-\ndren with HCM. JACC Cardiovasc Imaging 2020;13:2684–2686.\n744. Elliott PM, Sharma S, Varnava A, Poloniecki J, Rowland E, McKenna WJ. Survival\nafter cardiac arrest or sustained ventricular tachycardia in patients with hyper-\ntrophic cardiomyopathy. J Am Coll Cardiol 1999;33:1596–1601.\n745. Cecchi F, Maron BJ, Epstein SE. Long-term outcome of patients with hypertrophic\ncardiomyopathy successfully resuscitated after cardiac arrest. J Am Coll Cardiol\n1989;13:1283–1288.\n746. Maron BJ, Spirito P, Shen W-K, Haas TS, Formisano F, Link MS, et al. Implantable\ncardioverter-deﬁbrillators and prevention of sudden cardiac death in hypertrophic\ncardiomyopathy. JAMA 2007;298:405–412.\n747. Melacini P, Maron BJ, Bobbo F, Basso C, Tokajuk B, Zucchetto M, et al. Evidence\nthat pharmacological strategies lack efﬁcacy for the prevention of sudden death\nin hypertrophic cardiomyopathy. Heart 2007;93:708–710.\n748. McKenna WJ, Oakley CM, Krikler DM, Goodwin JF. Improved survival with amio-\ndarone in patients with hypertrophic cardiomyopathy and ventricular tachycardia.\nBr Heart J 1985;53:412–416.\n749. Link MS, Bockstall K, Weinstock J, Alsheikh-Ali AA, Semsarian C, Estes NAM, et al.\nVentricular tachyarrhythmias in patients with hypertrophic cardiomyopathy and\ndeﬁbrillators: triggers, treatment, and implications. J Cardiovasc Electrophysiol\n2017;28:531–537.\n750. Dallaglio PD, di Marco A, Moreno Weidmann Z, Perez L, Alzueta J, García-Alberola\nA, et al. Antitachycardia pacing for shock prevention in patients with hypertrophic\ncardiomyopathy and ventricular tachycardia. Heart Rhythm 2020;17:1084–1091.\n751. Adduci C, Semprini L, Palano F, Musumeci MB, Volpe M, Autore C, et al. Safety and\nefﬁcacy of anti-tachycardia pacing in patients with hypertrophic cardiomyopathy\nimplanted with an ICD. Pacing Clin Electrophysiol 2019;42:610–616.\n752. Vaseghi M, Hu TY, Tung R, Vergara P, Frankel DS, Di Biase L, et al. Outcomes of\ncatheter ablation of ventricular tachycardia based on etiology in nonischemic heart\ndisease: an international ventricular tachycardia ablation center collaborative study.\nJACC Clin Electrophysiol 2018;4:1141–1150.\n753. Igarashi M, Nogami A, Kurosaki K, Hanaki Y, Komatsu Y, Fukamizu S, et al.\nRadiofrequency catheter ablation of ventricular tachycardia in patients with hyper-\ntrophic cardiomyopathy and apical aneurysm. JACC Clin Electrophysiol 2018;4:\n339–350.\n754. Dukkipati SR, d’Avila A, Soejima K, Bala R, Inada K, Singh S, et al. Long-term out-\ncomes of combined epicardial and endocardial ablation of monomorphic ventricu-\nlar tachycardia related to hypertrophic cardiomyopathy. Circ Arrhythm Electrophysiol\n2011;4:185–194.\n755. Ross SB, Singer ES, Driscoll E, Nowak N, Yeates L, Puranik R, et al. Genetic archi-\ntecture of left ventricular noncompaction in adults. Hum Genome Var 2020;7:33.\n756. Weir-McCall JR, Yeap PM, Papagiorcopulo C, Fitzgerald K, Gandy SJ, Lambert M,\net al. Left ventricular noncompaction: anatomical phenotype or distinct cardiomy-\nopathy? J Am Coll Cardiol 2016;68:2157–2165.\n757. Aung N, Doimo S, Ricci F, Sanghvi MM, Pedrosa C, Woodbridge SP, et al.\nPrognostic signiﬁcance of left ventricular noncompaction: systematic review and\nmeta-analysis of observational studies. Circ Cardiovasc Imaging 2020;13:e009712.\n758. Grigoratos C, Barison A, Ivanov A, Andreini D, Amzulescu M-S, Mazurkiewicz L,\net al. Meta-analysis of the prognostic role of late gadolinium enhancement and glo-\nbal systolic impairment in left ventricular noncompaction. JACC Cardiovasc Imaging\n2019;12:2141–2151.\n759. Richard P, Ader F, Roux M, Donal E, Eicher J-C, Aoutil N, et al. Targeted panel se-\nquencing in adult patients with left ventricular non-compaction reveals a large gen-\netic heterogeneity. Clin Genet 2019;95:356–367.\n760. Seferović PM, Polovina M, Bauersachs J, Arad M, Gal TB, Lund LH, et al. Heart fail-\nure in cardiomyopathies: a position paper from the Heart Failure Association of the\nEuropean Society of Cardiology. Eur J Heart Fail 2019;21:553–576.\n761. Baig S, Edward NC, Kotecha D, Liu B, Nordin S, Kozor R, et al. Ventricular arrhyth-\nmia and sudden cardiac death in Fabry disease: a systematic review of risk factors in\nclinical practice. Europace 2018;20:f153–f161.\n762. Sperry BW, Ikram A, Hachamovitch R, Valent J, Vranian MN, Phelan D, et al. Efﬁcacy\nof chemotherapy for light-chain amyloidosis in patients presenting with symptom-\natic heart failure. J Am Coll Cardiol 2016;67:2941–2948.\n763. Kristen AV, Dengler TJ, Hegenbart U, Schonland SO, Goldschmidt H, Sack F-U,\net al. Prophylactic implantation of cardioverter-deﬁbrillator in patients with severe\ncardiac amyloidosis and high risk for sudden cardiac death. Heart Rhythm 2008;5:\n235–240.\n764. Merino JL, Peinado R. Arrhythmias associated with neuromuscular disorders. Card\nElectrophysiol Rev 2002;6:132–135.\n765. Punnoose AR, Kaltman JR, Pastor W, McCarter R, He J, Spurney CF. Cardiac dis-\nease burden and risk of mortality in hospitalized muscular dystrophy patients.\nPediatr Cardiol 2016;37:1290–1296.\n766. Wahbi K, Meune C, Porcher R, Bécane HM, Lazarus A, Laforêt P, et al.\nElectrophysiological study with prophylactic pacing and survival in adults with myo-\ntonic dystrophy and conduction system disease. JAMA 2012;307:1292–1301.\n767. Lallemand B, Clementy N, Bernard-Brunet A, Pierre B, Corcia P, Fauchier L, et al.\nThe evolution of infrahissian conduction time in myotonic dystrophy patients: clin-\nical implications. Heart 2012;98:291–296.\n768. Nogami A. Bundle branch reentry tachycardia. ESC CardioMed. 3rd ed. Oxford\nUniversity Press; 2022, pp. 2270–2275.\n769. Sanna T, Dello Russo A, Toniolo D, Vytopil M, Pelargonio G, De Martino G, et al.\nCardiac features of Emery-Dreifuss muscular dystrophy caused by lamin A/C gene\nmutations. Eur Heart J 2003;24:2227–2236.\n770. Menon SC, Etheridge SP, Liesemer KN, Williams RV, Bardsley T, Heywood MC,\net al. Predictive value of myocardial delayed enhancement in Duchenne muscular\ndystrophy. Pediatr Cardiol 2014;35:1279–1285.\n771. Florian A, Ludwig A, Engelen M, Waltenberger J, Rösch S, Sechtem U, et al. Left ven-\ntricular systolic function and the pattern of late-gadolinium-enhancement inde-\npendently and additively predict adverse cardiac events in muscular dystrophy\npatients. J Cardiovasc Magn Reson 2014;16:81.\n772. Prystowsky EN, Pritchett EL, Roses AD, Gallagher J. The natural history of conduc-\ntion system disease in myotonic muscular dystrophy as determined by serial elec-\ntrophysiologic studies. Circulation 1979;60:1360–1364.\n773. Trachtenberg BH, Hare JM. Inﬂammatory cardiomyopathic syndromes. Circ Res\n2017;121:803–818.\n774. Hulsmans M, Clauss S, Xiao L, Aguirre AD, King KR, Hanley A, et al. Macrophages\nfacilitate electrical conduction in the heart. Cell 2017;169:510–522.\n775. Youker KA, Assad-Kottner C, Cordero-Reyes AM, Trevino AR, Flores-Arredondo\nJH, Barrios R, et al. High proportion of patients with end-stage heart failure regard-\nless of aetiology demonstrates anti-cardiac antibody deposition in failing myocar-\ndium: humoral activation, a potential contributor of disease progression. Eur\nHeart J 2014;35:1061–1068.\n776. Adamo L, Rocha-Resende C, Prabhu SD, Mann DL. Reappraising the role of inﬂam-\nmation in heart failure. Nat Rev Cardiol 2020;17:269–285.\n777. Sagar S, Liu PP, Cooper LT. Myocarditis. Lancet 2012;379:738–747.\n778. Ammirati E, Cipriani M, Moro C, Raineri C, Pini D, Sormani P, et al. Clinical pres-\nentation and outcome in a contemporary cohort of patients with acute myocardi-\ntis: multicenter Lombardy registry. Circulation 2018;138:1088–1099.\n779. Fabre A. Sudden adult death syndrome and other non-ischaemic causes of sudden\ncardiac death. Heart 2005;92:316–320.\n780. Lynge TH, Nielsen TS, Gregers Winkel B, Tfelt-Hansen J, Banner J. Sudden cardiac\ndeath caused by myocarditis in persons aged 1–49 years: a nationwide study of 14\n294 deaths in Denmark. Forensic Sci Res 2019;4:247–256.\n781. Maron BJ, Udelson JE, Bonow RO, Nishimura RA, Ackerman MJ, Estes NAM, et al.\nEligibility and disqualiﬁcation recommendations for competitive athletes with car-\ndiovascular abnormalities: task force 3: hypertrophic cardiomyopathy, arrhythmo-\ngenic right ventricular cardiomyopathy and other cardiomyopathies, and\nmyocarditis. J Am Coll Cardiol 2015;66:2362–2371.\n782. Kindermann I, Barth C, Mahfoud F, Ukena C, Lenski M, Yilmaz A, et al. Update on\nmyocarditis. J Am Coll Cardiol 2012;59:779–792.\n783. Caforio ALP, Pankuweit S, Arbustini E, Basso C, Gimeno-Blanes J, Felix SB, et al.\nCurrent state of knowledge on aetiology, diagnosis, management, and therapy of\nmyocarditis: a position statement of the European Society of Cardiology\nWorking Group on Myocardial and Pericardial Diseases. Eur Heart J 2013;34:\n2636–2648.\n784. Singh V, Mendirichaga R, Savani GT, Rodriguez A, Blumer V, Elmariah S, et al.\nComparison of utilization trends, indications, and complications of endomyocardial\nbiopsy in native versus donor hearts (from the Nationwide Inpatient Sample 2002\nto 2014). Am J Cardiol 2018;121:356–363.\n785. Aoyama N, Izumi T, Hiramori K, Isobe M, Kawana M, Hiroe M, et al. National survey\nof fulminant myocarditis in Japan: therapeutic guidelines and long-term prognosis of\nusing percutaneous cardiopulmonary support for fulminant myocarditis (special re-\nport from a scientiﬁc committee). Circ J 2002;66:133–144.\n4118\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026\n\n\n786. Shah Z, Mohammed M, Vuddanda V, Ansari MW, Masoomi R, Gupta K. National\ntrends, gender, management, and outcomes of patients hospitalized for myocardi-\ntis. Am J Cardiol 2019;124:131–136.\n787. Anderson BR, Silver ES, Richmond ME, Liberman L. Usefulness of arrhythmias as\npredictors of death and resource utilization in children with myocarditis. Am J\nCardiol 2014;114:1400–1405.\n788. Kandolin R, Lehtonen J, Salmenkivi K, Räisänen-Sokolowski A, Lommi J, Kupari M.\nDiagnosis, treatment, and outcome of giant-cell myocarditis in the era of combined\nimmunosuppression. Circ Heart Fail 2013;6:15–22.\n789. Cooper LT, Berry GJ, Shabetai R. Idiopathic giant-cell myocarditis—natural history\nand treatment. N Engl J Med 1997;336:1860–1866.\n790. McMurray JJV, Adamopoulos S, Anker SD, Auricchio A, Böhm M, Dickstein K, et al.\nESC Guidelines for the diagnosis and treatment of acute and chronic heart failure\n2012: the task force for the Diagnosis and Treatment of Acute and Chronic Heart\nFailure 2012 of the European Society of Cardiology. Developed in collaboration\nwith the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012;33:\n1787–1847.\n791. Blauwet LA, Cooper LT. Myocarditis. Prog Cardiovasc Dis 2010;52:274–288.\n792. JCS Joint Working Group. Guidelines for diagnosis and treatment of myocarditis\n(JCS 2009): digest version. Circ J 2011;75:734–743.\n793. Ali-Ahmed F, Dalgaard F, Al-Khatib SM. Sudden cardiac death in patients with myo-\ncarditis: Evaluation, risk stratiﬁcation, and management. Am Heart J 2020;220:\n29–40.\n794. Rosier L, Zouaghi A, Barré V, Martins R, Probst V, Marijon E, et al. High risk of sus-\ntained ventricular arrhythmia recurrence after acute myocarditis. J Clin Med 2020;9:\nE848.\n795. Maron BJ, Towbin JA, Thiene G, Antzelevitch C, Corrado D, Arnett D, et al.\nContemporary\ndeﬁnitions\nand\nclassiﬁcation\nof\nthe\ncardiomyopathies:\nan\nAmerican Heart Association Scientiﬁc Statement from the Council on Clinical\nCardiology, Heart Failure and Transplantation Committee; Quality of Care and\nOutcomes Research and Functional Genomics and Translational Biology\nInterdisciplinary Working Groups; and Council on Epidemiology and Prevention.\nCirculation 2006;113:1807–1816.\n796. D’Ambrosio A, Patti G, Manzoli A, Sinagra G, Di Lenarda A, Silvestri F, et al. The fate\nof acute myocarditis between spontaneous improvement and evolution to dilated\ncardiomyopathy: a review. Heart 2001;85:499–504.\n797. Kasper EK, Agema WRP, Hutchins GM, Deckers JW, Hare JM, Baughman KL. The\ncauses of dilated cardiomyopathy: a clinicopathologic review of 673 consecutive pa-\ntients. J Am Coll Cardiol 1994;23:586–590.\n798. Grün S, Schumm J, Greulich S, Wagner A, Schneider S, Bruder O, et al. Long-term\nfollow-up of biopsy-proven viral myocarditis. J Am Coll Cardiol 2012;59:1604–1615.\n799. Bennett MK, Gilotra NA, Harrington C, Rao S, Dunn JM, Freitag TB, et al. Evaluation\nof the role of endomyocardial biopsy in 851 patients with unexplained heart failure\nfrom 2000–2009. Circ Heart Fail 2013;6:676–684.\n800. Schumm J, Greulich S, Wagner A, Grün S, Ong P, Bentz K, et al. Cardiovascular\nmagnetic resonance risk stratiﬁcation in patients with clinically suspected myocar-\nditis. J Cardiovasc Magn Reson 2014;16:14.\n801. Russo AD, Casella M, Pieroni M, Pelargonio G, Bartoletti S, Santangeli P, et al.\nDrug-refractory ventricular tachycardias after myocarditis: endocardial and epicar-\ndial radiofrequency catheter ablation. Circ Arrhythm Electrophysiol 2012;5:492–498.\n802. Maccabelli G, Tsiachris D, Silberbauer J, Esposito A, Bisceglia C, Baratto F, et al.\nImaging and epicardial substrate ablation of ventricular tachycardia in patients\nlate after myocarditis. Europace 2014;16:1363–1372.\n803. Berte B, Sacher F, Cochet H, Mahida S, Yamashita S, Lim H, et al. Postmyocarditis\nventricular tachycardia in patients with epicardial-only scar: a speciﬁc entity requir-\ning a speciﬁc approach: epicardial-only VT ablation. J Cardiovasc Electrophysiol 2015;\n26:42–50.\n804. Maleszewski JJ, Orellana VM, Hodge DO, Kuhl U, Schultheiss H-P, Cooper LT.\nLong-term risk of recurrence, morbidity and mortality in giant cell myocarditis.\nAm J Cardiol 2015;115:1733–1738.\n805. El-Assaad I, Al-Kindi SG, Oliveira GH, Boyle GJ, Aziz PF. Implantable cardioverter-\ndeﬁbrillator and wait-list outcomes in pediatric patients awaiting heart transplant-\nation. Heart Rhythm 2015;12:2443–2448.\n806. Ekström K, Lehtonen J, Kandolin R, Räisänen-Sokolowski A, Salmenkivi K, Kupari M.\nLong-term outcome and its predictors in giant cell myocarditis: giant cell myocar-\nditis. Eur J Heart Fail 2016;18:1452–1458.\n807. Rybicki BA, Iannuzzi MC, Frederick MM, Thompson BW, Rossman MD, Bresnitz\nEA, et al. Familial aggregation of sarcoidosis. A case-control etiologic study of sar-\ncoidosis (ACCESS). Am J Respir Crit Care Med 2001;164:2085–2091.\n808. Muchtar E, Blauwet LA, Gertz MA. Restrictive cardiomyopathy: genetics, pathogen-\nesis, clinical manifestations, diagnosis, and therapy. Circ Res 2017;121:819–837.\n809. Birnie DH, Sauer WH, Bogun F, Cooper JM, Culver DA, Duvernoy CS, et al. HRS\nexpert consensus statement on the diagnosis and management of arrhythmias as-\nsociated with cardiac sarcoidosis. Heart Rhythm 2014;11:1304–1323.\n810. Birnie DH, Kandolin R, Nery PB, Kupari M. Cardiac manifestations of sarcoidosis:\ndiagnosis and management. Eur Heart J 2016;38:2663–2670.\n811. Trivieri MG, Spagnolo P, Birnie D, Liu P, Drake W, Kovacic JC, et al. Challenges in\ncardiac and pulmonary sarcoidosis: JACC state-of-the-art review. J Am Coll Cardiol\n2020;76:1878–1901.\n812. Kandolin R, Lehtonen J, Airaksinen J, Vihinen T, Miettinen H, Ylitalo K, et al. Cardiac\nsarcoidosis: epidemiology, characteristics, and outcome over 25 years in a nation-\nwide study. Circulation 2015;131:624–632.\n813. Hoogendoorn JC, Sramko M, Venlet J, Siontis KC, Kumar S, Singh R, et al.\nElectroanatomical voltage mapping to distinguish right-sided cardiac sarcoidosis\nfrom arrhythmogenic right ventricular cardiomyopathy. JACC Clin Electrophysiol\n2020;6:696–707.\n814. Banba K, Kusano KF, Nakamura K, Morita H, Ogawa A, Ohtsuka F, et al.\nRelationship between arrhythmogenesis and disease activity in cardiac sarcoidosis.\nHeart Rhythm 2007;4:1292–1299.\n815. Takaya Y, Kusano KF, Nakamura K, Ito H. Outcomes in patients with high-degree\natrioventricular block as the initial manifestation of cardiac sarcoidosis. Am J Cardiol\n2015;115:505–509.\n816. Nordenswan H-K, Lehtonen J, Ekström K, Kandolin R, Simonen P, Mäyränpää M,\net al. Outcome of cardiac sarcoidosis presenting with high-grade atrioventricular\nblock. Circ Arrhythm Electrophysiol 2018;11.\n817. Greulich S, Deluigi CC, Gloekler S, Wahl A, Zürn C, Kramer U, et al. CMR imaging\npredicts death and other adverse events in suspected cardiac sarcoidosis. JACC\nCardiovasc Imaging 2013;6:501–511.\n818. Nadel J, Lanceﬁeld T, Voskoboinik A, Taylor AJ. Late gadolinium enhancement iden-\ntiﬁed with cardiac magnetic resonance imaging in sarcoidosis patients is associated\nwith long-term ventricular arrhythmia and sudden cardiac death. Eur Heart J\nCardiovasc Imaging 2015;16:631–641.\n819. Murtagh G, Lafﬁn LJ, Beshai JF, Maffessanti F, Bonham CA, Patel AV, et al. Prognosis\nof myocardial damage in sarcoidosis patients with preserved left ventricular ejec-\ntion fraction: risk stratiﬁcation using cardiovascular magnetic resonance. Circ\nCardiovasc Imaging 2016;9:e003738.\n820. Ekström K, Lehtonen J, Hänninen H, Kandolin R, Kivistö S, Kupari M. Magnetic res-\nonance imaging as a predictor of survival free of life-threatening arrhythmias and\ntransplantation in cardiac sarcoidosis. J Am Heart Assoc 2016;5:e003040.\n821. Coleman GC, Shaw PW, Balfour PC, Gonzalez JA, Kramer CM, Patel AR, et al.\nPrognostic value of myocardial scarring on CMR in patients with cardiac sarcoid-\nosis. JACC Cardiovasc Imaging 2017;10:411–420.\n822. Aizer A, Stern EH, Gomes JA, Teirstein AS, Eckart RE, Mehta D. Usefulness of pro-\ngrammed ventricular stimulation in predicting future arrhythmic events in patients\nwith cardiac sarcoidosis. Am J Cardiol 2005;96:276–282.\n823. Mehta D, Mori N, Goldbarg SH, Lubitz S, Wisnivesky JP, Teirstein A. Primary pre-\nvention of sudden cardiac death in silent cardiac sarcoidosis: role of programmed\nventricular stimulation. Circ Arrhythm Electrophysiol 2011;4:43–48.\n824. Okada DR, Smith J, Derakhshan A, Gowani Z, Zimmerman SL, Misra S, et al.\nElectrophysiology study for risk stratiﬁcation in patients with cardiac sarcoidosis\nand abnormal cardiac imaging. Int J Cardiol Heart Vasc 2019;23:100342.\n825. Zipse MM, Tzou WS, Schuller JL, Aleong RG, Varosy PD, Tompkins C, et al.\nElectrophysiologic testing for diagnostic evaluation and risk stratiﬁcation in patients\nwith suspected cardiac sarcoidosis with preserved left and right ventricular systolic\nfunction. J Cardiovasc Electrophysiol 2019;30:1939–1948.\n826. Blankstein R, Osborne M, Naya M, Waller A, Kim CK, Murthy VL, et al. Cardiac\npositron emission tomography enhances prognostic assessments of patients with\nsuspected cardiac sarcoidosis. J Am Coll Cardiol 2014;63:329–336.\n827. Crawford T, Mueller G, Sarsam S, Prasitdumrong H, Chaiyen N, Gu X, et al.\nMagnetic resonance imaging for identifying patients with cardiac sarcoidosis and\npreserved or mildly reduced left ventricular function at risk of ventricular arrhyth-\nmias. Circ Arrhythm Electrophysiol 2014;7:1109–1115.\n828. Schuller JL, Zipse M, Crawford T, Bogun F, Beshai J, Patel AR, et al. Implantable car-\ndioverter deﬁbrillator therapy in patients with cardiac sarcoidosis. J Cardiovasc\nElectrophysiol 2012;23:925–929.\n829. Betensky BP, Tschabrunn CM, Zado ES, Goldberg LR, Marchlinski FE, Garcia FC,\net al. Long-term follow-up of patients with cardiac sarcoidosis and implantable\ncardioverter-deﬁbrillators. Heart Rhythm 2012;9:884–891.\n830. Kron J, Sauer W, Schuller J, Bogun F, Crawford T, Sarsam S, et al. Efﬁcacy and safety\nof implantable cardiac deﬁbrillators for treatment of ventricular arrhythmias in pa-\ntients with cardiac sarcoidosis. EP Europace 2013;15:347–354.\n831. Mohsen A, Jimenez A, Hood RE, Dickfeld T, Saliaris A, Shorofsky S, et al. Cardiac\nsarcoidosis: electrophysiological outcomes on long-term follow-up and the role\nof the implantable cardioverter-deﬁbrillator. J Cardiovasc Electrophysiol 2014;25:\n171–176.\n832. Azoulay L-D, Waintraub X, Haroche J, Amoura Z, Cohen Aubart F. Factors asso-\nciated with implantable cardioverter deﬁbrillators appropriate therapy in cardiac\nsarcoidosis: a meta-analysis: implantable cardioverter deﬁbrillators in cardiac sar-\ncoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2020;37:17–23.\nESC Guidelines\n4119\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026\n\n\n833. Smedema J-P, van Geuns R-J, Ector J, Heidbuchel H, Ainslie G, Crijns HJGM. Right\nventricular involvement and the extent of left ventricular enhancement with mag-\nnetic resonance predict adverse outcome in pulmonary sarcoidosis. ESC Heart Fail\n2018;5:157–171.\n834. Velangi PS, Chen K-HA, Kazmirczak F, Okasha O, von Wald L, Roukoz H, et al.\nRight ventricular abnormalities on cardiovascular magnetic resonance imaging in\npatients with sarcoidosis. JACC Cardiovasc Imaging 2020;13:1395–1405.\n835. Ise T, Hasegawa T, Morita Y, Yamada N, Funada A, Takahama H, et al. Extensive late\ngadolinium enhancement on cardiovascular magnetic resonance predicts adverse\noutcomes and lack of improvement in LV function after steroid therapy in cardiac\nsarcoidosis. Heart 2014;100:1165–1172.\n836. Yodogawa K, Seino Y, Ohara T, Takayama H, Katoh T, Mizuno K. Effect of cortico-\nsteroid therapy on ventricular arrhythmias in patients with cardiac sarcoidosis: ef-\nfect of corticosteroid therapy. Ann Noninvasive Electrocardiol 2011;16:140–147.\n837. Naruse Y, Sekiguchi Y, Nogami A, Okada H, Yamauchi Y, Machino T, et al.\nSystematic treatment approach to ventricular tachycardia in cardiac sarcoidosis.\nCirc Arrhythm Electrophysiol 2014;7:407–413.\n838. Segawa M, Fukuda K, Nakano M, Kondo M, Satake H, Hirano M, et al. Time course\nand factors correlating with ventricular tachyarrhythmias after introduction of ster-\noid therapy in cardiac sarcoidosis. Circ Arrhythm Electrophysiol 2016;9:e003353.\n839. Kumar S, Barbhaiya C, Nagashima K, Choi E-K, Epstein LM, John RM, et al.\nVentricular tachycardia in cardiac sarcoidosis: characterization of ventricular sub-\nstrate and outcomes of catheter ablation. Circ Arrhythm Electrophysiol 2015;8:\n87–93.\n840. Muser D, Santangeli P, Liang JJ, Castro SA, Magnani S, Hayashi T, et al.\nCharacterization of the electroanatomic substrate in cardiac sarcoidosis. JACC\nClin Electrophysiol 2018;4:291–303.\n841. Jeﬁc D, Joel B, Good E, Morady F, Rosman H, Knight B, et al. Role of radiofrequency\ncatheter ablation of ventricular tachycardia in cardiac sarcoidosis: report from a\nmulticenter registry. Heart Rhythm 2009;6:189–195.\n842. Papageorgiou N, Providência R, Bronis K, Dechering DG, Srinivasan N, Eckardt L,\net al. Catheter ablation for ventricular tachycardia in patients with cardiac sarcoid-\nosis: a systematic review. EP Europace 2018;20:682–691.\n843. Siontis KC, Santangeli P, Muser D, Marchlinski FE, Zeppenfeld K, Hoogendoorn JC,\net al. Outcomes associated with catheter ablation of ventricular tachycardia in pa-\ntients with cardiac sarcoidosis. JAMA Cardiol 2022;7:175.\n844. Hoogendoorn JC, Venlet J, Out YNJ, Man S, Kumar S, Sramko M, et al. The precor-\ndial R’ wave: a novel discriminator between cardiac sarcoidosis and arrhythmogenic\nright ventricular cardiomyopathy in patients presenting with ventricular tachycar-\ndia. Heart Rhythm 2021;18:1539–1547.\n845. Bern C. Chagas’ disease. N Engl J Med 2015;373:456–466.\n846. Bocchi EA, Bestetti RB, Scanavacca MI, Cunha Neto E, Issa VS. Chronic chagas heart\ndisease management. J Am Coll Cardiol 2017;70:1510–1524.\n847. Nunes MCP, Dones W, Morillo CA, Encina JJ, Ribeiro AL. Chagas disease. J Am Coll\nCardiol 2013;62:767–776.\n848. Nunes MCP, Beaton A, Acquatella H, Bern C, Bolger AF, Echeverría LE, et al.\nChagas cardiomyopathy: an update of current clinical knowledge and management:\na scientiﬁc statement from the American heart association. Circulation 2018;138:\ne169–e209.\n849. Rassi A, Rassi A, Little WC, Xavier SS, Rassi SG, Rassi AG, et al. Development and\nvalidation of a risk score for predicting death in Chagas’ heart disease. N Engl J Med\n2006;355:799–808.\n850. Senra T, Ianni BM, Costa ACP, Mady C, Martinelli-Filho M, Kalil-Filho R, et al.\nLong-term prognostic value of myocardial ﬁbrosis in patients with chagas cardio-\nmyopathy. J Am Coll Cardiol 2018;72:2577–2587.\n851. Rassi FM, Minohara L, Rassi A, Correia LCL, Marin-Neto JA, Rassi A, et al.\nSystematic review and meta-analysis of clinical outcome after implantable\ncardioverter-deﬁbrillator therapy in patients with chagas heart disease. JACC Clin\nElectrophysiol 2019;5:1213–1223.\n852. Cardinalli-Neto A, Bestetti RB, Cordeiro JA, Rodrigues VC. Predictors of all-cause\nmortality for patients with chronic Chagas’ heart disease receiving implantable car-\ndioverter deﬁbrillator therapy. J Cardiovasc Electrophysiol 2007;18:1236–1240.\n853. Muratore CA, Batista Sa LA, Chiale PA, Eloy R, Tentori MC, Escudero J, et al.\nImplantable cardioverter deﬁbrillators and chagas’ disease: results of the ICD regis-\ntry Latin America. Europace 2008;11:164–168.\n854. Martinelli M, de Siqueira SF, Sternick EB, Rassi A, Costa R, Ramires JAF, et al.\nLong-term follow-up of implantable cardioverter-deﬁbrillator for secondary pre-\nvention in chagas’ heart disease. Am J Cardiol 2012;110:1040–1045.\n855. Gali WL, Sarabanda AV, Baggio JM, Ferreira LG, Gomes GG, Marin-Neto JA, et al.\nImplantable cardioverter-deﬁbrillators for treatment of sustained ventricular ar-\nrhythmias in patients with chagas’ heart disease: comparison with a control group\ntreated with amiodarone alone. Europace 2014;16:674–680.\n856. Carmo AAL, de Sousa MR, Agudelo JF, Boersma E, Rocha MOC, Ribeiro ALP, et al.\nImplantable cardioverter-deﬁbrillator in chagas heart disease: a systematic review\nand meta-analysis of observational studies. Int J Cardiol 2018;267:88–93.\n857. Stein C, Migliavaca CB, Colpani V, da Rosa PR, Sganzerla D, Giordani NE, et al.\nAmiodarone for arrhythmia in patients with chagas disease: a systematic review\nand individual patient data meta-analysis. PLoS Negl Trop Dis 2018;12:e0006742.\n858. Sosa E, Scanavacca M, D’Avila A, Piccioni J, Sanchez O, Velarde JL, et al. Endocardial\nand epicardial ablation guided by nonsurgical transthoracic epicardial mapping to\ntreat recurrent ventricular tachycardia. J Cardiovasc Electrophysiol 1998;9:229–239.\n859. Soto-Becerra R, Bazan V, Bautista W, Malavassi F, Altamar J, Ramirez JD, et al.\nVentricular tachycardia in the setting of chagasic cardiomyopathy: use of voltage\nmapping to characterize endoepicardial nonischemic scar distribution. Circ\nArrhythm Electrophysiol 2017;10:e004950.\n860. Pisani CF, Romero J, Lara S, Hardy C, Chokr M, Sacilotto L, et al. Efﬁcacy and safety\nof combined endocardial/epicardial catheter ablation for ventricular tachycardia in\nchagas disease: a randomized controlled study. Heart Rhythm 2020;17:1510–1518.\n861. Chizner MA, Pearle DL, deLeon AC. The natural history of aortic stenosis in adults.\nAm Heart J 1980;99:419–424.\n862. Delahaye JP, Gare JP, Viguier E, Delahaye F, De Gevigney G, Milon H. Natural his-\ntory of severe mitral regurgitation. Eur Heart J 1991;12:5–9.\n863. Groves P. Valve disease: surgery of valve disease: late results and late complications.\nHeart 2001;86:715–721.\n864. Blackstone EH, Kirklin JW. Death and other time-related events after valve replace-\nment. Circulation 1985;72:753–767.\n865. Urena M, Webb JG, Eltchaninoff H, Muñoz-García AJ, Bouleti C, Tamburino C, et al.\nLate cardiac death in patients undergoing transcatheter aortic valve replacement:\nincidence and predictors of advanced heart failure and sudden cardiac death.\nJ Am Coll Cardiol 2015;65:437–448.\n866. Yang F, Shah B, Iwai S, Markowitz SM, Lerman BB, Stein KM. ICD implantation and\narrhythmia-free survival in patients with depressed LV function following surgery\nfor valvular heart disease. Pacing Clin Electrophysiol 2008;31:1419–1424.\n867. Valles AG, Khawaja FJ, Gersh BJ, Enriquez-Sarano M, Friedman PA, Park SJ, et al.\nImplantable cardioverter deﬁbrillators in patients with valvular cardiomyopathy.\nJ Cardiovasc Electrophysiol 2012;23:1326–1332.\n868. Rodríguez-Mañero\nM,\nBarrio-López\nMT,\nAssi\nEA,\nExpósito-García\nV,\nBertomeu-González V, Sánchez-Gómez JM, et al. Primary prevention of sudden\ndeath in patients with valvular cardiomyopathy. Rev Esp Cardiol (Engl Ed) 2016;\n69:272–278.\n869. Fischer-Rasokat U, Renker M, Liebetrau C, Weferling M, Rolf A, Hain A, et al.\nLong-term survival in patients with or without implantable cardioverter deﬁbrilla-\ntor after transcatheter aortic valve implantation. J Clin Med 2021;10:2929.\n870. Nies RJ, Frerker C, Adam M, Kuhn E, Mauri V, Nettersheim FS, et al. Is there a bene-\nﬁt of ICD treatment in patients with persistent severely reduced systolic left ven-\ntricular function after TAVI? Clin Res Cardiol 2022;111:492–501.\n871. Eckart RE, Hruczkowski TW, Tedrow UB, Koplan BA, Epstein LM, Stevenson WG.\nSustained ventricular tachycardia associated with corrective valve surgery.\nCirculation 2007;116:2005–2011.\n872. Liang JJ, Castro SA, Muser D, Briceno DF, Shirai Y, Enriquez A, et al.\nElectrophysiologic substrate, safety, procedural approaches, and outcomes of cath-\neter ablation for ventricular tachycardia in patients after aortic valve replacement.\nJACC Clin Electrophysiol 2019;5:28–38.\n873. Delling FN, Vasan RS. Epidemiology and pathophysiology of mitral valve prolapse:\nnew insights into disease progression, genetics, and molecular basis. Circulation\n2014;129:2158–2170.\n874. Nalliah CJ, Mahajan R, Elliott AD, Haqqani H, Lau DH, Vohra JK, et al. Mitral valve\nprolapse and sudden cardiac death: a systematic review and meta-analysis. Heart\n2019;105:144–151.\n875. Nishimura RA, McGoon MD, Shub C, Miller FA, Ilstrup DM, Tajik AJ.\nEchocardiographically documented mitral-valve prolapse. Long-term follow-up of\n237 patients. N Engl J Med 1985;313:1305–1309.\n876. Perazzolo Marra M, Basso C, De Lazzari M, Rizzo S, Cipriani A, Giorgi B, et al.\nMorphofunctional abnormalities of mitral annulus and arrhythmic mitral valve pro-\nlapse. Circ Cardiovasc Imaging 2016;9:e005030.\n877. Sriram CS, Syed FF, Ferguson ME, Johnson JN, Enriquez-Sarano M, Cetta F, et al.\nMalignant bileaﬂet mitral valve prolapse syndrome in patients with otherwise idio-\npathic out-of-hospital cardiac arrest. J Am Coll Cardiol 2013;62:222–230.\n878. Kitkungvan D, Nabi F, Kim RJ, Bonow RO, Khan MA, Xu J, et al. Myocardial ﬁbrosis\nin patients with primary mitral regurgitation with and without prolapse. J Am Coll\nCardiol 2018;72:823–834.\n879. Nordhues BD, Siontis KC, Scott CG, Nkomo VT, Ackerman MJ, Asirvatham SJ,\net al. Bileaﬂet mitral valve prolapse and risk of ventricular dysrhythmias and death.\nJ Cardiovasc Electrophysiol 2016;27:463–468.\n880. Essayagh B, Sabbag A, Antoine C, Benfari G, Yang L-T, Maalouf J, et al. Presentation\nand outcome of arrhythmic mitral valve prolapse. J Am Coll Cardiol 2020;76:\n637–649.\n881. Narasimhan C, Jazayeri MR, Sra J, Dhala A, Deshpande S, Biehl M, et al. Ventricular\ntachycardia in valvular heart disease: facilitation of sustained bundle-branch reentry\nby valve surgery. Circulation 1997;96:4307–4313.\n4120\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026\n\n\n882. Moons P, Bovijn L, Budts W, Belmans A, Gewillig M. Temporal trends in survival to\nadulthood among patients born with congenital heart disease from 1970 to 1992 in\nBelgium. Circulation 2010;122:2264–2272.\n883. Marelli AJ, Ionescu-Ittu R, Mackie AS, Guo L, Dendukuri N, Kaouache M. Lifetime\nprevalence of congenital heart disease in the general population from 2000 to 2010.\nCirculation 2014;130:749–756.\n884. Koyak Z, Harris L, de Groot JR, Silversides CK, Oechslin EN, Bouma BJ, et al.\nSudden cardiac death in adult congenital heart disease. Circulation 2012;126:\n1944–1954.\n885. Gallego P, Gonzalez AE, Sanchez-Recalde A, Peinado R, Polo L, Gomez-Rubin C,\net al. Incidence and predictors of sudden cardiac arrest in adults with congenital\nheart defects repaired before adult life. Am J Cardiol 2012;110:109–117.\n886. Ghai A, Silversides C, Harris L, Webb GD, Siu SC, Therrien J. Left ventricular dys-\nfunction is a risk factor for sudden cardiac death in adults late after repair of tetral-\nogy of Fallot. J Am Coll Cardiol 2002;40:1675–1680.\n887. Khairy P, Landzberg MJ, Gatzoulis MA, Lucron H, Lambert J, Marçon F, et al. Value\nof programmed ventricular stimulation after tetralogy of fallot repair: a multicenter\nstudy. Circulation 2004;109:1994–2000.\n888. Kapel GFL, Sacher F, Dekkers OM, Watanabe M, Blom NA, Thambo J-B, et al.\nArrhythmogenic anatomical isthmuses identiﬁed by electroanatomical mapping\nare the substrate for ventricular tachycardia in repaired tetralogy of Fallot. Eur\nHeart J 2017;38:268–276.\n889. Atallah J, Gonzalez Corcia MC, Walsh EP. Participating members of the pediatric\nand congenital electrophysiology society. Ventricular arrhythmia and life-\nthreatening events in patients with repaired tetralogy of Fallot. Am J Cardiol 2020;\n132:126–132.\n890. Kammeraad JAE, van Deurzen CHM, Sreeram N, Bink-Boelkens MTE, Ottenkamp\nJ, Helbing WA, et al. Predictors of sudden cardiac death after Mustard or Senning\nrepair for transposition of the great arteries. J Am Coll Cardiol 2004;44:1095–1102.\n891. Schwerzmann M, Salehian O, Harris L, Siu SC, Williams WG, Webb GD, et al.\nVentricular arrhythmias and sudden death in adults after a Mustard operation\nfor transposition of the great arteries. Eur Heart J 2009;30:1873–1879.\n892. Miyazaki A, Sakaguchi H, Ohuchi H, Matsuoka M, Komori A, Yamamoto T, et al.\nEfﬁcacy of hemodynamic-based management of tachyarrhythmia after repair of tet-\nralogy of Fallot. Circ J 2012;76:2855–2862.\n893. Harrison DA, Harris L, Siu SC, MacLoghlin CJ, Connelly MS, Webb GD, et al.\nSustained ventricular tachycardia in adult patients late after repair of tetralogy of\nFallot. J Am Coll Cardiol 1997;30:1368–1373.\n894. Sabate Rotes A, Connolly HM, Warnes CA, Ammash NM, Phillips SD, Dearani JA,\net al. Ventricular arrhythmia risk stratiﬁcation in patients with tetralogy of Fallot at\nthe time of pulmonary valve replacement. Circ Arrhythm Electrophysiol 2015;8:\n110–116.\n895. Khairy P, Harris L, Landzberg MJ, Fernandes SM, Barlow A, Mercier L-A, et al.\nSudden death and deﬁbrillators in transposition of the great arteries with\nintra-atrial bafﬂes: a multicenter study. Circ Arrhythm Electrophysiol 2008;1:250–257.\n896. Roca-Luque I, Rivas Gándara N, Dos Subirà L, Francisco Pascual J, Pérez-Rodon J,\nPijuan Domenech A, et al. Intra-atrial re-entrant tachycardia in patients with con-\ngenital heart disease: factors associated with disease severity. Europace 2018;20:\n1343–1351.\n897. Zeppenfeld K, Schalij MJ, Bartelings MM, Tedrow UB, Koplan BA, Soejima K, et al.\nCatheter ablation of ventricular tachycardia after repair of congenital heart disease:\nelectroanatomic identiﬁcation of the critical right ventricular isthmus. Circulation\n2007;116:2241–2252.\n898. Kriebel T, Saul JP, Schneider H, Sigler M, Paul T. Noncontact mapping and radiofre-\nquency catheter ablation of fast and hemodynamically unstable ventricular tachy-\ncardia after surgical repair of tetralogy of Fallot. J Am Coll Cardiol 2007;50:\n2162–2168.\n899. van Zyl M, Kapa S, Padmanabhan D, Chen FC, Mulpuru SK, Packer DL, et al.\nMechanism and outcomes of catheter ablation for ventricular tachycardia in adults\nwith repaired congenital heart disease. Heart Rhythm 2016;13:1449–1454.\n900. Laredo M, Frank R, Waintraub X, Gandjbakhch E, Iserin L, Hascoët S, et al. Ten-year\noutcomes of monomorphic ventricular tachycardia catheter ablation in repaired\ntetralogy of Fallot. Arch Cardiovasc Dis 2017;110:292–302.\n901. Kapel GFL, Reichlin T, Wijnmaalen AP, Piers SRD, Holman ER, Tedrow UB, et al.\nRe-entry using anatomically determined isthmuses: a curable ventricular tachycar-\ndia in repaired congenital heart disease. Circ Arrhythm Electrophysiol 2015;8:\n102–109.\n902. Bokma JP, de Wilde KC, Vliegen HW, van Dijk AP, van Melle JP, Meijboom FJ, et al.\nValue of cardiovascular magnetic resonance imaging in noninvasive risk stratiﬁca-\ntion in tetralogy of Fallot. JAMA Cardiol 2017;2:678–683.\n903. Koyak Z, de Groot JR, Bouma BJ, Van Gelder IC, Budts W, Zwinderman AH, et al.\nSymptomatic but not asymptomatic non-sustained ventricular tachycardia is asso-\nciated with appropriate implantable cardioverter therapy in tetralogy of Fallot. Int J\nCardiol 2013;167:1532–1535.\n904. Khairy P, Harris L, Landzberg MJ, Viswanathan S, Barlow A, Gatzoulis MA, et al.\nImplantable cardioverter-deﬁbrillators in tetralogy of Fallot. Circulation 2008;117:\n363–370.\n905. Koyak Z, de Groot JR, Van Gelder IC, Bouma BJ, van Dessel PFHM, Budts W, et al.\nImplantable cardioverter deﬁbrillator therapy in adults with congenital heart dis-\nease: who is at risk of shocks? Circ Arrhythm Electrophysiol 2012;5:101–110.\n906. Cochet H, Iriart X, Allain-Nicolaï A, Camaioni C, Sridi S, Nivet H, et al. Focal scar\nand diffuse myocardial ﬁbrosis are independent imaging markers in repaired tetral-\nogy of Fallot. Eur Heart J Cardiovasc Imaging 2019;20:990–1003.\n907. Babu-Narayan SV, Kilner PJ, Li W, Moon JC, Goktekin O, Davlouros PA, et al.\nVentricular ﬁbrosis suggested by cardiovascular magnetic resonance in adults\nwith repaired tetralogy of fallot and its relationship to adverse markers of clinical\noutcome. Circulation 2006;113:405–413.\n908. Gatzoulis MA, Balaji S, Webber SA, Siu SC, Hokanson JS, Poile C, et al. Risk factors\nfor arrhythmia and sudden cardiac death late after repair of tetralogy of Fallot: a\nmulticentre study. Lancet 2000;356:975–981.\n909. Bokma JP, Winter MM, Vehmeijer JT, Vliegen HW, van Dijk AP, van Melle JP, et al.\nQRS fragmentation is superior to QRS duration in predicting mortality in adults\nwith tetralogy of Fallot. Heart 2017;103:666–671.\n910. Egbe AC, Kothapalli S, Borlaug BA, Ammash NM, Najam M, Bajwa N, et al.\nMechanism and risk factors for death in adults with tetralogy of Fallot. Am J\nCardiol 2019;124:803–807.\n911. Survivors of out-of-hospital cardiac arrest with apparently normal heart. Need for\ndeﬁnition and standardized clinical evaluation. Consensus statement of the joint\nsteering committees of the unexplained cardiac arrest registry of Europe and of\nthe idiopathic ventricular ﬁbrillation registry of the United States. Circulation\n1997;95:265–272.\n912. Leenhardt A, Glaser E, Burguera M, Nürnberg M, Maison-Blanche P, Coumel P.\nShort-coupled variant of torsade de pointes. A new electrocardiographic entity\nin the spectrum of idiopathic ventricular tachyarrhythmias. Circulation 1994;89:\n206–215.\n913. Eisenberg SJ, Scheinman MM, Dullet NK, Finkbeiner WE, Grifﬁn JC, Eldar M, et al.\nSudden cardiac death and polymorphous ventricular tachycardia in patients with\nnormal QT intervals and normal systolic cardiac function. Am J Cardiol 1995;75:\n687–692.\n914. Asatryan B, Schaller A, Seiler J, Servatius H, Noti F, Baldinger SH, et al. Usefulness of\ngenetic testing in sudden cardiac arrest survivors with or without previous clinical\nevidence of heart disease. Am J Cardiol 2019;123:2031–2038.\n915. Visser M, Dooijes D, van der Smagt JJ, van der Heijden JF, Doevendans PA, Loh P,\net al. Next-generation sequencing of a large gene panel in patients initially diagnosed\nwith idiopathic ventricular ﬁbrillation. Heart Rhythm 2017;14:1035–1040.\n916. Honarbakhsh S, Srinivasan N, Kirkby C, Firman E, Tobin L, Finlay M, et al.\nMedium-term outcomes of idiopathic ventricular ﬁbrillation survivors and family\nscreening: a multicentre experience. Europace 2017;19:1874–1880.\n917. Meissner MD, Lehmann MH, Steinman RT, Mosteller RD, Akhtar M, Calkins H, et al.\nVentricular ﬁbrillation in patients without signiﬁcant structural heart disease: a mul-\nticenter experience with implantable cardioverter-deﬁbrillator therapy. J Am Coll\nCardiol 1993;21:1406–1412.\n918. Conte G, Caputo ML, Regoli F, Marcon S, Klersy C, Adjibodou B, et al. True idio-\npathic ventricular ﬁbrillation in out-of-hospital cardiac arrest survivors in the Swiss\nCanton Ticino: prevalence, clinical features, and long-term follow-up. Europace\n2017;19:259–266.\n919. Stampe NK, Jespersen CB, Glinge C, Bundgaard H, Tfelt-Hansen J, Winkel BG.\nClinical characteristics and risk factors of arrhythmia during follow-up of patients\nwith idiopathic ventricular ﬁbrillation. J Cardiovasc Electrophysiol 2020;31:\n2677–2686.\n920. Conte G, Belhassen B, Lambiase P, Ciconte G, de Asmundis C, Arbelo E, et al.\nOut-of-hospital cardiac arrest due to idiopathic ventricular ﬁbrillation in patients\nwith normal electrocardiograms: results from a multicentre long-term registry.\nEuropace 2019;21:1670–1677.\n921. Blom LJ, Visser M, Christiaans I, Scholten MF, Bootsma M, van den Berg MP, et al.\nIncidence and predictors of implantable cardioverter-deﬁbrillator therapy and its\ncomplications in idiopathic ventricular ﬁbrillation patients. Europace 2019;21:\n1519–1526.\n922. Malhi N, Cheung CC, Deif B, Roberts JD, Gula LJ, Green MS, et al. Challenge and\nimpact of quinidine access in sudden death syndromes: a national experience.\nJACC Clin Electrophysiol 2019;5:376–382.\n923. Belhassen B, Glick A, Viskin S. Excellent long-term reproducibility of the electro-\nphysiologic efﬁcacy of quinidine in patients with idiopathic ventricular ﬁbrillation\nand Brugada syndrome. Pacing Clin Electrophysiol 2009;32:294–301.\n924. Belhassen B, Shapira I, Shoshani D, Paredes A, Miller H, Laniado S. Idiopathic ven-\ntricular ﬁbrillation: inducibility and beneﬁcial effects of class I antiarrhythmic agents.\nCirculation 1987;75:809–816.\n925. Viskin S, Belhassen B. Idiopathic ventricular ﬁbrillation. Am Heart J 1990;120:\n661–671.\nESC Guidelines\n4121\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026\n\n\n926. Belhassen B, Viskin S, Fish R, Glick A, Setbon I, Eldar M. Effects of\nelectrophysiologic-guided therapy with Class IA antiarrhythmic drugs on the long-\nterm outcome of patients with idiopathic ventricular ﬁbrillation with or without the\nBrugada syndrome. J Cardiovasc Electrophysiol 1999;10:1301–1312.\n927. Sadek MM, Benhayon D, Sureddi R, Chik W, Santangeli P, Supple GE, et al.\nIdiopathic ventricular arrhythmias originating from the moderator band: electro-\ncardiographic characteristics and treatment by catheter ablation. Heart Rhythm\n2015;12:67–75.\n928. Van Herendael H, Zado ES, Haqqani H, Tschabrunn CM, Callans DJ, Frankel DS,\net al. Catheter ablation of ventricular ﬁbrillation: importance of left ventricular out-\nﬂow tract and papillary muscle triggers. Heart Rhythm 2014;11:566–573.\n929. Santoro F, Di Biase L, Hranitzky P, Sanchez JE, Santangeli P, Perini AP, et al.\nVentricular ﬁbrillation triggered by PVCs from papillary muscles: clinical features\nand ablation. J Cardiovasc Electrophysiol 2014;25:1158–1164.\n930. Nakamura T, Schaeffer B, Tanigawa S, Muthalaly RG, John RM, Michaud GF, et al.\nCatheter ablation of polymorphic ventricular tachycardia/ﬁbrillation in patients\nwith and without structural heart disease. Heart Rhythm 2019;16:1021–1027.\n931. Moss AJ, Schwartz PJ, Crampton RS, Tzivoni D, Locati EH, MacCluer J, et al. The\nlong QT syndrome. Prospective longitudinal study of 328 families. Circulation\n1991;84:1136–1144.\n932. Schwartz PJ, Ackerman MJ, Antzelevitch C, Bezzina CR, Borggrefe M, Cuneo BF,\net al. Inherited cardiac arrhythmias. Nat Rev Dis Primers 2020;6:58.\n933. Andersen ED, Krasilnikoff PA, Overvad H. Intermittent muscular weakness, extra-\nsystoles, and multiple developmental anomalies. A new syndrome? Acta Paediatr\nScand 1971;60:559–564.\n934. Tawil R, Ptacek LJ, Pavlakis SG, DeVivo DC, Penn AS, Ozdemir C, et al. Andersen’s\nsyndrome: potassium-sensitive periodic paralysis, ventricular ectopy, and dys-\nmorphic features. Ann Neurol 1994;35:326–330.\n935. Splawski I, Timothy KW, Decher N, Kumar P, Sachse FB, Beggs AH, et al. Severe\narrhythmia disorder caused by cardiac L-type calcium channel mutations. Proc\nNatl Acad Sci U S A 2005;102:8089–8096; discussion 8086–8088.\n936. Jervell A, Lange-Nielsen F. Congenital deaf-mutism, functional heart disease with\nprolongation of the Q-T interval and sudden death. Am Heart J 1957;54:59–68.\n937. Schwartz PJ, Moss AJ, Vincent GM, Crampton RS. Diagnostic criteria for the long\nQT syndrome. An update. Circulation 1993;88:782–784.\n938. Rautaharju PM, Zhang Z-M, Prineas R, Heiss G. Assessment of prolonged QT and\nJT intervals in ventricular conduction defects. Am J Cardiol 2004;93:1017–1021.\n939. Viskin S, Postema PG, Bhuiyan ZA, Rosso R, Kalman JM, Vohra JK, et al. The re-\nsponse of the QT interval to the brief tachycardia provoked by standing: a bedside\ntest for diagnosing long QT syndrome. J Am Coll Cardiol 2010;55:1955–1961.\n940. Mazzanti A, Maragna R, Vacanti G, Monteforte N, Bloise R, Marino M, et al.\nInterplay between genetic substrate, QTc duration, and arrhythmia risk in patients\nwith long QT syndrome. J Am Coll Cardiol 2018;71:1663–1671.\n941. Behr ER, Roden D. Drug-induced arrhythmia: pharmacogenomic prescribing? Eur\nHeart J 2013;34:89–95.\n942. Weeke PE, Kellemann JS, Jespersen CB, Theilade J, Kanters JK, Hansen MS, et al.\nLong-term proarrhythmic pharmacotherapy among patients with congenital long\nQT syndrome and risk of arrhythmia and mortality. Eur Heart J 2019;40:\n3110–3117.\n943. Schwartz PJ, Priori SG, Spazzolini C, Moss AJ, Vincent GM, Napolitano C, et al.\nGenotype-phenotype correlation in the long-QT syndrome: gene-speciﬁc triggers\nfor life-threatening arrhythmias. Circulation 2001;103:89–95.\n944. Chockalingam P, Crotti L, Girardengo G, Johnson JN, Harris KM, van der Heijden JF,\net al. Not all beta-blockers are equal in the management of long QT syndrome\ntypes 1 and 2: higher recurrence of events under metoprolol. J Am Coll Cardiol\n2012;60:2092–2099.\n945. Ahn J, Kim HJ, Choi J-I, Lee KN, Shim J, Ahn HS, et al. Effectiveness of beta-blockers\ndepending on the genotype of congenital long-QT syndrome: a meta-analysis. PLoS\nOne 2017;12:e0185680.\n946. Priori SG, Napolitano C, Schwartz PJ, Grillo M, Bloise R, Ronchetti E, et al.\nAssociation of long QT syndrome loci and cardiac events among patients treated\nwith beta-blockers. JAMA 2004;292:1341–1344.\n947. Mazzanti A, Trancuccio A, Kukavica D, Pagan E, Wang M, Mohsin M, et al.\nIndependent validation and clinical implications of the risk prediction model for\nlong QT syndrome (1-2-3-LQTS-Risk). Europace 2021;24:697–698.\n948. Mazzanti A, Maragna R, Faragli A, Monteforte N, Bloise R, Memmi M, et al.\nGene-speciﬁc therapy with mexiletine reduces arrhythmic events in patients\nwith long QT syndrome type 3. J Am Coll Cardiol 2016;67:1053–1058.\n949. Ruan Y, Liu N, Bloise R, Napolitano C, Priori SG. Gating properties of SCN5A mu-\ntations and the response to mexiletine in long-QT syndrome type 3 patients.\nCirculation 2007;116:1137–1144.\n950. Zhu W, Mazzanti A, Voelker TL, Hou P, Moreno JD, Angsutararux P, et al.\nPredicting patient response to the antiarrhythmic mexiletine based on genetic vari-\nation. Circ Res 2019;124:539–552.\n951. Priori SG, Napolitano C, Schwartz PJ, Bloise R, Crotti L, Ronchetti E. The elusive\nlink between LQT3 and Brugada syndrome: the role of ﬂecainide challenge.\nCirculation 2000;102:945–947.\n952. Moss AJ, Zareba W, Hall WJ, Schwartz PJ, Crampton RS, Benhorin J, et al.\nEffectiveness and limitations of beta-blocker therapy in congenital long-QT syn-\ndrome. Circulation 2000;101:616–623.\n953. Jons C, Moss AJ, Goldenberg I, Liu J, McNitt S, Zareba W, et al. Risk of fatal arrhyth-\nmic events in long QT syndrome patients after syncope. J Am Coll Cardiol 2010;55:\n783–788.\n954. Liu JF, Jons C, Moss AJ, McNitt S, Peterson DR, Qi M, et al. Risk factors for recurrent\nsyncope and subsequent fatal or near-fatal events in children and adolescents with\nlong QT syndrome. J Am Coll Cardiol 2011;57:941–950.\n955. Seth R, Moss AJ, McNitt S, Zareba W, Andrews ML, Qi M, et al. Long QT syndrome\nand pregnancy. J Am Coll Cardiol 2007;49:1092–1098.\n956. Goldenberg I, Horr S, Moss AJ, Lopes CM, Barsheshet A, McNitt S, et al. Risk for\nlife-threatening cardiac events in patients with genotype-conﬁrmed long-QT syn-\ndrome and normal-range corrected QT intervals. J Am Coll Cardiol 2011;57:51–59.\n957. Jang SY, Cho Y, Kim NK, Kim C-Y, Sohn J, Roh J-H, et al. Video-assisted thoraco-\nscopic left cardiac sympathetic denervation in patients with hereditary ventricular\narrhythmias. Pacing Clin Electrophysiol 2017;40:232–241.\n958. Waddell-Smith KE, Ertresvaag KN, Li J, Chaudhuri K, Crawford JR, Hamill JK, et al.\nPhysical and psychological consequences of left cardiac sympathetic denervation in\nlong-QT syndrome and catecholaminergic polymorphic ventricular tachycardia.\nCirc Arrhythm Electrophysiol 2015;8:1151–1158.\n959. Anderson HN, Bos JM, Rohatgi RK, Ackerman MJ. The effect of left cardiac sympa-\nthetic denervation on exercise in patients with long QT syndrome. JACC Clin\nElectrophysiol 2019;5:1084–1090.\n960. Bos JM, Bos KM, Johnson JN, Moir C, Ackerman MJ. Left cardiac sympathetic de-\nnervation in long QT syndrome: analysis of therapeutic nonresponders. Circ\nArrhythm Electrophysiol 2013;6:705–711.\n961. Bhandari AK, Shapiro WA, Morady F, Shen EN, Mason J, Scheinman MM.\nElectrophysiologic testing in patients with the long QT syndrome. Circulation\n1985;71:63–71.\n962. Zareba W, Moss AJ, Daubert JP, Hall WJ, Robinson JL, Andrews M. Implantable car-\ndioverter deﬁbrillator in high-risk long QT syndrome patients. J Cardiovasc\nElectrophysiol 2003;14:337–341.\n963. Schwartz PJ, Spazzolini C, Priori SG, Crotti L, Vicentini A, Landolina M, et al. Who\nare the long-QT syndrome patients who receive an implantable cardioverter-\ndeﬁbrillator and what happens to them?: Data from the European long-QT syn-\ndrome implantable cardioverter-deﬁbrillator (LQTS ICD) registry. Circulation\n2010;122:1272–1282.\n964. Delannoy E, Sacher F, Maury P, Mabo P, Mansourati J, Magnin I, et al. Cardiac char-\nacteristics and long-term outcome in Andersen-Tawil syndrome patients related to\nKCNJ2 mutation. Europace 2013;15:1805–1811.\n965. Inoue YY, Aiba T, Kawata H, Sakaguchi T, Mitsuma W, Morita H, et al. Different\nresponses to exercise between Andersen-Tawil syndrome and catecholaminergic\npolymorphic ventricular tachycardia. Europace 2018;20:1675–1682.\n966. Krych M, Biernacka EK, Ponińska J, Kukla P, Filipecki A, Gajda R, et al.\nAndersen-Tawil syndrome: clinical presentation and predictors of symptomatic ar-\nrhythmias—possible role of polymorphisms K897T in KCNH2 and H558R in\nSCN5A gene. J Cardiol 2017;70:504–510.\n967. Mazzanti A, Guz D, Trancuccio A, Pagan E, Kukavica D, Chargeishvili T, et al.\nNatural history and risk stratiﬁcation in Andersen-Tawil syndrome type 1. J Am\nColl Cardiol 2020;75:1772–1784.\n968. Zhang L, Benson DW, Tristani-Firouzi M, Ptacek LJ, Tawil R, Schwartz PJ, et al.\nElectrocardiographic features in Andersen-Tawil syndrome patients with KCNJ2\nmutations: characteristic T-U-wave patterns predict the KCNJ2 genotype.\nCirculation 2005;111:2720–2726.\n969. Horigome H, Ishikawa Y, Kokubun N, Yoshinaga M, Sumitomo N, Lin L, et al.\nMultivariate\nanalysis\nof\nTU\nwave\ncomplex\non\nelectrocardiogram\nin\nAndersen-Tawil syndrome with KCNJ2 mutations. Ann Noninvasive Electrocardiol\n2020;25:e12721.\n970. Miyamoto K, Aiba T, Kimura H, Hayashi H, Ohno S, Yasuoka C, et al. Efﬁcacy and\nsafety of ﬂecainide for ventricular arrhythmias in patients with Andersen-Tawil syn-\ndrome with KCNJ2 mutations. Heart Rhythm 2015;12:596–603.\n971. Radwański PB, Greer-Short A, Poelzing S. Inhibition of Na+ channels ameliorates\narrhythmias in a drug-induced model of Andersen-Tawil syndrome. Heart Rhythm\n2013;10:255–263.\n972. Tristani-Firouzi M, Jensen JL, Donaldson MR, Sansone V, Meola G, Hahn A, et al.\nFunctional and clinical characterization of KCNJ2 mutations associated with\nLQT7 (Andersen syndrome). J Clin Invest 2002;110:381–388.\n973. Antzelevitch C, Brugada P, Borggrefe M, Brugada J, Brugada R, Corrado D, et al.\nBrugada syndrome: report of the second consensus conference: endorsed by the\nHeart Rhythm Society and the European Heart Rhythm Association. Circulation\n2005;111:659–670.\n4122\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026\n\n\n974. Savastano S, Rordorf R, Vicentini A, Petracci B, Taravelli E, Castelletti S, et al. A\ncomprehensive electrocardiographic, molecular, and echocardiographic study of\nBrugada syndrome: validation of the 2013 diagnostic criteria. Heart Rhythm 2014;\n11:1176–1183.\n975. Richter S, Sarkozy A, Paparella G, Henkens S, Boussy T, Chierchia G-B, et al.\nNumber of electrocardiogram leads displaying the diagnostic coved-type pattern\nin Brugada syndrome: a diagnostic consensus criterion to be revised. Eur Heart J\n2010;31:1357–1364.\n976. Veltmann C, Papavassiliu T, Konrad T, Doesch C, Kuschyk J, Streitner F, et al.\nInsights into the location of type I ECG in patients with Brugada syndrome: correl-\nation of ECG and cardiovascular magnetic resonance imaging. Heart Rhythm 2012;\n9:414–421.\n977. Adler A, Rosso R, Chorin E, Havakuk O, Antzelevitch C, Viskin S. Risk stratiﬁcation\nin Brugada syndrome: clinical characteristics, electrocardiographic parameters, and\nauxiliary testing. Heart Rhythm 2016;13:299–310.\n978. Hasdemir C, Payzin S, Kocabas U, Sahin H, Yildirim N, Alp A, et al. High prevalence\nof concealed Brugada syndrome in patients with atrioventricular nodal reentrant\ntachycardia. Heart Rhythm 2015;12:1584–1594.\n979. Behr ER, Ben-Haim Y, Ackerman MJ, Krahn AD, Wilde AAM. Brugada syndrome\nand reduced right ventricular outﬂow tract conduction reserve: a ﬁnal common\npathway? Eur Heart J 2021;42:1073–1081.\n980. Probst V, Veltmann C, Eckardt L, Meregalli PG, Gaita F, Tan HL, et al. Long-term\nprognosis of patients diagnosed with Brugada syndrome: results from the\nFINGER Brugada syndrome registry. Circulation 2010;121:635–643.\n981. Amin AS, Meregalli PG, Bardai A, Wilde AAM, Tan HL. Fever increases the risk for\ncardiac arrest in the Brugada syndrome. Ann Intern Med 2008;149:216–218.\n982. Adler A, Topaz G, Heller K, Zeltser D, Ohayon T, Rozovski U, et al. Fever-induced\nBrugada pattern: how common is it and what does it mean? Heart Rhythm 2013;10:\n1375–1382.\n983. Priori SG, Napolitano C, Gasparini M, Pappone C, Della Bella P, Giordano U, et al.\nNatural history of Brugada syndrome: insights for risk stratiﬁcation and manage-\nment. Circulation 2002;105:1342–1347.\n984. Rizzo A, Borio G, Sieira J, Van Dooren S, Overeinder I, Bala G, et al. Ajmaline testing\nand the Brugada syndrome. Am J Cardiol 2020;135:91–98.\n985. Poli S, Toniolo M, Maiani M, Zanuttini D, Rebellato L, Vendramin I, et al.\nManagement of untreatable ventricular arrhythmias during pharmacologic chal-\nlenges with sodium channel blockers for suspected Brugada syndrome. Europace\n2018;20:234–242.\n986. Hasdemir C, Juang JJ-M, Kose S, Kocabas U, Orman MN, Payzin S, et al. Coexistence\nof atrioventricular accessory pathways and drug-induced type 1 Brugada pattern.\nPacing Clin Electrophysiol 2018;41:1078–1092.\n987. Probst V, Wilde AAM, Barc J, Sacher F, Babuty D, Mabo P, et al. SCN5A mutations\nand the role of genetic background in the pathophysiology of Brugada syndrome.\nCirc Cardiovasc Genet 2009;2:552–557.\n988. Meregalli PG, Tan HL, Probst V, Koopmann TT, Tanck MW, Bhuiyan ZA, et al. Type\nof SCN5A mutation determines clinical severity and degree of conduction slowing\nin loss-of-function sodium channelopathies. Heart Rhythm 2009;6:341–348.\n989. Ishikawa T, Kimoto H, Mishima H, Yamagata K, Ogata S, Aizawa Y, et al. Functionally\nvalidated SCN5A variants allow interpretation of pathogenicity and prediction of\nlethal events in Brugada syndrome. Eur Heart J 2021;42:2854–2863.\n990. Gehi AK, Duong TD, Metz LD, Gomes JA, Mehta D. Risk stratiﬁcation of individuals\nwith the Brugada electrocardiogram: a meta-analysis. J Cardiovasc Electrophysiol\n2006;17:577–583.\n991. McNamara DA, Goldberger JJ, Berendsen MA, Huffman MD. Implantable deﬁbril-\nlators versus medical therapy for cardiac channelopathies. Cochrane Database Syst\nRev 2015;2015:CD011168.\n992. Priori SG, Gasparini M, Napolitano C, Della Bella P, Ottonelli AG, Sassone B, et al.\nRisk stratiﬁcation in Brugada syndrome: results of the PRELUDE (PRogrammed\nELectrical stimUlation preDictive valuE) registry. J Am Coll Cardiol 2012;59:37–45.\n993. Dereci A, Yap S-C, Schinkel AFL. Meta-analysis of clinical outcome after implantable\ncardioverter-deﬁbrillator implantation in patients with Brugada syndrome. JACC\nClin Electrophysiol 2019;5:141–148.\n994. Conte G, Sieira J, Ciconte G, de Asmundis C, Chierchia G-B, Baltogiannis G, et al.\nImplantable cardioverter-deﬁbrillator therapy in Brugada syndrome: a 20-year\nsingle-center experience. J Am Coll Cardiol 2015;65:879–888.\n995. Mascia G, Della Bona R, Ameri P, Canepa M, Porto I, Brignole M. Brugada syndrome\nand syncope: a systematic review. J Cardiovasc Electrophysiol 2020;31:3334–3338.\n996. Subramanian M, Prabhu MA, Harikrishnan MS, Shekhar SS, Pai PG, Natarajan K. The\nutility of exercise testing in risk stratiﬁcation of asymptomatic patients with type 1\nBrugada pattern. J Cardiovasc Electrophysiol 2017;28:677–683.\n997. Kubala M, Aïssou L, Traullé S, Gugenheim A-L, Hermida J-S. Use of implantable loop\nrecorders in patients with Brugada syndrome and suspected risk of ventricular ar-\nrhythmia. Europace 2012;14:898–902.\n998. Sakhi R, Assaf A, Theuns DAMJ, Verhagen JMA, Szili-Torok T, Roos-Hesselink JW,\net al. Outcome of insertable cardiac monitors in symptomatic patients with\nBrugada syndrome at low risk of sudden cardiac death. Cardiology 2020;145:\n413–420.\n999. Scrocco C, Ben-Haim Y, Devine B, Tome-Esteban M, Papadakis M, Sharma S, et al.\nRole of subcutaneous implantable loop recorder for the diagnosis of arrhythmias in\nBrugada syndrome: a United Kingdom single-center experience. Heart Rhythm\n2022;19:70–78.\n1000. Sieira J, Brugada P. Brugada syndrome: deﬁning the risk in asymptomatic patients.\nArrhythm Electrophysiol Rev 2016;5:164–169.\n1001. Nishizaki M, Sakurada H, Yamawake N, Ueda-Tatsumoto A, Hiraoka M. Low risk\nfor arrhythmic events in asymptomatic patients with drug-induced type 1 ECG.\nDo patients with drug-induced Brugada type ECG have poor prognosis? (Con).\nCirc J 2010;74:2464–2473.\n1002. Conte G, de Asmundis C, Sieira J, Ciconte G, Di Giovanni G, Chierchia G-B, et al.\nPrevalence\nand\nclinical\nimpact\nof\nearly\nrepolarization\npattern\nand\nQRS-fragmentation in high-risk patients with Brugada syndrome. Circ J 2016;80:\n2109–2116.\n1003. Kataoka N, Mizumaki K, Nakatani Y, Sakamoto T, Yamaguchi Y, Tsujino Y, et al.\nPaced QRS fragmentation is associated with spontaneous ventricular ﬁbrillation\nin patients with Brugada syndrome. Heart Rhythm 2016;13:1497–1503.\n1004. Probst V, Goronﬂot T, Anys S, Tixier R, Briand J, Berthome P, et al. Robustness\nand relevance of predictive score in sudden cardiac death for patients with\nBrugada syndrome. Eur Heart J 2021;42:1687–1695.\n1005. Honarbakhsh S, Providencia R, Garcia-Hernandez J, Martin CA, Hunter RJ, Lim\nWY, et al. A primary prevention clinical risk score model for patients with\nBrugada syndrome (BRUGADA-RISK). JACC Clin Electrophysiol 2021;7:210–222.\n1006. Andorin A, Gourraud J-B, Mansourati J, Fouchard S, le Marec H, Maury P, et al. The\nQUIDAM study: hydroquinidine therapy for the management of Brugada syn-\ndrome patients at high arrhythmic risk. Heart Rhythm 2017;14:1147–1154.\n1007. Belhassen B, Rahkovich M, Michowitz Y, Glick A, Viskin S. Management of Brugada\nsyndrome: thirty-three-year experience using electrophysiologically guided ther-\napy with class 1A antiarrhythmic drugs. Circ Arrhythm Electrophysiol 2015;8:\n1393–1402.\n1008. Ohgo T, Okamura H, Noda T, Satomi K, Suyama K, Kurita T, et al. Acute and\nchronic management in patients with Brugada syndrome associated with electrical\nstorm of ventricular ﬁbrillation. Heart Rhythm 2007;4:695–700.\n1009. Nademanee K, Raju H, de Noronha SV, Papadakis M, Robinson L, Rothery S, et al.\nFibrosis, connexin-43, and conduction abnormalities in the Brugada syndrome.\nJ Am Coll Cardiol 2015;66:1976–1986.\n1010. Nademanee K, Haissaguerre M, Hocini M, Nogami A, Cheniti G, Duchateau J, et al.\nMapping and ablation of ventricular ﬁbrillation associated with early repolarization\nsyndrome. Circulation 2019;140:1477–1490.\n1011. Nademanee K, Veerakul G, Chandanamattha P, Chaothawee L, Ariyachaipanich\nA, Jirasirirojanakorn K, et al. Prevention of ventricular ﬁbrillation episodes in\nBrugada syndrome by catheter ablation over the anterior right ventricular outﬂow\ntract epicardium. Circulation 2011;123:1270–1279.\n1012. Zhang P, Tung R, Zhang Z, Sheng X, Liu Q, Jiang R, et al. Characterization of the\nepicardial substrate for catheter ablation of Brugada syndrome. Heart Rhythm\n2016;13:2151–2158.\n1013. Haïssaguerre M, Extramiana F, Hocini M, Cauchemez B, Jaïs P, Cabrera JA, et al.\nMapping and ablation of ventricular ﬁbrillation associated with long-QT and\nBrugada syndromes. Circulation 2003;108:925–928.\n1014. Brugada J, Pappone C, Berruezo A, Vicedomini G, Manguso F, Ciconte G, et al.\nBrugada syndrome phenotype elimination by epicardial substrate ablation. Circ\nArrhythm Electrophysiol 2015;8:1373–1381.\n1015. Pappone C, Brugada J, Vicedomini G, Ciconte G, Manguso F, Saviano M, et al.\nElectrical substrate elimination in 135 consecutive patients with Brugada syn-\ndrome. Circ Arrhythm Electrophysiol 2017;10:e005053.\n1016. Yamagata K, Horie M, Aiba T, Ogawa S, Aizawa Y, Ohe T, et al.\nGenotype-phenotype correlation of SCN5A mutation for the clinical and electro-\ncardiographic characteristics of probands with Brugada syndrome: a Japanese\nmulticenter registry. Circulation 2017;135:2255–2270.\n1017. Haïssaguerre M, Derval N, Sacher F, Jesel L, Deisenhofer I, de Roy L, et al. Sudden\ncardiac arrest associated with early repolarization. N Engl J Med 2008;358:\n2016–2023.\n1018. Rosso R, Kogan E, Belhassen B, Rozovski U, Scheinman MM, Zeltser D, et al.\nJ-point elevation in survivors of primary ventricular ﬁbrillation and matched con-\ntrol subjects: incidence and clinical signiﬁcance. J Am Coll Cardiol 2008;52:\n1231–1238.\n1019. Macfarlane PW, Antzelevitch C, Haissaguerre M, Huikuri HV, Potse M, Rosso R,\net al. The early repolarization pattern: a consensus paper. J Am Coll Cardiol 2015;\n66:470–477.\n1020. Tikkanen JT, Anttonen O, Junttila MJ, Aro AL, Kerola T, Rissanen HA, et al.\nLong-term outcome associated with early repolarization on electrocardiography.\nN Engl J Med 2009;361:2529–2537.\nESC Guidelines\n4123\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026\n\n\n1021. Sinner MF, Reinhard W, Müller M, Beckmann B-M, Martens E, Perz S, et al.\nAssociation of early repolarization pattern on ECG with risk of cardiac and all-\ncause mortality: a population-based prospective cohort study (MONICA/\nKORA). PLoS Med 2010;7:e1000314.\n1022. Nunn LM, Bhar-Amato J, Lowe MD, Macfarlane PW, Rogers P, McKenna WJ, et al.\nPrevalence of J-point elevation in sudden arrhythmic death syndrome families.\nJ Am Coll Cardiol 2011;58:286–290.\n1023. Watanabe H, Nogami A, Ohkubo K, Kawata H, Hayashi Y, Ishikawa T, et al.\nElectrocardiographic characteristics and SCN5A mutations in idiopathic ventricu-\nlar ﬁbrillation associated with early repolarization. Circ Arrhythm Electrophysiol\n2011;4:874–881.\n1024. Chauveau S, Janin A, Till M, Morel E, Chevalier P, Millat G. Early repolarization syn-\ndrome caused by de novo duplication of KCND3 detected by next-generation se-\nquencing. HeartRhythm Case Rep 2017;3:574–578.\n1025. Takayama K, Ohno S, Ding W-G, Ashihara T, Fukumoto D, Wada Y, et al. A de\nnovo gain-of-function KCND3 mutation in early repolarization syndrome.\nHeart Rhythm 2019;16:1698–1706.\n1026. Rosso R, Glikson E, Belhassen B, Katz A, Halkin A, Steinvil A, et al. Distinguishing\n‘benign’ from ‘malignant early repolarization’: the value of the ST-segment morph-\nology. Heart Rhythm 2012;9:225–229.\n1027. Tikkanen JT, Junttila MJ, Anttonen O, Aro AL, Luttinen S, Kerola T, et al. Early re-\npolarization: electrocardiographic phenotypes associated with favorable long-\nterm outcome. Circulation 2011;123:2666–2673.\n1028. Nademanee K, Veerakul G, Mower M, Likittanasombat K, Krittayapong R,\nBhuripanyo K, et al. Deﬁbrillator versus beta-blockers for unexplained Death in\nThailand (DEBUT): a randomized clinical trial. Circulation 2003;107:2221–2226.\n1029. Brugada J, Brugada R, Brugada P. Pharmacological and device approach to therapy\nof inherited cardiac diseases associated with cardiac arrhythmias and sudden\ndeath. J Electrocardiol 2000;33:41–47.\n1030. Haïssaguerre M, Sacher F, Nogami A, Komiya N, Bernard A, Probst V, et al.\nCharacteristics of recurrent ventricular ﬁbrillation associated with inferolateral\nearly repolarization role of drug therapy. J Am Coll Cardiol 2009;53:612–619.\n1031. Aizawa Y, Chinushi M, Hasegawa K, Naiki N, Horie M, Kaneko Y, et al. Electrical\nstorm in idiopathic ventricular ﬁbrillation is associated with early repolarization.\nJ Am Coll Cardiol 2013;62:1015–1019.\n1032. Patocskai B, Barajas-Martinez H, Hu D, Gurabi Z, Koncz I, Antzelevitch C. Cellular\nand ionic mechanisms underlying the effects of cilostazol, milrinone, and iso-\nproterenol to suppress arrhythmogenesis in an experimental model of early repo-\nlarization syndrome. Heart Rhythm 2016;13:1326–1334.\n1033. Nam G-B, Kim Y-H, Antzelevitch C. Augmentation of J waves and electrical\nstorms in patients with early repolarization. N Engl J Med 2008;358:2078–2079.\n1034. Rodríguez-Capitán J, Fernández-Meseguer A, García-Pinilla JM, Calvo-Bonacho E,\nJiménez-Navarro M, García-Margallo T, et al. Frequency of different electrocar-\ndiographic abnormalities in a large cohort of Spanish workers. Europace 2017;\n19:1855–1863.\n1035. Sun G-Z, Ye N, Chen Y-T, Zhou Y, Li Z, Sun Y-X. Early repolarization pattern in\nthe general population: prevalence and associated factors. Int J Cardiol 2017;230:\n614–618.\n1036. Wu S-H, Lin X-X, Cheng Y-J, Qiang C-C, Zhang J. Early repolarization pattern and\nrisk for arrhythmia death: a meta-analysis. J Am Coll Cardiol 2013;61:645–650.\n1037. Malhi N, So PP, Cheung CC, Laksman ZWM, Healey JS, Chauhan VS, et al. Early\nrepolarization pattern inheritance in the cardiac arrest survivors with preserved\nejection fraction registry (CASPER). JACC Clin Electrophysiol 2018;4:1473–1479.\n1038. Sinner\nMF,\nPorthan\nK,\nNoseworthy\nPA,\nHavulinna\nAS,\nTikkanen\nJT,\nMüller-Nurasyid M, et al. A meta-analysis of genome-wide association studies of\nthe electrocardiographic early repolarization pattern. Heart Rhythm 2012;9:\n1627–1634.\n1039. Adhikarla C, Boga M, Wood AD, Froelicher VF. Natural history of the electrocar-\ndiographic pattern of early repolarization in ambulatory patients. Am J Cardiol\n2011;108:1831–1835.\n1040. Mahida S, Derval N, Sacher F, Leenhardt A, Deisenhofer I, Babuty D, et al. Role of\nelectrophysiological studies in predicting risk of ventricular arrhythmia in early re-\npolarization syndrome. J Am Coll Cardiol 2015;65:151–159.\n1041. Aizawa Y, Sato A, Watanabe H, Chinushi M, Furushima H, Horie M, et al.\nDynamicity of the J-wave in idiopathic ventricular ﬁbrillation with a special refer-\nence to pause-dependent augmentation of the J-wave. J Am Coll Cardiol 2012;59:\n1948–1953.\n1042. Priori SG, Mazzanti A, Santiago DJ, Kukavica D, Trancuccio A, Kovacic JC.\nPrecision medicine in catecholaminergic polymorphic ventricular tachycardia:\nJACC focus seminar 5/5. J Am Coll Cardiol 2021;77:2592–2612.\n1043. Bezzina CR, Lahrouchi N, Priori SG. Genetics of sudden cardiac death. Circ Res\n2015;116:1919–1936.\n1044. Kimura H, Zhou J, Kawamura M, Itoh H, Mizusawa Y, Ding W-G, et al. Phenotype\nvariability in patients carrying KCNJ2 mutations. Circ Cardiovasc Genet 2012;5:\n344–353.\n1045. Priori SG, Napolitano C, Memmi M, Colombi B, Drago F, Gasparini M, et al.\nClinical and molecular characterization of patients with catecholaminergic poly-\nmorphic ventricular tachycardia. Circulation 2002;106:69–74.\n1046. Krahn AD, Gollob M, Yee R, Gula LJ, Skanes AC, Walker BD, et al. Diagnosis of\nunexplained cardiac arrest: role of adrenaline and procainamide infusion.\nCirculation 2005;112:2228–2234.\n1047. Hayashi M, Denjoy I, Extramiana F, Maltret A, Buisson NR, Lupoglazoff J-M, et al.\nIncidence and risk factors of arrhythmic events in catecholaminergic polymorphic\nventricular tachycardia. Circulation 2009;119:2426–2434.\n1048. Leren IS, Saberniak J, Majid E, Haland TF, Edvardsen T, Haugaa KH. Nadolol de-\ncreases the incidence and severity of ventricular arrhythmias during exercise\nstress testing compared with β1-selective β-blockers in patients with catechola-\nminergic polymorphic ventricular tachycardia. Heart Rhythm 2016;13:433–440.\n1049. Peltenburg PJ, Kallas D, Bos JM, Lieve KVV, Franciosi S, Roston TM, et al. An inter-\nnational multicenter cohort study on β-blockers for the treatment of symptom-\natic children with catecholaminergic polymorphic ventricular tachycardia.\nCirculation 2022;145:333–344.\n1050. van der Werf C, Nederend I, Hofman N, van Geloven N, Ebink C, Frohn-Mulder\nIME, et al. Familial evaluation in catecholaminergic polymorphic ventricular tachy-\ncardia: disease penetrance and expression in cardiac ryanodine receptor\nmutation-carrying relatives. Circ Arrhythm Electrophysiol 2012;5:748–756.\n1051. Watanabe H, Chopra N, Laver D, Hwang HS, Davies SS, Roach DE, et al.\nFlecainide prevents catecholaminergic polymorphic ventricular tachycardia in\nmice and humans. Nat Med 2009;15:380–383.\n1052. Wang G, Zhao N, Zhong S, Wang Y, Li J. Safety and efﬁcacy of ﬂecainide for pa-\ntients with catecholaminergic polymorphic ventricular tachycardia: a systematic\nreview and meta-analysis. Medicine (Baltimore) 2019;98:e16961.\n1053. van der Werf C, Kannankeril PJ, Sacher F, Krahn AD, Viskin S, Leenhardt A, et al.\nFlecainide therapy reduces exercise-induced ventricular arrhythmias in patients\nwith catecholaminergic polymorphic ventricular tachycardia. J Am Coll Cardiol\n2011;57:2244–2254.\n1054. Padﬁeld GJ, AlAhmari L, Lieve KVV, AlAhmari T, Roston TM, Wilde AA, et al.\nFlecainide monotherapy is an option for selected patients with catecholaminergic\npolymorphic ventricular tachycardia intolerant of β-blockade. Heart Rhythm 2016;\n13:609–613.\n1055. Roses-Noguer F, Jarman JWE, Clague JR, Till J. Outcomes of deﬁbrillator therapy\nin catecholaminergic polymorphic ventricular tachycardia. Heart Rhythm 2014;11:\n58–66.\n1056. De Ferrari GM, Dusi V, Spazzolini C, Bos JM, Abrams DJ, Berul CI, et al. Clinical\nmanagement of catecholaminergic polymorphic ventricular tachycardia: the role\nof left cardiac sympathetic denervation. Circulation 2015;131:2185–2193.\n1057. Roston TM, Jones K, Hawkins NM, Bos JM, Schwartz PJ, Perry F, et al. Implantable\ncardioverter-deﬁbrillator use in catecholaminergic polymorphic ventricular tachy-\ncardia: a systematic review. Heart Rhythm 2018;15:1791–1799.\n1058. van der Werf C, Lieve KV, Bos JM, Lane CM, Denjoy I, Roses-Noguer F, et al.\nImplantable cardioverter-deﬁbrillators in previously undiagnosed patients with ca-\ntecholaminergic polymorphic ventricular tachycardia resuscitated from sudden\ncardiac arrest. Eur Heart J 2019;40:2953–2961.\n1059. Leenhardt A, Lucet V, Denjoy I, Grau F, Ngoc DD, Coumel P. Catecholaminergic\npolymorphic ventricular tachycardia in children. A 7-year follow-up of 21 patients.\nCirculation 1995;91:1512–1519.\n1060. Kannankeril PJ, Moore JP, Cerrone M, Priori SG, Kertesz NJ, Ro PS, et al. Efﬁcacy of\nﬂecainide in the treatment of catecholaminergic polymorphic ventricular tachy-\ncardia: a randomized clinical trial. JAMA Cardiol 2017;2:759–766.\n1061. Gollob MH, Redpath CJ, Roberts JD. The short QT syndrome: proposed diagnos-\ntic criteria. J Am Coll Cardiol 2011;57:802–812.\n1062. Thorsen K, Dam VS, Kjaer-Sorensen K, Pedersen LN, Skeberdis VA, Jurevičius J,\net al. Loss-of-activity-mutation in the cardiac chloride-bicarbonate exchanger\nAE3 causes short QT syndrome. Nat Commun 2017;8:1696.\n1063. Mazzanti A, Kanthan A, Monteforte N, Memmi M, Bloise R, Novelli V, et al. Novel\ninsight into the natural history of short QT syndrome. J Am Coll Cardiol 2014;63:\n1300–1308.\n1064. Dhutia H, Malhotra A, Parpia S, Gabus V, Finocchiaro G, Mellor G, et al. The\nprevalence and signiﬁcance of a short QT interval in 18 825 low-risk individuals\nincluding athletes. Br J Sports Med 2016;50:124–129.\n1065. Gallagher MM, Magliano G, Yap YG, Padula M, Morgia V, Postorino C, et al.\nDistribution and prognostic signiﬁcance of QT intervals in the lowest half centile\nin 12,012 apparently healthy persons. Am J Cardiol 2006;98:933–935.\n1066. Anttonen O, Junttila MJ, Rissanen H, Reunanen A, Viitasalo M, Huikuri HV.\nPrevalence and prognostic signiﬁcance of short QT interval in a middle-aged\nFinnish population. Circulation 2007;116:714–720.\n1067. Kobza R, Roos M, Niggli B, Abächerli R, Lupi GA, Frey F, et al. Prevalence of long\nand short QT in a young population of 41,767 predominantly male Swiss con-\nscripts. Heart Rhythm 2009;6:652–657.\n1068. Giustetto C, Schimpf R, Mazzanti A, Scrocco C, Maury P, Anttonen O, et al.\nLong-term follow-up of patients with short QT syndrome. J Am Coll Cardiol\n2011;58:587–595.\n4124\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026\n\n\n1069. El-Battrawy I, Besler J, Liebe V, Schimpf R, Tülümen E, Rudic B, et al. Long-term\nfollow-up of patients with short QT syndrome: clinical proﬁle and outcome. J\nAm Heart Assoc 2018;7:e010073.\n1070. Mazzanti A, Maragna R, Vacanti G, Kostopoulou A, Marino M, Monteforte N, et al.\nHydroquinidine prevents life-threatening arrhythmic events in patients with short\nQT syndrome. J Am Coll Cardiol 2017;70:3010–3015.\n1071. El-Battrawy I, Besler J, Li X, Lan H, Zhao Z, Liebe V, et al. Impact of antiarrhythmic\ndrugs on the outcome of short QT syndrome. Front Pharmacol 2019;10:771.\n1072. Malik M. Drug-induced QT/QTc interval shortening: lessons from drug-induced\nQT/QTc prolongation. Drug Saf 2016;39:647–659.\n1073. Giustetto C, Scrocco C, Schimpf R, Maury P, Mazzanti A, Levetto M, et al.\nUsefulness of exercise test in the diagnosis of short QT syndrome. Europace\n2015;17:628–634.\n1074. Mason JW, Ramseth DJ, Chanter DO, Moon TE, Goodman DB, Mendzelevski B.\nElectrocardiographic reference ranges derived from 79,743 ambulatory subjects. J\nElectrocardiol 2007;40:228–234.\n1075. Bun S-S, Maury P, Giustetto C, Deharo J-C. Electrical storm in short-QT syn-\ndrome successfully treated with Isoproterenol. J Cardiovasc Electrophysiol 2012;\n23:1028–1030.\n1076. Siu SC, Sermer M, Colman JM, Alvarez AN, Mercier LA, Morton BC, et al.\nProspective multicenter study of pregnancy outcomes in women with heart dis-\nease. Circulation 2001;104:515–521.\n1077. Drenthen W, Pieper PG, Roos-Hesselink JW, van Lottum WA, Voors AA, Mulder\nBJM, et al. Outcome of pregnancy in women with congenital heart disease: a lit-\nerature review. J Am Coll Cardiol 2007;49:2303–2311.\n1078. Roos-Hesselink JW, Ruys TPE, Stein JI, Thilén U, Webb GD, Niwa K, et al.\nOutcome of pregnancy in patients with structural or ischaemic heart disease: re-\nsults of a registry of the European Society of Cardiology. Eur Heart J 2013;34:\n657–665.\n1079. Linde C, Bongiorni MG, Birgersdotter-Green U, Curtis AB, Deisenhofer I,\nFurokawa T, et al. Sex differences in cardiac arrhythmia: a consensus document\nof the European Heart Rhythm Association, endorsed by the Heart Rhythm\nSociety and Asia Paciﬁc Heart Rhythm Society. Europace 2018;20:1565–1565ao.\n1080. Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, Blomström-Lundqvist C,\nCífková R, De Bonis M, et al. 2018 ESC Guidelines for the management of cardio-\nvascular diseases during pregnancy. Eur Heart J 2018;39:3165–3241.\n1081. Silversides CK, Harris L, Haberer K, Sermer M, Colman JM, Siu SC. Recurrence\nrates of arrhythmias during pregnancy in women with previous tachyarrhythmia\nand impact on fetal and neonatal outcomes. Am J Cardiol 2006;97:1206–1212.\n1082. Sliwa K, Mebazaa A, Hilﬁker-Kleiner D, Petrie MC, Maggioni AP, Laroche C, et al.\nClinical characteristics of patients from the worldwide registry on peripartum car-\ndiomyopathy (PPCM): EURObservational Research Programme in conjunction\nwith the Heart Failure Association of the European Society of Cardiology Study\nGroup on PPCM. Eur J Heart Fail 2017;19:1131–1141.\n1083. Ware JS, Li J, Mazaika E, Yasso CM, DeSouza T, Cappola TP, et al. Shared genetic\npredisposition in peripartum and dilated cardiomyopathies. N Engl J Med 2016;\n374:233–241.\n1084. Wang Y-C, Chen C-H, Su H-Y, Yu M-H. The impact of maternal cardioversion on\nfetal haemodynamics. Eur J Obstet Gynecol Reprod Biol 2006;126:268–269.\n1085. Barnes EJ, Eben F, Patterson D. Direct current cardioversion during pregnancy\nshould be performed with facilities available for fetal monitoring and emergency\ncaesarean section. BJOG 2002;109:1406–1407.\n1086. Miyoshi T, Kamiya CA, Katsuragi S, Ueda H, Kobayashi Y, Horiuchi C, et al. Safety\nand efﬁcacy of implantable cardioverter-deﬁbrillator during pregnancy and after\ndelivery. Circ J 2013;77:1166–1170.\n1087. Abello M, Peinado R, Merino JL, Gnoatto M, Mateos M, Silvestre J, et al.\nCardioverter deﬁbrillator implantation in a pregnant woman guided with transe-\nsophageal echocardiography. Pacing Clin Electrophysiol 2003;26:1913–1914.\n1088. Hartz J, Clark BC, Ito S, Sherwin ED, Berul CI. Transvenous nonﬂuoroscopic pace-\nmaker implantation during pregnancy guided by 3-dimensional electroanatomic\nmapping. HeartRhythm Case Rep 2017;3:490–492.\n1089. Bauersachs J, König T, van der Meer P, Petrie MC, Hilﬁker-Kleiner D, Mbakwem A,\net al. Pathophysiology, diagnosis and management of peripartum cardiomyopathy:\na position statement from the Heart Failure Association of the European Society\nof Cardiology Study Group on peripartum cardiomyopathy. Eur J Heart Fail 2019;\n21:827–843.\n1090. Duncker D, König T, Hohmann S, Bauersachs J, Veltmann C. Avoiding untimely\nimplantable cardioverter/deﬁbrillator implantation by intensiﬁed heart failure\ntherapy optimization supported by the wearable cardioverter/deﬁbrillator-the\nPROLONG study. J Am Heart Assoc 2017;6:e004512.\n1091. Duncker D, Westenfeld R, Konrad T, Pfeffer T, Correia de Freitas CA, Pﬁster R,\net al. Risk for life-threatening arrhythmia in newly diagnosed peripartum cardio-\nmyopathy with low ejection fraction: a German multi-centre analysis. Clin Res\nCardiol 2017;106:582–589.\n1092. Jeejeebhoy FM, Zelop CM, Lipman S, Carvalho B, Joglar J, Mhyre JM, et al. Cardiac\narrest in pregnancy: a scientiﬁc statement from the American heart association.\nCirculation 2015;132:1747–1773.\n1093. European Society of Gynecology (ESG), Association for European Paediatric\nCardiology\n(AEPC),\nGerman\nSociety\nfor\nGender\nMedicine\n(DGesGM),\nRegitz-Zagrosek V, Blomstrom Lundqvist C, Borghi C, et al. ESC Guidelines on\nthe management of cardiovascular diseases during pregnancy: the task force on\nthe Management of Cardiovascular Diseases during Pregnancy of the European\nSociety of Cardiology (ESC). Eur Heart J 2011;32:3147–3197.\n1094. Rashba EJ, Zareba W, Moss AJ, Hall WJ, Robinson J, Locati EH, et al. Inﬂuence of\npregnancy on the risk for cardiac events in patients with hereditary long QT syn-\ndrome. LQTS investigators. Circulation 1998;97:451–456.\n1095. Ishibashi K, Aiba T, Kamiya C, Miyazaki A, Sakaguchi H, Wada M, et al. Arrhythmia\nrisk and β-blocker therapy in pregnant women with long QT syndrome. Heart\n2017;103:1374–1379.\n1096. Cheung CC, Lieve KV, Roston TM, van der Ree MH, Deyell MW, Andrade JG,\net al. Pregnancy in catecholaminergic polymorphic ventricular tachycardia. JACC\nClin Electrophysiol 2019;5:387–394.\n1097. Wu L, Liang E, Fan S, Zheng L, Hu F, Liu S, et al. Effect of pregnancy in arrhythmo-\ngenic right ventricular cardiomyopathy. Am J Cardiol 2020;125:613–617.\n1098. Bauce B, Daliento L, Frigo G, Russo G, Nava A. Pregnancy in women with arrhyth-\nmogenic right ventricular cardiomyopathy/dysplasia. Eur J Obstet Gynecol Reprod\nBiol 2006;127:186–189.\n1099. Gandjbakhch E, Varlet E, Duthoit G, Fressart V, Charron P, Himbert C, et al.\nPregnancy and newborn outcomes in arrhythmogenic right ventricular cardiomy-\nopathy/dysplasia. Int J Cardiol 2018;258:172–178.\n1100. Rodríguez-Mañero M, Casado-Arroyo R, Sarkozy A, Leysen E, Sieira JA, Namdar\nM, et al. The clinical signiﬁcance of pregnancy in Brugada syndrome. Rev Esp Cardiol\n(Engl Ed) 2014;67:176–180.\n1101. Benito B, Berruezo A. Brugada syndrome and pregnancy: delving into the role of\nsex hormones in ion channelopathies. Rev Esp Cardiol (Engl Ed) 2014;67:165–167.\n1102. Ostrowska B, Kommata B, Malmborg H, Lundqvist CB. Arrhythmias in pregnancy.\nESC CardioMed. 3rd ed. Oxford University Press; 2022, p2868–2870.\n1103. Sliwa K, Blauwet L, Tibazarwa K, Libhaber E, Smedema J-P, Becker A, et al.\nEvaluation of bromocriptine in the treatment of acute severe peripartum cardio-\nmyopathy: a proof-of-concept pilot study. Circulation 2010;121:1465–1473.\n1104. Hilﬁker-Kleiner D, Haghikia A, Berliner D, Vogel-Claussen J, Schwab J, Franke A,\net al. Bromocriptine for the treatment of peripartum cardiomyopathy: a multicen-\ntre randomized study. Eur Heart J 2017;38:2671–2679.\n1105. Driver K, Chisholm CA, Darby AE, Malhotra R, Dimarco JP, Ferguson JD.\nCatheter ablation of arrhythmia during pregnancy. J Cardiovasc Electrophysiol\n2015;26:698–702.\n1106. Wang Z, Chen YW, Jiang YH, Sun LP, Chen XJ, Tao HL, et al. Electrophysiological\ncharacteristics and therapeutic efﬁcacy of radiofrequency ablation of focal atrial\ntachycardia originating from the right atrial appendage during pregnancy.\nZhonghua Xin Xue Guan Bing Za Zhi 2020;48:859–865.\n1107. Tuzcu V, Kilinc OU. Implantable cardioverter deﬁbrillator implantation without\nusing ﬂuoroscopy in a pregnant patient. Pacing Clin Electrophysiol 2012;35:\ne265–266.\n1108. Fröhlich GM, Holzmeister J, Hübler M, Hübler S, Wolfrum M, Enseleit F, et al.\nProphylactic implantable cardioverter deﬁbrillator treatment in patients with end-\nstage heart failure awaiting heart transplantation. Heart 2013;99:1158–1165.\n1109. Sandner SE, Wieselthaler G, Zuckermann A, Taghavi S, Schmidinger H, Pacher R,\net al. Survival beneﬁt of the implantable cardioverter-deﬁbrillator in patients on\nthe waiting list for cardiac transplantation. Circulation 2001;104:I171–176.\n1110. Algalarrondo V, Perault R, Bories M-C, Narayanan K, Garcia R, Combes N, et al.\nProphylactic implantable cardioverter deﬁbrillators for primary prevention: From\nimplantation to heart transplantation. Arch Cardiovasc Dis 2018;111:758–765.\n1111. Cantero-Pérez EM, Sobrino-Márquez JM, Grande-Trillo A, Lage-Gallé E,\nRangel-Sousa D, Esteve-Ruiz IM, et al. Implantable cardioverter deﬁbrillator for\nprimary prevention in patients with severe ventricular dysfunction awaiting heart\ntransplantation. Transplant Proc 2013;45:3659–3661.\n1112. Pezawas T, Grimm M, Ristl R, Kivaranovic D, Moser FT, Laufer G, et al. Primary\npreventive cardioverter-deﬁbrillator implantation (Pro-ICD) in patients awaiting\nheart transplantation. A prospective, randomized, controlled 12-year follow-up\nstudy. Transpl Int 2015;28:34–41.\n1113. Kao AC, Krause SW, Handa R, Karia D, Reyes G, Bianco NR, et al. Wearable de-\nﬁbrillator use in heart failure (WIF): results of a prospective registry. BMC\nCardiovasc Disord 2012;12:123.\n1114. Alba AC, Foroutan F, Hing NKVNF, Fan C-PS, Manlhiot C, Ross HJ. Incidence and\npredictors of sudden cardiac death after heart transplantation: a systematic re-\nview and meta-analysis. Clin Transplant 2018;32:e13206.\n1115. Vakil K, Taimeh Z, Sharma A, Abidi KS, Colvin M, Luepker R, et al. Incidence, pre-\ndictors, and temporal trends of sudden cardiac death after heart transplantation.\nHeart Rhythm 2014;11:1684–1690.\n1116. Alba AC, Fan C-PS, Manlhiot C, Dipchand AI, Stehlik J, Ross HJ. The evolving risk\nof sudden cardiac death after heart transplant. An analysis of the ISHLT thoracic\ntransplant registry. Clin Transplant 2019;33:e13490.\n1117. Eskander MA, Adler E, Hoffmayer KS. Arrhythmias and sudden cardiac death in\npost-cardiac transplant patients. Curr Opin Cardiol 2020;35:308–311.\nESC Guidelines\n4125\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026\n\n\n1118. Tsai VW, Cooper J, Garan H, Natale A, Ptaszek LM, Ellinor PT, et al. The efﬁcacy\nof implantable cardioverter-deﬁbrillators in heart transplant recipients: results\nfrom a multicenter registry. Circ Heart Fail 2009;2:197–201.\n1119. Klein HU, Meltendorf U. Bridging a temporary high risk of sudden arrhythmic\ndeath. Experience with the wearable cardioverter deﬁbrillator. PACE 2010;33:\n353–367.\n1120. Corrado D, Zorzi A. Sudden death in athletes. Int J Cardiol 2017;237:67–70.\n1121. Rajan D, Garcia R, Svane J, Tfelt-Hansen J. Risk of sports-related sudden cardiac\ndeath in women. Eur Heart J 2021;43:1198–1206.\n1122. Corrado D, Basso C, Schiavon M, Thiene G. Screening for hypertrophic cardiomy-\nopathy in young athletes. N Engl J Med 1998;339:364–369.\n1123. Malhotra A, Dhutia H, Finocchiaro G, Gati S, Beasley I, Clift P, et al. Outcomes of\ncardiac screening in adolescent soccer players. N Engl J Med 2018;379:524–534.\n1124. Corrado D, Pelliccia A, Bjørnstad HH, Vanhees L, BifﬁA, Borjesson M, et al.\nCardiovascular pre-participation screening of young competitive athletes for pre-\nvention of sudden death: proposal for a common European protocol. Consensus\nStatement of the Study Group of Sport Cardiology of the Working Group of\nCardiac Rehabilitation and Exercise Physiology and the Working Group of\nMyocardial and Pericardial Diseases of the European Society of Cardiology. Eur\nHeart J 2005;26:516–524.\n1125. Corrado D, Schmied C, Basso C, Borjesson M, Schiavon M, Pelliccia A, et al. Risk of\nsports: do we need a pre-participation screening for competitive and leisure ath-\nletes? Eur Heart J 2011;32:934–944.\n1126. Baggish AL, Hutter AM, Wang F, Yared K, Weiner RB, Kupperman E, et al.\nCardiovascular screening in college athletes with and without electrocardiog-\nraphy: a cross-sectional study. Ann Intern Med 2010;152:269–275.\n1127. Corrado D, Basso C, Pavei A, Michieli P, Schiavon M, Thiene G. Trends in sudden\ncardiovascular death in young competitive athletes after implementation of a pre-\nparticipation screening program. JAMA 2006;296:1593–1601.\n1128. Sharma S, Estes NAM, Vetter VL, Corrado D. Clinical decisions. Cardiac screening\nbefore participation in sports. N Engl J Med 2013;369:2049–2053.\n1129. Sarto P, Zorzi A, Merlo L, Vessella T, Pegoraro C, Giorgiano F, et al. Serial versus\nsingle cardiovascular screening of adolescent athletes. Circulation 2021;143:\n1729–1731.\n1130. Steinvil A, Chundadze T, Zeltser D, Rogowski O, Halkin A, Galily Y, et al.\nMandatory electrocardiographic screening of athletes to reduce their risk for sud-\nden death proven fact or wishful thinking? J Am Coll Cardiol 2011;57:1291–1296.\n1131. Corrado D, Pelliccia A, Heidbuchel H, Sharma S, Link M, Basso C, et al.\nRecommendations for interpretation of 12-lead electrocardiogram in the athlete.\nEur Heart J 2010;31:243–259.\n1132. Sharma S, Drezner JA, Baggish A, Papadakis M, Wilson MG, Prutkin JM, et al.\nInternational recommendations for electrocardiographic interpretation in ath-\nletes. Eur Heart J 2018;39:1466–1480.\n1133. Crescenzi C, Zorzi A, Vessella T, Martino A, Panattoni G, Cipriani A, et al.\nPredictors of left ventricular scar using cardiac magnetic resonance in athletes\nwith apparently idiopathic ventricular arrhythmias. J Am Heart Assoc 2021;10:\ne018206.\n1134. Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, et al. 2016\nEuropean Guidelines on cardiovascular disease prevention in clinical practice:\nThe Sixth Joint task force of the European Society of Cardiology and Other\nSocieties on Cardiovascular Disease Prevention in Clinical Practice (constituted\nby representatives of 10 societies and by invited experts) Developed with the spe-\ncial contribution of the European Association for Cardiovascular Prevention &\nRehabilitation (EACPR). Eur Heart J 2016;37:2315–2381.\n1135. Rizzo M, Spataro A, Cecchetelli C, Quaranta F, Livrieri S, Sperandii F, et al.\nStructural cardiac disease diagnosed by echocardiography in asymptomatic young\nmale soccer players: implications for pre-participation screening. Br J Sports Med\n2012;46:371–373.\n1136. Heidbuchel H, Arbelo E, D’Ascenzi F, Borjesson M, Boveda S, Castelletti S, et al.\nRecommendations for participation in leisure-time physical activity and competi-\ntive sports of patients with arrhythmias and potentially arrhythmogenic condi-\ntions.\nPart\n2:\nventricular\narrhythmias,\nchannelopathies,\nand\nimplantable\ndeﬁbrillators. Europace 2021;23:147–148.\n1137. Drezner JA, Peterson DF, Siebert DM, Thomas LC, Lopez-Anderson M, Suchsland\nMZ, et al. Survival after exercise-related sudden cardiac arrest in young athletes:\ncan we do better? Sports Health 2019;11:91–98.\n1138. Drezner JA, Rogers KJ, Horneff JG. Automated external deﬁbrillator use at NCAA\nDivision II and III universities. Br J Sports Med 2011;45:1174–1178.\n1139. Borjesson M, Serratosa L, Carre F, Corrado D, Drezner J, Dugmore DL, et al.\nConsensus document regarding cardiovascular safety at sports arenas: position\nstand from the European Association of Cardiovascular Prevention and\nRehabilitation (EACPR), section of Sports Cardiology. Eur Heart J 2011;32:\n2119–2124.\n1140. Drezner JA, Owens DS, Prutkin JM, Salerno JC, Harmon KG, Prosise S, et al.\nElectrocardiographic Screening in National Collegiate Athletic Association\nAthletes. Am J Cardiol 2016;118:754–759.\n1141. Erbel R, Möhlenkamp S, Moebus S, Schmermund A, Lehmann N, Stang A, et al.\nCoronary risk stratiﬁcation, discrimination, and reclassiﬁcation improvement\nbased on quantiﬁcation of subclinical coronary atherosclerosis: the Heinz\nNixdorf Recall study. J Am Coll Cardiol 2010;56:1397–1406.\n1142. Yeboah J, McClelland RL, Polonsky TS, Burke GL, Sibley CT, O’Leary D, et al.\nComparison of novel risk markers for improvement in cardiovascular risk assess-\nment in intermediate-risk individuals. JAMA 2012;308:788–795.\n1143. Pappone C, Vicedomini G, Manguso F, Saviano M, Baldi M, Pappone A, et al.\nWolff-Parkinson-White syndrome in the era of catheter ablation: insights from\na registry study of 2169 patients. Circulation 2014;130:811–819.\n1144. Obeyesekere MN, Leong-Sit P, Massel D, Manlucu J, Modi S, Krahn AD, et al. Risk\nof arrhythmia and sudden death in patients with asymptomatic preexcitation: a\nmeta-analysis. Circulation 2012;125:2308–2315.\n1145. Heidbuchel H, Adami PE, Antz M, Braunschweig F, Delise P, Scherr D, et al.\nRecommendations for participation in leisure-time physical activity and competi-\ntive sports in patients with arrhythmias and potentially arrhythmogenic condi-\ntions: part 1: supraventricular arrhythmias. A position statement of the Section\nof Sports Cardiology and Exercise from the European Association of\nPreventive Cardiology (EAPC) and the European Heart Rhythm Association\n(EHRA), both associations of the European Society of Cardiology. Eur J Prev\nCardiol 2020;28:1539–1551.\n1146. Pappone C, Santinelli V, Manguso F, Augello G, Santinelli O, Vicedomini G, et al. A\nrandomized study of prophylactic catheter ablation in asymptomatic patients with\nthe Wolff-Parkinson-White syndrome. N Engl J Med 2003;349:1803–1811.\n1147. Perry JC, Garson A. Supraventricular tachycardia due to Wolff-Parkinson-White\nsyndrome in children: early disappearance and late recurrence. J Am Coll Cardiol\n1990;16:1215–1220.\n1148. Pediatric and Congenital Electrophysiology Society (PACES), Heart Rhythm\nSociety (HRS), American College of Cardiology Foundation (ACCF), American\nHeart Association (AHA), American Academy of Pediatrics (AAP), Canadian\nHeart Rhythm Society (CHRS), et al. PACES/HRS expert consensus statement\non\nthe\nmanagement\nof\nthe\nasymptomatic\nyoung\npatient\nwith\na\nWolff-Parkinson-White (WPW, ventricular preexcitation) electrocardiographic\npattern: developed in partnership between the Pediatric and Congenital\nElectrophysiology Society (PACES) and the Heart Rhythm Society (HRS).\nEndorsed by the governing bodies of PACES, HRS, the American College of\nCardiology Foundation (ACCF), the American Heart Association (AHA), the\nAmerican Academy of Pediatrics (AAP), and the Canadian Heart Rhythm\nSociety (CHRS). Heart Rhythm 2012;9:1006–1024.\n1149. Barsheshet A, Moss AJ, Huang DT, McNitt S, Zareba W, Goldenberg I.\nApplicability of a risk score for prediction of the long-term (8-year) beneﬁt of\nthe implantable cardioverter-deﬁbrillator. J Am Coll Cardiol 2012;59:2075–2079.\n1150. Expósito\nV,\nRodríguez-Mañero\nM,\nGonzález-Enríquez\nS,\nArias\nMA,\nSánchez-Gómez JM, Andrés La Huerta A, et al. Primary prevention implantable\ncardioverter-deﬁbrillator and cardiac resynchronization therapy-deﬁbrillator in\nelderly patients: results of a Spanish multicentre study. Europace 2016;18:\n1203–1210.\n1151. Alhakak A, Østergaard L, Butt JH, Vinther M, Philbert BT, Jacobsen PK, et al.\nCause-speciﬁc death and risk factors of one-year mortality after implantable\ncardioverter-deﬁbrillator implantation: a nationwide study. Eur Heart J Qual\nCare Clin Outcomes 2022;8:39–49.\n1152. Poupin P, Bouleti C, Degand B, Paccalin M, Le Gal F, Bureau M-L, et al. Prognostic\nvalue of Charlson Comorbidity Index in the elderly with a cardioverter deﬁbrilla-\ntor implantation. Int J Cardiol 2020;314:64–69.\n1153. Aktaa S, Batra G, Wallentin L, Baigent C, Erlinge D, James S, et al. European society\nof cardiology methodology for the development of quality indicators for the quan-\ntiﬁcation of cardiovascular care and outcomes. Eur Heart J Qual Care Clin Outcomes\n2022;8:4–13.\n1154. Minchin M, Roland M, Richardson J, Rowark S, Guthrie B. Quality of care in the\nUnited Kingdom after removal of ﬁnancial incentives. N Engl J Med 2018;379:\n948–957.\n1155. Song Z, Ji Y, Safran DG, Chernew ME. Health care spending, utilization, and quality\n8 years into global payment. N Engl J Med 2019;381:252–263.\n4126\nESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/43/40/3997/6675633 by guest on 14 January 2026",
      "keywords": [
        "heart failure",
        "systolic dysfunction",
        "guideline",
        "framingham",
        "author",
        "blood pressure",
        "age",
        "recommended",
        "cardiomyopathy",
        "genetic",
        "echocardiography",
        "angiography",
        "nyha",
        "coronary artery",
        "stenosis",
        "sex",
        "male",
        "family history",
        "class i",
        "lifetime risk",
        "risk factor",
        "atherosclerosis",
        "diabetes",
        "calcium channel",
        "hereditary",
        "secondary prevention",
        "sglt2",
        "primary prevention",
        "arrhythmia",
        "syncope"
      ],
      "tables": []
    }
  ]
}